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ABSTRACT
Cyclic adenosine 5 '-diphosphate ribose (cADPR), a second messenger that mobilises 
calcium ions from intracellular stores, is biologically synthesised by ADP ribosyl cyclase 
(ADPRC). Among the ADPRC family, Aplysia cyclase is thought to only catalyse the 
cyclisation reaction. Incubation o f Aplysia cyclase with 2-FNAD+ (nicotinamide 2F- 
adenine dinucleotide) demonstrated interestingly that the Aplysia cyclase, similar to other 
ADP ribosyl cyclases, is indeed a multifunctional enzyme that also possesses a 
NAD+glycohydrolase function. Other potential non-cyclisable NAD+ analogues, such as 2- 
NH2-NAD* 6-A-methyl-NAD+ and 8 -bromo-NGD+ were also designed, synthesised and 
evaluated in this work.
8-Substituted-cADPR/2'-deoxy-cADPR analogues were synthesised in order to further 
investigate the key elements that control the agonistic/antagonistic activities o f cADPR 
analogues. It has been found that the 2 -hydroxyl group is a cmcial m otif for antagonistic 
effects. Removal o f the 2'-OH group also increased the agonistic effects o f  these cADPR 
analogues. In sea urchin egg system, interestingly, 8-bromo-2-deoxy-cADPR is a full 
agonist instead o f an antagonist and more importantly it is also cell permeant, although 
weak, suggesting that further modification of the molecule may lead to a potent membrane 
permeable agonist for the first time.
Nicotinic acid adenine dinucleotide phosphate (NAADP) is another second messenger that 
triggers calcium release from intracellular stores. In order to develop tools to study the 
signalling pathway of NAADP and its protein components, a library o f drug-like small 
molecules that might mimic/antagonise the NAADP molecule biologically (according to 
the SAR of NAADP) was designed and synthesised. An in vitro study o f these candidates 
in T cells thus leads to the in vivo evaluation of two lead compounds 3-carboxy-l- 
dibutylcarbamoylmethyl-pyridinium (BZ52) and 3-carboxy-l-octylcarbamoylmethyl- 
pyridinium (BZ194). These two compounds exhibit beneficial effects in both active and 
transfer experimental autoimmune encephalomyelitis (EAE), T cell mediated disease 
models for Multiple Sclerosis, thus providing potential leads for future clinical 
development. Also, the in vitro and in vivo studies suggest that the Ca2+ messenger 
NAADP is essential for the pathogenic potential o f autoaggressive T cells and thus it 
qualifies as novel potential target for the treatment of T cell-mediated autoimmune disease.
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1.1 Cell Signaling Systems
It is essential for multicellular organisms to communicate with each other in order to 
regulate their growth and differentiation. The mechanisms for such communication include 
direct contact between cells and secretion of hydrophilic signaling molecules such as 
growth factors, hormones and neurotransmitters. These signaling molecules, however, are 
often limited by their own hydrophilic properties and cannot cross the lipid bilayer plasma 
membrane of the target cells, therefore transduction mechanisms are required to couple an 
incoming signaling to the particular intracellular response. In general, these signaling 
molecules interact with receptors on the surface of the plasma membrane, which transduce 
the signal across the membrane, and then internal events interact with cytoplasmic 
machineries or regulate gene expression. However, some hydrophobic signaling molecules 
such as steroids and nitric oxide (NO) can diffuse freely across cell membrane and 
therefore do not need to use the transduction mechanisms.
1.1.1 Cell Surface Receptor
There are several types of cell surface receptor that interact with external signals and 
transduce them across the membrane to trigger the corresponding cellular response.
a) Tyrosine kinase receptors (RTKs)-a family of transmembrane polypeptides containing 
protein kinase domain in the intracellular portion. When binding with external signaling 
molecules (normally growth factors), these receptors can initiate intracellular functions 
such as proliferation, differentiation and cell motility etc. This kind of receptor comprises 
three structural regions, an extracellular domain containing a binding site for the signal 
molecule, a transmembrane region and an intracellular portion with a tyrosine kinase 
domain attached. In the event of binding with a signaling molecule like a growth factor, 
two receptor molecules are brought together to form a dimer. This dimerization will in turn 
promote the trans-phosphorylation o f each member of the pair to form the phosphotyrosine 
derivative which is able to tightly bind to intracellular proteins containing SH2 or PTB 
domain in turn, triggering the activation of intracellular enzymes or transcription factors. 
One of the signaling pathways in RTK signalling involves PLC-y, a protein which 
catalyses the hydrolysis of Ptdlns (4,5) P2 into diacylglycerol and inositol-1,4,5- 
triphosphate (IP3), a second messenger inducing calcium release from intracellular stores.1 
This molecule (IP3) will be introduced in later sections.
b) Cytokine receptors-cvtokines are known as a class of protein mediators that precisely 
control the growth and differentiation of cells in the homeostasis of multicellular organs 
such as the immume and hematopoietic systems. Cloning of the receptors of these
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cytokines revealed a large family of membrane proteins referred to as the class I cytokine 
receptors.2 Ligand binding with these receptors triggers the dimerization of the familiar 
members and then induces the tyrosine phosporylation of cellular proteins including the 
receptors themselves. If there is a lack of a built-in tyrosine kinase domain, 
phosphorylation is accomplished via association of the non-receptor cytoplasmic tyrosine 
kinase known as the Jak fam ily .3 The result of the dimerization leads to initiation of gene 
transcription. Recent study suggests that ligand stimulation of these receptors induces the 
tyrosine phosphorylation and activation of the latent cytoplasmic transcription factors 
STATs (signal transducers and activators of transcription).4
c) G-protein-coupled receptors- G protein (guanine nucleotide binding protein)-coupled 
receptors demonstrate similar structural and functional properties. These receptors all 
display seven-transmembrane fragments connected by extracellular and intracellular loops. 
G proteins are composed of three subunits a p y  and these subunits serve to transduce 
external signals across the cell membrane to the intracellular effectors. The receptor is 
activated upon binding with the agonist such as a hormone or a neurotransmitter and it then 
interacts with, and activates, the G-protein by promoting the replacement of GDP with 
GTP in the nucleotide-binding site at the a  subunit. After binding with GTP, the a  subunit 
is dissociated from the Py subunit and from the receptor and it then interacts with various 
effector enzymes, ion channels or other receptors to trigger further cellular functions. An 
example related to research in our group is that the a  unit interacts with the C2 domain of 
PLC-P, resulting in the activation and translocation of the enzyme to the plasma membrane. 
Once the PLC-p contacts the membrane, it initiates the hydrolysis of the minor membrane 
lipid PtdIns(4 ,5 )P2, producing the calcium releasing second messenger IP3 and 
diacylglycerol (DAG). IP3 then induces calcium release from intracellular stores, triggering 
other downstream cellular activities.
d) Ligand gated ion channels (LGICs)- are cell surface proteins that play an important role 
in fast synaptic transmission and in the modulation of cellular function. LGICs respond to 
external signal such as neurotransmitters and other effectors and transduce the binding of a 
ligand into an electrical current on a microsecond timescale. Following activation, LGICs 
open allowing an ion flux across the cell membrane. LGICs are composed of both the 
ligand binding site and the ion-conducting pore, which can be modulated between the on 
and off status upon ligand binding. These ion channels are formed from the assembly of 
subunits and these subunits can be homomeric or heteromeric, which results in these ion 
channels possessing a great diversity of physiological and pharmacological properties. In
mammalian cells, LGIC are classified into three families, based on the number of 
transmembrane segments present in the subunits that form the channels. The three known 
families are the P2X (adenosine triphosphate ATP) receptor family, the glutamate- 
activated cationic receptor family and the Cys-loop receptor superfamily.
These plasmic membrane proteins are of vital importance in terms of transducing signals 
into the cell and then initiating important cellular activities. In our project, we will focus on 
calcium signaling and some of above proteins will be mentioned here in the processes 
including calcium entry, second messenger generation etc. Apart from the cell surface 
proteins introduced above, there are other membrane receptors such as hematopoietic 
antigen receptors, serine/threonine kinase receptors, tumor necrosis factor receptor family 
and many others.
1.2 Calcium Signaling
The importance o f calcium in regulating the biological functions of living organism was 
reported 120 years ago. The idea that calcium is biologically important derives from the 
observation that the “lime salt” is vital for the muscle contractility of frog heart.5 Now it is 
well established that calcium plays an important role in the fertilisation of cells and is used 
as an internal signal to control a great variety of cell function, including muscle contraction, 
secretion, metabolism, neuronal excitability and proliferation. Basically, when calcium 
concentration is in the range of 10-100 nM, cells keep inactive. While the calcium 
concentration is between 500-1000 nM, cells are activated to perform their specified 
functions. Calcium can bind to proteins directly to alter their enzymatic activity, as is the 
case for intramitochondrial dehydrogenases,6 and can also indirectly affect cellular activity
7  Rthrough calcium binding proteins, for example calmodulin (CaM) or calcineurin. ’ It 
could even regulate cell functions at the genetic level through transcriptional regulators. 
Among the numerous proteins targeted by CaM, there are biologically important proteins 
for the calcium signaling pathways and for particular calcium permeable ion channels. It 
has been reported that CaM tightly regulates voltage-gated calcium channels (VGCCs), 
cyclic nucleotide-gated channels, W-methyl-D-aspartate receptors and the transient receptor 
potential channel fam ily (TRP) at the plasma membrane .9 CaM has also been reported to 
bind to the ryanodine receptor (RyR) and the inositol 1,4,5-triphosphate receptor (IP3R). 
We will discuss these receptors later in the next section.
There are two major sources of calcium that cells can access: extracellular calcium stores 
and intracellular calcium stores. Calcium entry from the external source is usually
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regulated by: a) VGCCs, a class of calcium channel which is activated by membrane 
depolarization allowing extracellular calcium to enter the cell.10 A large amount of 
evidence also support the fact that CAM plays an important role in VGCC channel 
activation; b) receptor-operated channels, another class of important ion channel, which is 
activated by the binding of extracellular agonists, usually neurotransmitters such as 
glutamine and ATP. On the plasma membrane there exists another kind o f channel that is 
regulated indirectly by the state of fullness of the ER calcium store. These calcium 
channels are controlled by a mechanism known as capacitative calcium entry . 11,12 Calcium 
entry is denied when the ER stores are full and is activated while the stores are empty. The 
mechanism of this calcium entry was proposed, involving a release of internal messenger, 
calcium influx factor (CIF), which in turn diffuses to the membrane and open the calcium- 
release activated calcium (CRAC) channels to allow calcium influx .13 To date, CIF has not 
been unambiguously identified.
The calcium released from stores inside the endoplasmic reticulum (ER) or sarcoplasmic 
reticulum (SR) is controlled by IP3 receptors, ryanodine receptors, and putative NAADP 
(nicotinic acid adenosine dinucleotide phosphate) receptors. Binding of these receptors 
with respective second messengers IP3, cADPR and NAADP induces calcium release from 
the appropriate intracellular store. These second messengers will be introduced in section 
1.3. Intracellular calcium can also be released by a ubiquitous mechanism known as 
calcium induced calcium release (CICR) . 14 In this process, calcium release from the ER or 
SR is triggered by and amplifies an increase of intracellular calcium concentration. 
Through the CICR mechanism, calcium release can be relayed from one intracellular 
channel to the next, generating calcium waves which broadcast local signals into the entire 
cytoplasm, as well as the nucleoplasm as in the case of fertilisation .15 Studies suggest that 
CICR is caused by the activation of RyRs, normally Ry type 3 receptors 16for example in 
heart17 and in the (3 cell18and it is suggested that phosphorylation of RyRs by the cAMP- 
dependent protein kinase is required for this process. IP3RS are also involved in the 
generation o f CICR. It should be noticed that although calcium acts as a solo trigger for 
activating o f RyRs, IP3R usually require the simultaneous presence of calcium and IP3.19
Calcium signaling could be highly regulated and the control of free calcium concentration 
inside cells is of tremendous importance in the development of the living organism. One of 
the efficient ways of altering the calcium concentration is to modulate the calcium release 
from intracellular sources. It is known that calcium released from intracellular stores is
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triggered upon binding of second messengers with receptors on the store’s membrane. 
Chemical modification of these second messengers allows us to design agonists as well as 
antagonists, which serve as tools to investigate and control the calcium release from 
internal stores. Small molecule second messenger analogues could even be developed for 
potential future pharmaceutical use.
1.3 Calcium Releasing Second Messengers
Three known or putative calcium mobilising second messengers are inositol 1,4,5-
trisphosphate l ,20 cyclic ADP ribose 2 (cADPR)21and nicotinic acid adenosine dinucleotide
00phosphate 3 (NAADP) and are shown in Figure 1.1.
O
Figure 1.2 and the detailed signaling pathways and receptors involved in the calcium 






Figure 1.1 Structures of calcium releasing second messengers.










Figure 1.2 Schematic mechanism of calcium release induced by second messengers. 
IP3 is generated through the PLC signaling pathway (section 1.1). It interacts with the IP3R 
on the membrane of the intracellular calcium stores to trigger calcium release. Upon 
external stimulation, Aplysia ADP ribosyl cyclase is activated and used to catalyse the 
transformation from NAD+ to the cADPR, which in turn binds with the RyR to initiate 
calcium release. The receptor for NAADP is still not clear. Intracellular calcium is also 
released by calcium itself through a process known as CICR.
1.3.1 Inositol-1,4,5-Trisphosphate (IP3) and Its Receptor
Inositol 1,4,5-trisphosphate is the first known second messenger found to mobilise calcium 
from intracellular stores and in the biological system IP3 is synthesised via the PLC 
pathway. The receptors for IP3 are regulated by the cytosolic calcium and IP3, and are also 
modulated by adenosine nucleotides,23 pH ,24 phosphorylation,25and calmodulin (CaM) etc. 
Three mammalian IP3 receptor subtypes have been reported so far. Type 1, Type 2 and 
Type 3 receptors are over 70% identical in their amino acid sequence and they are all 
capable of modulating DVinduced calcium release from intracellular stores.20 These 
subtypes, however, are different in terms of their affinity towards IP3. When compared to 
each other, the IP3R type 1 has a medium IP3 affinity, high ATP affinity (not co-operative) 
and low calcium affinity; IP3R type 2 has high IP3 affinity, medium calcium affinity and is 
ATP independent; IP3R type 3 has low IP3 affinity, low ATP affinity and high calcium
27 28 29affinity." ’ ’ The high affinity of IP3R type 2 for IP3 is determined within the amino- 
terminal ligand-binding domain;30 high affinity of IP3R type 1 for ATP is because of a 
unique high affinity ATP-binding site in the IP3R type sequence,3’and the differences in
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calcium sensitivity are encoded within a sequence of the calcium sensor region. Most cells 
express several IP3 receptor subtypes, however almost invariably type 1 is expressed. As 
we discussed in the earlier section, CICR mediated by the IP3 receptor relies on the binding 
of EP3. It seems that binding of IP3 changes the conformation of the target protein1- and 
then exposes the calcium binding site which is otherwise hidden in the receptor. In turn, 
calcium has a profound effect on the interaction between IP3 and its receptors. A modest 
increase of calcium will increase the response of the IP3 receptor to submaximal 
concentration of EP3 while substantial increase of calcium will inhibit the response to most 
IP3 concentrations.33This inhibition effect sometimes can be overcome by further increase 
of the IP3 concentration. It is noteworthy that binding of IP3 with the EP3 receptor somehow 
inactivates the calcium conduction activity (around 10 fold). It has been reported that, upon 
binding with EP3. the receptor adopts a conformation which exhibits high affinity for IP3 
but poor affinity for calcium.34Similar to other second messengers, IP3 has a short half-life 
and is metabolised either by nV5P-ases pathway,35which produces an inactive Ins(l ,4)P2 4 
by removing the 5-phosphate from the inositol ring or by a DV3K pathway36 that further 
phosphorylates IP3 on the 3-hydroxyl group resulting in the formation of In s(l,3 ,4 ,5 )P4 5. 
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Figure 1.3 Metabolism pathways of IP3.
1.3.2 cADPR and Ryanodine Receptors
Unlike the well established second messenger EP3, cADPR as a second messenger still 
needs further studies on aspects such as the calcium activation mechanisms, binding 
proteins, receptors etc. cADPR was first discovered as a calcium releasing metabolite of a 
well known co-enzyme NAD+ by Lee and his colleagues in 1987.21 NAD+ and NADP+ as 
coenzymes for cellular oxidation-reduction reactions are well known and, moreover, NAD+ 
plays non-oxidation-reduction reaction roles by acting as an ADP-ribose donor in the post- 
translational modification of proteins. When tested in sea urchin egg homogenates, NAD+
demonstrated its ability to trigger calcium release almost as much as that o f IP3, but this 
release had a 1-4 min time delay. It was found later that the time delay was caused by the 
synthesis of a novel metabolite, which was later isolated and structurally determined to be 
cADPR. The cyclic linkage of cADPR in early studies was first believed to exist between 
the ribosyl C -l" of “northern ribose” and the amino group at C -6  of the adenosine 
moiety.37 However, a further X-ray study suggested that though it leads to a less stable 
positively charged structure, the cyclisation occurs between the ribosyl C - l” and the N-l 
position of the adenosine. The numbering system of cADPR and the so called northern 
ribose and southern ribose is shown in Figure 1.4 and, under biological conditions, cADPR 
may adopt one of the two possible structures according to the pH of the environment.
Northern ribose
Southern ribose
Figure 1.4. Numbering system of the two possible cADPR structures. Both the N-l 
northern ribose linkage and the N-9 southern ribose linkage are in the P configuration.
1.3.2.1 cADPR as a Calcium Releasing Second Messenger.
cADPR induces calcium release, independent of the IP3 pathway, in diverse cellular 
systems including smooth muscle, skeletal muscle, cardiac muscle, neuronal and neuronal- 
related cells, hemopoietic cells, acinar cells and in the oocyte.39 It was also reported that 
cADPR promotes calcium release in protozoa and plant cells, which suggests 
cADPR/calcium signaling to be a phylogenetically old and conserved system. cADPR as a 
second messenger however has not been firmly established and the signalling pathway of 
cADPR activation has not been fully identified. It is believed that in Jurkat T-cells, the T 
cell receptor/CD3 complex (TCR/CD3) plays an important role in the generation of 
cADPR.40Upon stimulation of the complex, a soluble ADP ribosyl cyclase is activated and 
in turn it initiates a sustained release of cADPR. This soluble protein in the cytosol is 
different from the known ADP ribosyl cyclase, such as the soluble one purified from 
Aplysia califomica or the membrane bound CD38 in mammalian cells. The unique
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property of this soluble enzyme is that it did not use as a substrate nicotinamide guanine 
dinucleotide (NGD+). It was reported that G-protein coupling and tyrosine phosphorylation 
have also been implicated in ADP ribosyl cyclase activation .41
As a result of the TCR/CD3 activation, cADPR is released as a second messenger that 
interacts with receptors on the membrane of the intracellular stores. The receptors activated 
by cADPR are proposed to be the ryanodine receptors (RyRs). The interaction between 
cADPR and the RyR was initially established based on the fact that the cADPR induced 
calcium release from internal stores is sensitive to the pharmacological inhibitors of RyRs 
such as ruthenium red or inhibitory concentrations of ryanodine.42More evidence came 
from the molecular knock-out of RyR type 3 in T-lymphocytes, which resulted in a 
significant reduction of the cADPR induced calcium release .43
The Ryanodine receptors calcium channel complex is a homotetramer, of which each 
monomer has a molecular weight about 550 kDa.^There are three isoforms of RyRs 
known so far: RyR type 1 existing in mammalian skeletal muscle;45RyR type 2 that shows 
6 6 % identity with the type 1 receptor is expressed in brain and cardiac muscle; RyR type 3 
which has 67% identity with the type 1 receptor, is located in the brain and at low levels in 
many other tissues. In sarcoplasmic reticulum (SR) of bird and fish, there exists two other 
isoforms of ryanodine receptor .46 The a  receptor shows 80% identity with the RyR type 1, 
while the P isoform shows 8 6 % identity with the RyR type 3.
1.3.2.2 Binding Protein of cADPR
The mechanism of cADPR induced calcium release through type 2 and/or type 3 RyR is 
not yet adequately investigated and a direct binding site of cADPR on RyRs has not been 
reported. Some studies suggested that cADPR might not directly interact with RyRs on the 
membrane of the intracellular calcium stores but interact via a binding with cADPR 
binding proteins (cADPR-BP) .47 In attempts to identify the cADPR-BP, radio active [32P] 
8 -N3-CADPR was used to label putative binding proteins in sea urchin eggs47and proteins 
with molecular weight about 100 and 140 kDa were screened. These proteins are either the 
proteolytic fragments of RyRs or distinct binding proteins that connect the cADPR with 
the RyRs. In some cellular systems, FKBP 12.6, a binding protein of the 
immunosuppressive drug FK 506, was suggested to be the binding protein of cADPR and 
the specific binding of cADPR to FKBP 12.6 was demonstrated.48A putative model was 
established to explain the mechanism of FKBP mediated calcium release, in which binding
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of FKBP 12.6 with RyR results in a decrease o f its open probability while binding of 
cADPR to the FKBP triggers a conformational change and therefore results in the release 
of the binding protein and opening of the calcium channel.
In addition to cADPR binding proteins, there are other accessory proteins. For example the 
calcium sensor calmodulin (CAM) is involved in the process of cADPR induced calcium 
release. It has been reported that CAM is involved in the feedback of calcium on ion 
channels and specific calcium channels. In most case CAM behaves as a channel subunit, 
interacting with the channel at low calcium concentration. When binding with calcium 
ions, CAM undergoes conformational changes to interact with a different part of the ion 
channel, in turn regulating its gating.
1.3.2.3 Metabolism o f cADPR
In biological systems, cADPR is synthesised by ADP ribosyl cyclases (ADPRC). The first 
identified ADPRC is a soluble protein purified from Aplysia califomica ovotestis and this 
ADP ribosyl cylase was cloned49,50 and its structure was determined by Lee et a / .51 In 
mammalian cells, however, it was a problem to determine how cADPR was produced, 
because the enzymes underlying the synthesis of cADPR had not been identified until 
approximately 10 years ago. The first mammalian ADP-ribosyl cyclase CD38 was 
identified by several groups and shortly after a second mammalian ADP-ribosyl cyclase 
CD157 (BST1) was purified and cloned .53 CD38 is known as a plasma membrane protein 
expressed widely in hematopoietic cells.54Protein sequence analysis revealed that it was 
highly homologous to the cytosolic Aplysia  ADPRC at the extracellular 
domain.55Differently from Aplysia ADP-ribosyl cyclase, CD38 transforms its substrates 
largely to the hydrolysed products, while it was well established that Aplysia ADP-ribosyl 
cyclase produces only the cyclic products under standard conditions. Similar to CD38, 
CD 157 also leads to largely the hydrolysis products. Aplysia ADP-ribosyl cyclase and 
CD 157 share remarkable similarity in their three-dimensional structures, while for CD38, 
since the cry stall ographic data for the full-length enzyme is not yet available (crystal 
structure of CD38 extracellular domain is recently published56), the structural similarity 
between CD38 and Aplysia ADPRC is therefore not directly demonstrated. However, 
because of the high protein sequence homology between CD38 and Aplysia ADPRC and 
the excellent alignment of the conserved cysteine residues, a hypothetical three- 
dimensional model was established for CD38 and the key residues of this enzyme were 
identified .57 Another enzyme NAD+ glycohydrolase was also reported to catalyse the
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formation of cADPR .58 Classified as a multifunctional enzyme, NAD+ glycohydrolase 
catalyses both the hydrolysis and cyclisation of NAD+, where of course, the classical 
“hydrolase” function is dominant and hydrolysis compounds are therefore the major 
products. For all of these enzymes, formation of cADPR or the hydrolysis product ADPR 
is achieved through an enzyme-substrate intermediate. Two models of this intermediate 
were reported so far. Both the models were established according to the understanding that 
the nicotinamide moiety of NAD+could be spontaneously cleaved at acidic or neutral pH. 
In presence of ADPRC, the cleavage leads to an enzyme-oxocarbenium ion transition state 
in which the ribosyl C -l” adopts an sp2 like structure that is ready to undergo further 
nucleophilic attack. In the first model a covalent bond is formed linking the ribosyl C -l"  to 
the Glu226 of CD38 (Glu 179 for Aplysia ADPRC), while in the second model the 
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Figure 1.5 Molecular mechanism of the reactions catalysed by ADPRC. Two models 
are proposed to demonstrate the enzyme-substrate intermediate; model 1 is stabilized 
through a covalent bonding while model 2 was stabilised via an ion pair. Drawing is based 
on the report published by Schuber et a l 59
There are a number of experimental observations that favour the stabilised ion-pair model. 
It was found that the methanolysis and transglycosidation reactions catalysed by CD38
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occurred with retention of configuration, indicating that the reactions m ust occur through a 
stabilising ion pair intermediate, in which the a-face of the northern ribose is shielded by 
the stabilising residue, thus leading to exclusive p-selectivity. However, the covalent 
intermediate model was also supported by different research groups,60’61 and was later 
confirmed by Lee et u/51 since they observed a covalent bond, linking the “catalytic 
residue” G lul79 with the ribose-5'-phosphate in their X-ray studies. A more recent X-ray
69crystallographic study by Lee et al, however, is rather in favour of the ion pair stablising 
intermediate. It was observed that when incubating CD38 with NGD+ at low temperature a 
stablising ion-pair intermediate could be trapped and observed. So far, both intermediate 
models were supported by evidence and a thorough debate is beyond the scope of this 
thesis. To simplify the drawing, the covalent bond model is favoured in our project and is 
used in the enzymology studies discussed in later chapters.
In the enzyme-substrate intermediate, the substrate is aligned in a hairpin conformation, 
which allows only specified positions of the base moiety to accomplish the nucleophilic 
attack on the ribosyl C -l". Three possible reactions could occur from this intermediate. For 
the NAD+ analogues, a N1 cyclization occurs to form the cADPR analogues; for the 
nicotinamide guanine 5 '-dinucleotide (NGD+) or nicotinamide hypoxanthine 5'- 
dinucleotide (NHD+) derivatives, a N7 cyclisation happens to produce the cGDPR and 
cIDPR analogues; for other pyrophosphates that cannot cyclise, a hydrolysis reaction 
occurs leading to the ADPR analogues. The details of ADPRC catalysed reactions will be 
further discussed in chapter two. The cADPR produced by ADP-ribosyl cyclase acts as a 
second messenger to induce calcium release from the intracellular calcium stores. After 
this calcium release, it is assumed that cADPR is degraded by cADP-ribose hydrolase to 
ADPR, a metabolite lacking the ability to trigger further calcium release. Although ADPR 
has been reported to also mediate calcium influx by activating TRPM2, ■ a member of the 
TRP family of calcium influx channels, it is not likely that the amount of ADPR generated 
from cADPR degradation could stimulate the activation of TRPM 2 because the 
intracellular cADPR exists in low concentration while activation of TRPM2 requires 
higher concentrations.
1.3.2.4 Summary of cADPR Induced Calcium Release
The role of cADPR as a second messenger to trigger the calcium release from intracellular 
store is widely accepted. However, the signaling pathway and the enzymes responsible for 
the synthesis of cADPR are not fully understood. In mammalian cells, CD38 and CD157
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are the enzymes involved in the generation of cADPR. It is interesting to note that the 
catalytic sites of these two enzymes are located outside the cell or in the intracellular 
vesicles. This leads to a situation that intracellular NAD+ cannot directly interact with the 
active site of CD38 and the synthesised cADPR cannot contact the calcium release 
channel. This situation is know as the ‘topological paradox’.^D e Flora and his colleagues 
figured out a putative signaling pathway for CD38 to solve this problem. Intracellular 
NAD+ first leaves the cell via connexin 43 hemichannels65and then interacts with the 
extracellular catalytic site of CD38 triggering the release o f cADPR. As we mentioned in 
last section, CD38 leads mainly to the hydrolysis product ADPRC (>98%). It is also true 
that CD38 produces a small amount of cADPR (<2%) and this cADPR is transported back 
to the cytosol through either CD38 itself66or nucleotide transporters,67then interacting with 
RyRs or the cADPR binding proteins to promote calcium release. This signaling pathway 
for CD38 and CD157, although explaining the transport of NAD+and cADPR across cell 
membranes, still has drawbacks. One of the problems for this pathway is that the connexin 
43 hemi-channel only opens for NAD+ at conditions where the concentration of 
intracellular calcium is around 100 nM. This indicates that the transport system is not 
likely to work when calcium is elevated above basal level (normally 50-100 nM, which is 
controlled by a ATP-driven calcium pump). Another question is why Nature chooses such 
a complicated system to regulate the important calcium signaling rather than a simpler 
one? This CD38 signaling system, however, also has advantages. For example, cADPR 
synthesised in this way could serve as a paracrine messenger,68which could be taken by 
other cells via the nucleotide transporters.
A simpler calcium-signaling pathway has also been proposed. In this pathway, cADPR is 
synthesised through a soluble cytosolic ADPRC and then interacts with RyRs. This soluble 
ADPRC, as mentioned earlier in Jurkat T cells, is different from the membrane bound 
CD38 and CD37. The soluble cytosolic ADPRC was also found in pancreatic acinar 
cells .69 Both the CD38 (CD 157) signaling pathway and the soluble ADPRC signaling 
pathway are shown in Figure 1.6 . Other cellular functions including cADPR degradation, 
calcium release triggered by ADPRC etc are also demonstrated in this figure.
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Figure 1.6 Summary of cADPR induced calcium release.
1.3.3 NAADP and its Receptors
NAADP, a derivative of NADP, was first identified as the most potent calcium releasing 
second messenger in sea urchin eggs approximately a decade ago. Thereafter, it has been 
reported to be active in a great variety of organisms from plants to human. NAADP 
(structure see Figure 1.1) induced calcium release is distinct from that triggered by the 
other second messengers, IP3 and cADPR and it cannot be modulated by divalent cations 
including calcium itself. As the most potent calcium releasing second messenger, NAADP 
triggers calcium release from intracellular stores at low nanomolar concentrations. The 
second messenger property of NAADP is now proved by a number of publications. It is 
found that NAADP is generated in cells that are stimulated by external physiological 
stimuli. For example NAADP was synthesised in sea urchin sperm when contacts with egg 
jelly70and NAADP was produced in pancreatic P cells upon treatment with an increased 
glucose concentration .71 Several other proofs to confirm NAADP as a calcium mobilising 
second messenger have also been published by Galione et al.72'73
In sea urchin egg homogenate, a unique inactivation property of NAADP was observed. 
Incubation of sea urchin eggs with a sub-threshold concentration of NAADP results in a 
complete blockage of further NAADP stimulation74 and even with a normally maximal
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concentration of NAADP, no detectable calcium release could be observed. This 
inactivation of NAADP, different from that o f IP3 and cADPR, is actually irreversible and 
no recovery has been reported in the egg homogenate; while in the intact see urchin egg, 
the cell recovered from the inactivation in 20 min. The mechanism of this recovery is 
currently not known. Several models have so far been proposed to explain the inactivation, 
in one of which a NAADP receptor with two different binding sites was proposed and 
interaction with the high affinity binding site leads to the inactivation, while interaction 
with low affinity site initiates the calcium release. In mammalian cells, for example the 
pancreatic acinar cell, NAADP induced inactivation is much different from that in sea 
urchin eggs. Not the low concentration of NAADP, but the high concentration o f NAADP 
(micromolar level) triggers the inactivation. The “bell-shaped” concentration response 
curve for NAADP is therefore the hallmark of NAADP released calcium release in 
mammalian cells.75
The mechanism of NAADP induced calcium release is now under intense scrutiny. 
Although we still don’t know the underlying signaling pathway and the precise NAADP 
binding receptors, several hypotheses have been put forward to explain the calcium release 
evoked by NAADP. One hypothesis proposes a “trigger mechanism” that NAADP 
interacts with an unknown calcium release channel to initiate a localised calcium  release, 
which in turn triggers a global release of calcium through interaction with IP3 receptors or 
RyRs by a mechanism known as CICR .76 This hypothesis is based on the fact that 
antagonists that block IP3 and cADPR mediated calcium release also block NAADP 
induced calcium release but, on the other hand, antagonists of NAADP induced calcium 
release have no effect on other second messengers. Another hypothesis published by Guse 
et al indicated that NAADP might directly interact with RyRs in Jurkat T  cells ,77 since 
m olecular knockdown of RyRs type 3 greatly reduces the NAADP induced calcium 
release. This process could not be explained by the “trigger hypothesis”, since no localised 
calcium release was observed in this experiment. In contrast to the direct interaction 
hypothesis, there are several other papers published by different research groups indicating 
that antagonists of RyRs did not abolish the NAADP induced calcium release .78,79
In order to understand the molecular mechanism of NAADP induced calcium  release, 
identification and purification of the NAADP binding protein is of vital importance. So far, 
a radio-labeled [32P] NAADP has been used to tag desired proteins from the homogenate, 
which may possibly lead to the identification o f the NAADP receptor.80 On the other hand,
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affinity resins are routinely used to separate and identify the protein/receptors. However, 
the difficult synthetic route and unstable nature of NAADP analogues marred the effort of 
immobilising those compounds on affinity resins. Our group recently synthesised a library 
of small molecules, some of which demonstrate interesting ability to inhibit the NAADP 
induced calcium release. These small molecules are valuable tools to study the mechanism 
of NAADP induced calcium mobilisation and could possibly be used as affinity tags to 
isolate the NAADP receptors. M ost importantly, these small molecules may have potential 
to be utilised in the pharmaceutical area vide infra.
1.4 Medicinal Chemistry and Pharmacology of cADPR Analogues.
As a biologically important compound, cADPR is now under intense scrutiny. Numerous 
analogues have been synthesised, either through a chemoenzymatic method or by total 
chemical synthesis. Modifications have been made on the southern ribose, northern ribose, 
the nucleoside base moiety and even the pyrophosphate, leading to a variety of 
compounds, which serve as agonists as well as antagonists of cADPR induced calcium 
release. These compounds are vital tools to study the molecular mechanism of cADPR 
induced calcium release from intracellular calcium stores and some of the compounds 
could be used as leading molecules for the development of future drugs.
1.4.1 Chemo-enzymatic Synthesis of cADPR Analogues
The first generation of cADPR analogues was synthesised using the chemo-enzymatic 
approach which relies on the loose substrate selectivity of the cADPR producing enzyme,81 
Aplysia ADP ribosyl cyclase. The soluble ADPRC from Aplysia califom ica  was adopted 
as the catalysing enzyme because this enzyme is commercially available and also this 
enzyme gives nearly 100% of cyclic products for the NAD+ substrate. In this chemo- 
enzymatic strategy, the key intermediate NAD+ analogues are either synthesised 
chemically or enzymatically. NAD+ has been synthesised from ATP 6 enzymatically using 
NAD+ pyrophosphorylase,82and the ATP was produced from AM P through a combined 
action of adenylate kinase and creatine kinase. This enzymatic approach, however, is not 
applicable to all NAD+ analogues and suffers from the relatively strict selectivity of the 
enzymes involved in the synthetic route. For example, 8-substituted AMP analogues are 
bad substrates for adenylate kinase and the 8-bromo-ATP could not be catalysed by NAD+ 










Figure 1.7 Enzymatic synthesis of cADPR analogues. Drawing is from published 
data.82
Compared to the full enzymatic synthesis, chemical synthesis will provide more varieties 
of NAD+ analogues. In the chemical method, NAD+ analogues are synthesised by the 
condensation of corresponding AMP analogues with (3-nicotinamide mononucleotide (p- 
NMN+) using the carbodiimide84or diphenylphosphate anhydride derivative85as the 
coupling reagents. Alternatively, coupling of an active intermediate, such as AMP
RA 07
morpholidate or imidazolate instead of the monophosphate itself, with nicotinamide 5'- 
mononucleotide (p-NMN*) will greatly increase the reaction rate and the final yield of 
NAD+ analogue. All of these coupling reactions, however, rely on the commercially 
available, but expensive, p-NMN* 7, which limits the application of these coupling 
reactions in large-scale synthesis. Total chemical synthesis of p-NMN+ has therefore been
88 89 90attempted by several groups, ’ ’ and Lee et al published a synthetic route in which the 
P-NMN+ was synthesised in 5 steps in relatively good yield91 (Figure 1.8).
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Figure 1.8 Synthetic route towards P-NMbT.
Tanimori et aP2 also reported a synthesis of p-NMN+ via compound 11, which was 
synthesised in more than 58% yield by Vorbriiggen condensation of the nicotinamide and 
the ribose tetra-acetate using TMSOTf as the catalyst. A more ambitious method was also 
reported where a Zincke route was adopted to form the linkage between the ribose 5 -  
phosphate and the nicotinamide (Figure 1.9).90This method, although it cleverly bypasses 
the seemingly inevitable phosphorylation step, has its own drawbacks. Lacking of control 
of the stereochemistry, this method produces the final compound in both the p 
configuration and a  configuration. It is unfortunately difficult to separate these from each 
other. For all the chemically synthesised p NMlSf, purification has been a real challenge. 
Because the P-NMN+ is only water-soluble and is positively charged, it is impossible to 
separate it from the inorganic salt formed in the phosphorylation step or from the a-N M N+ 
produced in the Zincke route. Combined usage of ion-exchange chromatography and 
reverse phase column will greatly reduce the yield. We, like other groups, mostly rely on 
the commercial p-NMbT in the chemo-enzymatic synthesis of cADPR analogues.
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Figure 1.9 Synthesis of p-NMN* via Zincke route.
1.4.1.1 Adenosine Modified cADPR Analogues
To date, numerous biologically active compounds have been made through the chemo- 
enzymatic approach and their pharmacological activities have been evaluated. The first 
generation of chemo-enzymatically synthesised cADPR analogues were compounds 
modified at the 8 -position of the base moiety. The structures of the 8 -substituted cADPR 
analogues are shown in Figure 1.10. Markedly, instead of triggering calcium release from 
intracellular stores, these 8-substituted compounds were found to competitively block the 
cADPR induced calcium release in the sea urchin egg homogenate system. Among them, 
8 -amino cADPR 16 has the best antagonistic effect, and exhibits an IC50 of 9 nm. By now, 
a great number of studies have proved that 8 -NH2-CADPR plays an important role in 
blocking cADPR induced calcium release in many cellular systems including smooth 
muscle,9T-cell activation,94 sea urchin egg fertilisation,95neurotransmitter
release,96excitation-contraction coupling in cardiac myocyte,97neuronal calcium 
regulation,98pancreatic acinar cells99and abscisic acid signalling in plants. 100It has been 
reported that Aplysia ADPRC also tolerates large substitutions at its substrates. 
Compounds with larger 8 -substitution including the bromo, azido and even the piperidyl 
were also synthesised by the chemo-enzymatic method. 8 -Bromo-cADPR 17, though not 
as active as the 8 -amino cADPR, it was considered to be a valuable tool to study the 
cADPR induced calcium release, since this molecule is membrane permeable.1018 -Azido
cADPR 18 is also an antagonist of cADPR triggered calcium release. Moreover, radio- 
labeled [32P] 8 -azido cADPR has been used as a photoaffinity probe to tag the possible 
cADPR binding protein as we mentioned in previous sections. Two other 8 -substituted 
cADPR derivatives, 8 -methyl cADPR 19 and 8 -methoxy cADPR 20 were also biologically 
evaluated. It was suggested that both the compounds have an antagonistic effect in T
109lymphocytes. "With a more bulky piperidyl substitution, the cADPR analogue becomes 
inactive which probably reflects the fact that although ADPRC cyclises almost everything, 
the RyRs could not accommodate large substitutions on its ligands. Apart from the 8 - 
position modification, other positions of the base have also been altered. 7-Deaza-cADPR 
21 is a partial agonist, which is about 3 fold less potent than cADPR in the L. pictus egg 
system (EC50 90 nM) and is about 3 fold more active than cADPR in the S. purpuratus egg 
system (EC50 25 nM). In addition, 7-deaza-cADPR is hydrolysis resistant. 1037-Deaza-8- 
bromo cADPR 22 is a cADPR analogue modified both at the 7- position and 8 -position. It 
has been reported that 7-deaza-8-bromo cADPR is a hydrolysis resistant, membrane 
permeable antagonist. In sea urchin eggs, 7-deaza-8-bromo cADPR is about 2 fold more 
potent than 8 -bromo-cADPR. 101 3-Deaza-cADPR 23, unlike the 7-deaza counterpart, is a 
full agonist with an EC50 of 1 nM in S. purpuratus system and, compared to cADPR, this 
compound is 70 times more potent. As reported by W agner et al, 8 -bromo substituted 
NHD was cyclised at the N1 position instead of conventional N7 position for NHD. The 
resulting 8 -bromo-cIDPR acts as a membrane permeable agonist in Jurkat T cells. 104
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Figure 1.10 Structures and activities of base modified cADPR analogues.
1.4.1.2 cADPR Analogues Modified in the Southern Ribose
Many cADPR analogues have been modified in the southern ribose. It has been reported 
that the 3'-hydroxyl group is essential for the biological activity of the cADPR analogues. 
Replacing the 3'-hydroxyl group with hydrogen will greatly reduce the calcium release 
activity. Analogues with a phosphate at the 3' position or a 2\3'-cyclic phosphate are 
inactive. 1(bThe fact that 3 -methoxy cADPR 25 is an antagonist leads to a hypothesis that 
the 3 -hydroxyl group may be required for calcium release, but not for ligand binding. 
Different from the 3' modifications, removal of 2'-hydroxyl groups does not weaken the 
calcium release ability of cADPR analogues. Structures of these southern ribose modified 




X = OH, Y = H, 3'-deoxy-cADPR 24 
X = OH, Y = OMe, 3‘-methoxy-cADPR 25 
X = H, Y = OH, 2-deoxy-cADPR 26
Figure 1.11 Structures of cADPR analogues modified in the southern ribose.
1.4.1.3 cADPR Analogues Modified in the Pyrophosphate Moiety
To date, a few pyrophosphate-modified cADPR derivatives have been produced and 
biologically evaluated. Treatment of cADPR with l-(2-nitrophenyl)
caging group on one of the two phosphate moieties. This caged cADPR 27 (Figure 1.12) is 
inactive, but can release biologically active cADPR under UV light by breaking the caging 
group.
cATPR (cyclic adenosine triphospho-ribose) has also been synthesised and
northern riboses. It was found that the cATPR was 30 fold more potent than cADPR in rat 
brain microsomes. Another pyrophosphate modified cADPR analogue is the cADPR(CH2) 
28 (Figure 1.12), which contains a methylene group replacing a oxygen between the two
system indicating that the pyrophosphate is essential for the calcium release activity. 
Markedly, even with a modified pyrophosphate, the linear precursors of cATPR and 
cADPR(CH2) have also been cyclised, revealing a truly broad selectivity of ADPRC.
Figure 1.12 cADPR analogues modified in pyrophosphate.
Although the chemo-enzymatic approach allows us to synthesise most of the bioactive 
cADPR analogues, this method has its drawbacks. The major disadvantage of the chemo- 
enzymatic method is the limited selectivity of the ADPRC. Though ADPRC has a 
relatively broad selectivity, it cannot always produce the N1 linkage between the northern 
ribose and the base. The N1 linkage has been found to be essential for the calcium release 
ability of cADPR analogues. As we mentioned before, ADPRC cyclises NGD+, NHD+ and 
nicotinamide xanthine dinucleotide (NXD+) at the N7 position instead of N l. For some 
NAD+ analogues such as 2-fluoro-NAD+, 2-amino NAD+ and 8 -bromo NGD+, ADPRC 
leads to the hydrolysis reaction, which produces the corresponding ADP ribose as the
I AZ
diazaoethane resulted in a cADPR analogue with a photoactivable 2-(nitrophenyl) ethyl
characterized. 107This cADPR analogue has three phosphates linking the southern and
phosphate. 108 This analogue is a weak agonist with an EC50 of 1000 nM in sea urchin egg
O' OH
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cADPR(CH2) 28caged cADPR 27
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products. Another drawback is that the chemo-enzymatic approach cannot supply cADPR 
analogues with a stable, hydrolysis resistant linkage between Nl and the northern ribose. 
In order to overcome these disadvantages of chemo-enzymatic approach, the total 
synthesis of cADPR analogues has been attempted in the past decade.
1.4.2 Total Synthesis of cADPR Analogues
Chemical synthesis of cADPR itself is not of practical interest since cADPR could be 
easily prepared by enzymatic or chemo-enzymatic synthesis from p-NAD+. Instead, 
considerable efforts have been devoted to the total synthesis of the cyclic ADP- 
carbocyclic-ribose (cADPcR) 29 and related compounds such as cIDPcR. In these 
analogues, the ring oxygen in the northern ribose is replaced by a methylene group, 
resulting in a stable Nl-ribosyl linkage, which is resistant to both enzymatic and chemical 
hydrolysis. These carbocyclic analogues cannot be synthesised from either the enzymatic 
or the chemo-enzymatic method, because in theory the formation of the Nl-ribosyl linkage 
proceeds through an oxocarbenium intermediate (section 1.3.2.3) which, however, is not 
possible to form for these carbocyclic analogues. Indeed, ADPRC was not able to cyclise 
the NAD+-type precursor having a carbocyclic northern ribose. 109 The strategy to 

















Figure 1.13 Strategy for synthesising cADPcR anlogues. The northern carbocyclic- 
ribose synthon 31 was synthesised from a commercial available chiral compound 32 in 4 
steps. Drawing based on the literature. 110
Early attempts to chemically cyclise the bisphosphate precursor 30 using water-soluble
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carbodiimide EDC failed.11’it was assumed that the conformation of the precursor might 
determine whether or not the intramolecular condensation between the two phosphate 
groups occurred. The syn-anti conformation around the glycosyl linkage has been 
recognised as an important determinant of the three dimensional structure of the 
nucleosides. Although the ^vn-conformation in the bisphosphate precursor facilitates the 
intramolecular condensation, as in this conformation these two phosphates are closer to 
each other, the natural dominating anti-form, which has two phosphates group apart from 
each other, makes this condensation not successful. Shuto et al made real progress in total
119synthesis in 1998. "By introducing a bulky bromo group at the 8 -position of the inosine 
base, they reorientated the dominating anti-form around the glycosyl linkage, into the syn- 
form,113which therefore promoted the cyclisation between the two phosphates in the 
precursor. The anti and .sy/i-form are shown in Figure 1.14.
N
O P ° 3 2' 0 P 0 32-
N
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X = H, anti > syn 
X = Br, anti < synd .0
Figure 1.14 The synlanti conformation of the 8 -substituted bisphosphates.
The sy«-form 8 -substituted bisphosphates was cyclised successfully in 23% yield using 
EDC (l-ethyl-3-(3-dimethylaminopropyl) carbodiimide) and, after hydrogenolysis and 
deprotection, cIDPcR was obtained as the first carbocyclic analogue prepared by total 
synthesis. In order to increase the yield of the key intramolecular condensation step, a 
AgNO^ or E-mediated coupling reaction was explored. With pyridine as the reaction 
solvent, the phenylthiophosphate-type precursors (Figure 1.15) were cyclised in more than 
90% yield. Notably, this AgNO.VE mediated reaction also worked for substrates without 
conformational restriction, namely substrates in their anti-forms . 114
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Figure 1.15 AgNO.i or F  mediated cyclization of phenylthiophosphate substrates
So far, a very efficient total synthesis method for preparing cIDPcR, 8 -modified cIDPcR 
and cADPcR has been established. This chemical method alone or in combination with 
earlier developed chemo-enzymatic methods offers a unique access to wide variety of 
cADPR analogues, which are now being used in studying the mechanism of cADPR 
induced calcium release and other events that are of importance in biology and 
pharmacology.
1.5 Chem istry and Structure Activity Relationship of NAADP
Despite being the most potent calcium releasing second messenger known so far, the 
molecular mechanism of NAADP induced calcium release, however, has not been 
efficiently investigated. It is clear that further understanding of NAADP biology heavily 
relies on the development of selective molecules to probe novel signalling pathways and 
the NAADP binding proteins. NAADP and a small group of analogues have been 
generated by a chemo-enzymatic route, in which an ADPRC mediated base exchange was 
applied to replace the nicotinamide moiety with nicotinic acid analogues. Clearly, the 
chemistry that can be performed on this unstable molecule and the compatibility with the 
enzyme limits the range of available analogues. A synthetic route however could provide a 
wider range of NAADP derivatives, such as non-hydrolysable analogues, that could not be 
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Figure 1.16 ADPRC mediated base-exchange reaction. A group of NAADP analogues 
(including NAADP itself) were synthesised, biologically evaluated and were used to 
establish the SAR of NAADP.
Dowden et al] 15explored a synthetic route towards NAADP and its derivatives. After 
selectively protecting both 3' and 5'-hydroxyl groups, phosphate group was successfully 
introduced onto the 2-position. The 5'-hydroxyl group was selectively released and 
phosphorylated producing the 2'-phosphate AMP analogue in a relative high yield. Similar 
to the synthesis of NAD+-type molecules, the linear precursors of cADPR analogues, a 
coupling reaction between p-NMN* and the 2 '-phosphate AMP analogue was performed to 
produce the desired pyrophosphate linkage. Clearly, the presence of the 2'-phpsphate on 
the ribose makes the synthesis of NAADP more complex in terms of the reaction 
selectivity and the stability. With carefully selected protecting groups, the 2'-phosphate 
was successfully protected before the coupling reaction and was released afterward without 
breaking the newly formed pyrophosphate bond. After successfully producing the 
precursor NADP, the final compound NAADP, however, was synthesised by an ADPRC 
induced base-exchange reaction, because the attempts to seek chemical conversion of 
nicotinamide to nicotinic acid all failed. Although this synthetic route provides a chemical 
method to produce NAADP, it is considerably difficult and therefore is not suitable to 
prepare a great number of NAADP derivatives in order to probe the NAADP binding 
proteins. We recently designed and synthesised a library of small molecules based on the 
SAR of NAADP established by Lee and his colleagues. These small molecules have been 
tested in vitro and in vivo, presenting interesting inhibition effects on NAADP induced 
calcium release, therefore indicating a tight binding with the as yet unknown NAADP 
receptors. More detailed information will be introduced in later chapters.
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The SAR of NAADP (Figure 1.17) was established based on the biological activities of the 
first generation of NAADP derivatives, which were synthesised using the base-exchange 
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Figure 1.17 Brief SAR of NAADP. Three structural features were identified for 
effective calcium release of NAADP: 1) pyridinium ring and the 3-position carboxylic 
acid; 2) the amino group on the purine base; 3) the 2'-phosphate group.
It was found that three structural units are critical to the activity of NAADP. The first one 
is the negative charge at the 3-position of the pyridinium ring. Elimination of the charge or 
changing to the 4-position completely abolishes calcium-releasing activity. It has been 
indicated that this site has some tolerance towards the size of the group containing the 
negative charge. The more bulky the charge is, the weaker the analogue is to trigger the 
calcium release from intracellular stores. The second important site of activity is the 2'- 
phosphate. Removal of this phosphate leads to inactive NADP analogues. The NAADP 
type of molecule retains activity whether the phosphate is on 2'- or 3'-position or cyclically 
linked to both phosphates. The third important site is the amino group at the 6 -position of 
the adenine moiety. Conversion of NIL to OH reduces the calcium release ability by 
approximately 1000 fold, even though OH is about the same size as NH2. These SAR study 
results indicate that the NAADP induced calcium release is highly specific and is 
consistent with it being mediated by a high affinity receptor(s).
1.6 Aims of This Project
In order to further investigate the novel mechanism of cADPR and NAADP induced
calcium release from intracellular stores, biologists and pharmacologists require
structurally modified compounds that are membrane permeable, hydrolysis resistant and
excellent antagonists. From the medicinal chemistry point of view, potent antagonists can
be used as lead compounds to design molecules that could be of pharmaceutical value.
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Thus, the main objective of this project is to design and synthesise antagonists that can 
selectively block the cADPR and NAADP triggered calcium release. Compounds that can 
competitively inhibit ADP-ribosyl cyclase activity are also targeted in this project. These 
inhibitors might lead to a better understanding o f the mechanism of ADP-ribosyl cyclase 
catalysed enzymatic reactions, then facilitate the design and synthesis of new 
pharmacologically important molecules; also, These inhibitors might be useful tools to 
further investigate the second messenger properties of cADPR and the mechanism of 
cADPR induced calcium release. To fulfil the above targets, we thus have the following 
plan for this project.
a) Some structurally modified NAD+ analogues have been earlier identified as the ADP- 
ribosyl cyclase inhibitors. We therefore also plan to synthesise NAD+ analogues, especially 
non-cyclisable NAD+ analogues as potential ADPRC inhibitors.
b) We also plan to design and synthesise 8-modified cADPR/2'-deoxy-8-modified cADPR 
analogues as potential antagonists of cADPR-sensitive calcium release and investigate 
their biological activities. This will serve to investigate the potential key role played by the 
2 '-hydroxyl group in cADPR and analogues.
c) As modifications on the NAADP molecule are greatly limited by their difficult synthetic 
approach and poor stability, we thus plan to design and synthesise small molecule, 
membrane permeable NAADP analogues and to investigate their activities as antagonists 
of NAADP induced calcium release, in vitro and in vivo.
The broader aims of this project are to design and synthesise any nucleotide related 
molecules, which have the potential to modulate the cADPR and NAADP induced calcium 
signalling.
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CHAPTER TWO: SYNTHESIS OF NON-CYCLISABLE NAD+ 
ANALOGS AS APLYSIA ADP-RIBOSYL CYCLASE INHIBITORS 




To date numerous structurally modified NAD+ analogues have been synthesised and
biologically evaluated. Among these, some were identified as inhibitors of ADP-ribosyl
cyclase. For example, ara-F-NAD+, an arabino analogue of NAD+, has been synthesised
by Sleath et alu land reported to inhibit the activity of CD38 with its inhibition constant
118(iQ  value at nanomolar level. This arabino analogue has been found to function via a 
slow-binding mechanism, demonstrating the 2-O H  of the nicotinamide-ribose moiety as a 
important motif for the binding of this compound with CD38.118 Two other NAD+ 
analogues NHD+ and NGD+ have also been reported to inhibit competitively the Aplysia 
ADP-ribosyl cyclase and the inhibition constants (Kj)  of these two molecules are calculated 
as 70 and 142 nM, respectively.119 Slama et al reported their pseudo-carbocyclic NAD+ as 
a classical linear competitive inhibitor of the NAD+ glycohydrolase.120 It was found that 
NGD+ and NHD+ were only slowly transformed by the cyclase to produce inactive N7 
cyclised molecules and pseudo-carbocyclic NAD+ was not hydrolysed by CD38 because it 
cannot form the enzyme-substrate intermediate occurring in cleaving the nicotinamide. 
These inhibitors were also found to have high affinity with their enzyme for example 
NGD+ and NHD+ have K m values of 8.8 and 15.5 pM , which are close to that of the 
naturally occurring substrate NAD+ 4.6 pM. From above findings a conclusion can be 
made that to be an inhibitor, a molecule needs to have high affinity with respect to the 
enzyme and also to have structural features to perturb the corresponding enzyme function, 
in turn blocking the formation of corresponding enzymatic product. In the light of these 
findings, we have designed and synthesised a small library of non-cyclisable NAD+ 
analogues, which share great structural similarity with the natural substrate NAD+ (high 
affinity), but with either electronic or steric perturbations on the molecule, designed to 
impede the cyclase mediated N l or N7 cyclisation. It is highly possible for these molecules 
to form a stable enzyme-substrate intermediate and therefore to inhibit the Aplysia cyclase 
catalysed tranformation of NAD+ to cADPR, thus blocking the cADPR-induced calcium 
release. These molecules are also potential tools to study the molecular mechanism of 
ADP-ribosyl cyclase-mediated enzymatic reactions. Being non-cyclisable, these 
compounds are possible to amplify the hydrolysis function of ADP-ribosyl cyclases, 
especially for Aplysia cyclase, whose hydrolysis activities are otherwise masked by the 
prefered cyclisation reaction. The general synthetic route of these non-cyclisable NAD+ 
analogues is shown in Figure 2.1.
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Figure 2.1 Retrosynthesis of base modified NAD+ analogues.
To date, synthesis of NAD+ and its analogues from the corresponding nucleotides is still a 
difficult process. The amount of chemical reactions that can be applied to synthesise these 
NAD+ analogues is greatly limited by the nature of the pyrophosphate bond. These 
compounds are highly water soluble due to the presence of the ionised hydroxyl group in 
the pyrophosphate bond, the positive charge on the nicotinamide moiety and the hydroxyl 
groups of the riboses and thus are not soluble in organic solvent without protecting these 
structural features. These NAD+ analogues are also prone to rapid degradation by cleaving 
the nicotinamide moiety or breaking down the pyrophosphate bond at elevated temperature 
and non-neutral pH. Therefore, only considerably mild conditions can be used for the 
purpose of generating NAD+ analogues. It is for these reasons that the formation of the 
final NAD+ analogues is often the final step of the chemical synthesis and several 
methodologies have been developed to facilitate such syntheses. Methodologies for 
coupling the modified nucleotide b (Figure 2.1) with P-NMNf are outlined in this chapter.
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Todd et al ~ published the first chemical synthetic route towards a biologically important 
coenzyme ATP in which the tetraester of the pyrophosphate bond of ATP was produced 
via a coupling reaction of adenosine 5'-benzyl phosphate silver salt with dibenzyl 
phosphorochloridate. This synthetic method was later modified and used to generate the 
pyrophosphate-containing inositol polyphosphates (PP-InsPn).I22The phosphate diester 33 
lithium salt was directly coupled with dibenzyl chlorophosphonate to form the protected 
pyrophosphate. Desired product 34 was produced after hydrogenation and was purified by 
ion-exchange chromatography in 6 8 % over 2 steps. (Figure 2.2).
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Figure 2.2 Synthetic method of PP-InsPn (34).
Real NAD+ analogues were produced by a method modified from the above synthesis. In
10'?the modified method, known as the Michelson procedure ‘, diphenyl phosphochloridate 
(DPPC), instead of dibenzyl phosphorochloridate was adopted as the coupling reagent to 
generate the protected pyrophosphate, which was then attacked by the 5 '-phosphate of the 
p-NMNT, leading to the formation of NAD+ analogues. This method also works well when 
the p-NMN+ was first activated by DPPC and then reacted with corresponding nucleotides.
2-Azido-NAD+ 36 was successfully synthesised as a photoprobe using this DPPC method 
by Kim et al (Figure 2.3b) . 124 The tri-n-octylammonium salt of p-NMN* was first activated 
by addition of DPPC to form the product 35, which was then reacted with 2-azido-AMP 37 
to yield the asymmetrical pyrophosphate 36. Using the same Michelson method, several 
other NAD+ analogues have been synthesised and biologically evaluated. 8 -Azido-carba- 
NAD+ 38 and its isomer 8 -azido-pseudocarba-NAD+ 39 were synthesised to serve as 
photoaffinity labels. 125 Pseudo-carba-NAD+ 40 (Figure 2.3a) was also synthesised and this 
NAD+ analogue was demonstrated to be a potent inhibitor for a variety of NAD+ 
glycohydrolases.120 In addition, ara-F-NAD+, a potent inhibitor of CD38, was also 
synthesised by this method. 7-Deaza-NAD+, a precursor for a hydrolysis resistant agonist 
of the cADPR-sensitive calcium channel was also synthesised by this method, illustrating 
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Figure 2.3b Synthesis of 2-azido NAD+ by the DPPC mediated coupling reaction.
Besides the Michelson procedure, several modified NAD+ analogues were also reported to 
be produced by a A^/V-dicyclohexyl carbodiimide (DCC) mediated coupling reaction.126127 
In general, DCC as a coupling reagent first links to the hydroxyl group of the 
monophosphate forming a good leaving group. Subsequently, nucleophilic attack by 
nicotinamide 5 '-mononucleotide (p-NMlSf) promotes the elimination of the hydrated DCC, 
thereby forming the desired asymmetrical pyrophosphate and the insoluble N,N- 
dicyclohexyl urea, which is easy to be filtered out from the reaction system (Figure 2.4). 
Though the DCC mediated reaction was first developed in anhydrous DMF or pyridine, 
later developments in water-pyridine enabled the coupling reaction of some otherwise 
insoluble substrates such as P-NMN+ to form NAD+ analogues. However, as a coupling 
method for synthesising important NAD+ analogues, the DCC method has its 
disadvantages. The major drawback of this synthetic method is that when using equal 
amount of AMP and p-NMN*, both the desired asymmetrical product NAD+ and the 
undesired symmetrical products diAMP 41 and diNMN 42 are generated (Figure 2.4). The 
presence of these symmetrical products not only reduces the yield of the desired NAD+ 
analogues (normally less than 40%), but also makes the purification more difficult. Apart 
from the low yield, this method also suffers from a long reaction time (normally 7 days). 
Clearly, as limited by its reaction mechanism, the synthetic method cannot be further 
optimised in terms of increasing the yield and reducing the formation of symmetrical
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Figure 2.4 Synthesis of NAD+ analogues via DCC coupling.
In addition to the above methodology, a coupling method involving the usage of 
nucleoside 5'-phosphoramidates as the reactive intermediates was reported by Khorana et 
al. 129-130 phosphoramidates 43 (Figure 2.5) were earlier synthesised by the 
condensation of the unprotected nucleoside 5'-monophosphates with amines in the 
presence of dicyclohexylcarbodiimide (DCC). However, the solubilities of these 
phosphoramidates in organic solvents are considerably poor. Pyridine was found to be the 
best medium for the pyrophosphate formation, but of all the nucleoside phosphoramidates, 
only the uridine derivative was soluble and only as an amorphous lyophilized powder.
HO 'OH
43 46
Figure 2.5 Structure of Phosphoroamidates 43 and phosphoromorpholidates 46.
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More soluble phosphoramidates, the phosphoromorpholidates 46, have earlier been utilised 
to synthesise the biological important molecule coenzyme A. To date, 
phosphoromorpholidates were found to be a versatile reaction intermediate and were 
widely used to synthesise NAD+ analogues. The preparation of the 
phosphoromorpholidates has been carefully studied. 131 As was observed for 
phosphoroamidates, formation of these compounds using DCC mediated condensation 
could not always succeed in good yield. The failure of the condensation reaction between 
nucleotides and amines was often caused by a side-reaction, in which amines themself 
were added to the carbodiimide, leading to the formation of the strongly basic 
trisubstituted guanidines. 132 In the case of producing morpholidates, the by-product seen in 
this DCC mediated reaction was 4-morpholine A,A-dicyclohexylcarboxamidine 47. The 
structure of the by-product 47 is shown in Figure 2.6.
/  \
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Figure 2.6 Structure of morpholine AVV-dicyclohexylcarboxamidine (47).
It has been found that this strong base by-product 47 inhibits the reaction of nucleotides 
with the carbodiimide, and in turn blocks the formation of morpholidate .133 This problem 
was later overcome by dropwise addition of DCC in r-butyl alcohol to a refluxing solution 
of nucleotide and morpholine in aqueous r-butyl alcohol. It seems that by having the 
nucleotide and morpholine in place, interaction of DCC with nucleotide is quicker than 
that with morpholidate, therefore promoting the formation of phosphoromorpholidates. In 
order to improve the yield of the phosphoromorpholidate, a condensation reaction 
mediated by triphenylphosphine/dipyridyl disulfide was reported. 134This high yielding 
condensation method was adopted in our work to facilitate the synthesis of nucleotide 
morpholidates and the reaction detail will be discussed later sections. An EDAC (1-ethyl-
3-(3-(dimethylamino)propyl)-carbodiimide hydrochloride mediated synthesis of 
morpholidate-like compounds was also reported. 135 This method however was not used in 
our work.
Though the method involving the coupling of a suitable salt of a sugar phosphate and a 
phosphoromorpholidate has widely been used for the synthesis of various sugar
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nucleotides, the early reaction between P-NMN* and AMP-morpholidate was not 
successful. In order to optimise this coupling reaction, activation methods have been used 
to improve the yield of the pyrophosphate. It has been reported that coupling of glycosyl 
phosphate triethylammonium salt 48 with a nucleoside phosphoromorpholidate is very 
slow and yields rarely exceed 70% and, GDP-Fuc is formed in particular only in 20-50% 
yield.136 It is reasoned that the morpholino group in the phosphoromorpholidate must be 
protonated before acting as a leaving group. But in the reaction system the only proton 
source present probably are the counterions (triethylammonium salt or morpholinium salt), 
which have the pATa value of 10-11, therefore slowing down the protonating process. 1H- 
tetrazole, which has a pAfa of 4.9, is commonly used for the activation of 
phosphoroamidates137and accelerates coupling during oligonucleotide synthesis by the 
phosphotriester method. 138Wong et al reported that lAf-tetrazole was also efficient to 
activate phosphoromorpholidate. 139This heterocyclic compound is proposed to act both as 
an acid catalyst to activate phosphoromorpholidates by protonation of the leaving group 
and as a nucleophile catalyst by forming highly reactive phosphotetrazolide derivatives 49. 
It was also found lAf-tetrazole increased the solubility of otherwise insoluble GM P 
morpholidate in anhydrous pyridine. The normal yield of the lif-tetrazole activated 
coupling reaction is between 76-91%.
A Lewis acid catalysed coupling method has been reported by Lee et al to couple P-NMN* 
with AMP morpholidate in a relatively high yield.91 In this method, M nCh and MgS(>4 are 
used as the Lewis acid and the reaction was carried out in formamide. Typically, a solution 
of manganese chloride in formamide was prepared in advance and was dried under 
molecular sieves for 4 days to remove any residual moisture. The resulting crude 
pyrophosphate was purified by ion-exchange resin chromatography and pure NAD+ was 
obtained in 58% yield.
So far, we outlined several condensation methodologies towards the successful synthesis 
of NAD+ analogues. Among these, Lewis acid mediated condensation of morpholidates 
and p-NMN+ was followed in our project and was used to synthesise most of the NAD+ 
analogues. W hat we didn’t include in the above introduction is the 1,1'- 
carbonyldiimidazole mediated condensation, in which the imidazolates were formed as the
0-7
reaction intermediate. This coupling methodology was adopted in our project to 
synthesise the unstable 2'-deoxy NAD+ analogues and details will be discussed in chapter 
3.
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2.2 Design and Synthesis of 2-F NAD+
The first structurally modified NAD+ analogue designed and synthesised, as a potential 
inhibitor of Aplysia ADP-ribosyl cyclase in our lab was the 2-fluoro-NAD+ 56 (scheme 
2.1). The reasons to design 2-fluoro-NAD+ as a potential ADPRC inhibitor are: 1) Since 
fluorine is a small atom whose size is comparable with hydrogen, 2-fluoro-NAD+ is 
sterically one of the closest analogues of the natural substrate NAD+ and therefore could be 
readily recognised by Aplysia ADPRC; 2) As the fluorine atom has a strong electron 
withdrawing activity, it should dramatically reduce the electron density at N1 position and 
since electron density parallels the nucleophicility, the N1 cyclisation should thus be 
impeded; 3) N7 cyclization, as seen for NHD+ and NGD+, is also unlikely to happen; this 
has never been observed before for NAD+ or an adenine derivative as these adenosine 
derivatives, including 2-fluoro-NAD+ are likely to adopt a syn conformation in the 
enzyme-substrate complex and disable any N7 cyclization. l^V6-Etheno NAD+ is a known 
exception, that is cyclized enzymatically at the N7 position of the 1 ,N6-ethenoadenine ring. 
However, since the enzymatic cyclisation (unlike chemical cyclization) does not occur at 
its most nucleophilic etheno N6 position140,141 we assume that the l,N 6-etheno NAD+, in 
contrast to other adenosine derivatives, may be arranged by the Aplysia  ADP-ribosyl 
cyclase in an anti conformation due to the presence of the rigid and bulky etheno ring. In 
agreement with our proposal, the conformational difference was also observed by 
Yamamoto-Katayama et a lu l  when co-crystallising 1 ,N6-etheno-NAD+ and ATP with 
CD 157 (BST-1). Since a more nucleophilic N7 has been proposed in the case of NGD+ and 
NH D .143,144 we assume that the etheno ring of l,N6-etheno-NAD+ may also increase the 
nucleophicility of the N7 position by donating the electron density via the conjugated 
system, thus also facilitating N7 cyclization. In contrast, the nucleophilicility of N7 in 
NAD+ is expected to be very low (pKa of 5'-AMP is -1.6)145 and should be lower in 2- 
fluoro-NAD+ due to the electron-withdrawing effect of fluorine group. W ith the above 
arguments, we conclude that 2-fluoro-NAD+, like the natural substrate NAD+, is not likely 
to undergo Aplysia cyclase mediated cyclisation at N7 to produce A7-2-fluoro-cADPR 
(structure b, Figure 2.7).
In Figure 2.7, residues Glu98 and T rp l40  of ADP-ribosyl cyclase were found to probably 
position the purine group of substrates in to a proper conformation, facilitating 
nucleophilic attack on the G lul79 bearing carbon and seemingly they always position the 
adenosine derivative in the syn confirmation. Glu98, as a strong hydrogen bond acceptor,
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is found to be a part of the nicotinamide-binding site and is thought to help stabilise the 









Figure 2.7 Aplysia ADPRC catalysed enzymatic reaction of 2-fluoro-NAD+. 2-Fluoro- 
NAD+ was proposed to attach with the Glu 179 of Aplysia ADPRC and the Trp 140 was 
found to help orient the substrate in a syn confirmation. The N1 nucleophilic attack on the 
anomeric carbon is impeded in this case.
Above all, as a close analogue to NAD+, 2-fluoro-NAD+ is expected to compete effectively 
in antagonising ADPRC induced cADPR production by forming a stable folded 
intermediate, which is not able to cyclise at N1 or N7 position. It was of interest to explore 
that whether this will be a ‘dead-end’ intermediate or whether the analogue could be 
hydrolysed by the enzyme.
2.2.1 Design of 2-Fluoro-Nicotinamide Adenine Dinucleotide
2-Fluoro-NAD+, as a non-cyclisable NAD+ analogue was also explored by computer 
modelling (Figure 2.8). Partial charges on the N1 nitrogen of 2-fluoro-adenosine and 
adenosine were compared in this study. The expected decrease in electron density at the 
N1 position of 2-fluoro-adenosine was explored relative to the unsubstituted adenosine 
(Figure 2.8). Note the pink (-0.060) to dark blue transformation at N1 in adenosine and 2- 
fluoro-adenosine respectively. Based on the above observation, we thus assumed that the 
electron density on N1 of 2-fluoro-NAD+ also decreased compared with that of NAD+. 
Since the electron density of N1 was reduced and, since electron density parallels 
nucleophicility, the attack of the N1 on the nicotinamide-bearing ribose at C-l" of 2-
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fluoro-NAD+ should be blocked and therefore the cyclisation catalysed by ADP-ribosyl 
cyclase at N 1 position of 2-fluoro-NAD+ is not likely to happen.
F igure  2.8 Com puter modelling results of adenosine (a) and 2-F adenosine (b). Values 
at the colour boundaries (partial charge): white 0.090; Red 0.030; yellow 0.010; green 
0.000; light blue -0.010; dark blue -0.030; Pink, purple -0.060.
Another important line of evidence came from the published work o f Laxer and 
collaborators . 145,146 In their studies on a different, but related, system they experimentally 
calculated the pKa value of N1 of 2-modified ATP using 15N NM R measurements. 15N 
NM R is a tool to study the basicity of nucleotide base in an unambiguous fashion147and 
because 15N NM R is measured in H 20 ,  it can provide pKa values that are of biological 
reference. W ith an electron-withdrawing group attached at the 2-position, the pKa value 
decreases dramatically. The experimental pKa value o f N1 of 2-C1 ATP (Figure 2.9, 
structure a) is -0.2 and, compared to that of ATP (Figure 2.9 structure b; pKa 4.16), the 
value decreased strikingly by around 10000 fold. NAD+ shares the same adenine base 
moiety as ATP and since fluorine has a stronger electron-withdrawing ability than chlorine, 
the pK& o f 2-fluoro-NAD+ should therefore be further decreased.
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2-CI-ATP a ATP b
Figure 2.9 Structure of 2-CI-ATP a and ATP b. Due to the electron withdrawing effect 
of chlorine, the electron density at N1 of 2-CI-ATP (shown in dashed circle) is 
dramatically reduced compared with that of ATP.
A nitrogen atom of such an apparently low pKa will not be likely to accomplish a 
nucleophilic attack on the ribose C -l"  of the enzyme ADP ribosyl intermediate, as 
normally low basicity parallels low nucleophilicity. This is then compelling evidence that 
allows us to rule out the possibility of A^7-2-fluoro-cADPR (Figure 2.7, structure a) as a 
potential product after incubation of 2-fluoro-NAD+ with the cyclase. 2-Fluoro-NAD+ may 
therefore be an ADPRC inhibitor or a new molecule to study the enzyme substrate 
interaction mechanism.
2.2.2 Synthesis of 2-Fluoro-NAD+
As discussed earlier in section 2.1, formation of NAD+ analogues is a difficult process and 
the yield of these asymmetrical pyrophosphates is limited by their stability. Thus, a 
synthetic route involving less protecting groups and purification steps is preferred. We, 
like many other research groups, use the synthetic route published by Lee and 
collaborators91 to produce the desired compound 2-fluoro-NAD+ and several other NAD+ 
analogues. The key compound 2-fluoro-adenosine was synthesised from guanosine 50 
(Scheme. 2.1). Treatment of guanosine 50 with trifluoroacetic acid anhydrate at 0°C, 
followed by addition of pentafluorophenol activated the C-6  position by forming a good 
leaving group. 148 Compound 51 was produced in 79% yield as an oil, which was then 
heated in concentrated aqueous ammonia solution in a pressure tube giving 2 -amino- 
adenosine 52 in 60% yield. 149The crucial fluorine group was introduced to the C-2 position 
by a Schiemann reaction. 150To the dark coloured solution of 2-amino-adenosine 52 in 
HF/pyridine, KNCF aqueous solution was added dropwise to produce a less polar 
compound which was confirmed as 2-fluoro-adenosine 53 from the following evidence: in 
the ]H NMR, we observed the disappearance of the 2-NtL peak which normally has a
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chemical shift at 5.7 ppm and integration of two protons; in the I9F NMR, a single peak 
appeared at -53 ppm suggesting the occurrence of fluorine substitution; and in 13C NMR, 
coupling constant ( 7 c f )  between 2-fluoro group and C-2 was ca. 200 Hz which was in 
agreement with the reported fluorine carbon coupling constant of trifluroacetic acid. 151 
This structure was further confirmed by mass spectrometry where a three mass unit 
increase comparing to 2-amino adenosine was observed. Phosphorylation of unprotected 2- 
fluoro-adenosine 53 was accomplished using the TEP/POCH/water method reported by 
Tomomi Ikemoto and his colleagues.152 Several other methods involving the usage of NJf- 
diisopropyl dibenzyl phosphoramidite153or H-phosphonate115 have also been explored to 
successfully phosphorylate the hydroxyl group of the ribose of nucleosides. These methods 
however are not regioselective and normally require the substrate nucleotides or 
phorsphorylating reagents to be protected. Thus, one or two more protecting or 
deprotecting steps are needed in order to achieve the desired monophosphate. In order to 
shorten the synthetic route and reduce the number of purification steps, reactions that 
require minimum protecting steps are favoured in our project and, therefore these 
phosphorylation methods involving usage of protecting groups were not adopted. In favour 
of our requirement, Yoshikawa et a /154reported that the phosphorylation of unprotected 
nucleotide with phosphorus oxychloride (POCI3) in presence of water in trialkyl phosphate 
(TAP) gave 5 '-monophosphates selectively in high yield. Ikemoto et al carefully 
investigated the mechanism of this reaction using unprotected guanosine as the substrate. 
They found after heating, that guanosine formed a complex (Figure 2.10) with the solvent 
TEP. In this complex, the 5 '-hydroxyl group was highly activated, promoting selective 
phosphorylation at this position. Heating was found to be the key requirement for complex 






Figure 2.10 Proposed TEP-guanosine complex where guanosine is in the high-anti 
conformation. Drawing is modified from the literature. 152
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In the case of phosphorylation of 2-fluoro-adenosine, 6 -8  equivalents of POCI3 were added 
in order to drive the reaction to completion. The 2-fluoro-AMP 54 was converted to its 
lithium salt before purification as, according to our experiments, the lithium salt had a 
better separation from the inorganic phosphate than the sodium salt on the reverse phase 
column. The crude 2-fluoro-AMP was purified on a RP-18 column and was then treated 
with charcoal to remove any excessive inorganic phosphate. Prior to coupling with p- 
NMN+, the mono-phosphate 2-F-AMP 54 was activated through a 
triphenylphosphine/dipyridyl disulfide-mediated condensation with morpholine. A putative 
mechanism was proposed by Mukaiyama and his colleagues (Figure 2.11), 155in which a 
cyclic transition state b was suggested. Starting from 2-fluoro-AMP free acid, this 
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Figure 2.11 Mechanism of triphenylphosphine/dipyridyl disulfide mediated 2-fluoro- 
AMP morpholine condensation. A cyclic transition state b is suggested.
Ferries et a llMused the free acid in their work as the appropriate starting material in 
formation of morpholidate. However, we observed that this reaction could also be 
performed on the triethylammonium salt without affecting the reaction rate and yield. 1|P 
NMR was employed to monitor the formation of morpholidate 55 where a new singlet at 
5.8 ppm (<i6-DMSO) or at 8 .1 ppm (D2O) was observed. 2-Fluoro-AMP morpholidate was 
precipitated by addition of a solution of Nal in acetone, washed with acetone, dried and 
used in the next step without any further purification. 2-Fluoro-AMP morpholidate 55 was 
then condensed with P-NMN+ in MnCF/formamide solution, in the presence of dry MgSC>4. 
The crude reaction residue was purified by Q-sepharose ion-exchange chromatography,
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and product was eluted with a gradient of 1M TEAB (triehthylammomium bicarbonate) 
buffer against MilliQ to give the desired 2-fluoro-NAD+ 56 in 55% yield. Compound 56 
was quantified using total phosphate analysis, from which the extinction coefficient was 
















Scheme 2.1 Reagents and conditions: (a) i-TFAA, pyridine, 0°C, 15min; ii- 
pentafluorophenol, r.t, 24 h, 79%; (b) Saturated ammonia aqueous solution, 55 °C, 36 h, 
60%; (c) HF/pyridine 56%, K N 02, 1 h, 54%; (d) TEP, POCl3, H20 , 0°C, 3 h, 47%; (e) 
triphenylphosphine, dipyridyl disulfide, morpholine, r.t, 2 h, 87%; (f) MnCl2/formamide, 
M gS04, p-NMlSC, r.t, 48 h, 55%.
2.2.3 Incubation of 2-Fluoro-NAD+ with ADPRC
2-Fluoro-NAD+ as an ADP-ribosyl cyclase inhibitor has not yet been tested, but 2-fluoro- 
NAD+ as a non-cyclisable tool to reveal the multiplicity of Aplysia ADP-ribosyl cyclase 
mechanism has been explored in our work. As we briefly mentioned in chapter one, both 
cADP-ribose and NAADP are synthesised by a same family of enzyme, the ADP-ribosyl 
cyclase. Since cADP-ribose and NAADP are well accepted as second messengers, each 
inducing calcium release from a large variety of cells by distinct mechanisms, the enzymes 
which synthesise them are likely to play important and potential roles in regulating 
signalling transduction in cells. To date, three ADP-ribosyl cyclases have been identified 
and intensively studied. Aplysia ADP-ribosyl cyclase, a cyclase purified from the cytosol 
of invertebrate Aplysia californica was found to exclusively transform NAD+ into the 
cyclic form cADP-ribose, 156 whilst the mammalian ADP-ribosyl cyclases, CD38 and 
5S77/CD157 were classified as multi-functional enzymes, comprising cyclase, cADP-
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ribose hydrolase and NAD+ glycohydrolase activities. It was found that CD38/CD157 
produced only limited amount of cADP-ribose, but a large amount of the hydrolytic 
product ADP-ribose. Since these three enzymes share such great structural and amino 
sequence similarities (see sectionl.3.2.3), one important issue is thus raised as to why these 
enzymes are so differentiated in their enzymatic activities. To address this issue, a good 
understanding of the cADP-ribose and ADP-ribose formation mechanisms at a molecular 
level is required.
A “sequential mechanism” was first proposed to explain the CD38/CD157 catalysed low 
yielding formation of cADP-ribose. In this sequential mechanism, cADP-ribose, 
transformed by CD38/CD 157, is quickly turned over to ADP-ribose by the cADP-ribose 
hydrolase function of the same enzyme. Accordingly, the “apparent” NA D+ 
glycohydrolase activity of CD38 seems to result from the addition of its ADP ribosyl 
cyclase and cADP-ribose hydrolyse activities. A hydrophilic interaction of cADP-ribose 
with Lysl29 residue of CD38 has been recently identified to reason the outstanding cADP- 
ribose hydrolysis activity of CD38.157,56 The sequential mechanism although nicely 
explaining the low yielding formation o f cADP-ribose, has been proved misleading since it 
has been reported that CD38 and NAD+ glycohydrolase are actually the same 
enzyme,158’159 and hence they work by a same mechanism.
A “partitioning mechanism” (Figure 2.12)160 was then proposed, according to which a 
common enzyme-ADP-ribosyl intermediate partitions between two competing pathways: a 
reversible intramolecular pathway producing cyclic ADP-ribose (ADP-ribosyl cyclase 
activity) and a macroscopically irreversible intermolecular pathway leading to formation of 
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R = H; ADP-ribose 57
R = methyl; I'-beta-O-methyl ADP-ribose 58
Figure 2.12 Partitioning mechanism of CD38/NAD+ glycolhydrolase mediated reactions. 
The cyclic product and the hydrolytic product 57/58 are formed in competition from a 
communal covalent intermediate a.
So far, the partitioning mechanism best describes the enzymatic reactions mediated by 
those multi-functional enzymes including CD38, CD 157 and NAD+ glycosylhydrolase. 
Aplysia ADP-ribosyl cyclase seems to be an exception as seemingly it exclusively 
generates cADP-ribose, but in fact there is now evidence that small amounts of ADP- 
riboses are also produced in reactions catalysed by Aplysia ADP-ribosyl cyclase, 161’162and 
the ADP-ribose production was remarkably increased when incubating NAD+ with high 
concentration of highly purified Aplysia cyclase, indicating a hidden cADP-ribose 
hydrolase activity of this enzyme at low concentrations. 163 Since Aplysia cyclase is now 
also classified as a multi-functional enzyme, it therefore assumed to catalyse enzymatic 
reactions by the same partitioning mechanism. Schuber et alm  thus proposed a unified
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enzymatic reaction scheme for all the members of ADP-ribosyl cyclase family as is shown 
in Figure 2.13.
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kcH3OH  ^ E + methyl ADP-ribose + H" 
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E + ADP-ribose + H+
hydrolysis pathway (NAD* glycohydrlase 
---------------------------- activity)
cADP-ribose hydrolase
Figure 2.13 Unified partitioning mechanism for the ADP-ribosyl cyclase family.
The cyclisation pathway (k.-? step) of Aplysia ADP ribosyl cyclase has been fully studied 
and, in most cases, Aplysia ADP ribosyl cyclase produces cADP-ribose as a single product. 
The hydrolysis pathway (kH20 step), however is not yet formally confirmed and the 
hydrolytic product ADP-ribose is kinetically highly disfavoured and could only be 
markedly observed at high concentration of enzyme. The resulting ADP-ribose seems to be 
derived from its cyclic precursor since the maximal rate (V max) for hydrolysis reaction, for 
example the cADP-ribose hydrolase catalysed hydrolysis is few magnitudes slower than 
that of the NAD+ cyclization (k  ^ » LO and the ratio of Vm*JKm is more than 10,000 fold 
higher towards the NAD+ cyclization. 163 From these kinetic data the formation of a cyclic 
intermediate seems inevitable during the production of ADP-ribose and this raises the 
critical issue as to whether the hydrolysis pathway truly exists or is just a consequence of 
the combined activities of ADP-ribosyl cyclase and cADP-ribose hydrolase (sequential 
mechanism)? Studies on the poorly hydrolysable pyridinium analogues of NAD+ such as 








Figure 2.14. Structure of PyAD+.
PyAD+ possesses a high-energy pyridinium bond and is thought to amplify the importance 
of cADP-ribose hydrolase pathway by a significantly slowed formation of the enzyme- 
substrate intermediate (k2 step). It was found that when incubating PyAD+ with Aplysia 
ADP ribosyl cyclase, both cADP-ribose and ADP-ribose were formed and at 10% reaction 
progress the [cADP-ribose]/[ADP-ribose] ratio was found to be 2.2, which was later 
decreased as the reaction progresses, indicating a progressive hydrolysis of cADP-ribose. 
So far, it seems well established for pyridinium NAD+ analogues being hydrolysed by 
Aplysia ADP ribosyl cyclase via sequential mechanism with cADP-ribose as the reaction 
intermediate. However, hydrolysis of the non-cyclisable simple substrate nicotinamide 
mononucleotide (NMN*) by highly purified Aplysia ADP ribosyl cyclase revealed 
formally the existence of the hydrolysis pathway and indicated that the seemingly 
compulsory cyclic intermediate formation may not be inevitable. 163'51 However, NMN+ is 
very different in structure from the natural substrate NAD+ and therefore may not be an 
effective substrate mimic to investigate the hydrolysis process catalysed by Aplysia ADP- 
ribosyl cyclase. This raised the critical issue as to whether the hydrolysis pathway (Kh2o 
step) can be uncovered during the transformation of NAD+ and dinucleotide substrate 
analogues, or is just a consequence of combined activities of ADP-ribosyl cyclase and 
cADP-ribose hydrolase?
We have synthesised 2-fluoro-NAD+, a non-cyclisable analogue that is a sterically close 
mimic to the natural substrate of Aplysia ADP-ribosyl cyclase, as a potential tool to reveal 
the hydrolysis pathway of Aplysia cyclase. Compound 56 was first incubated with 
commercially available invertebrate Aplysia ADP ribosyl cyclase in pH 7.4 buffer. HPLC 
analysis of the reaction mixture indicated that all the starting 56 was consumed and a new 
peak at 10.51 min was observed. Purification by Q-sepharose ion-exchange 
chromatography, eluted with a gradient 1M TEAB buffer against MilliQ water to give the 
product in 70% yield. The product seen in this reaction was indeed confirmed to be the
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hydrolytic product 2-fluoro-ADP-ribose 59 in its trethylammonium form as a mixture of a, 
(3 anomers (Scheme. 2.2).
O
Scheme 2.2 Reagents and conditions: (a) Aplysia cyclase, pH 7.4, 25mM HEPEs buffer 
or pH 7.4, 10 mM potassium phosphate buffer; (b) Aplysia cyclase, pH 7.4 potassium 
phosphate buffer, 2M/3 M methanol.
Three lines of evidence suggested that the reaction product was 2-fluoro-ADP-ribose. First,
ADP-ribose (ADP-ribose was obtained from the heat induced hydrolysis of cADP-ribose, 
NMR see experimental section). Two sets of doublets at 5.3 ppm and 5.1 ppm that 
integrated as 1/3 proton and 2/3 protons respectively indicated that both an a hydroxyl and 
a (3 hydroxyl group were formed at the anomeric carbon of the terminal ribose derived 
from the nicotinamide end (Figure 2.15). Secondly, the elution time of 2-fluoro-ADP- 
ribose in an ion-pair HPLC system [details see experimental section] is ca 10.51 min, 
which is close to that of ADP-ribose standard (10.00 min). Thirdly, mass spectrometry of 
the 2-fluoro-ADP-ribose product showed a major positive ion of 576 mass units, which is 
17 mass units greater than that calculated for the 2-fluoro-cADP-ribose consistent with the 
linear form. Since it was crucial to control the potential activity of a contaminating 
glycohydrolase in the commercial enzyme, we undertook a full enzyme kinetic study using 
highly purified Aplysia cyclase. 163
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R = H; 2-fluoro-ADP-ribose 59 
R = Methyl; 2-fluoro-1"-0-methyl ADP-ribose 60
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Figure 2.15 Typical anomeric proton H -l' and H -l"  of ADP-ribose analogues. Two 
doublets were observed for H -l" which have integrations of 1/3 H and 2/3 H respectively, 
representing both a  and P anomers.
HPLC analysis of the transformation of 2-fluoro-NAD+, catalysed by this highly purified 
cyclase, indicated that during the whole reaction course, only a single product was formed 
that had an elution time very similar to ADP-ribose (Figure 2.16) (this work is in 
collabration with Professor Francis Schuber and Dr H. Muller-Steffner, France. Thanks for 
their contributions to the thesis). The same reaction product was also obtained by 
hydrolysis of 2-fluoro-NAD+ catalyzed by recombinant human CD38, which acts 
predominantly as a glycohydrolase rather than a cyclase. This product, when incubated in 
the presence of nucleotide pyrophosphatase was also totally transformed into a compound 
that had an elution time similar to that of adenosine 5 '-monophosphate. These experiments 
indicated that, by analogy with CD38, Aplysia califomica ADP-ribosyl cyclase did 
hydrolyse the 2-fluoro-NAD+ into 2-fluoro-ADP-ribose 59 without forming 2-fluoro- 
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Figure 2.16 Hydrolysis of 2-fluoro-NAD+ by highly purified Aplysia ADP ribosyl 
cyclase. HPLC analysis indicates 2-fluoro-NAD+ was transformed into 2-fluoro-ADP- 
ribose as the single product during the whole reaction course. Kinetic studies were carried 
out by Professor Schuber et al.
Kinetic parameters of this hydrolysis reaction were determined and were: Km = 16.05 ± 
3.36 pM and Vmax = 15.47 ± 0.69 pmol.min^.mg ' 1 for 2-fluoro-NAD+. Compared to the 
Fmax of NAD+ cyclisation, this Aplysia califomica ADP-ribosyl cyclase catalyzed 
hydrolysis reaction is about 2-orders of magnitude slower. The Km for the unnatural 
substrate is a little higher than that for NAD+ (Km = 4.6 ± 0.4 pM). Aplysia califomica 
ADP-ribosyl cyclase was also found to catalyse the methanolysis of cADP-ribose and the 
rate of this reaction was reported to be 2 0 0  fold faster than that of the hydrolysis 
reaction . 164 In order to further rationalise the partitioning theory and to reveal the hidden 
NAD+ glycohydrolase activity of Aplysia califomica ADP-ribosyl cyclase the enzyme- 
mediated methanolysis of 2-fluoro-NAD+ was also studied. Under the experimental 
conditions used, a new product was formed at 7.9 min (HPLC system B) when 2-fluoro- 
NAD+ was incubated with the Aplysia califomica ADP-ribosyl cyclase in presence of 2-3 
M methanol (Figure 2.17). The elution time of this newly formed product corresponded to 
what would be expected for the 2-fluoro-T-O-p-methyl ADP-ribose 60. This observation 
clearly indicated the existence of the methanolysis activity of ADP ribosyl cyclase, as 
formation of 2-fluoro-cADP ribose was highly unlikely in this case and the methanolysis 
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Figure 2.17 Methanolysis of 2-fluoro-NAD+ by highly purified Aplysia ADP-ribosyl 
cyclase.
The ratios between methanolysis and hydrolysis products were found to be proportional to 
the methanol concentration (0-3 M; not shown). We estimated the relative efficacy of 
water and methanol in the nucleophilic attack of the E-ADP-ribosyl intermediate by 
calculating the partitioning ratio using the following equation:
K -  [p methyl 2-F ADP-ribose][H20]/[2-F ADP-ribose][methanol]
The ratio K was found to be around 100, which is in agreement with the fact that methanol 
is a better nucleophile than water in this reaction. Importantly, in the presence of 3 M 
methanol which greatly increases the turnover rate of the E-ADP-ribosyl intermediate, the 
overall rate of 2-fluoro-NAD+ transformation was also affected. The observed doubling of 
the initial rate (not shown) indicates, in agreement with the finding on the Vmax (see above), 
that for the catalytic transformation of this substrate, the kn2o step is part of the rate 
limiting step. It appears therefore that 2-fluoro-NAD+ is a molecular tool which allows 
dissection of the kinetic scheme (Figure 2.13 and below) and its solvolysis data confirm 
that, in contrast to CD38, in the Aplysia cyclase catalysed reactions the capture of the E- 
ADP-ribosyl intermediate by water is a relatively slow process as opposed to the 











E + 2F-ADP-ribose + H+
(hydrolysis)
E + (3-O-methyl 2F-ADP-ribose + H+
(methanolysis)
Figure 2.18. Reaction scheme of the transformation of 2-fluoro-NAD+ by Aplysia 
califomica ADP-ribosyl cyclase.
2.2.4 Conclusion
We synthesised 2-fluoro-NAD+ as a close analogue of NAD+ and verified the partitioning 
pathway for Aplysia califomica  ADP-ribosyl cyclase. Incubating 2-fluoro-NAD+ with 
ADP ribosyl cyclase produced a single compound, which was separated and shown to be 
2-fluoro-ADP ribose, demonstrating that the hydrolysis pathway in the partitioning theory 
holds for the Aplysia enzyme since formation of 2-fluoro-cADP ribose is impossible and a 
sequential route through the cADPR analogue is not applicable in this case. We conclude 
therefore that there is “classical” NAD+ glycohydrolase function in the Aplysia cyclase. 
This was further demonstrated by the methanolysis o f 2-fluoro-NAD+ from which 2- 
fluoro-P-methyl ADP ribose was produced. In conclusion, although Aplysia califomica  
ADP-ribosyl cyclase exhibits biological functions different from that of CD38 and NAD 
glycohydrolase, it can indeed be classified as a multifunctional enzyme even though this is 
normally masked by the kinetically favoured cyclase function.
2.3 Synthesis of 2-Amino-Nicotinamide Adenosine Dinucleotide.
We also synthesised 2-amino-NAD+ 63 as a potential tool to study the Aplysia cyclase 
mediated enzymatic reactions, which is different from 2-fluoro-NAD+. It has an electron- 
donating amino group at 2 position of the adenosine base and flanks the crucial N1 
position with a second amino group markedly larger than fluorine to explore potential 

















Scheme 2.3 Reagents and conditions: (a) TEP, POCI3, H2O, 0 °C, 3h, 41%; (b) 
Triphenylphosphine, dipyridyl disulfide, morpholine, r.t, 2h, 46%; (c) MnCL/formamide, 
M gS04, (3-NMNT, r.t, 48h, 35%.
Compound 52 was phosphorylated by adaptation of the early method published by 
Ikemoto et al. “ 2-Amino-adenosine 5 '-monophosphate 61 was then activated using 
triphenylphosphine, morpholine and dipyridyl disulfide to form phosphormorpholidate 62 
which was purified by ion-exchange chromatography in 46% yield. Condensation of (3- 
NMN* with compound 62 was achieved in the presence of Lewis acid (MnCL/MgSCU) and 
the reaction residue was purified by ion-exchange chromatography twice to give 2 -amino- 
NAD+ 63 in 35% yield. A better yield would be expected by using reverse column 
chromatography as the purification method. 2-Amino-NAD+ was then incubated with 
Aplysia cyclase in pH 7.4 HEPES buffer for 48 h and the resulting product was isolated by 
ion-exchange chromatography in 84% yield (Figure 2.20). Compound 64 was later 
identified to be the hydrolytic product by its characteristic ’HNMR of the anomeric H - l”. 
HPLC trace of this Aplysia cyclase mediated reaction is shown in Figure 2.19 and the long 
reaction time further proved that Aplysia cyclase induced hydrolysis is a rather slow 













1  v .
5.00 8.00
Figure 2.19 HPLC trace of Aplysia cyclase mediated hydrolysis of 2-amino-NAD+: a) 
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Figure 2.20 Hydrolysis of 2-amino-NAD+ by Aplysia cyclase.
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The enzymatic reaction result however is rather intriguing as the N1 electron density is 
actually increased by the electron-donating effect of the amino group and since electron 
density parallels the nucleophilicity, a N1 cyclisation is expected rather than the observed 
hydrolysis reaction. But compared to the size of a proton, the amino group is considerably 
bulkier; we therefore reasoned that the failed cyclisation is possibly caused by the steric 
hindrance in this case. Since 2-amino-NAD+ is not able to cyclise, it can thus be 
considered as a potential competitive inhibitor to block the Aplysia ADP-ribosyl cyclase 
mediated cADP-ribose formation.
2.4 Synthesis And Enzymology Study of 6-iV-Methyl-NAD+.
As was found in earlier sections, Aplysia cyclase catalysed N1 cyclisation was impeded by 
both electronic and steric perturbations at the 2 -position of the adenosine ring, 
demonstrating the 2 -position as a potential site for designing and synthesising various 
Aplysia cyclase inhibitors. Sih et al]62 reported that modifications at the 6 -position also 
lead to non-cyclisable NAD+ analogues. 6 -S-methyl-NAD+ 65 as well as some 6 -N- 
modified analogues (Figure 2.21) were reviewed in their work and Aplysia cyclase 
catalysed hydrolysis reactions were observed for these analogues.
Figure 2.21 Structures of 6 -modified NAD analogues.
We thus designed 6 -iV-methyl-NAD+, a close analogue to the natural substrate NAD+, as a 
potential target of Aplysia cyclase inhibitors. 6 -iV-methyl-NAD+ was synthesised from a 
non-commercial staring material 6 -A-methyl adenosine 6 8 . Compound 6 8  as a biologically 
active nucleoside had been earlier synthesised, from 1 -N-methyl adenosine 67, via a 
Dimroth rearrangement165 that involves an opening and recyclisation of the adenosine ring
0
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Figure 2.22 6 -N-methyl-adenosine synthesised via Dimroth rearrangement.
Instead of the Dimroth rearrangement route, we synthesised compound 68  by a different 
synthetic route (scheme 2.4). 6 -Chloro-adenosine 69 was first activated at N9 position by a 
treatment of trimethylsilyl triflate and then condensed with ribose-tetraacetate 70 to 
produce compound 71 in its (3 configuration in 72% yield . 166 The p configuration was 
controlled by the formation of a complex between the 2 '-position acetate group and the 
anomeric carbon of the ribose, which then blocked the nucleophilic attack of 6-chloro- 
adenosine from a  side of the ribose, leading to a formation of the 71 as an P isomer. 
Compound 71 was reacted with methylamine hydrochloride 167to form a more polar product 
by tic, which was then isolated chromatographically to give the desired 6 -N-methyl 
derivative 72 in 67% yield. The 5'-acetate of compound 72 was removed by a treatment of 
this compound with methanolic ammonia to produce the 6 -iV-methyl adenosine in 8 6 % 
yield, which was then used as the starting material to synthesise the targeted 6 -JV-methyl 
NAD+.
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Scheme 2.4 Reagents and conditions: (a) TMSOTf, DBU, dry methanol, 72%; (b) 
methylamine hydrochloride, DCM/ethanol/triethylamine, heating, 67%; (c) NTf/methanol, 
r.t, 8 6 %.
Phosphorylation of compound 6 8  was achieved by using the established POCf/TEP/FFO 
method but, in contrast to that of 2-fluoro adenosine, both 5 '-monophosphate 73a and 3',5'- 
bisphosphate 73b as a mixture were formed in this case. Compound 73a and 73b could not 
be isolated from each other, as they appeared to have an identical eluting time on our ion-
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pair HPLC system. We assumed that the production of the bisphosphate 73b might be 
caused by the rotation of the methyl group which interferes the formation of the substrate - 
TEP compex (see Figure 2.10), thus reduces the 5-O H  selectivity. The yield of the desired 
monophosphate 73a was calculated from the 'HNMR integration. Treatment of 73a/73b 
mixture with triphenylphosphine, morpholine and dipyridyl disulfide produced two 
morpholidates that had HPLC elution time at 2.78 min and 6.54 min, respectively. The 
desired morpholidate 74 (HPLC 2.78 min) was now isolated by ion-exchange 
chromatography in 78% yield and, then was condensed with (3-NMN+ to form the target 6 - 
A-methyl-NAD* 75, which was isolated by reverse phase chromatography in 64% yield as 
its triethylammonium salt. (Scheme 2.5) Incubating 75 with Aplysia cyclase, as we 
expected, generated 6 -iV-methyl-ADP-ribose 76 as a mixture of a  and (3 anomers, showing 
the 6 -position as another crucial site to form the non-cyclisable NAD+ analogues. The 
’HNMR spectra of 6 -A-methyl-NAD+ (spectrum a) and the enzymatic reaction product 6 - 
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Figure 2.23 'HNMR spectra of Aplysia cyclase mediated hydrolysis of 6 -TV-Methyl 
NAD+ (spectrum A). The product 6 -A-Methyl-ADPR (spectrum B) presents typical 
anomeric proton NMR pattern fro ADP-ribose; a broad methyl peak is shown in spectrum 
A, indicating that the methyl group is constantly rotating.
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Scheme 2.5 Reagents and conditions: (a) TEP, POCI3, H2O, 0 °C, 3h, 51 %; (b) 
Triphenylphosphine, dipyridyl disulfide, morpholine, rt, 2h, 78%; (c) MnCH/formamide, 
M gS04,13-NMNT, r.t, 48h, 64%; (d) 25 mM HEPEs buffer, pH 7.4, r.t, 59%.
It was initially assumed that N1 cyclisation of 6 -A^-methyl NAD+ was blocked by the steric 
hindrance brought about by the free rotation of methyl group. However, compound 6 6 , an 
analogue lacking a 6 -amino group, was found also to be unable to cyclise, indicating 
cyclisation catalysed by Aplysia cyclase might involve the participation of 6 -position 
amino group. Therefore, the reason for 6 -iV-methyl NAD+ being non-cyclisable might be 
more fundamental and relate to the cyclisation reaction mechanism. It is assumed that the 
6 -amino group donates the electrons through the conjugated system, facilitating the N1 
cyclisation (Figure 2.24 a). We reason this mechanism might also hold for 6 -A-methyl- 
NAD+, but with a substitution of methyl group, the compound might be stabilised in the 
“imine” form b, limiting the formation of reactive “enamine”c thus blocking the N1 
cyclisation (Figure 2.18). However, it is rather unlikely that the imine structure is stablised 
only by a methyl group and from Figure 2.23 a broad methyl peak is observed in the 
]HNMR spectrum for 6 -iV-methyl NAD+, suggesting the 6 -A-methyl group is constantly 
rotating rather than being locked in an imine form. Also, the proposed imine structure 
seems also capable of N1 cyclisation due to the high nucleophicility of N 1 position, but 
only if it is in the anti geometrical isomeric form relative to N l, as shown in Figure 2.24.
Figure 2.24 Role of amino group during N1 cyclisation. It is assumed that formation of 
enamine c is limited by the substitution of methyl group.
It was also assumed that, by analogy to NHD+ or NGD+, the 6 -A-methyl-analogue is 
arranged in an anti conformation by the cyclase to impede the expected N1 cyclisation. We 
thus attempted to synthesise the 6 -iV-methyl-8 -bromo-NAD+, a NAD+ analogue known to 
have a dominant syn conformation due to repulsion between the bromo-group and the 
ribose moiety. The crude synthetic data for the key compounds 6 -amino-8-bromo- 
nucleoside 77 and 6 -A-methyl-8 -bromo-NAD+ 78 (Figure 2.25) were given in the 
experimental section and for some reason no clear molecular ion could be identified for 
compound 78. It was found that when incubated with Aplysia cyclase, 6 -A-methyl-8 - 
bromo-NAD+ was not cyclised but hydrolysed, indicating that the conformation changes 
alone might not be a reason for the hydrolysis of 6 -A-methyl-NAD+ analogues.
O
Figure 2.25 Synthetic plan of 6 -A-methyl-8 -bromo-NAD+.
The reason for the 6 -A-methyl NAD+ being non-cyclisable is still not clear. But from the 
above argument, we reason that it’s most likely that the steric hindrance of the methyl 
group disturbs the electrophilic attack at N1 position, and therefore blocks the cyclisation. 
There is another likely reason that the methyl group might possibly interfere with the 
binding of 6 -A-methyl-NAD+ with Aplysia cyclase by reducing the H-bonding sites and 
then block the cyclisation.
2.5 Synthesis of NGD+ and NXD+ as Precursors of Fluorescent cADPR Analogues.
Apart from its known NAD+ cyclisation ability, Aplysia cyclase also transforms 
nicotinamide guanine dinucleotide (NGD+) into cyclic-GDP-ribose (cGDPR 79) and
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nicotinamide hypoxanthine dinucleotide (NHD+) into cyclic-IDP-ribose (cIDPR 80). 





R = NH2, cGDPR 79 
R = H, cIDPR 80 
R = OH cXDPR 81
Figure 2.26 Structures of N7 cyclised cADPR analogues.
cGDPR and cIDPR as hydrolytically resistant analogues with weak calcium mobilising 
abilities were synthesised and structurally studied by Sih et a / . 143 The 2D HMBC spectrum 
of cGDPR suggested that H-8  of the guanine base exhibited three-bond coupling with both 
C -l' and C-l", indicating a connection of the northern ribose at the N7 position of the 
purine base instead of the N1 position as in cADPR. The N7 cyclisations of cGDPR and 
cIDPR were also confirmed by the pH dependence of their UV absorption maximium. 
Upon increased pH, longer wavelength shifts were observed for these two compounds, 
consisting with that of the 7-methyguanosine and 7-methylinosine, further demonstrating a 
bond formation at N7-position. 168 Graeff et a /,69has showed that the N7 substituted 
nucleoside or nucleotide is fluorescent, but N1 substituted one are not. Thus the finding 
that cGDPR, cIDPR and cyclic-XDP-ribose (cXDPR 81) are also fluorescent again 
indicates a cyclisation at N7 position. Since N7 cyclic analogues are fluorescent, but 
neither the precursor dinucleotides nor the hydrolysis products is fluorescent, the 
cyclisation reaction mediated by Aplysia cyclase can therefore be constantly monitored by 
simply measuring the fluorescence of the cyclic products. Using this fluorescence method, 
Km values and reaction rate for NGD+, NHD+ and nicotinamide xanthine dinucleotide 
(NXD+) were determined. In addition, it is conceivable that this fluorimetric method also 
provides an efficient way of investigating the activities of Aplysia cyclase inhibitors. By 
using the precursor such as NGD+, NHD+ or NXD+ as substrate, the inhibition effects of 
competitive cyclase inhibitors can be clearly monitored by calculating the fluorescence of 
the corresponding N7 cyclic products and K\ values of these inhibitors can be determined. 
In order to determine the antagonistic activities of our proposed cyclase inhibitors such as 
the 2-fluoro-NAD+, 2-amino-NAD+ and 6 -N-methyl-NAD+, we also synthesised NGD+ 85
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and NXD+ 8 8  as potential fluorescent substrates using our established condensation 
method where a morpholidate was introduced and coupled with p-NMN* in presence of 
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Scheme 2.6 Reagents and conditions: (a) Triphenylphosphine, dipyridyl disulfide, 
morpholine, r.t, 2h; (b) MnCL/formamide, MgSC>4, P-NMN'1’, r.t, 48h; (c) 25 mM HEPES 
buffer, pH 7.4, r.t.
As we introduced in an earlier section, the phosphoromorpholidate can either be formed 
from the nucleotide free acid or from the triethylammonium salt. Sodium salts, however, 
were found not suitable to serve as starting material possibly because nucleotides in their 
sodium salt form are not soluble in DMSO, the reaction solvent. Thus, commercially 
available guanosine-5'-monophosphate disodium salt was transformed to its free acid by 
treatment with Dowex (H* form) ion-exchange resin. Treatment of the free acid 82 with 
triphenyl phosphine, morpholine and dipyridyl disulfide combination at room temperature 
gave the desired morpholidate 83 as a yellow solid in 84% isolated yield. HPLC was 
employed to monitor the reaction process and a new peak at 4.04 min was observed as the 
sole product, while the peak at 13.02 min representing the starting free acid was found to 
disappear completely. However, attempts to reproduce this compound failed, as suggested 
by HPLC with only small amount of new products being formed, even after prolonging the 
reaction time to 24 h. It was later found that the reaction worked only when the reagents 
were added in a sequence in which the morpholine was required to be added in between 
other two reagents. The reason for this is still not clear, but when adenosine derivatives 
were used as the substrates, the reagents were not required to be added in sequence, 
possibly reflecting a higher reactivity of adenosine analogues towards this activation 
reaction. Synthesis of NGD+ 85 was however achieved by treatment of morpholidate 83 
with (J-NMN* in the presence of MnCL/MgSCL at room temperature. Purification using 
ion-exchange chromatography gave NGD+ as a glassy solid in 46% yield showing the
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characteristic anomeric protons at 6.07 and 5.77 ppm and the nicotinamide signal in the 
aromatic region in the 1HNMR. HPLC of this compound showed a single peak at 6.53 min. 
NXD+ 88 was also synthesised by the Lewis acid mediated condensation of XMP 
morpholidate 87 and p-NMN*. Purification using a reverse phase column gave 86 as its 
triethylammonium salt in 63% yield. It was noteworthy that these xanthine derivatives had 
unexpectedly long HPLC elution times in the ion-pair HPLC systems. It was found that the 
XM P triethylammonium salt was eluted at more than 40 min while normal AMP was 
found to elute at around 7 min. Also, the elution time of NXD+ was found to be more than 
12 min in contrast to the retention time of NAD+ which was only less than 4 min. We 
reasoned that the long retention time was probably caused by the formation of enol or 
enolate at the 2 and 6 position o f the base, thus increasing the negative charge of the 
molecule, in turn increasing the retention time on the ion-pair HPLC column.
2.6 Synthesis of 8-Bromo-NGD+ as a Potential Cyclase Inhibitor.
As NGD+ cyclised at the N7 position of the base, a substitution of an electron withdrawing 
group at 8-position is therefore possible to decrease the electron density o f N7, then block 
the cyclisation at this position (shown in Figure 2.27). W e herein report a synthesis of 8- 
bromo-NGD+ 89. It is conceivable that the N7 cyclisation of this compound is not only 
impeded by the electronic perturbation of the 8-position bromo group, but also by the steric 
hindrance brought about by the bulky bromo atom. Compound 87 is assumed to adopt a 
syn conformation due to the non-bonded repulsion between the bromo group and the 
ribose,113which should block the N7 cyclisation, as in the syn conformation the N1 of the 
base instead of N7 is oriented close to the nicotinamide bearing ribose. The N1 cyclisation 
is also not able to occur because of the steric hindrance brought about by the amino group 
at 2-position. The same steric effect has been observed for 2-amino-NAD+ as we 










Figure 2.27 Structure of 8-bromo-NGD+ and factors that block the cyclisation both at 
N1 and N7.
63
Above all, all these considerations led to a synthesis and enzymatic investigation of 8 - 
bromo-NGD+ 89. Commercially available 8-bromo-guanosine 90 was initially designed as 
the starting building block due to its availability and reasonable price. However, 
phosphorylation using TEP/POCI3 combination could not yield the targeted 8 -bromo- 
NGD+ 89 because of a rapid degradation of the compound during aqueous work up in 
acidic conditions. The result is disappointing but not inconceivable. Jordan e ta l]1° reported 
that 8 -bromo guanosine was prone to acid hydrolysis at the N9-glycosyl linkage as the 
electron withdrawing effect of bromo decreases the electron density of N9 thereby 
accelerating heterolytic C-N fission. A mechanism for acid catalysed degradation of 
nucleosides is shown in Figure 2.28.
HO OH
Figure 2.28 Mechanism of acid induced N9-glycosyl bond degradation.
Based on the above mechanism, the nucleoside was first mono-protonated or diprotonated 
at the purine base prior to the cleavage of the ribosyl-N9 bond. In our case the protonation 
is assumed to occur at N7 position, which further decreases the electron density of N9, also 
contributes to the break down of the ribosyl-N9 linkage. Since phosphorylation of 
compound 90 is not successful, we therefore use the commercially available but expensive 
8 -bromo-GMP 91 as the staring material. Compound 91 free acid was activated using a 
sequence of tripenylphosphine, morpholine and dipyridyl disulfide to form 8 -bromo-GMP 
morpholidate 92, which was then reacted with P-NMN+ using Lewis acid (MnCL/MgSC^) 
catalysed condensation method producing the final 8 -bromo-NGD+ in 71% isolated yield 
(Scheme 2.7).
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Scheme 2.7 Reagents and conditions: (a) Triphenylphosphine, morpholine, dipyridyl 
disulfide, r.t, 2h, 32%; (b) MnCb/formamide, M gS04, 0-NMN+, r.t, 48h, 71%.
With 8 -bromo-NGD+ 89 in hand, the enzymatic reaction of the compound and Aplysia 
cyclase was then studied. It was found indeed that compound 89 was not cyclised by the 
cyclase in agreement with the assumption we made earlier this section. But unexpectedly, 
compound 89 was also not hydrolysed by a standard concentration of Aplysia cyclase. The 
interaction of compound 89 with cyclase was monitored by ion-pair HPLC. It was found 
that after 4 day’s incubation in pH 7.4 HEPES buffer, the HPLC peak at 6.14 min, which 
represented 8 -bromo-NGD+ 89 still kept nearly 100% integrity. The reason why 8-bromo- 
NGD+ is resistant to enzyme-induced hydrolysis is still not known. But with this hydrolytic 
resistance, compound 89 was marked to be a interesting inhibitor candidate which has 
potential to competitively inhibit the Aplysia cyclase induced cyclisation without being 
rapidly hydrolysed by the same enzyme. When incubating of 89 with high concentrations 
of enzyme, hydrolysis reactions were however detected. HPLC analysis of the reaction 
mixture however gave an unclear HPLC pattern, possibly reflecting a breaking down of the 
N9-ribosyl linkage or less likely even the pyrophosphate bond.
2.7 Summary of C hap ter Two
So far, we have made 2-fluoro-NAD+, 2-amimo-NAD+, 6 -A-methyl-NAD+ and 8-bromo- 
NGD+ as potential Aplysia cyclase inhibitors. We also synthesised NGD+ and NXD+ as 
precursors of fluorescent cADPR analogues. Using NGD+ and NXD+ as substrates, 
inhibitory effects of our non-cyclisable analogues can be easily monitored by the 
fluorescence assay and the Kj value of these inhibitors can thus be calculated. But so far, 
none of these potential inhibitors has been kinetically studied in our work due to the 
unavailability of purified Aplysia cyclase. A crude HPLC analysis was performed instead, 
showing that one of these non-cyclisable NAD+ analogues, 8 -bromo-NGD+ did inhibit the 
cyclisation reaction mediated by the commercial Aplysia cyclase. 8 -Bromo-NGD+ was
selected as the model because of its unexpected resistance towards cyclase induced 
hydrolysis at low enzyme concentrations. It was found from the HPLC analysis that upon 
addition of 40 |liM  of 8 -bromo-NGD+, the cyclisation of NAD+ was severely disturbed. 
After incubation of NAD+ alone with the cyclase for 30 min, more than 70% percent of the 
starting NAD+ was reacted. However, when co-incubated with 40 jiM of 8 -bromo-NGD+ 
for 30 min, only a small amount of starting material was transformed, clearly indicating an 
inhibitory activity of the added 8 -bromo-NGD+. The HPLC traces for inhibitory effect of 
40|LlM 8 -bromo-NGD+ are shown in Figure 2.29 and more detailed inhibitory effects of 10, 
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Figure 2.29 HPLC traces showing the inhibitory effect of 8 -bromo-NGD+ upon cyclase 
mediated NAD+ cyclisation; a) NAD+ alone for 30 min; b) NAD+ plus 40 pM of 8 -bromo 












F igure  2.30 Inhibitory effect of 8 -brom o-NGD+ upon Aplysia  cyclase mediated N A D + 
cyclisation.
The HPLC trace clearly indicates that 8 -brom o-NGD+, as well as other non-cyclisable 
NAD+ analogues is a potential inhibitor of the Aplysia  cyclase. W ith these potential 
inhibitors in hand, we thus plan to perform  full kinetic studies in future work. 8 -Bromo- 
NGD+ is a novel cADPR analogue worthy of future investigation.
NAD alone
plus 10uM 8-Br- 
NGD
plus 40 uM of 8-Br- 
NGD
plus 60uM of 8-Br- 
NGD
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CHAPTER THREE: CHEMO-ENZYMATIC SYNTHESIS OF 8- 
MODIFIED cADPR AND 2 -DEOXY cADPR ANALOGUES
68
3.1 Introduction
Although numerous cADPR analogues have been synthesised and biologically evaluated, 
the key structural features that control the agonist/antagonist activity of these cADPR 
analogues have still not yet been identified. It is known that 8 -substitution of cADPR can 
convert cADPR from an agonist into an antagonist, indicating 8 -substitution as an 
important motif for producing cADPR antagonists. However, the idea that all 8 -substituted 
cADPR analogues are antagonists, leaving aside inactive compounds such as 8 -piperidyl- 
cADPR, has been found misleading, as some 8 -substituted cADPR agonists that are also 
modified at other parts of the molecule are reported to be agonists of cADPR-sensitive 
calcium release. Shuto et al have reported the synthesis of a small library of 8 -substituted 
cADPcR analogues, using the total synthesis method, which is shown in Figure 3.1.171
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Figure 3.1 Total synthesis of 8 -substituted cADPcR analogues.
It was found that 8 -N3-cADPcR 94 and 8-NH2-cADPcR 95, in contrast to the 
corresponding non-carbocyclic analogues, 8 -N3-cADPR and 8 -NH2-cADPcR, were full 
agonists, which were ca. 80 and 2 times less potent then cADPR in mobilising calcium 
from intracellular stores. Compounds 94 and 95 also exhibit the property of cross-
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desensitization with cADPR-induced calcium release. 8-Cl-cADPcR 93 was also found to 
mobilise calcium, but was 400 times less potent than cADPR. The other analogue 8-SPh- 
cADPcR 96 was found to be inactive possibly due to the bulky SPh group, which may 
block the interaction of the molecule with RyR receptors. In agreement with the above 
biological results, a series of 8-substituted cIDPR analogues synthesised by W agner et al 
were also reported to be agonists of cADPR sensitive calcium release in Jurkat T  cell 
systems. These findings clearly underscore the need for more understanding of such 8- 
substituted compounds, in order to identify the key structural features controlling the 
agonistic/antagonistic behaviour of these molecules, and led us to design, synthesise and 
biologically evaluate some 8-substitued-2'-deoxy cADPR analogues, which have both the 
8-substitutions and the C-2' modification. Aslamu et al reported that 3'-OH deletion results 
in dramatic decrease of cADPR Ca2+ mobilising activity, while 2'-OH deletion hardly 
affects the calcium releasing ability in sea urchin egg system.^This indicates that 3'-OH 
but not the 2'-OH is the key m otif to keep cADPR activity. However, in case o f 8- 
substituted cADPR derivatives, it is possible that the 8-substitutent interacts with 2 -OH to 
aid or modify the conformation of the southern ribose, therefore worth making this class of 
compound. To the best of our knowledge, these have not been reported in any previous 
publications. Combined modification at the 2 '-position of the ribose and the 8-position of 
the purine base will extend the current SAR of cADPR analogues and, in addition, these 2'- 
deoxy analogues could be cell permeant, as removal of a hydroxyl group should increase 
the lipophicility o f these compounds. We report here the synthesis of a series of 8-modified 
2'-deoxy cADPR analogues, namely 8-bromo-2'-deoxy-cADPR 98, 8-amino-2'-deoxy- 
cADPR 99, 8-0-methyl-2'-deoxy-cADPR 100 and 8-phenyl-2'-deoxy-cADPR 101. Their 
ribose counterparts, 8-Bromo-cADPR 17, 8-amino-cADPR 16 and 8-phenyl-cADPR 97 
(Figure 3.2) were also synthesised as control compounds and, their pharmacological 
activities were directly compared with that of the 8-substituted-2'-deoxy cADPR analogues. 
These pharmacological results will be discussed in chapter five.
3.2 Synthetic P lan
To date, cADPR analogues have been synthesised either by total synthesis or by the 
chemoenzymatic method. Both of these approaches have their disadvantages. The major 
drawback of the chemoenzymatic method is the selectivity of the Aplysia cyclase, which 
cannot always catalyse the transformation of NAD+ analogues into the active N1 cyclised 
products. Hydrolysis or N7 cyclisation is often the result for some NAD+ analogues. The 
drawback of the total synthesis approach is that this method currently only works
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efficiently for producing cADPcR analogues and the long synthetic route is tedious just to 
produce a single analogue. None of the published cADPR analogues were produced by this 
method, possibly due to the poor stability of the northern ribose-Nl linkage of these 
analogues. In the light of the fact that the early generation of 8-substituted cADPR 
analogues were all synthesised by the chemoenzymatic approach, we sought to adopt this 
method in our project.
In consideration of the above targeted molecules, it is obvious that the 8-bromo-substituted 
analogues are the most convenient molecules to synthesise, as bromination o f nucleotides 
has been widely reported in many publications and can be achieved in one step in high
172yield. Based on this consideration, W agner et al reported a quick synthetic route towards 
a limited number of 8-substituted-A7-cIDPR derivatives, including 8-amino-cIDPR and 8- 
phenyl-cIDPR. This synthetic approach was centered on 8-bromo-cIDPR, from which 
syntheses of other cIDPR analogues were achieved by replacement of brom o with other 
nucleophiles or by a Suzuki cross coupling reaction. However, this approach relies heavily 
on the excellent and unusual stability of JV7-cIDPR analogues and is therefore not 
applicable in our case, as cADPR analogues are known to undergo rapid hydrolysis at the 
N l-C l"  linkage at raised temperatures. The 8-bromo-NAD+ analogues are also not stable 
for modifications at the 8-position, as the nicotinamide moiety of the m olecule is also 
labile for heat-induced hydrolysis. In consideration of the poor stabilities of these 
pyrophosphate compounds, 8-modifications were therefore introduced at the nucleotide or 
nucleoside stage in our project. These 8-substituted nucleotides were then condensed with 
p-NMN* using the morpholidate/Lewis acid method introduced in the last chapter or by 
using the carbonyldiimidazole mediated condensation, which will be introduced in a later 
section o f this chapter, forming 8-substituted dinucleotides, which were then incubated 
with Aplysia  cyclase, leading to the synthesis of the desired 8-substituted cADPR 




X = OH, Y = Br, 8-Br-cADPR 17
X = OH, Y = NH2, 8-NH2-cADPR 16 
X = OH, Y = Ph, 8-Ph-cADPR 97 
X = H, Y = Br, 8-Br-2'-deoxy-cADPR 98 
X =H, Y = NH2, 8-NH2-2'-deoxy-cADPR 99 
X = H, Y = OMe, 8-OMe-2'-deoxy-cADPR 100 
X = H, Y = Ph, 8-Ph-2'-deoxy-cADPR 101
Figure 3.2 General synthetic plan for 8 -substituted cADPR/2'-deoxy-cADPR.
To fulfill the synthesis of these cADPR analogues, the first objective is to synthesise the 8 - 
modified nucleotides. As we mentioned above, 8 -bromo-substituted nucleotides or 
nucleosides could be synthesised conveniently in one step from commercially available 
starting material. We therefore employed these 8 -bromo-compounds as the initial building 
blocks, from which the synthesis of 8 -azido, 8 -amino, 8 -O-methyl, and 8 -phenyl 
substituted nucleotides or nucleosides could be achieved in one or two steps using 
published protocols. The functional group replacements from 8 -bromo-compounds are 
shown schematically in Figure 3.3 and the reagents that will be used in our experiments are 
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Figure 3.3 Schematic plan of functional group replacements from 8 -bromo-nucleotides 
or nucleosides.
3.3 Synthesis of 8-Substituted Nucleotides and 8-Substituted-2'-Deoxy-Nucieotides.
3.3.1 Synthesis of 8-Bromo-AMP and 8-Bromo-2'-Deoxy-AMP.
Bromination at the 8 -position of AMP and 2'-deoxy-AMP was achieved by adaptation of 
the published protocol of Ikehara et al} 1' 174 Taking bromination of AMP for example, a 
solution of AMP in NaOAc pH 4.2 buffer was treated with an aqueous solution of bromine 
at room temperature (Scheme 3.1). Purification using reverse phase chromatography gave 
8 -bromo-AMP 102 in 85% yield in its triethylammonium salt, showing only one singlet at 
8.25 ppm in the ]HNMR spectrum, representing H-2. The use of AMP as the starting 
material in this case allows the synthetic route to 102 to be shortened sufficiently 
compared with the method in which adenosine was first brominated at C-8  and, then 
phosphorylated at 5 '-OH using POCI3/TEP mixture. Also, another advantage of using 
AMP as the starting material is to avoid the formation of 8 -chloro-AMP, a frequently seen 
by-product in the phosphorylation of 8 -bromo-adenosine. 175 By adaptation of the above 
bromination for AMP, 8-Bromo-2'-deoxy-AMP 103 was also synthesised from 
commercially available 2'-deoxy-AMP in 55% yield as its triethylammonium salt.
NH.
HO'
R-! = PO3H, R2 = OH, 102 
Rt = P 0 3H,R2 = H, 103 
Rt = H, R2 = OH, 104 
R1 = H, R2 = H, 105
Scheme 3.1 Reagents and conditions: (a) bromine in MilliQ water, sodium acetate 
buffer, 0.9 M, pH 4.2.
Two nucleosides, 8 -bromo-adenosine 104 and 8-bromo-2'-deoxy-adenosine 105 were also 
prepared by the same reaction. Purification using flash chromatography gave these two 
compounds as white solids in over 80% yield.
3.3.2 Synthesis of 8-Amino-AMP and 8-Amino-2'-Deoxy-AMP.
Obviously, the convenient way of producing 8 -amino-nucleotides (and nucleosides) from
the corresponding 8 -bromo-nucleotides (nucleosides) is to directly replace the bromo
group with ammonia. However, although nucleophilic addition of amines, for example n-
butylamine, to replace the 8 -bromo-group on purines has been previously reported, 176
using ammonia as the nucleophile was found to be not successful, only producing the
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desired compounds, e.g. 8-amino-adenosine in low yield. 177 It is likely that the low yield 
was caused by the low nucleophicility of ammonia and therefore could not be improved by 
simply changing the reaction conditions. Fortunately, instead of using direct nucleophilic 
attack of ammonia, preparation of 8 -amino-analogues can also be achieved by reduction of 
the corresponding azido compounds, which can be conveniently produced by replacement 
of the bromo with the nucleophilic azido group . 178179-180 However, the standard literature 
procedures for the reduction of azido compounds to amines, such as catalytic 
hydrogenation and various hydride reductions, are not readily applicable in the case of 
synthesising nucleotides (or unprotected nucleosides), as these compounds require aqueous 
solutions as the reaction media. Knowles et al have reported a dithiothreitol (DTT)-
1 o 1
mediated method to reduce aryl azides. This method was later utilised to facilitate the 
reduction of 3'-azido-3'-deoxy-thymidine (AZT) . 182 This DTT-mediated reduction is 
normally performed in aqueous solution at near neutral pH and room temperature thus 
increasing the solubility of polar reactants, e.g., 8 -azido-nucleotides and reduces the risk of 
breaking down these molecules. In the light of above advantages of the DTT-reduction, we 
thus adopted this method in our experiments to facilitate the synthesis of 8 -amino- 
nucleotides (nucleosides) from their azido precursors.
With the above considerations in mind, we thus sought to synthesise 8 -amino-AMP 108 
from the corresponding 8 -azido-AMP 107. In order to shorten the synthetic route, 8 - 
bromo-AMP 102 was first employed in our project, as the starting material to synthesise 
the desired 8 -azido compound 107. The reaction of 102 with sodium azide, as suggested by 
Ashamu ' however failed, as addition of sodium azide in this case transformed 8 -bromo- 
AMP triethylammonium salt into the sodium salt, which was insoluble in the reaction 
solvent DMF (or DMSO), thus blocking the reaction progress.
NH2
• N





HO OHHO' OH 
102
Figure 3.4 Attempts to synthesise 8 -azido-AMP from 8 -bromo-AMP.
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An alternative route, starting from the 8 -bromo-nucleoside 104, was adopted instead to 
achieve the synthesis of 8 -azido-AMP 107 and then 8 -amino-AMP 108 (Scheme 3.2). 8 - 
Azido-adenosine 106 was produced by treatment of 104 with sodium azide in DMF at 
80°C overnight. Purification using flash chromatography gave the desired 8 -azido- 
adenosine 106 in 92% yield, showing a characteristic IR peak at 2156 cm '1' and a 
migration of UVmax from 262 nm to 281 nm . 184 The 8-azido-adenosine was then selectively 
phosphorylated at the 5'-OH using a POCb/TEP/water combination, purified by reverse 
phase chromatography, and then treated with DTT in 0.05 M pH 7.5-8.0 TEAB buffer at 
room temperature in the dark overnight. Purification using reverse phase chromatography 
produced 8 -amino-AMP 108 as its triethylammonium salt in 56% yield over both steps 
(step b and c, Scheme 3.2). A clear shift of UVmax from 281 nm to 274 nm was noticed in 
our project consisting with the observation of Armstrong et alm  The 8 -amino-nucleoside 
109 was also synthesised using the same DTT reduction from compound 106 in 83% yield 
(Scheme 3.2).
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Scheme 3.2 Reagents and conditions: (a) sodium azide, DMF, 80°C, 92%; (b) POCI3, 
TEP, 0°C; (c) DTT, 0.05 M, pH 7.5-8.0 TEAB, rt. overnight, 56% for step b and c.
Adaptation of the above synthetic route to synthesise 8-amino-2'-deoxy-AMP 112 was 
then attempted. 8-Amino-2'-deoxy adenosine 111 was successfully produced by a DTT 
mediated reduction of 8 -azido-2 '-adenosine 110, which was synthesised from 8 -bromo-2 '- 
deoxy-adenosine by replacement of the bromo with an azido group (Scheme 3.3). However, 
phosphorylation of 8 -amino-2 '-deoxy-adenosine was not successful due to the rapid
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degradation of this compound at the N9-glycosyl linkage at acidic pH. We found in our
experiments that 2 '-deoxy-analogues are less stable towards acid induced hydrolysis than
18^their ribose counterparts. This is consistent with previous observations by Garrett et al. 
They found that the apparent first order rate constant for the acid solvolysis of 2'-deoxy- 
adenosine was about 1 000  times that of adenosine under the same condition, suggesting a 
great stablilising effect of 2 '-hydroxyl group on the stability of Cl -N9 linkage. Assuming 
that 2 '-deoxy-compounds, in general, are hydrolysed by the same mechanism that we 
described for the hydrolysis of 8 -bromo-guanosine (Figure 2.29), then, in this case the 
purine base of compound 111 was protonated and then cleaved, forming an oxonium ion at 
the ribosyl C-T position that was then attacked by a water molecule, producing 8 -amino- 
adenine 113 and 2'-deoxy-ribose 114 as the final products (scheme 3.3). The oxonium ion 
was thought to be stabilised by the 2'-OH deletion.
113 114
Scheme 3.3 Reagents and conditions: (a) sodium azide, DMF, 80°C, 91%; (b) DTT, 
0.05 M, pH 7.5-8.0 TEAB buffer, 85%; (c) POCl3, TEP, 0°C.
In order to bypass the difficult phosphorylation reaction, 8-bromo-2'-deoxy-AMP 103 was 
then adopted as the starting material to facilitate the synthesis of 8-azido-2'-deoxy-AMP 
115 and, then the desired amino compound 112. The synthesis of 8-azido-2'-deoxy-AMP 
was achieved by treatment of 8-bromo-2'-deoxy-AMP 103 with sodium azide using 
DMF/MilliQ water 5:1 as the reaction solvent instead of using DMF or DMSO alone. The 
sodium salt that formed in this case was successfully solubilised in this polar solvent 
system and the reaction was completed after heating at 80°C. Purification using reverse 
phase chromatography gave 8-azido-2-deoxy-AMP 115 in 59% yield as the 
triethylammonium salt. The reaction process could not be monitored by HPLC as the 8 - 
azido-2'-deoxy-AMP has the same retention time as the starting bromo compound using
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our solvent systems. Instead, the reaction was monitored by change in the maximum UV 
absorption. A clear shift from 262 to 282 nm was noticed in this case, indicating the 
formation of the 8-azido-2'-deoxy-AMP 112 (Scheme 3.4) . 184
b
103 115 112
Scheme 3.4 Reagents and conditions: (a) sodium azide, DMF-MilliQ 5:1, 80°C, 59%; 
(b) DTT, 0.05 M, pH 7.5-8.0 TEAB buffer, 79%.
The transformation from 8 -azido to 8 -amino was then achieved using DTT-mediated 
reduction (Scheme 3.4). Purification using reverse phase chromatography gave the desired 
8-amino-2'-deoxy-AMP in 79% yield in its triethylammonium form. A maximium UV 
absorption shift from 282 to 274 nm was also observed in this experiment.
3.3.3 Synthesis of 8 -Phenyl-AM P and 8-Phenyl-2'-Deoxy-AMP.
C-modified nucleotides have recently received much attention as these compounds are
18A 18*7 1 fifiinteresting targets for antiviral ’ and anticancer pharmaceuticals, and synthetic 
routes have been designed for these active molecules. Among these, Verlinde et al 
demonstrated a synthesis of 8 -phenyl-adenosine via the Stille-type cross-coupling reaction
189of a protected 8 -bromo-adenosine. A Suzuki-Miyaura cross coupling reaction was also 
recently reported, 190’191’192 facilitating the synthesis of 8 -phenyl-nucleosides from the 
corresponding unprotected 8 -bromo-nucleosides. In general, the Suzuki-type coupling 
reactions are easier to handle than the Stille type as they work in moist or even aqueous 
solutions, and they tolerate the presence of some unprotected functional groups, e.g. the 
hydroxyl group on the nucleoside ribose. Another advantage of the Suzuki cross coupling 
is that many boronic acids are commercially available and inexpensive and non-toxic. Very 
recently, Wagner et al reported a synthesis of 8 -phenyl-cIDPR from 8 -bromo-cIDPR by 
adaptation of the Suzuki cross coupling reaction, demonstrating the wide application of 
this reaction to nucleotide-type compounds. 172 In the light of the above findings, we 
therefore employed the Suzuki cross coupling reaction to produce the desired 8 -phenyl- 
AMP and 8-phenyl-2'-deoxy-AMP. 8 -Bromo-nucleotides 102 and 103 were adopted as the
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starting material in our experiments. It is predictable that the Suzuki coupling reaction will 
also work on the unprotected nucleotides, for example 8 -bromo-AMP, although no 
previous reports of this reaction could be found. Taking the Suzuki reaction of 8-bromo- 
AMP 102 as an example, compound 102 dissolved in MeCN-MilliQ water 1:2 was treated 
with Na2CC>3, phenylboronic acid and the palladium catalyst Pd(PPh3)4 under an argon 
atmosphere at 80°C for 3 h. HPLC analysis indicated that most of the starting material was 
consumed and a new product formed with a retention thime of 12.10 min. Purification 
using reverse phase chromatography gave the desired 8 -phenyl-AMP 116 in 55% yield as 
its triethylammonium salt, showing a multiplet (integration 5H) at the aromatic region of 
its *HNMR spectrum, representing the phenyl group. It was also noticed that the UVmax of 
the phenyl compound migrated to ca 276 nm consistent with the value reported by Wagner 
et al. ]72 8-Phenyl-2'-deoxy-AMP 117 was synthesised in the same manner. In this case, an 
excess of phenylboronic acid (4 eqv.) and Pd(PPh3)4 were added in two stages to the 
reaction system in order to drive the reaction to completion. Indeed, the RP-HPLC trace 
indicated that the starting material had been nearly 1 0 0 % consumed and a new compound 
at 13.71 min was seen as the sole product. Purification using reverse phase media, however, 
gave a mixture of the desired compound 117 triethylammonium salt (92% yield based on 
the ]HNMR integration) and unreacted phenylboronic acid, suggesting that the RP system 
might not work efficiently to separate these two compounds, that have close polarities. The 
mixture was not further purified in this case, but was directly used in the next step to 
produce corresponding morpholidate. It was found that the impurity phenylboronic acid 
was easily removed at the morpholidate step, as it possibly formed a morpholinium salt 
that dissolved in acetone, and therefore was removed in the filtrate together with other 







R = OH, 102 R = OH, 116
R = H, 103 R = H, 117
Scheme 3.5 Reagents and conditions: (a) phenylboronic acid, Pd(PPh3)4, Na2C0 3 , 
MeCN/H20  1:2, 80°C.
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3.3.4 Synthesis of 8-Methoxy-2f-Deoxy-AMP.
It is conceivable that the most convenient way of synthesising 8-0-methyl-2'-deoxy-AM P 
119 is to directly replace the bromo group of 8-bromo-2-deoxy-AMP 103 with a methoxy 
group. Employing 8-bromo-2'-deoxy-AMP as the starting material would certainly shorten 
the synthetic route and also bypass the difficult phosphorylation step. However, the 
attempt failed as the insoluble sodium salt was formed upon addition of sodium methoxide 
to the reaction mixture. Since the reaction requires anhydrous condition, the idea of using 
aqueous solution is not applicable in this case. However, the synthesis o f 8-0-methyl-2'- 
deoxy-adenosine 118 from 8-bromo-2'-deoxy-adenosine 105 was easily achieved by 
refluxing 105 with sodium methoxide in anhydrous methanol for overnight. 178 Purification 
using flash chromatography gave the desired 8-0-methyl-2'-deoxy-adenosine 118 in 95% 
yield, showing a singlet (integration 3 H) at 4.08 ppm in the ]HNMR spectrum, indicating 
the presence of the O-methyl group at the 8 -position (Scheme 3.6). With 8-0-m ethyl-2'- 
deoxy-adenosine in hand, the task now was to introduce the phosphate group to the 5 -OH. 
It was found in the previous section that phosphorylations of 2 -deoxy compounds were 
rather difficult due to the relatively rapid hydrolysis of these molecules at acidic pH. We 
thus carried out this reaction under anhydrous conditions and also at low temperature. 8 -0 - 
methyl-2'-deoxy-adenosine was treated with POCI3 in trimethylphosphate at -20°C for 2 h. 
HPLC analysis indicated that all the starting material had been consumed and a new 
product was detected at 6.21  min, indicating the formation of a mono-phosphate. 
Quenching of this reaction using water, however, resulted in rapid hydrolysis o f compound 
118 at the N9-glycosyl bond, suggesting that a buffer might be required to reduce the 
acidity of the solution after quenching. Water/pyridine mixture and 1 M TEAB buffer were 
earlier tried in our experiments, but both of these failed. Real progress was made when an 
aqueous solution of NH4HCO3 was added to the reaction system. HPLC analysis indicated 
that after quenching with NH4HCO3 solution the peak at 6.21 min was only moderately 
degraded. We later found that the reaction could be quenched by ice, followed by 
immediate addition of 5 M NaOH, adjusting the pH to ca 7. After quenching, the reaction 
solution was extracted with cold ethyl acetate and purified by reverse phase 
chromatography. Further purification using ion-exchange chromatography removed any 
residual trimethylphosphate, giving the desired 8-<9-methyl-2'-deoxy-AMP in 20% yield. 
A singlet at 1.33 ppm in the 31PNMR spectrum was seen, representing the 5'-mono- 
phosphate.
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Scheme 3.6 Reagents and conditions: (a) sodium methoxide, anhydrous methanol, 
reflux, 24 h; (b) POCI3, trimethylphosphate, -20°C, 2 h, 20%.
3.4 Synthesis of 8-Substituted NAD+ /2'-Deoxy-NAD+ analogues.
3.4.1 Synthesis of 2 -Deoxy-NAD+ Analogues via CDI-m ediated Condensation.
Although the Lewis acid catalysed condensation of P-NMhT and nucleotide morpholidates 
was well established in chapter two, it was not initially adopted in synthesising the 8 - 
substituted-2'-deoxy-NAD+ analogues, because the syntheses of morpholidates from the 
corresponding 8-substitued-2'-deoxy-AMP were not successful. Initially, it was believed 
that the nucleotide free acids were the appropriate starting material to produce the 
morpholidates. However, attempts to convert our 8-substituted-2'-deoxy-AMP 
triethylammonium salts into free acids failed, as these molecules were prone to rapid 
hydrolysis on the ion-exchange resin (H+ form). Therefore, a carbonyldiimidazole (CDI) 
mediated condensation was used instead to synthesise the desired 2'-deoxy-NAD+ 
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X = Br, 103
X = NH2, 112 X = NH2, 123
X = OMe, 119 X = OMe, 124
X = H,121 X = H, 125
Scheme 3.7 Reagents and conditions: (a) CDI, TEA, r.t, anhydrous DMF, 3 h; (b) 
anhydrous DMF, 2 days.
In general, (3-NMN+ was first treated with TEA then with an excess of CDI in anhydrous 
DMF to provide the activated phosphoimidazolium intermediate 120, showing a
O 1
characteristic singlet at ca -9.0 ppm in the ' PNMR spectrum. After the remaining CDI was 
quenched by addition of methanol, the intermediate was treated with nucleotides in 
anhydrous DMF to form the desired NAD analogues. Taking the CDI condensation of 8 - 
bromo-2'-deoxy-AMP as an example, purification using ion-exchange chromatography 
gave desired 8-bromo-2'-deoxy-NAD+ 122 in 31% yield, the product showing a triplet at 
6.38 min and a doublet at 5.98 min in the ]HNMR spectrum, representing the H -l' and H- 
1” anomeric protons, respectively. In the 31PNMR spectrum, two doublets were seen at - 
11.17 ppm and -10.53 ppm, indicating the formation of the pyrophosphate bond. The 
31PNMR spectrum of compound 122 is shown in Figure 3.5.
81
|—i ■—i-  . I i i ' i I '  ■ i  i | ■ i I i i - r  i | i ■ f r-'i~T  ■■ i ■ " | ■ ■ ■ i | ■ '
-6.0 -7.0 -8.0 -9.0 —10.0 -1J.O -12.0 -13.0 -14.0 —15.0 -16.0 -17.0 -18.0
T
.O -7 O 8 . O 9
Figure 3.5 31PNMR spectrum of 8-bromo-2'-deoxy-NAD+. This spectrum is also
applicable to all other NAD+ or 2'-deoxy-NAD+ analogues (/pp normally 15-20 Hz).
8-Amino-2'-deoxy-NAD+ 123, 8-0-methyl-2'-deoxy-NAD+ 124 and 2'-deoxy-NAD+ 125 
were synthesised in the same manner. Purification using ion-exchange chromatography 
gave compound 123,124,125 in 39%, 39% and 42%, respectively.
3.4.2 Synthesis of 8-Substituted NAD+ Analogues via Corresponding M orpholidates.
It was later found that morpholidates could also be synthesised from the corresponding 
nucleotide triethylammonium salts, instead of the free acids, without decreasing the 
reaction rate and yield. Based on this finding, we thus attempted to also synthesise the 
morpholidates for our 2'-deoxy-AMP analogues. 8-Bromo-2'-deoxy-AMP morpholidate 
126 was then synthesised by treatment of compound 103 with a combination of 
triphenylphosphine, morpholine and dipyridyl disulfide in anhydrous DMSO at room 
temperature. Work-up of this reaction gave the desired 8-bromo-2'-deoxy-AMP 
morpholidate 126 as a yellow solid in 72% yield, showing a characteristic singlet at 8.20 
ppm in the 31PNMR spectrum, representing the formation of morpholidate (Scheme 3.8). 
The successful synthesis of compound 126 indicated that desired 8-substituted-2'-deoxy- 
NAD+ analogues could also be produced via the Lewis acid mediated condensation of p- 
NMN* and corresponding 8-substituted-2'-deoxy-AMP morpholidates. We thus adopted
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this coupling procedure as the unified method to facilitate the synthesis of dinucleotide 
compounds 131,132,133 and 134.
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X = Br, Y = H, 126 
X = Br, Y = OH, 127 
X = NH2, Y = OH, 128 
X = Ph, Y = OH, 129 
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X = NH2, Y = OH, 132 
X = Ph, Y = OH, 133 
X = Ph, Y = H, 134
Scheme 3.8 Reagents and conditions: (a) triphenylphosphine, morpholine, dipyridyl 
disulfide, DMSO, rt.; (b) p-NMIsT, 0.2 M MnCL in formamide, MgSCL, rt. 2 days.
Prior to condensing with P-NMbT, monophosphates 102, 108, 116 and 117 were first 
activated to form the corresponding morpholidates 127-130 by treatment of these 
compounds with triphenyl phosphine, morpholine and dipyridyl disulfide. The yields and 
selected spectroscopic data of these mopholidates are listed in table 3.1.
Compounds H-L (ppm) J 1 \T (Hz) 31P NMR (ppm) Yields
127 6 .0 0 4.7 8.26 85%
128 5.92 7.2 7.90 67%
129 5.79 4.9 8.29 74%
130 6.26 7.4 8.21 82%
Table 3.1 Summary of data for morpholidates synthesised in our project.
The above morpholidates were then condensed with p-NMN+ in the presence of a Lewis 
acid (MnCh) in formamide at room temperature. Purification using reverse phase 
chromatography gave the desired dinucleotides, 8 -bromo-NAD+ 131, 8 -amino-NAD+ 132, 
8 -phenyl-NAD+ 133 and 8-phenyl-2'-deoxy-NAD+ 134 as their triethylammonium salts 
(Scheme 3.8). Data for these NAD+ analogues are summarised in Table 3.2.
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Compounds H -l' (ppm) J y r  (Hz) H -l" (ppm) J\'\2" (Hz) HPLC (min) Yields
131 5.93 5.5 5.96 3.4 3.31 63%
132 5.84 7.1 6.08 5.1 3.25 51%
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3.5 Enzymatic Synthesis of 8-Substituted-cADPR/2'-Deoxy-cADPR Analogues.
In contrast to what we introduced in chapter two, incubation of the above 8 -substituted- 
NAD+/2'-deoxy-NAD+ analogues with Aplysia cyclase resulted in the formation of N l-  
cyclised cADPR analogues. NAD+ analogues 122-124 and 131-134 were incubated with 
Aplysia cyclase at room temperature in pH 7.4 HEPES buffer. Purification of products 
using ion-exchange chromatography gave the desired 8 -substituted-cADPR analogues 16, 
17 and 97-101 (Figure 3.2) as their triethylammonium salts. These 8 -substituted analogues 
are summarised in Table 3.3. The cyclic structures of these cADPR analogues were 
confirmed by the ’HNMR spectrum: 1) the aromatic peaks at 8-9 ppm representing 
nicotinamide had disappeared, indicating the cleavage of the nicotinamide moiety in this 
reaction; 2) two doublets were observed at ca 6.0 ppm, representing both the H -l ' and H -l", 
demonstrating that these two riboses were still connected with the purine base by a 
glycosyl bond. Typical ]HNMR data for these cyclic analogues are shown in Figure 3.6.
Compounds H -l'(ppm ) J  r,2'
(Hz)
H -l" (ppm) Jy\2" (Hz) HPLC (min) Yields
17 6 .0 2 5.3 5.99 4.0 8.40 78%
16 5.80 5.6 6.01 4.0 4.41 74%
97 6.07 6 .0 6 .2 0 4.2 11.34 69%
98 6.55 6.7, 6.2 6.11 4.0 7.78 8 6 %
99 6.06 6.9, 6 .6 5.89 4.1 3.97 77%
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Figure 3.6 Typical 'HNMR spectrum of 8 -substituted-cADPR analogues, in which the 
nicotinamide region and the anomeric region are highlighted with dashed rectangles.
The enzymatic reaction was monitored by ion-pair HPLC. It was found that the above 
NAD+ analogues were turned over by the Aplysia cyclase at a similar rate to that of NAD+ 
itself. The fact that 8 -phenyl-NAD+ and 8-phenyl-2'-deoxy-NAD+ were also converted by 
the cyclase into the corresponding cyclic compounds further indicated, perhaps 
surprisingly, that the enzyme has excellent tolerance towards even large substitutions at the 
8 -position.
3.6 Conformational Assignment of the above cADPR Analogues.
The three-dimensional structure of the cADPR analogues in aqueous solutions is very 
important from the viewpoint of identifying the bioactive conformations. We thus, in this 
section, focused on determining the NMR solution structures of our 8 -substituted- 
cADPR/2'-deoxy-cADPR analogues. It has been reported that from ]HNMR data, the 
conformation of the furanose ring, the conformation around the glycosyl bond and the 
conformation around the P and y  bonds could be estimated . 194 195196 The conformation 
around the P and y  bonds (see Figure 3.7), known as the backbone conformation, require 
more detailed NMR analysis or the assistance of molecular modeling, and thus were not 
included in this project. It is known that the furanose ring conformation of cADPR 
analogues in solution can be described as an equilibrium between C2'-endo (south type or 
S-type) and C3'-endo (north type or N-type). The furanose rings are twisted out of the 
plane in order to minimise the nonbonded interactions between their substituents. This 
puckering is described by identifying the major displacement of C2' and C3' from the C l'-  
04'-C4' plane. For example, C2'-endo is defined when the endo displacement of C2' is
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greater than the exo displacement of C3' (endo face is on the same side as C5' and the 
base). These two conformations are shown in Figure 3.7, in which P and y bonds are also 
defined. The magnitude of the H l'-H2' coupling constant has been found to be related to 
the ratio of C2'-endo conformer to C3'-endo conformer and Altona et al have reported that 
the percentage of C2'-endo can be determined mathematically as lO Jyr.194 In the light of 
the above findings, we then calculated the conformation of the southern ribose of our 8 - 
substituted-cADPR/2'-deoxy-cADPR analogues, based on the coupling constants listed in 






R = OH or H R = OH or H
C2'-endo, large J V 2  C3'-endo, small J v  2'
Figure 3.7 Schematic drawing of the two conformers of furanose ring.
We also summarise the synlanti conformation about the N9-glycosyl bond for these 8 - 
substituted-cADPR/2'-deoxy-cADPR analogues in table 3.4. The term syn and anti are 
defined by rotation of the base in relation to the sugar about the glycosyl bond. The 
rotation is defined by the torsion angle x formed by the atoms C4-N9-CT-04'. The torsion 
angle range of 0 ± 90° is referred to syn and the range of 180 ± 90° is defined as anti. It is 
known that during the enzymatic reaction the Aplysia cyclase must arrange the NAD+ into 
the syn conformation, leading to the formation of A7-cADPR also in the syn conformation. 
The crystal structure of cADPR indicated that the torsion angle % of cADPR is 64 (± 1)°. It 
is also known that substitution at the 8 -position often induces a change of the conformation 
from anti for unsubstituted compounds to syn, due to the nonbonded repulsion between the 
8 -substitution and the ribose ring . 11'1' 197 Combining the above findings, it is thus likely that 
our 8-substituted-cADPR/2'-deoxy cADPR analogues also adopt the syn conformation 
about the N9-glycosyl bond. ]HNMR data for syn and anti conformers of nucleotides were 
compared and it was found that among resonances for the relevant protons, H-2' is 
influenced by the glycosyl bond conformation. The chemical shift of H-2' has therefore 
been explored as an indicator of the syn/anti conformation and a significant downfield 
migration of H-2' for a syn conformer, compared to that of the anti conformer, is normally 
expected (a +0.59 ppm shift was observed for cADPR with respect to that of AM P198). 
This downfield shift was explained by a ring current deshielding effect or the magnetic
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anisotropy effect of the N3 position of the base, since this position is proximal to H-2' in 
the syn conformation. The H-2' chemical shifts of our 8 -substituted-cADPR analogues 16, 
17 and 97-101 are summarised in table 3.4. It was found that for all our cyclic molecules, 
the signal corresponding to H-2' was shifted significantly downfield, demonstrating the 
presence of the syn conformation at the N9-glycosyl bond of these molecules.
Compounds C2'-endo % (10J L2) H-2' ppm A h - 2 ' Syn/anti
17 53 5.35 0.91 Syn
16 56 5.36 0.92 Syn
97 60 5.56 1 .1 2 Syn
98 62-67 3.20 (H-2'a) 0.4 Syn
99 66-69 3.19 (H-2'a) 0.39 Syn











analogues. A h-2' values represent the difference between the chemical shift of H-2' of the 
above cyclic compounds and H-2' of AMP or 2'-deoxy-AMP. H-2' chemical shifts for 
AMP and 2'-deoxy-AMP are 4.62 and 2.80 (H-2'a), respectively.
In conclusion, the cyclic compounds synthesised in our project all adopted mainly C2'- 
endo in the southern ribose and, syn conformation about the glycosyl bond.
3.7 A ttem pt to Synthesise 2',3'-Deoxy-cADPR.
Apart from the synthesis of the above 8-substituted-2'-deoxy-cADPR analogues, we also 
sought to synthesise the 8-substituted-2',3'-dideoxy-cADPR analogues in our project. With 
a dideoxy southern ribose, these molecules are potential targets to exhibit biological 
activities differing from their ribose counterparts by adaptating unusual conformations. 
Zhang et al199 reported that deletion of whole of southern ribose give weak membrane 
permeable agonist, suggesting that 8 -substituted 2',3'-dideoxy-cADPR may also be 
potentially more membrane permeable than their ribose counterparts, thus also cell 
permeant. It is clear that synthesis of these molecules can lead to an extended 
understanding of the SAR of the 8 -substituted-cADPR analogues and thus contribute to the 
synthesis of potent antagonists in future work. The synthesis was first attempted on a
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model compound, 2',3'-dideoxy-cADPR. The starting building block 2',3'-deideoxy-




Scheme 3.9 Reagents and conditions: (a) terf-butyldimethylsilyl chloride, imidazole, 
anhydrous DMF, rt. 24 h, 94%; (b) lj'-thiocarbonyldiimidazole, anhydrous DMF, 
overnight, 91%, (c) Bu^SnH, AIBN, toluene, refluxing 3 h, 69%; (d) TBAF, THF, rt. 4 h, 
79%; (e) i- Bis(benzyloxy)diisopropylaminophosphine, DCM, imidazolium triflate, ii- 
mCPBA, 37%. (f) Pd(OH>2, cyclohexane, 80°C.
2 -Deoxy-adenosine was first selectively silylated at the 5 '-hydroxyl group using tert- 
butyldimethylsilyl chloride/imidazole in anhydrous DMF. Purification using flash 
column chromatography, eluting with DCM-MeOH gave the desired 5'-OH protected 
compound 137 as a white solid in 94% yield. Treatment of the compound with 1,1'- 
thiocarbonyldiimidazole in DMF overnight resulted in the formation of an imidazolide 138. 
Purification using flash chromatography gave the compound as a yellow oil in 91% yield. 
Radical deoxygenation of the compound 138 with tributyltin hydride (Bu^SnH) and AIBN 
azobis(2-methylpropionitrile) in refluxing toluene provided the 5'-protected-2',3'-deoxy 
compound 139 as the major product. Purification using flash column chromatography, 
eluting with a gradient of 0-5% methanol against DCM, gave compound 139 in 69% yield. 
Treatment of compound 139 with TBAF led to the cleavage of the protecting group, giving 
2',3'-dideoxy-adenosine 140 in 79% yield. With the desired building block 140 in hand, we 
then attempted to phosphorylate the compound at the 5 '-OH position. However, the 
conventional POCI3/TEP method failed due to the poor solubility of the compound in the 
reaction solution. We therefore tried phosphitylation with 
bis(benzyloxy)diisopropylaminophosphine under the catalysis of imidazolium triflate. The
reaction was completed in a low yield as both the 5'-OH and 6-position NH2 were 
phosphorylated due to the addition of excess equivalents of phosphitylating reagent. 
Purification using flash column chromatography gave the desired compound 141 as 
colourless oil in 37% yield. Hydrogenolysis of the compound however was not successful 
and resulted in the degradation of the compound at the N9-glycosyl bond. The reason for 
the degradation is not clear, but it is assumed that the extremely weak acid stability of 
2',3'-dideoxy com pound185 may contribute to the degradation in this case. So far, an 
efficient method for phosphorylating compound 141 has not yet been found in our project. 
Due to the difficulty of this phosphorylation and the limitation of the research time, the 
syntheses of these 2',3'-dideoxy-compounds were therefore not accomplished in this 
project. Further studies will be carried out in future work.
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CHAPTER FOUR: SYNTHESIS OF 7-DEAZA-cADPR ANALOGUES 
AS POTENTIAL HYDROLYSIS RESISTANT, MEMBRANE 




The first useful cADPR analogues were substituted at the 8-position of the purine base. 
These 8-substituted compounds are widely used as competitive antagonists to investigate 
the role of cADPR in mobilising the calcium from intracellular stores. However, these 
compounds, like cADPR, are still prone to chemical or enzymatical hydrolysis.81 Clearly, 
the average stability of these compounds prevents their use in time dependent experiments 
and in extended whole cell work, illustrating the need for stable, hydrolysis-resistant 
cADPR antagonists. Among the cADPR analogues, 7-deaza-cADPR, a cADPR partial 
agonist, was found to be stable during high temperature experiments and also to be a poor
i msubstrate for cADPR hydrolysis. Notably, a single modification increased the stability to 
the compound by simply replacing the N7 with a carbon atom, demonstrating that this 
single modification gives hydrolysis resistant analogues. This finding later led to the 
synthesis of 7-deaza-8-bromo-cADPR, a compound possessing the 7-deaza modification 
and also the 8-bromo-substitution, as a potential hydrolysis resistant antagonist of cADPR 
induced calcium release. Indeed, 7-deaza-8-bromo-cADPR 22, was found to be an 
antagonist in both the sea urchin system and in T-cells. In sea urchin eggs it was nearly 
twice as potent as the 8-bromo-cADPR. This compound was also found to  be resistant 
towards chemical and enzyme induced hydrolysis. Interestingly, the compound was also 
cell permeant, which was possibly brought about by the combined lipophilic modification 
of 7-deaza and 8-bromo-substitution. 7-Deaza-8-bromo-cADPR is one of the best-known 
pharmacological tools, facilitating studies in fertilisation and stimulus-secretion coupling, 
which were otherwise hindered by the poor stabilities of other cADPR antagonists.144 The 
cell membrane permeability of 7-deaza-8-bromo-cADPR also contributes to the passage of 
this antagonist into intact cells, which usually relies on techniques like microinjection or 
patch pipette technique. Nevertheless, the existing route to this important compound is not 
optimised and is low yielding.
Due to the interesting properties of compound 22, we endeavoured to optimise a synthetic 
route, since our previously chemo-enzymatic route of 22 was rather low yielding, in which 
the key intermediate 7-deaza-8-bromo-NAD+ 147 was synthesised via a 
dicyclohexylcarbodiimide (DCC) mediated condensation of 7-deaza-8-bromo-AMP 145 
and p-NMN+ (Scheme 4.1, step d).202 Here, we describe a new optimised synthetic route 
towards compound 22, by employing the chemo-enzymatic approach, in which the 
morpholine activated intermediate 146 was introduced, followed by a Lewis acid catalysed 
condensation with (3-NMN* (Scheme 4.1, step c and e) to give the desired intermediate
dinucleotide 147 in a high yield over 2 steps. In this chapter we also report a synthesis of 
the novel 7-deaza-2'-deoxy-cADPR 164 (Scheme 4.4), a potential cell permeable, 
hydrolysis-resistant agonist of cADPR-sensitive calcium release.
4.2 Synthesis of 7-Deaza-8-Bromo-cADPR.
Compound 22 was synthesised using the commercially available compound, 7-deaza- 
adenosine (Tubercidin 143) (scheme 4.1).
147
Scheme 4.1 Reagents and conditions: (a) potassium acetate, NBS, dry DMF, rt; (b) 
triethylphosphate, POCI3, 0°C; (c) morpholine, dipyridyldisulfide, PPhi, DMSO, rt.; (d) (3- 
NMN+, DCC, MilliQ water/pyridine, rt.; (e) (3-NMN\ MnCh, MgSCU, formamide, rt.; (f) 
Aplysia. californica ADP-ribosyl cyclase, 25 nM HEPES buffer (pH 7.4), rt.
Compound 143 was selectively brominated at the pseudo-8 -position (6 -position) using a 
combination of A-bromosuccinimde (NBS) in DMF,203 which has been reported to be a 
mild combination of electrophilic bromination.204 A solution of 7-deaza-adenosine in DMF 
was treated with freshly crystallised NBS and the resulting red solution was stirred at rt for 
15 min. Purification using flash column chromatography gave the desired compound 144 
showing a singlet at 6.74 ppm, representing H-7, indicating that a bromination had 
occurred at the 8 -position. The occurrence of the 8 -bromination was confirmed by gHMBC 
(Figure 4.1). The 7-deaza-8-bromo-adenosine 144 was assumed to adopt a syn
92
conformation around the N9-glycosyl bond to minimise the nonbonded repulsion between 
the 8 -bromo group and the ribose. W e introduced already in chapter three (section 3.7) that 
the chemical shift o f H-2' has been explored as an indicator of the syn/anti conformation. 
A significant downfield shift of H-2' for the syn conform er is normally expected. The 
chemical shift o f H-2' o f 8-brom o-7-deaza-adenosine 144 is 8 5.12 ppm, and is 
significantly shifted downfield compared to its unsubstituted counterparts, indicating a syn 
conformation about the N9-glycosyl linkage. An explanation was proposed to rationalise 
the 8 -position selectivity, in which the reaction was assum ed to go through an electrophilic 
substitution, as the free radical reaction was not likely to happen under these conditions. 
Under the basic buffer condition, the 3- and 6 - position nitrogen atoms were not protonated 
or complexed with Lewis acid and therefore the lone pair on these nitrogen atoms donated 
electron density through the conjugated system, facilitating the electrophilic attack at C -8 , 
producing 8 -brom o-tubercidin as the major product. This stabilising effect by conjugation 





Figure 4.1 M echanism  of 6 -amino group directed brom ination reaction at the pseudo- 
8 -position (a). The 8 -bromination was determined by the gHM BC and a three-bond 
coupling between C - l ' proton and the C -8  carbon was observed (b). 8-Bromo-7-deaza- 
adenosine is proposed to adopt a syn- confirmation.
Dry 8-brom o-7-deaza-adenosine was selectively phosphorylated at the 5 '-hydroxyl group 
by adaptating a previously published method. Treatm ent o f compound 144 in TEP with 
POCI3 and a trace am ount of water at 0°C for 1 h, resulted in the formation o f a single 
product 145 showing a characteristic HPLC peak at 9.17 min. The desired 7-deaza-8- 
bromo-AM P 145 was first purified using reverse phase chrom atography to remove any 
residual inorganic phosphate. Further purification on a Q-Sepharose ion-exchange column 
removed the rem aining starting material and the compound 145 was isolated as a 
triethylam m onium  salt in 77% yield. Having synthesised 7-deaza-8-brom o-AM P, we now 





7-deaza-8-bromo-NAD+ had been synthesised using a DCC mediated formation o f the 
pyrophosphate bond. A solution o f 7-deaza-8-bromo-AMP 145 and P-NMN* in pyridine- 
water (4:1) was treated with DCC at rt for 7 days. Purification using ion-exchange 
chromatography gave the desired dinucleotide 147 as its triethylammonium salt in only 
28% yield. Clearly, the DCC coupling reaction also generates symmetrical product as we 
mentioned in the earlier chapter and cannot be further optimised to increase the yield o f the 
desired NAD+ analogs and reduce the amount o f symmetrical products, and therefore is not 
ideal for synthesising the novel pyrophosphate 147. Here we synthesise compound 147 by 
adapting the Lewis acid condensation method, as shown in scheme 4.1. The nucleoside 
monophosphate 145 (Scheme 4.1) was first activated using a combination of 
triphenylphosphine/dipyridyl disulfide and morpholine to give the phosphoromopholidate 
146 as the single product in 87% yield. The phosphoromopholidate 146 was then 
condensed with p-NMNf in the presence of Lewis acid (MnCL/formamide) to give the 
desired pyrophosphate 147, which was then purified by reverse phase chromatography in 
79% yield. The overall yield of this two-step synthesis was 69%. 1.7 Equivalents o f (3- 
NMN+ were used in our procedure in order to completely consume the starting 
morpholidate. The residual J3-NMN* was conveniently removed by reverse phase 
chromatography as it has higher polarity than the desired compound 147 and therefore has 
a shorter elution time. The synthesis of the final compound 7-deaza-8-bromo-cADPR 22 
was achieved by incubating compound 147 with commercial Aplysia cyclase at rt and pH
7.4 (HEPES buffer). HPLC analysis indicated that the cyclisation of 147 finished at a 
similar rate to that of NAD+, demonstrating an excellent enzyme-substrate binding of 
compound 147 with Aplysia cyclase. The resulting cyclic compound 7-deaza-8-bromo- 
cADPR 22 was purified by Q-Sepharose ion-exchange chromatography in 72% yield as its 
triethylammonium salt, representing a considerable improvement on the old synthesis. It 
was noteworthy that in the HPLC analysis, 7-deaza-8-bromo-NAD+ was converted into the 
cyclic analogues in quantitative yield, but some product was lost during the purification 
process. gHM BC Data of the cyclic compound 22 were collected and are shown in Figure 
4.2. From this 2D spectrum (Figure 4.2), the three-bond connection between C - l ' proton 
and a quaternary carbon was clearly observed, indicating a substitution at 8-position. 
However, the C - l"  proton and C-2/C-6 connections were not identified, possibly reflecting 
a weaker bond linkage between C -l"  and the purine N l. Indeed, as demonstrated in the X- 
ray structure o f cADPR,205 the C-1"-N1 bond (1.54 A) is significantly weaker than the C- 
l'-N 9 bond (1.44 A). The cyclic structure o f compound 22 was firmly identified by the ID
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'HNMR spectrum where the nicotinamide signals were lost and two characteristic doublets 
were observed at 6.12 and 6.05 ppm.
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Figure 4.2 HMBC spectrum and DEPT spectrum of 8-bromo-7-deaza-cADPR.
4.3 Conform ational Study of Com pound 22.
To date, some hypotheses have been proposed to answer the important issue why 8- 
substitued cADPR analogs are antagonists while cADPR itself is agonist. In one of the 
hypotheses, it was assumed that substitutions such as the bromo group at 8-position push 
the southern ribose into a C3'-endo conformation to give a molecule which is then an 
antagonist. Kudoh et a/206also reported that 2”,3'-dideoxydihydro cADPcR, an inactive 
compound, adopted a major C3'-endo and high anti conformation, indicating the ribose
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and glycosyl linkage conformations are of crucial importance for calcium release activities 
of cADPR analogues. To determine the active conformation of compound 22 in aqueous 
solutions, its ribose C2'-endo/ C3'-endo ratio and glycosyl bond conformations were 
calculated. It is well established that the C2'-endo/ C3'-endo ratio of nucleotide can be 
mathematically calculated from ]HNMR data by adaptating the equation [C2'-endo\ (%) = 
U vpA J wt + / 3\4-)] x lOO.206’207’194 Using ID *H NMR, 2D gCOSY and HMQC, the 
chemical shifts of each proton of compound 22 were clearly identified and the coupling 
constants of these protons were calculated. The coupling constants of protons in northern 
ribose and southern ribose are listed in table 4.1.
Southern ribose 7]'j2' 5.9 Hz J T,y 5.6 Hz Jy,A' 3.5 Hz 74-5'a7 .0H z 74-,5-bn.da
Northern ribose 7,-,2-4.1 Hz 72",3"4.6 Hz Jy'A'-2.3 Hz / /
Table 4.1 Selected coupling constant from ID ]H NMR of 22 (pH 6.0 in D 2O).
Among these coupling constants, the important Jy# of the southern ribose could not be 
easily identified from the ID  1HNMR spectrum since H-3' overlapped with H-2” and H-4” 
and therefore the its coupling with H-2' and H-4' could not be directly identified. 
Fortunately, H-4' was clearly separated from all other signals and therefore it was possible 
to calculate the desired H-374' coupling constant (73-4-). After decoupling of one of the two 
H-5' protons, H-4' was observed as a double doublet. The coupling constants (Jw  and / 4',5'a) 
of this double doublet were found to be 3.5 and 7.0 Hz. Further decoupling experiments for 
the H-3'4”2” multiplet made H-4' also a double doublet in which two coupling constant 
( / 4',5'a and / 4',5'b) were extracted. One of the coupling constants was found to be 7.0 Hz and 
the other was to small to be calculated. Clearly, the large coupling constant (7.0 Hz) was 
derived from the coupling of H-4' and H-5'a, while the smaller one (3.5 Hz) was produced 
by the coupling of H-3' and H-4'. The assignment of J y y  was agreed by the finding that the 
summary of 7 j-,y and J y ^  closes to 10 Hz.194
From the coupling constants listed in table 4.1, we found in aqueous solution (ca pH 6.0) 
that, 7-deaza-8-bromo-cADPR adopts 62% C2'-endo of the southern ribose which is 
consistent with the observation in the crystal structure, that the m ajor puckering mode of 
cADPR is C2'-endo.205 The conformation of the northern ribose was calculated to be 64%
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C2"-endo. In agreement with our observation, three cyclic compounds, cADPR, 2'-OMe- 
cADPR and 3'-OMe-cADPR were studied by Graham et al.m  and all of these compounds 
demonstrated the dominant C2"-endo conformation of the northern ribose.
Clearly, the C2'-endo/ C3'-endo ratio of 7-deaza-8-bromo-cADPR (southern ribose 62% 
C2 -endo) is close to that of cADPR (southern ribose 64% C2'-endo reported by Shuto et 
al).206 In addition, 7-deaza-8-bromo-cADPR adopts a syn conformation around the N9 
glycosyl linkage due to a repulsion of the bulky bromo group and the ribose moiety. H-2' 
of compound 22 has a downfield shift of +1.03 ppm with respect to that of 7-deaza-AMP, 
further indicating a syn conformation. cADPR also has a syn conformation around the 
glycosyl bond as indicated in the crystal structure. Based on the above findings, we 
therefore assume that at least for 7-deaza-8-bromo-cADPR 22, the antagonistic activity is 
not caused by the C2'-endo/C3'-endo conversion or the syn/anti conformation changes and 
this issue remains open. The one with conformationally restricted analogues in both riboses 
would be an interesting future direction. The comformation of 22 is shown in Figure 4.3.
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Figure 4.3 Dominant conformations of 22. 22 adopts mainly C2'-endo at both riboses 
and syn conformation around N9-ribose linkage.
4.4 Synthesis of 7-Deaza-2'-Deoxy cADPR.
By adaptating the synthetic route for compound 22, we also synthesised 7-deaza-2'-deoxy- 
cADPR 164 (scheme 4.2) as a potential cell permeant, hydrolysis resistant partial agonist. 
Due to the absence of 2'-hydroxyl group, compound 164 is thought to be more lipophilic 
than its ribose counterparts and therefore has more potential to be cell permeant, as it is 
well known that cell membrane permeability parallels lipophilicity. It is also conceivable 
that compound 164 is an agonist for calcium release like its ribose analogue, 7-deaza- 
cADPR 21 since it has been reported that the 2'-deoxy modification will not essentially 
decrease the activity of cADPR analogues.84 An additional hydrolysis resistant property
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was also expected for compound 164 and indeed, 7-deaza-2'-deoxy-cADPR 164 is more 
stable than other 2 '-deoxy compounds according to our later hydrolysis studies.
The synthesis of compound 164 employed compound 159 as the important building block, 
which could conveniently react with a range of nucleophilic amines and introduce a variety
reaction with ammonia (scheme 4.4). Compound 159 was synthesised by the condensation 
of 6-chloro-7-deaza-adenine 154 (4-chloro-pyrrolo-[2,3-<7]-pyrimidine) and the a- 
halogenose 158 (scheme 4.4). Compound 154 was synthesised using the procudure of
cyanoacetate 148 led to the formation of ester 150 (54%), which was condensed with 
thiourea in a basic medium (EtONa in ethanol in this case) to gave the substituted 
amidopyrimidine 151 as a yellow solid in 60% yield. Compound 151 was cyclised by 
treatment of this compound with 0.2 M HC1 overnight, giving compound 152 in 
quantitative yield. Desulfurisation of compound 152 using Raney nickel gave compound 
153, which was then treated with POCI3 to form the desired chloro derivative 154 as a 
yellow solid (Scheme 4.2) in a yield of 48% for the last two steps.
Scheme 4.2 Reagents and conditions: (a) K2CO3 , KI, refluxing, 54%; (b) sodium
ethoxide, refluxing, 60%; (c) 0.2 M HC1, quantitive yield; (d) Raney nickel, 73%; (e) 
POCI3 , 65%.
a-Halogenose 158 was synthesised from 2'-deoxy-ribose 155 using known protocols . 209 
Compound 155 was first treated with a solution of HC1 (gas) in dry MeOH for 15 min, 
forming l'-methoxy-2'-deoxy ribose the 156, showing a fast moving spot on tic as a 
mixture of anomers. Treatment of 156 with p-toluoyl chloride provided 3',5' protected 
compound 157 as a mixture of anomers, which was treated with a saturated solution of 
HC1 (gas) in AcOH, producing the desired compound 158 in 50% yield over 3 steps 
(Scheme 4.3), as a pure a  anomer. The a  chlorine attack was possibly controled by an
of N - 6  substituted adenosine analogs, including compound 160, which was formed by a
Tsytovich et al.208 Reaction of bromoacetic aldehyde diethylacetal 149 and ethyl
a OEt CN b cO OEt OEt
OEtEtO
149 150 O O 151
OEt
O O 153152 154
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anomeric effect, where the product was stabilised by the interaction between the lone-pair
Scheme 4.3 Reagents and conditions: (a) MeOH in HC1; (b) p-toluoyl chloride, 
anhydrous pyridine; (c) HC1 (gas) in AcOH.
Condensation of compound 154 and 158 was performed under phase-transfer conditions in 
acetronitrile in the presence of excess powdered potassium hydroxide and the tris-[2-(2- 
methoxyethoxy)ethyl]amine (TDA-1) as catalyst.210 Purification using flash 
chromatography gave compound 159 as the P diastereoisomer in 81% yield, showing a 
characteristic anomeric H -l" resonance in the ]HNMR spectrum at 6.80 ppm as a double 
doublet.
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Scheme 4.4 Reagents and conditions: (a) TDA-1, KOH, MeCN; (b) methanolic 
ammonia 60°C; (c) TEP, POCI3, 0°C, 14a; (d) morpholine, dipyridyldisulfide, PPh;„ 
DMSO, rt, 15a; (e) p-NMN+, MnCL, MgS0 4 , formamide, rt; (f) Aplysia. califomica ADP- 
ribosyl cyclase, 25 nM HEPES buffer (pH 7.4), rt.
7-Deaza-2'-deoxy-adenosine 160 was synthesised by treatment of 159 with methanolic 
ammonia in 60°C for 4 days and was isolated by flash column chromatography in 53% 
yield. The yield however is particularly low compared with the adenosine analogues, 
where it is normally more than 80%.211 It was reasoned that nucleophlic attack of 
methanolic ammonia at the electron-deficient C6  position was possibly perturbed by the 
electron donation from the more basic N1 position of compound 159, as it was known that 
N1 of 7-deaza-adenosine was more basic than that of adenosine (p£a 5.2 vs 3.6). A similar 
low yield for this reaction was was also achieved by Seela et al.210 The introduction of the 
5'-monophosphate was also accomplished using POCI3/TEP combination, under anhydrous 
conditions, as 2 '-deoxy-compounds were found to be particular labile to acid-induced 
hydrolysis of the N9-glycosyl linkage. It was found that phosphorylation of compound 160 
was completed at a similar rate to that of adenosine but, unexpectedly, a mixture of 
products 161a and 161b were produced as indicated by the signals in 'HNMR and 
31PNMR. However, HPLC analysis of the reaction mixture only showed one new peak. We 
assumed that compound 161a and 161b might have the same retention time since we found 
ATP eluted at the same time as AMP under our HPLC condition (data not shown). It is not 
entirely clear why phosphorylation of 7-deaza-2'-deoxy-adenosine produced two products
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while phosphorylation of adenosine only produced one product in high yield, but Ikemoto
152et al assumed that N7 might be involved in the formation a TEP-adenosine complex to 
activate 5 '-position hydroxyl group (Figure 2.10), and facilitated the selective 5'- 
phosphorylation. Since N7 is missing, the phosphorylation was not selective and therefore 
gave the unexpected product 161b in this case. Anhydrous condition might also contribute 
to the formation o f 161b, since water might be crucial to modulate the reactivity of the 
phosphorylating reagent, thus maintaining a 5'-OH selectivity.
In the activation step, compounds 161a and 161b were not separated since they have the 
same elution time on HPLC, but were reacted directly with triphenylphosphine, dipyridyl 
disulfide and morpholine at rt for 3 h. Two morpholidates (162a/162b) were clearly 
separated on ion-pair HPLC and the retention time of these two molecules were found to 
be 2.56 and 7.26 min respectively. Purification using ion-exchange chromatography 
produced the desired morpholidate 162a in 83% yield based on the 5 '-monophosphate 
161a as its triethylammonium salt. The minor product 162b was also isolated whose 
structure was confirmed by the following spectroscopic evidence: in the 31PNMR, two 
singlets were observed at 8.05 and 7.77 ppm, indicating the existence of two 
morpholidates, since it is known that morpholidate normally has a chemical shift at around 
8 ppm; in ]HNMR, multiplets at 3.66, 3.45, 3.08, 2.85 ppm were assigned for the two 
morpholine moieties. The structure was further confirmed by the LCMS study where a 
molecular-ion of 574.4 was identified. Evidence was also found in the 13CNMR, in which 
the C-3' was identified as a doublet suggesting the direct connection of a phosphate group 
at this position. Phosphoromorpholidate 162a was then condensed with P-NMN* in 
presence of Lewis acid (MnCL/formamide), producing the desired 7-deaza-2'-deoxy- 
NAD+ 163 that was isolated by reverse phase chromatography in 60% yield. Finally, 7- 
deaza-2'-deoxy-cADPR 164 was synthesised by incubating compound 163 with Aplysia  
cyclase at room temperature in pH 7.4 HEPES buffer. The reaction mixture was purified 
by Q-Sepharose ion-exchange chromatography, the product eluting with a gradient o f 1 M 
TEAB buffer against MilliQ water to give compound 164 in 67% yield, based on the 
starting dinucleotide 163, as a triethylammonium salt.
4.5 Hydrolysis Study
In order to further elucidate the nature of the hydrolysis-resistance of 7-deaza-cADPR 
analogues, the hydrolysis of 7-deaza-8-bromo-cADPR 22 and 7-deaza-2'-deoxy cADPR 
164 was investigated and compared with that of 8-bromo-cADPR 17 and 8-amino-2'-
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deoxy-cADPR 99 at different pH and temperature values. These cADPR analogs were 
dissolved in pH 7.4 phosphate buffer, 0.2 M HC1 solution (pH 0.6) and 0.01 M NaOH 
solution (pH 12) and were incubated at either room temperature or at 70°C. The hydrolysis 
of these compounds were monitored by ion-pair HPLC (conditions see experimental 
section). At room temperature at pH 7.4 and pH 12, all cADPR analogues were found to be 
perfectly stable for at least 24 h; Under acidic condition (pH 0.6), 7-deaza-8-bromo- 
cADPR 22, 7-deaza-2'-deoxy cADPR 164 and 8-bromo-cADPR 17 remained largely in the 
cyclic form for 24 h, whilst 8-amino-2'-deoxy-cADPR 99 was completely degraded in 2 h. 
The degradation products of compound 99 were analysed by HPLC and a m ajor product 
eluting at 2.56 min was observed. It is assumed that compound 99 was degraded at N9- 
glycosyl linkage since the N1 degradation product, by analogy to ADPR, should have an 
elution time of more than 10 min instead of the observed 2.56 min. It is o f course not 
inconceivable that both the N1 and N9 linkage were broken, but is not likely to happen 
since the N1 of 8-bromo-cADPR was perfectly stable under these conditions. From the 
above acidic degradation, we conclude that 2 '-deoxy-cADPR analogues are more acidic 
labile at the N9-ribosyl linkage than their ribose counterparts. The fact that 7-deaza-2'- 
deoxy cADPR 164 exhibited better resistance to acid hydrolysis demonstrated that N7 is a 
crucial position for the N9-glycosyl linkage hydrolysis, which presumably proceeds 
requiring the N7 to be initially protonated. Indeed, the N9-glycosyl bond of 7-deaza- 
cADPR analogs was proved to be perfect stable in our later studies.
The hydrolysis reactions of these cADPR analogs were also studied at elevated 
temperatures. The cADPR analogs (22, 17, 164 and 99) were incubated at pH  7.4 and 
70°C, and the cyclic structures remaining for each compounds were monitored by HPLC 
and are shown in table 4.2.
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Compound Cyclic structure after 
incubating 1 h
Cyclic structure after 
incubating for 3 h
Cyclic structure after 
incubating for 4 h
7-deaza-8-Br- 
cADPR 22
92% Not tested 70%
8-Br-cADPR 17 30% Not tested 0%
7-deaza-2'-deoxy- 
cADPR 164
97% 88% Not tested
8-NH2-2'-deoxy- 
cADPR 99
78% 49% Not tested
Table 4.2 Hydolysis studies of cADPR analogues at 70°C and neutral pH.
The degradation product of 8-bromo-cADPR 17 was isolated and was identified to be 8- 
bromo-N9-ADPR 165 by NMR and HMBC (see experimental section). With all the above 
evidence in table 4.2, it is not in doubt to conclude that 7-deaza-cADPR analogues (22 and 
164) are much more resistant to heat induced hydrolysis at pH 7.4. Overnight incubation of 
7-deaza-compound 22 at 70°C (pH 7.4) resulted in a complete degradation of this 
compound, producing a single new product that has a HPLC retention time of 18.40 min. 
We assume the new product is N9 7-deaza-8-bromo-ADPR 166 (Figure 4.5) which is 
formed by breaking the N1-glycosyl linkage, as we have shown the N9-glycosyl linkage of 
7-deaza-cADPR analogs are rather resistant to the hydrolysis and evidence for heat 
induced pyrophosphate bond cleavage is less conceivable. It has been reported by Moreau 
et al that at acidic pH and at elevated temperature, the hydrolysis-resistant 8-bromo- 
cIDPR was degraded at both the N9-glycosyl bond and the pyrophosphate bond, producing 
a novel nucleotide with ribose connected at the N1 position. Thus, we studied the 
hydrolysis of these 7-deaza-cADPR analogues under both acidic and basic conditions at 
70°C. It was found that these 7-deaza-cADPR analogues degraded much faster at acidic 
pH than under neutral pH, consistent with the theory that under acidic conditions, cADPR 
analogs mainly adopt the “amino form”, thus forming a better leaving group at the N1 





amino form imine form
Figure 4.4 Different forms of cADPR. At acidic pH, cADPR adopts mainly the amino 
form; whilst at basic pH, cADPR adopts the imino form.
After heating at pH 0.6 for 4 h, 7-deaza-8-bromo-cADPR 22 was degraded more than 90%, 
producing two major products that have HPLC elution times of 9.03 and 18.36 min
deaza-8-bromo-A9-ADPR 166. It seems the product of 9.03 min was derived from 
compound 166 since this product was greatly increased after prolonged incubation, whilst 
the amount of product at 18.36 min is dramatically reduced. After incubating for 24 h, the 
peak at 18.36 min was completely consumed to give a single product having a retention 
time at 9.03 min. This HPLC study thus leads to the hypothesis that under acidic 
conditions, 7-deaza-cADPR derivatives are first decomposed at the N1-glycosyl bond 
producing the 7-deaza-A9-ADPR analogues, and the pyrophosphate bond is then further 
degraded, forming 7-deaza-nucleotides as the final compounds. Clearly, the HPLC peak at
9.03 min agrees with the formation of the nucleotide (normally elutes at 6-10 min under 
our HPLC conditions). In order to clearly identify the final hydrolysis product, the same 
hydrolysis reaction was performed in 0.2 M DC1 and the resulting product was analysed by 
'HNMR and 31PNMR. We found in the 31PNMR spectrum, the peak at ca -10 ppm 
representing pyrophosphate was clearly consumed and a new peak at ca -2  was formed, 
indicating the formation of a monophosphate; in the 'HNM R spectrum, H-2' was clearly 
separated from all other signals with a chemical shift value of 5 ppm, suggesting that the 
original “southern ribose” was still linked to the N9 of the purine base. The final 
hydrolysis product was therefore assumed to be the 7-deaza-8-bromo-A9-AMP 145 rather 
than a novel N1 nucleotide as observed by Moreau et a ir  “ Further evidence came from 
the acid induced hydrolysis of 7-deaza-2'-deoxy cADPR 3. After being incubated at 70°C 
and pH 0.6 for lh , compound 164 was completely decomposed resulting in an HPLC 
profile similar to that described for the acid hydrolysis of 7-deaza-8-bromo-cADPR. Two
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respectively. The newly formed product, which eluted at 18.36 min, is assumed to be the 7-
peaks were generated after an incubation time of 1 h and the elution times for these peaks 
were 6.40 min and 12.15 min, respectively. After prolonged incubation, the peak at 12.15 
min, assumed to be the 7-deaza-2'-deoxy-7V/-ADPR 167, was clearly consumed, resulting
deoxy-A^7-AMP by coeluting with the authentic standard compound 161a. There is no 
doubt that at acidic pH and elevated temperature, the 7-deaza-cADPR compounds (22 and 
164) were decomposed at the N1 glycosyl linkage and at the pyrophosphate bond. The N9- 
glycosyl bond was found subsequently to be stable under these conditions. From the acid 
hydrolysis studies, it was also observed that 7-deaza-cADPR analogs degraded in a kinetic 
order of N1 then pyrophosphate bond. Based on this order, we proposed a mechanism for 
the acid hydrolysis of 7-deaza-cADPR analogues, in which 7-deaza-7/9-ADPR analogues 
166 and 167 were assumed to be the reactive intermediates (Figure 4.5).
Figure 4.5 Proposed mechanism and products of acid induced hydrolysis.
Degradation of 7-deaza-cADPR analogues 22 and 164 was also evaluated under basic 
conditions and elevated temperatures. After incubation at pH 12 and 70°C, though 
presumable adopting imino forms, compounds 22 and 164 also decomposed faster than at 
neutral pH, suggesting a rapid break down of the pyrophosphate bond under basic 
conditions. The final products of base induced hydrolysis were also identified as the 7- 
deaza-N9-nucleotides.




In conclusion, 7-deaza-cADPR analogues were found to be more resistant to heating at 
neutral pH. At acidic and basic pH, 7-deaza-cADPR analogues were degraded at both the 
N1 glycosyl linkage and the pyrophosphate bond to give 7V9-nucleotide as the final 
products. N9-glycosyl linkages of 7-deaza-cADPR analogues were found to be resistant to 
hydrolysis in all studies. This, combined with their stablility to enzyme mediated 
degradation101 and under cellular conditions, makes this class of compound attractive for 
development of biological tools.
4.6 Summary of Chapter Four.
In summary, we have presented a high yielding synthetic route to 7-deaza-8-bromo- 
cADPR 22, which is a hydrolysis resistant, membrane permeable antagonist of cADPR 
induced calcium release from intracellular calcium stores. The synthetic route was also 
extended to facilitate the synthesis of 7-deaza-2'-deoxy-cADPR 164, a candidate for a 
hydrolysis resistant agonist at ryanodine receptors, which is also possible to be membrane 
permeable. Here the hydrolysis resistant property of the 7-deaza-cADPR analogues was 
carefully investigated, and the products of hydrolysis were found to be 7-deaza-iV9- 
nucleotides, suggesting a stable N9-glycosyl linkage of these 7-deaza-compounds. The 
biological properties o f 164 regarding potential cellular permeability remains to be 
determined.
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CHAPTER FIVE: BIOLOGICAL EVALUATION OF cADPR
ANALOGUES
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5.1 In tro d u c tio n
8 -Substituted cADPR/2'-deoxy-cADPR analogues and 7-deaza-analogues as discussed in 
chapter three and chapter four were used in our project to investigate the SAR of cADPR. 
These analogues were tested in two systems, sea urchin egg hom ogenates and 
perm eablised Jurkat T cells with the aid o f two collaborators, Prof A Guse (Hamburg) and 
P rof A Galione (Oxford). The biological activities of those cADPR analogues were 
com pared with those of cADPR and the activities o f each analogue on cADPR induced 
calcium  release were also compared in this chapter.
5.2 Biological E valuation  o f cAD PR A nalogues in T  Cells.
The biological activities of 8-am ino-2'-deoxy-cADPR and 8-O m ethyl-2 '-deoxy-cA D PR  in 
perm eabilised T cells were compared with that o f the 8 -amino-cADPR in order to study 
the effect o f the missing 2 '-hydroxyl group on the antagonistic activities o f those 8 - 
substituted cADPR analogues. It was found that antagonistic effect o f 8-amino-2'-deoxy- 
cAD PR (IC5o about 20 pM ) was about 20 times less potent than that o f 8 -amino-cADPR 
(IC50 about 1 pM ), demonstrating that 2'-hydroxyl group, although is not a essential 
moiety for effective calcium release of cADPR (Chapter one), is however, important for 
antagonising cADPR induced calcium  release in T cell systems at least for 8 -amino series 
(Figure 5.1). 8 -Amino-cADPR is thought to be the m ost potent antagonist available for 
perm eablised cells, although it is not membrane permeable.
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F ig u re  5.1 Antagonistic activities of 8 -am ino-cADPR (IC50 around 1 pM ), 8-amino-2'- 
deoxy-cADPR (IC50 around 1 pM ), 8-phenyl-2'-deoxy-cADPR (cannot reach IC50) and 8 - 
0-m ethyl-2 '-deoxy-cA D PR (IC50 around 50 pM ) in hum an T-cells. Jurkat T-cells were 
perm eabilised as described in the Experimental section. Data are the mean ± SEM (n > 3).
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8-0-methyl-2'-deoxy-cADPR, an analogue possessing a different 8-substitution, is a 
weaker antagonist (IC50 about 5 0  jllM ) compared to 8-amino-2'-deoxy-cADPR in 
agreement with the fact that 8-<9Me-cADPR is weaker in antagonistic effect than 8-amino- 
cADPR. The reasons for above 2'-deoxy-cADPR analogues being weaker antagonists are 
so far not clear. In order to explain the effect of the 2 '-hydroxyl group, an issue has to be 
answered as to what exactly makes 8-substituted cADPR analogues, for example 8-amino- 
cADPR, antagonists. As we discussed in chapter four, agonistic/antagonistic activity of 
these 8-substituted cADPR analogues may not controlled by their conformation. Indeed, 
these 8-substituted compounds, as described in Table 3.4, all adopted a C2'-endo at the 
southern ribose and a syn conformation about the N9-glycosyl linkage, which is essentially 
the same as that of cADPR itself. We assume that possible H-bonding between the 8- 
substituent and the RyR receptor may cause the antagonistic activities of 8-substituted 
cADPR analogues, as it has been shown that 8-amino-cADPR, a compound that has a 
stronger H-bond donor at the 8-position, has stronger antagonistic effect than that of 8- 
bromo-cADPR. This might explain the weaker activities of the 2'-deoxy-analogues, as the 
2'-hydroxyl group is also considered as a potential moiety to form H-bonds with the 
receptor and therefore removal of this group may cause a decreased affinity and thus 
activity. In addition to the potential H-bonding with the receptor, an H-bond between the 
2'-hydroxyl group and the 8-substitutent is also possible, fixing the compound in a correct 
conformation in the receptor and further contributing to the antagonistic effects of these 
cADPR analogues. This possibility of H-bonding was explored by the minimum energy 
calculation of 8-amino-cADPR as shown in Figure 5.2. It is also possible that simply 
having a bulky group at the 8-position may interfere with the conformational mobility of
94-the cADPR receptor in some, as yet not understood, fashion thus blocking Ca releasing 
activity. No correlations of potency, size etc have yet shed light at this possibility however. 
Figure 5.1 also shows the effects of 8-phenyl-2'-deoxy-analogue, which appears to be a 
similarly weaker antagonist than the other compounds. The large phenyl group is 
remarkably much less well tolerated.
Apart from the cADPR analogues discussed above, several more 8-substituted cADPR 
analogues were tested in T cell systems and their antagonistic effects are shown in Figure 
5.3. It was found that, in agreement with a previous report, 8-bromo-cADPR is indeed a 
weaker antagonist and is unable to reach its IC 50 in our experiment. 8-Bromo-2'-deoxy- 
cADPR was also found less potent (Figure 5.3). 8-Phenyl-2'-deoxy-cADPR exhibits very 
weak antagonistic activity at high concentrations (10-100 pM) and 8-phenyl-cADPR was
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inactive, indicating that large substitutions such as a phenyl group will not be 
accommodated by the RyR receptor.
F igu re  5.2 M inimium energy of 8 -amino-cADPR in aqueous solutions. Model was 
built with specified chirality in SYBYL 7.1 (Tripos). The molecule was then subjected to 
energy minimisation using the M M FFs forcefield and Gasteiger-Huckel charges until 
convergence. In this minimium energy figure, a H-bonding is shown between the 8 -amino 
group and the 2'-OH.
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Effect o f 2'-deoxy-8-X, 2'-deoxy-7-deaza- and 8-X-cADPR analogues on cADPR
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F igure  5.3 Anatagonistic effects of cADPR analogues in human permeabilised T-cells 
that are discussed in the text. It is shown that 8 -am ino-cADPR, as previously described, is 
indeed the best antagonist. Removal o f 2'-OH generally reduces the antagonistic effect. For 
8 -bomo-cADPR and 8 -amino-cADPR, agoniostic activity was also observed at high 
concentration. Data are the mean ± SEM (n > 3).
Since some compounds surprisingly appear to show agonistic activity at high 
concentrations, the agonistic activities of all those cADPR analogues were also evaluated 
(Figure 5.4). It was found that 7-deaza-2'-deoxy-cADPR, like its ribose counterpart 7- 
deaza-cADPR, was a partial agonist, consistent with previous conclusion that 2'-hydroxyl 
group is not crucial for the calcium  release. Unexpectedly, all above 8 -substituted cADPR 
analogues, including the well-established antagonists 8 -brom o-cADPR and 8 -amino- 
cADPR were also found to be partial agonists o f cADPR sensitive calcium channels 
(Figure 5.4). Such agonistic effects of 8 -amino and 8 -brom o-cADPR had not been 
previously observed, possibly because the concentration o f these synthetic compounds 
used in previous biological evaluations was always below 10 pM , due to the only limited 
availability o f these compounds. Notably, 8-am ino-2'-deoxy-cADPR and 8-0-m ethyl-2f- 
deoxy-cADPR are stronger agonists than the 8 -am ino-cADPR, leading to the idea that the 
2'-deoxy structure may reduce the antagonistic effects o f those 8 -substituted cADPR 
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F igure  5.4 Concentration response relationship o f Ca2+ mobilisation by cADPR and 8 - 
substituted cADPR analogues in permeablised human T-cells. All compounds, including 8 - 
amino-cADPR that had been thought to be the best antagonist, show agonistic effect. Data 
are the mean ± SEM (n > 3).
These novel and surprising observations that previously categorised antagonistic 
compounds may actually be partial agonists, was worth of further exploration, particularly 
in the “classical” sea urchin homogenate system.
5.3 B iological E va luation  o f cAD PR A nalogues in Sea U rch in  Eggs.
Guse et al has demonstrated that 2 '-deoxy-cADPR induces calcium release in sea urchin 
eggs but not in T cells, suggesting that sea urchin egg system may be more suitable for 
investigating the biological activities o f our 8-substituted-2'-deoxy-cADPR analogues 
(unpublished data). Several 8 -substituted cADPR analogues, including 8-brom o-2'-deoxy- 
cADPR, 8-am ino-2'-deoxy-cADPR and 8 -am ino-cADPR were thus evaluated in sea urchin 
eggs with the aim o f further exploring the effects o f 2 '-hydroxyl group on the antagonistic 
activity of these 8 -substituted compounds. Strikingly, in this system, we found that 
removal of the 2'-hydroxyl group converted 8 -brom o-cADPR from an antagonist into a 
weak but essentially full agonist (Figure 5.5). The 8 -bro m o-2'-deoxy-cADPR induced 
calcium release and also cross-desensitised the calcium  mobilisation triggered by further
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addition of cADPR, demonstrating that the agonistic effect o f 8-brom o-2'-deoxy-cADPR 
was not caused by any artefactual interactions of this com pound with fluorescent reagents 
(Figure 5.5). More importantly, incubation of 8-brom o-2'-deoxy-cADPR with intact sea 
urchin eggs revealed that it is also cell permeant (Figure 5.6), although the Ca2+ response is 
small and cortical compared with that o f the sperm (interestingly this is similar to the 
responses with 5 mM caffeine - data not shown), suggesting that further structural 
modification on this compound will potentially lead to an interesting mem brane perm eable 
agonist for the first time (vide infra).



























Blue: calcium release to cADPR
Red: calcium release to 500nM cADPR after cADPR
Green: calcium release to 8Br-2deoxy-cADPR
Black: calcium release to 500nM cADPR after 8Br-2deoxy-cADPR
F igu re  5.5 Ca+ mobilisation induced by cADPR and 8-brom o-2'-deoxy-cADPR in sea 
urchin homogenate. 8-Bromo-2'-deoxy-cADPR shows weak but almost full agonistic 
activity (green line) and cross-desensitises the Ca2+ mobilisation by cADPR (black line). 
The agonistic result is compared with cADPR (blue and red line). Data are the mean ± 
SEM (n > 3).
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F igu re  5.6 Agonistic effect o f 8-brom o-2-deoxy-cA D PR in intact sea urchin eggs. The 
graphic shows the Ca2+ release in response to the indicating concentrations of the 8 -bromo- 
2 '-deoxy-cADPR in sea urchin eggs m icroinjected with the Ca2+ dye rhod dextran (-10 pM  
final). Image are F/FO where blue = low, red = high Ca2+.
The finding that 8-brom o-2'-deoxy-cADPR is a full agonist further amplified the idea that
removal o f 2 '-hydroxyl group will decrease the antagonistic effects and increase the
agonistic effects of these 8 -substituted cADPR analogues. However controversially,
biological evaluation of 8-am ino-2'-deoxy-cADPR indicated that the 8-am ino-2'-deoxy
compound, like its ribose counterpart, was still a potent antagonist (Figure 5.7).
Comparision of 8-am ino-2'-deoxy-cADPR with 8 -am ino-cADPR demonstrated that
removal o f 2 '-hydroxyl group in this case only slightly diminished the antagonistic activity
of the 8 -am ino-cADPR (IC50 o f these two compounds are shown in Table 5.1). In addition
to the antagonistic effects, the agonistic effect o f 8 -am ino-cADPR and 8-amino-2'-deoxy-
cADPR was also compared in our experiments. W e found that unlike that o f 8-bromo-2'-
deoxy-cADPR, the agonistic effects of 8-am ino-2'-deoxy-cADPR was not increased
compared to that o f the 8 -amino-cADPR (EC50 89 pM , Table 5.1). Nevertheless, like in T
cells both 8 -amino and 8-am ino-2'-deoxy cAD PR showed agonistic property. The
difference between the 8-brom o-2f-deoxy-cADPR and 8-am ino-2'-deoxy-cADPR in sea
urchin system was not immediately understood. It is assumed that the apparently more
bulky brom o-group may have more interaction with the 2'-OH than the amino group, thus
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2'-OH deletion may cause more change on the biological activity. It is also proposed that 
the amino group may have a more vital interaction with the receptor through H-bonding 
than that with 2'-OH, therefore removal o f 2 '-OH may not dram atically affect the activity. 
However, none of the assumptions has been experim entally proved so far.
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F igure  5.7 Comparision of the biological activities of 8 -amino-cADPR and 8 -amino- 
2 '-deoxy-cADPR. It shows that both 8 -NH2-cADPR and 8-NH 2-2'-deoxy cADPR exhibit 
antagonistic avtivity upon 0.5 pM  cADPR induced Ca2+ mobilisation (red line and yellow 
line). At high concentration both show agonistic effect (blue line and green line).
Compounds EC50 IC50
8 -amino-cADPR 89 pM  (69-116) 0.105 pM  (0.088-0.126)
8-am ino-2'-deoxy-cADPR 89 pM  (plateau not defined, 
constraining to 1 0 0 % gives 
89 pM  (73-108)
0.22 pM  (0.16-0.3)
T ab le  5.1 Comparision of agonistic and antagonistic potency of 8 -am ino-cADPR with 
8-am ino-2'-deoxy-cADPR.
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5.4 Sum m ary of cADPR Analogue P ro jec t
In this project, we have successfully synthesised a small series of non-cyclisable NAD+ 
analogues as potential Aplysia ADP ribosyl cyclase inhibitors. The SAR of these NAD+ 
analogues is shown in Figure 5.8. It was found that substitution at the 2-position of the 
NAD+ analogues with either an electron-withdrawing group or an electron-donating group 
blocks the N1 cyclisation mediated by the Aplysia cyclase. Substitution at the 6-amino- 
group of the base is also found to block the N1 cyclisation, possibly due to the steric 
hindrance brought about by the substitution. For NGD+ analogues, cyclisation occurred at 
the N7 position and was abolished by the substitution of bromo group at 8-position. We 
reasoned that this might be caused by both the electron-withdrawing effect o f bromo group 
and its steric hindrance. Using these non-cyclisable NAD+(NGD+) analogues as substrates, 
Aplysia ADP ribosyl cyclase, an enzyme known to exclusively catalyse cyclisation 
reaction, was revealed also to catalyse the hydrolysis of NAD+ analogues as a 
glycohydrolase. This novel NAD+glycosyl hydrolase activity of Aplysia cyclase indicates 
that this enzyme, like other enzymes in the ADP-ribosyl cyclase family, is also a multi­
functional enzyme, catalysing both the synthesis and metabolism of NAD+ analogues in 
biological systems.
A small library of 8-substituted-2'-deoxy-cADPR analogues was also sysnthesised in this 
project as potential antagonists of the cADPR/Ca2+ channel. Their pharmacological effects 
were compared with those of the ribose counterparts in both T cells and sea urchin egg 
systems. It has been found that in T cells, these 8-substituted-2'-deoxy-cADPR are weaker 
antagonists compared to the ribose compounds, indicating the 2'-hydroxyl group to be a 
crucial moiety for maintaining the antagonistic effects of those 8-substitued cADPR 
analogues. These 2'-deoxy-compounds were also stronger partial agonists in the systems, 
suggesting that reduction of the antagonistic effects may caused by the increase of the 
agonistic effects of these molecules. In sea urchin systems, controversial results were 
observed. 8-Bromo-2-deoxy-cADPR is a weak full agonist, suggesting that the 2'-deoxy 
moiety had a novel effect converting the 8-substituted-cADPR analogues into agonists. 
However in contrast, biological evaluation of 8-amino-2'-deoxy-cADPR indicated that 
removal o f 2'-hydroxyl group had no or little effect on the antagonistic activity. Also, 
removal o f 2 -hydroxy group did not increase that agonistic effect of the compound either. 
Nevertheless, agonistic activity was observed for 8-amino-substituted compounds for the 
first time that, up until now had been thought to be pure antagonists. To understand the 
difference, sereral more 2'-deoxy-compounds will be investigated in sea urchin systems in
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future work. A brief SAR is summarised based on current pharmacological data and is
shown in Figure 5.8.
2-F substitution at the base will 
decrease the electron density of N1, thus 
block the cyclisation at this position; 2-NH2 
substitution also block the cyclisation at the 
N1 position possibly due to the steric hindrance 
of the bulky amino group.
Nam N
O j ) -.oh
_ 0  g  V  OH
Substitution at the 6-amino group will 
also block the cyclisation at N1 position.We reason 
hat this is possibly caused by the steric hindrance of 
the substitution
8-substitution of the base  
will block the cyclisation of 
NGD analogues at N7 position
b
It w as found that removal of the 2'-hydroxyl group 
reduced the antagonistic effect of 8-substituted 
cADPR analogues in T cells. It also incresed the 
agonistic activity of these analogues in aT cell 
system . In se a  urchin eggs, removal of 2'-hydroxyl 
group converted 8-bromo-cADPR into a full agonist, 
while it had less effect on 8-amino-cADPR in this system .
Figure 5.8 Brief new SAR of NAD+ and cADPR analogues synthesised in this project: 
a) SAR of non-cyclisable NAD+ analogues; b) SAR of cADPR/2'-deoxy-cADPR 
analogues.
5.5 Suggestions for Future Study.
1. Kinetic studies of non-hydrolysable NAD+ analogues including 2-fluoro-NAD+, 2- 
amino-NAD+, 6 -A-methyl-NAD+ and 8 -bromo-NGD+.
2. Synthesis of 8-bromo-7-deaza-2'-deoxy-cADPR as a potential hydrolysis resistant, cell 
permeant antagonist. The membrane permeability of this compound is proposed to be
7-deaza-modification results in hydrolysis resistant, possibly cell 
permeant analogues.
It is known that 8-substitution of the base
converts cADPR into antagonists. We found
that the 8-substituted-2'-deoxy-cADPR analogues also present
antagonistic effects.
Unexpectly, those antagonists are also partial 
agonists.
117
better than that of 8-bromo-7-deaza-cADPR, as removal of 2'-hydroxyl group will 
decrease polarity and thus increase the permeability.
3. Synthesis of 8-substituted-2',3'-deoxy-cADPR analogues. Their pharmacological 
activities will be studied and compared with that of 8-substituted-cADPR analogues.
4. More pharmacological evaluations of 8-substituted-2-deoxy-cADPR in sea urchin egg 
systems.
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CHAPTER SIX: SYNTHESIS AND PHARMACOLOGICAL 
EVALUATION OF NOVEL SMALL-MOLECULE, MEMBRANE 




As reviewed in chapter 1, NAADP 3, a potent calcium release second messenger, has been 
shown to be active in many cell types, including T cells,75 heart myocytes,213 and neurons78 
etc. NAADP releases calcium from intracellular stores independent of IP3 and cADPR, 
suggesting that this second messenger employs a novel signalling-pathway that is distinct 
from that of IP3 and cADPR. In order to identify this novel signalling pathway and its 
protein components, many studies have been carried out in recent years. Unfortunately, 
such studies are currently restricted due to the limited array of any chemical tools, let alone 
any ones that are membrane permeable, that specifically interact with the unknown 
NAADP receptors. NAADP is a complex nucleotide with a sensitive 2'-phosphate group 
on the adenosine bearing ribose. Therefore, synthesis of such tools by structurally 
mimicking the whole NAADP molecule is rather difficult and is likely to be inefficient in 
terms of number of candidate molecules produced. A chemo-enzymatic route was 
previously reported by Lee et al, facilitating the synthesis of a small library of NAADP 
analogues.116 This method relies on the ADP ribosyl cyclase mediated base-exchange 
reaction and is, however, largely limited by the selectivity of the enzyme and the 
availability of the substrates, and therefore can not produce a wide range of NAADP 
analogues. A more flexible route to NAADP via the total synthesis of NA DP was also 
reported in recent years by our group .115 This method certainly provides a wider scope for 
structural modification of the NAADP molecule, but in consideration o f the cost and 
difficulty of the synthesis, is also not likely to be implicated for synthesising a great variety 
of NAADP analogues. It also relies on the base-exchange process in the last step of the 
synthesis. Apart from the difficulties of their syntheses, NAADP analogues are prone to 
hydrolysis at the nicotinic acid-ribose glycosyl bond and, more importantly, they are not 
membrane permeant. In consideration of above difficulties, we thus sought to investigate 
the rational design of small molecule, membrane permeant NAADP analogues in our 
project by adapting a simple basic strategy.
Lee et al has previously published a brief SAR for NAADP (Chapter one, section 1.5).116 
They have concluded, not surpringly, that the pyridinium ring and the negative charge on 
the 3-position are essential for calcium mobilising activity. Replacement of the carboxylic 
acid with amide or removal of this moiety results in completely loss of the activity. Later 
experiments confirmed that this part of the molecule is important for both binding affinity 
and calcium release,214 thus leading us to consider that rational design of small molecule 
NAADP analogues could initially focus on mimicking only this structural feature. Based
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on this consideration, a lead compound known as CMA008 (Figure 6.1) was first 
synthesised in our group and later biologically investigated. In this molecule, an acetamide 
side chain was also designed, as a potential linker for further modifications.
F igure 6.1 Structure of CMA008, a lead compound of small molecule modulators of 
NAADP induced calcium release.
It was found that CMA008 is indeed a relatively potent modulator of NAADP induced 
calcium release (IC50 of 15 jjM) in the sea urchin egg systems. This compound was 
confirmed to be weakly competitive at the NAADP binding site, as total binding of radio­
active [32P] NAADP with the (unknown) receptor was decreased upon addition of 
CMA008 at relatively high concentration.215 Further studies of this compound on intact sea 
urchin eggs indicated that CMA008, despite its apparently polar structure, was indeed cell 
permeant. In addition to the above interesting data in sea urchin egg systems, the 
compound was also found to be active in mammalian cells.215 Notably, nicotinic acid, 
nicotinic acid ribose and nicotinamide derivative of CMA008 were not active in both sea 
urchin eggs and mammalian cells, suggesting that both the pyridinium ring and the 
acetamide side chain of the compound are crucial for the presented activities.
These preliminary biological data of CMA008 highlight this compound as the first small 
molecule, membrane permeable modulator of NAADP-sensitive calcium release, thus 
prompting us to seek further modifications of the molecule with the aim of exploring really 
potent molecules, that could be employed to identify the NAADP receptor(s) or as lead 
compounds for developing future pharmaceutical agents. CMA008, while a prototype 
competitive antagonist is difficult to handle and appears not to be active in some cell types 
that utilise NAADP signaling (e.g T cells), although it does work in the mammalian 
cells.215It is believed that the physicochemical properties of this molecule need to be 
further optimised. We report here the synthesis of a small library of CMA008-like 
pyridinium salts. These compounds are different from the parent compound, CMA008, by
O ' OH
CM A008
R = -P O 3H
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adopting different acetamide side-chains. The reason for us to modify CMA008 at the side 
chain rather than at the nicotinic acid moiety is that the SAR for the nicotinic acid moiety 
seems rather tight and modifications at this part of the molecule will possibly result in loss 
of activity. These CMA008-like pyridinium salts were also tested in vitro and later in vivo 
in our project and, their pharmacological activities will be introduced in later sections in 
this chapter.
6.2 Synthesis of P yrid in ium  Salts by Alkylation o f N icotinic Acid.
Synthesis of the nicotinic acid pyridinium salt was conveniently achieved by treatment of 
nicotinic acid with a series of bromoacetamides. These bromoacetamides were produced 
by treatment of 2 equivalents of the selected amines with 1 equivalent of bromoacetyl 
bromide at -15-20°C (Scheme 6.1, step a). Purification using acid work-up or flash column 
chromatography gave these bromoacetamides in normally more than 60% yields.









These bromoacetamides were then treated with nicotinic acid in anhydrous DMF at 60- 
70°C overnight. Purification (precipitation in MeOH/ether) gave the desired pyridinium 
salts (yield see experimental section), showing a characteristic singlet (integration 2H) at 
5.5-6.0 ppm in 1HNM R, representing the CH2 that is directly connected with the nicotinic 
acid. It was found that these pyridinium salts all contained the bromide counterion. 
Addition of AgNC>3 resulted in AgBr precipitate suggesting the presence of bromide. Thus 
it is believed that the carboxylic acid of the nicotinic acid moiety is protonated not ionised 
and the bromide counterion ensures electronical neutrality of the molecule. However, our 
latest X-ray crystallographic study of compound 194 (BZ194) indicated that it should also 
be possible to prepare a zwitterionic species with ionised carboxylic acid. In the crystal 
structure, an asymmetric unit was formed by linking the 0 2  of the protonised species with 
the carbonyl 0 3  of the zwitterionic counterpart via hydrogen bonding. Interestingly, only
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one bromide counterion was observed for this unit, clearly suggesting the existence of the 
BZ194 zwitterions. Since BZ194 is a novel biologically active compound (see later 
sections), the crystallographic study result then triggers an interesting idea that by 
producing pure zwitterionic form of BZ194 using ion-exchange method, we may possibly 
discover a more potent biologically active compound in future work. The X-ray-crystal 
structure and hydrogen bonding of compound 194 is shown in Figure 6.2a (supporting 
information is shown in appendices). Figure 6.2b shows nicely the stacking o f the aromatic 
region and the lipid-like alignment of the non-polar 8-carbon side chains of compound 194 
(BZ194).
The bromoacetamides and pyridinium salts synthesised in our project are shown in Figure
6.3 and Figure 6.4.
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F igure  6.2a Crystal structure of compound 194 (BZ194). Compound 194 was crystalised using M eOH and acetone as a m ixed solvent. Asymmetric unit 
consists of 2  hydrogen bonded molecules and one bromide counter ion. Nitrogen bound hydrogens were located and refine at 0.89 A from the parent atoms. 
The hydrogen atom attached to 0 2  was located and refined without constraints.
•;n
v *  *
F igu re  6.2b M olecular packing graphic o f B Z 194.
f t
Figure 6.3 Bomoacetamides synthesised in our project.
Figure 6.4 Pyridinium salts synthesised in our project (active compounds are presented 
in bold font).
6.3 Synthesis of Pyridinium  Salt via Zincke Salt.
Although a good series of pyridinium salts has been successfully synthesised by the 
alkylation of nicotinic acid this method, however, is greatly limited as it only works 
efficiently with primary alkylating agents. We thus explored a route via a Zincke salt 
intermediate216'217 with the aim to synthesise pyridinium salts of greater varieties. The 
Zincke salt 197 was prepared by heating the mixture of nicotinamide with 1 -chloro-2,4- 
dinitrobenzene at 90-100°C for 2 h (Scheme 6.2). After cooling, the reaction mixture was 
dissolved in a small amount of methanol and the product was precipitated with ether. This 
procedure was repeated three times, giving pure Zincke salt as an orange foam in 71% 
yield. This Zincke salt was then treated with amines in anhydrous methanol for 5-6 h at 
room temperature, providing pyridinium salts in normally 60%-80% isolated yield
(Scheme 6.2). Some model compounds have been made in our experiments using the 
Zincke reaction and these compounds are shown in Figure 6.5, all of which have 









Scheme 6.2 Reagents and conditions: (a) heating, 90°C, 3 h; (b) anhydrous MeOH, rt. 6 
h.
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Figure 6.5 List of nicotinamide pyridinium salts synthesised by Zinke reaction.
It has been emphasised earlier in this chapter that the 3-position carboxylic acid moiety is 
of crucial importance to the calcium mobilising inhibition activity of CMA008. Thus, the 
above molecules (Figure 6.5) that have amide groups at the 3-position of the pyridinium 
ring require to be further modified. Conversion of amide into carboxylic acid was achieved 
by treatment of the above compounds (we have so far only tried compound 2 0 2  as an 
example) with concentrated aqueous solution of HCl (Scheme 6.3). Purification of the 
reaction mixture gave carboxylic compound 203 as a yellow solid in 80% yield. The 
occurrence of the carboxylic acid was confirmed by comparing its IR spectrum with that of 
the amide precursor. It was found that the carbonyl band was shifted from 1702 to 1731 
nm, suggesting the formation of a carboxylic acid. The presence of compound 203 was 
further confirmed by comparing its mass with that of compound 202. In this case, a one 













Scheme 6.3 Reagents and conditions: (a) concentrated HC1, refluxing, 2 h, then rt. 
overnight.
With the method to successfully transform an amide to a carboxylic acid established, we 
then attempted to use the Zincke route to synthesise pyridinium salts that have the similar 
acetamide side-chain as that of CMA008. Compound 184 was selected as a model and this 
compound was constructed by reaction of Zincke salt 204 (carboxylic acid form, obtained 
by treatment of 195 with concentrated HC1) with 2-amino-acetamide 207 (Scheme 6.4, 
step c). We employed jV-phenyl-bromoacetylbromide 170 as the starting building block for 
synthesising the important reagent 207. Treatment of 170 with potassium phthalimide in 
DMF at 80°C for 2.5 h gave the intermediate 205 in 82% isolated yield (a model 
compound 206 was also synthesised from 179 using the same method in 80% yield). The 
intermediate was then refluxed with a solution of hydrazine in ethanol for 3 h. Purification 
using acid-base extraction gave the desired compound 207 as a white solid in 65% yield. 
Compound 205 was then reacted with Zincke salt 204 in anhydrous DMF at 65-70°C 
overnight. Purification gave pure 184 as a yellow oil, showing identical ’HNMR and mass 
spec with the compound 184 synthesised by the alkylation method (Scheme 6.4).
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Scheme 6.4 Reagents and conditions: (a) HC1 (conc.), refluxing; (b) potassium 
phthalimide, DMF, 80°C, 2.5 h; (c) hydrazine, ethanol, reflux 3 h; (d) DMF, heating 60- 
70°C.
We have so far successfully developed an alkylation method and a Zincke method to 
prepare CMA008-like pyridinium salts with varied length of acetamide side-chains. In 
order to provide wider scopes of such pyridinium salts, we also sought to modify the 
nicotinic acid moiety. With the apparent tight SAR of the nicotinic acid moiety, we have so 
far only explored the substitution at the 5-position, as known from the in vitro test of 
compound 193 that substitution at this position will not diminish the biological activity of 
these pyridinium salts. Compound 211 was then synthesised as an example of such 5- 
position substitution (Scheme 6.5). By using a Suzuki-cross coupling protocol,“ 5-bromo- 
nicotinic acid methyl ester 209, synthesised from commercially available material 208 by 
refluxing 208 with concentrated H2SO4 in methanol, was treated with 4-methoxy- 
phenylboronic acid and Pd(PPh3)4 under basic condition at 80°C for 6  h. Purification using 
flash chromatography gave the 5-substituted compound 210 as a white solid in 41% yield. 
The compound was then treated with bromoacetamide 171 to produce the desired 5- 




Scheme 6.5 Reagents and conditions: (a) concentrated H2SO4, MeOH, refluxing, 
overnight; (b) Pd(PPh3)4, toluene, 2M sodium carbonate, 80°C; (c) compound 171, DMF, 
60°C, overnight.
6.4 In  Vitro and In Vivo Studies of Pyridinium  Salts.
In order to explore the biological activity of our pyridinium salts, these compounds have 
been tested in vitro in Jurkat T cell systems by our collaborator Professor Andreas Guse 
and Werner Dammermann in the University Medical Centre Hamburg-Eppendorf, Centre 
of Experimental Medicine, Institute of Biochemistry and Molecular Biology. Four 
compounds, namely compounds 188, 191, 193 and 194 (structures see Figure 6.4), were 
screened in the preliminary study and showed interesting antagonistic effects of 
NAADP/Ca2+ signalling in this system. However, compounds 191 and 193 (known as 
BZ71 and BZ185, respectively), were found to be poorly soluble in the biological buffer, 
even with addition of DMSO, and therefore were not further explored at this stage. We 
thus, in this section, focused on the in vitro and in vivo activities of compound 188 and 194 
(also known as BZ52 and BZ194, respectively). Compound 188 was first extensively 
studied biologically.
6.4.1 In  Vitro And In Vivo Studies of 188 (BZ 52).
6.4.1.1 Inhibitory Effect of BZ52 on NAADP induced Ca2+ Signalling in T Cells.
With the structual features that mimic NAADP, BZ52 (compound 188, structure shown in 
Figure 6 .6 ) was designed, like its parent molecule CMA008, to selectively modulate the 
NAADP/Ca2+ signalling pathway in biological systems. Indeed, it was proved in our 
experiment that BZ52 was an antagonist that specifically targeted the NAADP pathway. 
Microinjection of NAADP into Jurkat T cells induced a rapid (peak) and sustained (plateau) 
calcium signal that was not seen when intracellular buffer was injected (Figure 6 .6 ). Co­
injection of BZ52 almost completely antagonised the effect of NAADP, indicating an 
inhibitory effect of this compound on NAADP/Ca2+ signalling (Figure 6.7).
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Figure 6.6 Effect of NAADP microinjection in Jurkat T cells (a) compared with the 
effect of buffer microinjection (b). Molecular structure of BZ52 is also shown in this figure 
(experiments were carried out by Professor Andreas Guse and Mr Werner Dammermann).
Evidence for the specificity of the inhibitory effect of BZ52 was obtained by co-injection 
with the Ca2+ mobilising second messenger IP3. In these experiments IP3 induced a similar 
calcium signal consisting of a rapid (peak) and sustained (plateau) phase as compared to 
NAADP. However, no difference between the presence and absence of BZ52 was 
observed (Figure 6 .6 ). BZ52 also had no effect on cADPR induced calcium release, further 
proving its specificity on NAADP pathways (Figure 6 .8 )
to
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Effect of BZ52 on [Ca?+]j in human Jurkat T cells
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Figure 6.7 Inhibitory effect of BZ 52 on Ca2+ signalling evoked by microinjection of
Ca2+ mobilising second messengers in human Jurkat T cells. NAADP (final concentration
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100 nM), IP3 (final concentration 4 pM), and BZ52 (final concentration 1 mM) were 
injected into single Jurkat T cells while [C a2+]j was analysed by Ca2+ imaging. Data are 
presented as mean±SEM (n = 4 to 13).
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Figure 6 .8  Effects of BZ52 upon Ca+ mobilisation by 100 pM cADPR.
6.4.1.2 Inhibitory Effect of BZ52 on Ca2+Release Evoked by Ligation of TCR/CD 3.
Activation of T cell lymphocytes via the binding of antigen to the T cell receptor/CD3 
complex (TCR/CD3) initiates multiple intracellular signalling pathways.219 Among these 
pathways, an elevated calcium concentration has been found to be essential for T cell 
proliferation and clonal expansion.- The increase in calcium concentration results from 
intracellular calcium release as well as calcium entry though specific calcium channels in 
the plasma membrane. Second messengers such as IP3 and cADPR and NAADP are 
known to mobilise the calcium from intracellular stores and, therefore play important roles 
in TCR/CD3 mediated activation. Among these second messengers, NAADP is not only 
the most potent, but also serves as a trigger for IP3 and cADPR induced calcium release. It 
has been found that self-inactivation of NAADP will completely block the subsequent 
signalling by cADPR and IP3 in T cell systems. Most importantly, Guse et al have 
demonstrated that self-inactivation of NAADP/calcium release system will completely 
antagonise the calcium signalling mediated by ligation of the TCR/CD3 75 With the above 
findings, it is assumed that the NAADP signalling pathway plays an essential role of 
controlling the T cell activation and proliferation. Due to the importance of NAADP/Ca2+ 
pathway in T cell receptor/CD3 mediated activation and also due to the specific 
antagonistic activity of BZ 52 upon this pathway, we expected that BZ52 would also have 
an inhibitory effect on stimulation of rat encephalitogenic CD4-positive T cells via CD3 
crosslinking. Thus, Fura2-loaded rat encephalitogenic CD4-positive T cells (resting) were 
stimulated by anti-CD3 followed by crosslinking of the primary antibody (Figure 6.9,
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black line). A rapid high increase of [Ca2+]j followed by a briefly elevated sustained phase 
was observed. It was noticed that indeed BZ52 had an inhibitory effect on Ca2+ signalling 
upon CD3-crosslinking, as preincubation of the cells for 60 min with 500 pM BZ52 
significantly reduced the [Ca2+]j increase in this case (Figure 6.9, grey line). This 
experiment also demonstrated importantly that BZ52 was indeed cell permeant as was 
initially expected. CMA008 by contrast showed no activity in this system.
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Figure 6.9 Inhibitory effect of BZ 52 on Ca2+ signalling evoked by crosslinking of 
CD3 in rat encephalitogenic rat T cells. Fura2-loaded rat T cells were analysed for [C a_+]i 
by fluorimetry. First arrow indicates addition of anti-CD3 mAb, second arrow indicates 
addition of a crosslinking secondary antibody. In case of BZ 52, cells were preincubated 
with BZ 52 (500 pM) for 60 min at RT. Data obtained from Professor Guse et al.
6.4.1.3 Inhibitory Effect of BZ52 on Antigen and Mitogen Induced Proliferation in 
M yelin-Basic Protein (MBP) Specific CD4-Positive Rat T Cells
A more downstream event of T cell activation was analysed in myelin-basic protein (MBP) 
specific CD4-positive rat T cells. These cells can be driven into proliferation by MBP 
presented by irradiated thymocytes or by the mitogen concanavalin A (ConA).
It was found that BZ52 (lot l ) concentration-dependently blocked both MBP and ConA- 
mediated proliferation. IC50 values were approx. 100 pM for ConA mediated and 500 pM 
for MBP mediated proliferation (Figure 6.10). Experiments were carried out by our 
collaborators Ms Chiara Cordiglieri and Professor Alexander Flugel.
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Figure 6.10 Inhibitory effect of BZ52 on antigen and mitogen induced proliferation in 
myelin-basic protein (MBP) specific, CD4-positive rat T cells. Data are presented as 
mean±SD from one representative experiment carried out in quadruplicates.
In contrast to its inhibitory effect on proliferating T cells (Figure 6.10), BZ52 up to 500 
pM did not significantly reduce the number of T cell blasts when incubated with these 
cells for 48 h (Figure 6.11). This indicates that BZ52 does not have a large cytotoxic effect 
per se on resting cells, but specifically affects proliferating T cells.
Figure 6.11 Toxicity assay of BZ52 on non-proliferating myelin-basic protein (MBP) 
specific, CD4-positive rat T cell blasts. Data are presented as mean±SD from one 
representative experiment carried out in triplicates
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6.4.1.4 Protective Effect o f BZ52 in the M ultiple Sclerosis Model Experimental 
Autoimmune Encephalomyelitis (EAE).
Multiple sclerosis (MS) is a chronic autoimmume disease of the central nervous system 
(CNS) and, with a lifetime risk of one in 400, is considered to be the most common cause 
of neurological disability in young adults. Pharmaceutical agents that are used for this 
disease, however, are either not very specific, such as steroidal immunosuppressants and 
cytostatic drugs, or have severe side effects such as cyclosporine A. Clearly, dmgs that 
treat MS with more efficacy, better tolerance and easier administration are urgently 
required. It has been found that T cell proliferation and activation is a major event in 
initiating MS. Only upon activation by specific antigens do these encephalitogenic T cells 
invade the CNS via the endothelial blood-brain barrier (BBB) to initiate disease.221 This 
finding thus led us to test BZ52 in vivo as a potential agent for treatment of MS, as we 
know from the above section that BZ52 blocks the proliferation of MBP specific T cells 
and also it is not toxic (the in vivo study was carried out by our collaborators Ms Chiara 
Cordiglieri and Professor Alexander Fliigel in M ax-Planck-Institute for Neurobiology, 
Martinsried, Germany). The most widely used animal model for MS is the rodent 
experimental autoimmune encephalomyelitis (EAE) model and, in our experiments the 
adaptive transfer model of EAE (tEAE) was used in collaboration with Dr A Fliigel, 
Martinsread Germany.222 Transfer of MBP-specific CD4-positive T cells were used at day 
0 to induce experimental autoimmune encephalomyelitis (EAE) in Lewis rats. Animals 
injected with PBS (vehicle) or nicotinic acid (control compound with structural similarities 
to BZ52) developed severe paralysis of tail and rear legs due to the inflammation. Clinical 
symptoms started on day 3.5 and reached their maxima day 4 to 6 (or 6.5). Between day
3.5 and day 6, no difference between PBS and nicotinic acid was observed, while 
importantly a beneficial effect of BZ52 was visible (Figure 6.12). Animals treated with 
BZ52 showed a less rapid increase of symptoms, a decreased maximum score and a more 
rapid decline of clinical symptoms as compared to the other two groups (Figure 6.12).
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Effect of BZ 52 on clinical score in transfer EAE
4n
-■ -P B S
NicAcid 
HB-BZ 52
-1  . i . i i i---------------1---------------1 i
0 1 2 3 4 5 6 7 8 9
tim e  [d]
Figure 6.12 Protective effect of BZ52 in transfer experimental autoimmune 
encephalomyelitis (EAE). Animals (6  per group, body weight approx. 150 g) were injected 
i.p. twice per day with either PBS (vehicle control), nicotinic acid (50 mmol/100 g body 
weight), or BZ 52 (50 mmol/100 g body weight). Clinical scores indicate the degree of 
paralysis of tail and legs. Data are presented as mean±SD from one representative 
experiment (n = 6 ).
The beneficial effect of BZ52 is also mirrored by a less pronounced decrease in body 
weight, a marker for the disease that is less operator-based as compared to clinical scores 
(Figure 6.13).
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Figure 6.13 Protective effect of BZ52 in transfer experimental autoimmune 
encephalomyelitis (EAE). Animals (6  per group, body weight approx. 150 g) were injected 
i.p. twice per day with either PBS (vehicle control), nicotinic acid (50 pmol/100 g body 
weight), or BZ 52 (50 |nmol/100 g body weight). Body weight was set to zero on day zero 
and changes relative to the initial body weight are displayed. Data are presented as 
mean±SD from one representative experiment (n = 6 ).
Since GFP-transfected encephalitogenic T cells were used for the transfer EAE experiment, 
the localisation of these cells were determined on day 4 post transfer in different organs of 
one animal. It is known from previous studies223 that the transferred encephalitogenic T 
cells first move to the spleen, and then migrate via the parathymic lymph nodes to the CNS 
(day 4). Figure 6.14 demonstrates that the number of CNS-infiltrating encephalitogenic T 
cells decreased by about 50%. In addition, the number of encephalitogenic T cells was 
reduced significantly.
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Figure 6.14 Effect of BZ52 on the localization of encephalitogenic T cells on day 4 post 
transfer in transfer experimental autoimmune encephalomyelitis (EAE).
Animals (6  per group, body weight approx. 150 g) were injected i.p. twice per day with 
either PBS (vehicle control), nicotinic acid (50 pmol/100 g body weight), or BZ 52 (50 
p.mol/100 g body weight). One animal per group was sacrificed on day 4 and the number 
of GFP-transfected cells was determined for the organs displayed. Data are corrected for 
organ mass and presented as mean±SD from one representative experiment.
6.4.1.5 Conclusion for BZ52
So far, two lots of BZ52 have been produced in our experiments. In contrast to BZ52 loti, 
BZ52 lot2 that was further purified by column chromatography was found to apparently be 
unable to inhibit the proliferation of MBP specific T cells in some experiments (data not 
shown), thus leading to a concern that the novel antagonistic effect of BZ52 loti was 
possibly caused by a small amount of unknown impurities rather than BZ52 itself. 
Compound 212 was first isolated from large scale of BZ52 as an impurity and few other 
compounds, namely the compound 213, 214, 215 and 216 (Figure 6.15) were therefore 
synthesised as possible impurities. These compounds, however, were found to be not 
active in proliferation assays, suggesting that the proposed active impurities might not exist. 
We later found that microinjection of BZ52 lot2 also inhibited NAADP induced calcium 
signalling in Jurkat T cells. More importantly, BZ52 lot 2 presented obvious protecting 
activity in the animal tests, proving that BZ52 is indeed the active species. Since 
microinjection of BZ52 lot2 also blocks NAADP/Ca2+ in T cells, we assume that the weak 
anti-proliferative effect of BZ52 lot2 is possibly caused by the poor membrane 
permeability of this lot. However, the exact reason why BZ52 lot 2 is less cell-permeant
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than loti is so far not clear but this is no longer seem to be of concern. What is, however, 








Figure 6.15 Possible impurities in BZ52 loti.
Based on the evidence presented in the above sections, BZ52 was confirmed to be a 
potential cell permeant antagonist of the NAADP/Ca+ signalling system in T cells. Testing 
of this compound in an animal EAE model revealed that BZ52 has a novel protective (and 
therapeutic) effect on MS, suggesting that further development of this compound may lead 
to the discovery of new drugs that specifically target MS and other autoimmune disease. 
Because of the above important data, but in the light of the unfavourable physicochemical 
problems with BZ52, we looked to design more optimised compounds.
6.4.2 In  Vitro and In Vivo Studies of BZ194.
Another active compound 194 (BZ194), with only a mono substituted amide moiety was
also studied in vitro and in vivo (the in vitro and in vivo studies were carried out by our
collaborators Professor Guse, Professor Fliigel, Ms Chiara Cordiglieri and Mr Werner
Dammermann. Thanks for their contributions to the thesis). Compared to BZ52, this
compound, though more polar, is less water-soluble and therefore requires the presence of
small amount of DMSO in the biological sample solutions. Prior to in vitro testing, BZ194
was further purified, after synthesis and normal work up, by flash column chromatography
and crystallised (MeOH/acetone), giving pure BZ194 as a needle-like crystalline solid. It
was found that the BZ194 indeed blocked TCR/CD3 mediated Ca2+ signaling in intact
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primary myelin basic protein (MBP)-specific CD4+ effector T cells (Figure 6.16, a,b). Both 
the initial Ca2+ peak and the sustained Ca2+ plateau phase were inhibited by BZ194 (Figure
6.16, a,b). These data are well in accordance with the known time course of TCR/CD3 
mediated NAADP formation, which consisted of a rapid and a sustained phase of elevated 
NAADP concentration. A Ca2+-free/Ca2+-reintroduction protocol demonstrates that BZ194 
decreased all (i) Ca2+ release from internal stores, (ii) the rapid Ca2+ overshoot observed 
upon re-addition of extracellular Ca2+, and (iii) the sustained Ca2+ signaling phase (Figure
6.16, c,d). Importantly, capacitative Ca2+ entry, considered to be a major pathway of Ca2+
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Figure 6.16 NAADP antagonist BZ194 inhibits Ca2+ signalling and activation of rat 
MBP-specific T cells in vitro. Arrows indicate time point of addition of antibody or Ca2+ 
solution. A, Cells were preincubated with 1 mM BZ194 overnight. Addition of anti-CD3- 
mAb (1st arrow) and a crosslinking, secondary antibody (2nd arrow). B, Concentration- 
response curves summarising data from A (transient Ca + peak and Ca2+ plateau; mean± 
s.e.m, n = 8-9). C, Cells were preincubated with 1 mM BZ194 overnight. Under Ca2+ free
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conditions the anti-CD3-mAb (1st arrow) and secondary crosslinking antiserum (2nd arrow) 
were added; then [Ca2+] was increased to 1 mM (3rd arrow). D, Bar chart summarising data 
from C (transient Ca2+ release peak, Ca2+ influx peak, Ca2+ influx plateau and the 
difference between Ca2+ influx peak and plateau (=overshoot); mean± s.e.m, n = 6-7). The 
negative controls are without stimulation by anti-CD3-mAb. E, Cells were preincubated 
with 1 mM BZ194 overnight. Addition of thapsigargin (1 pM, arrow). Inset: mean± s.e.m, 
n = 9).
BZ194 dose-dependently suppressed T cell activation elements downstream of Ca2+ 
signaling: anti gen-driven cytokine expression and proliferation of MBP-specific rat T cells 
retrovirally engineered to express GFP as genetic marker (Tm bp-gfp cells)224 (Figure 6.17). 
Half maximal inhibition of proliferation was reached at 100 to 250 pM BZ194, complete 
block was achieved at 250pM. The carrier (DMSO) alone or increasing doses of nicotinic 
acid did not affect T cell amplification (Figure 6.17). This effect o f BZ194 was 
independent of the specificity of the T cells as tested with ovalbumin (OVA), myelin 
oligodendrocyte glycoprotein (MOG), and S I00(3 specific T cells after stimulation with 
OVA, MOG, and S100(3, respectively (not shown). BZ194 was not toxic for Tmbp cells: 
cell survival in the presence of 500 pM or 1 mM BZ194 and antigen responsiveness after 
withdrawal of the NAADP antagonist were comparable in treated and control cells (Figure 
6.18).
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Figure 6.17 Inhibitory effect of BZ194 on antigen-driven proliferation of MBP-specific 
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Figure 6.18 BZ194 has no toxic effect on T m b p - g f p  cells
We then studied the potential role of BZ194 in rat EAE, a T cell mediated autoimmune 
disease model of Multiple Sclerosis. In the absence of BZ194 the animals developed 
weight loss and paralytic disease (maximal weight loss: 3.2, +/- 0.2; maximal score: 3.2, 
+/- 0.2) 10-12 d after immunisation (p.i.), and recovered from clinical signs 7 days later 
(Figure 6.19, a). Daily intraperitoneal injections of 500 pM BZ194 (180 mg/kg for 14 days) 
delayed and significantly ameliorated clinical EAE (Figure 6.19, a). I.p. treatment with 
nicotinic acid had no effect on clinical EAE. Cytofluorometric and histological analysis at 
the peak of clinical disease (12 d p.i.) revealed classic EAE lesions in control animals with 
influx of T cells, macrophages, B cells and dendritic cells. The infiltrates were spread 
throughout the CNS parenchyma (Figure 6.19, b,c). In contrast, BZ194-treated animals 
revealed only mild inflammation which was mainly restricted to meningeal and 
perivascular areas (Figure 6.19, b). The recruitment of inflammatory cells into the CNS 
was drastically reduced (Figure 6.19, c).
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F igu re  6.19 a) Clinical EAE course after im m unization with MBP. Grey bar: treatm ent 
with vehicle (white) or BZ194 (black). N = 7 animals/group. * P values; b) 
Cytofluorom etric quantification of immune cell recruitm ent 12 d post imm unisation (p.i.). 
Vehicle treated animals (white), BZ194 treatm ent (black). M eans o f triplicate 
m easurem ents; c) Histological evaluation of spinal cord EAE lesions at day 12 p.i.. Upper 
panels: W 3/13 labeling for T cells (red, arrows). Lower panels: ED I staining for activated 
m onocytes/m acrophages (red, arrows). M: meninges. M agnification bars: 10mm.
Active EAE involves two phases: during the disease free prim ing phase autoantigen- 
specific T cells arise in the peripheral immune organs where the autoantigen is presented in 
the context of M HC class II antigens. Thereafter the prim ed effector T cells leave the 
immune organs and invade the CNS where they upon local reactivation by local antigen
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presenting cells induce severe CNS inflammation and paralytic disease. NAADP 
antagonist BZ194 seemed not to interfere with the generation of MBP-specific T cell 
response. The reactivity towards MBP in draining lymph nodes (LNs) after BZ194 
treatment was not compromised. Further, the capacity of LN cells to present antigen and to 
stimulate antigen-primed effector T cells, remained intact. NAADP antagonism rather 
seemed to be effective during the effector phase of EAE. BZ194 applied i.p. 8  days after 
immunisation, i.e. immediately before onset of clinical disease significantly ameliorated 
EAE severity. This finding might be of clinical importance since patients suffering from an 
autoimmune attack usually passed the T cell priming period, i.e. they carry autoantigen- 
specific effector T cells within their immune repertoire.
6.4.2.1 Clinical Effects of NAADP-Antagonism in the Effector Phase of EAE (tEAE).
In order to study the effect BZ194 on autoaggressive T cells during the effector phase of 
EAE more detail, we transferred of 5 x 106 T m b p  cells retrovirally engineered to express 
GFP as genetic marker ( T m b p - g f p  cells). The fluorescent label does not interfere with the T 
cell function and allows tracing and functional characterisation of the effector T cells in the 
recipient organism during the entire EAE course225. Vehicle or nicotinic acid treated 
animals developed clinical signs (maximal weight loss: 3.2, +/- 0.2; maximal score: 3.2, 
+/- 0.2) 3 d after T cell transfer (p.t.), and recovered 7 days later (Figure 6.20). I.p. 
injections of BZ194 (for 5 d) significantly delayed and shortened disease duration and 
reduced paralytic disease and weight loss (maximal score: 1.6, +/- 0.3; maximal weight 
loss: 1.6, +/- 0.3) (Figure 6.20).
3.5 j  
3 -- 
2 £  - -





□  DMSO 
■ B2194
I 1 H i 1------- 1
0 24 48 57 72 81 96 105 120 129 144 153 168 216 240 264
Time (hours post transfer)
Figure 6.20 Clinical course of EAE after transfer of T m b p - g f p  cells. Treatment with 
vehicle (white) or BZ194 (black). N = 6  animals/group. Representative EAE courses of 5 
independent experiments.
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Suppression of clinical EAE was mirrored by reduced CNS inflammation: The numbers of 
autoaggressive T m b p - g f p  cells and recruited inflammatory cells in EAE lesions were 
reduced (Figure 6.21) and the infiltrates were mainly confined to perivascular and 
meningeal regions (data not shown). This picture closely resembled EAE pathology 
evoked by weakly pathogenic T cells reactive against the astrocytic antigen SlOOp.226 
These S 1 OOp-specific T cells are able to penetrate the blood brain barrier. However, within
their target organ they reach lower activation levels and thus, produce less amounts of pro-
111inflammatory cytokines." The cytokine levels within the spinal cord of BZ194 treated 
animals were markedly reduced compared to vehicle treated controls (data not shown). 
Importantly, a clear decrease of cytokine production was observed in T m b p - g f p  cells sorted 
from the spinal cord of BZ194-treated animals indicating insufficient reactivation of the 
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Figure 6 .2 1  a) T m b p - g f p  cell invasion into the spinal cord at day 3 and 4 after T cell 
transfer (p.t.) evaluated with cytofluorometry. White: vehicle treated animals, black: 
BZ194. Means +/- SD of triplicate assays. Representative data of five independent 
experiments; b) Quantification of immune cell recruitment into the spinal cord 3 and 4 
days p.t.. Cytofluorometry. Vehicle treated animals (white), BZ194 treatment (black). 
Means +/- SD of triplicate measurements. Representative data of five independent 
experiments.
With the above evidence, we concluded that the novel compound BZ194, as a specific 
antagonist of the NAADP/Ca2+ channel, is indeed effective in EAE models and is thus 
possible to serve as a lead compound for further development of clinical drugs for MS. The 
above results also suggested that NAADP/Ca2+ plays an important role in the effector 
phase of encephalitogenic T cells and thus, might represent a novel therapeutic target for 
treatment strategies of autoimmune diseases.
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Based on BZ194, two other analogues 195 (known as BZ320) and 196 (BZ321) were also 
synthesised. Both compounds are active in permeablised T cells, antagonising NAADP 
induced calcium signaling. Compound 195 and 196, however, have weaker antagonistic 
effect compared with BZ194, suggesting that the length of the side is crucial for the 
antagonistic activity (data not shown). So far it has been found that a 4-10-carbon side- 
chain is required for the molecule to perform antagonistic activity. Compounds with side- 
chain longer than 10 carbons are normally not soluble in the biological solution and 
therefore their activities has so far not been studied.
6.5 Sum mary of C hapter Six.
In this chapter, we have synthesised a series of pyridinium salts as potential NAADP/Ca2+ 
modulators using either the alkylating method or the Zincke route. Two lead compounds, 
namely BZ52 and BZ194, were evaluated, showing interesting antagonistic effects of 
NAADP induced Ca2+ release and importantly protective effects of MS in a tEAE model. 
We expect that the compounds are also potential agents for other T cell mediated diseases, 
for example, rheumatoid arthritis and Crohn’s disease. Due to the promising in vivo results, 
these two compounds are thus important candidates for further synthetic and biological 
investigation and potentially future clinical development.
6.5 Future W ork.
In order to further exploit BZ52 and BZ194, we plan to synthesise the following 




X= O, S, CH2, or (H, H)
Ri=H, Me, Et; R2= hydrocarbyl or oxyhydrocarbyl based around hydrocarbon chain 
lengths C5 to C9 only to include ideally, if possible, also chains that could terminate in:
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R-4 is halo or aryl, methoxy aryl etc, R4.R5 =H; or R3 R4 are saturated or aryl rings or R5 =H; 
R4.R5 are saturated or aryl rings or R3 =H.
One of the difficult issues in NAADP project is to identify the protein receptor(s) of the 
NAADP signalling pathway. With active compounds such as BZ52 and BZ194 in hand, we 
thus plan to synthesis following two compounds that can link to affinity resins in future
CHAPTER SEVEN: EXPERIMENTAL
7.1 General
All reagents and solvents were of commercial quality and used without any further 
purification unless described otherwise. Aplysia califom ica  ADP-ribosyl cyclase was 
purchased from Sigma-Aldrich Company Ltd., Gillingham, England. Highly purified 
ADP-ribosyl cyclase was purified from Aplysia califom ica  (in collaboration with Professor 
Francis Schuber, Strasbourg, France) and the nucleotide pyrophosphatase obtained from 
Crotalus atrox venom. H2O was of MilliQ quality. M nCL/formamide solution was dried 
over molecular sieves (4A) for at least 4 days before usage. Unless otherwise stated, all 
reactions were carried out under a nitrogen atmosphere. All proton, carbon, and phosphorus 
NMR spectra were collected either on a JEOL Delta machine at 270 M Hz (proton) or 109 
MHz (phosphorus) or on a Varian system at 400 M Hz (proton) and 100.5 MHz (carbon). 
Chemical shifts (8) are given in parts per million (ppm). Abbreviations of the coupling 
patterns are as follows: brs, broad single peak; s, singlet; d, doublet; t, triplet; m, multiplet 
etc. UV spectra were collected on a Perkin Elmer Lambda EZ 201 or lambda 3B 
spectrophotometer. FAB mass spectra were recorded on samples in m-nitrobenzyl alcohol 
matrix with PEG-H/PEG-monomethylether as reference substance for accurate mass 
measurements on a Microsmass Autospec instrument. Some mass spectra were obtained 
though access to the EPSRC mass spectrometry service, Swansea University. HPLC 
analysis was carried out on a Waters 2695 Alliance module equipped with a Waters 2996 
Photodiode Array Detector (210-350 nm). A Phenomenex Synergi 4p  MAX-RP 80A 
column (150 x 4.6mm) and Hichrom Guard Column was used as stationary phase and the 
ion-pair buffer (45% phosphate buffer (pH 6.4) in M eOH and 0.17% (m/v) cetrimide) was 
adopted as the mobile phase. All nucleotide compounds were purified on a Pharmacia 
Biotech Gradifrac system equipped with a peristaltic P -l Pump and a fixed wavelength 
UV-1 Optical Unit (280 nm). The following chromatography conditions were employed: 
ion-pair system, stationary phase: Q-Sepharose washed with MilliQ, Gradient: 1M TEAB 
buffer (pH 7.1-7.6) against H2O (0-50%), flow rate 5 mL/min; RP system: stationary phase 
LiChroprep RP-18 saturated with 0.05 M TEAB buffer, gradient: 0.05 M TEAB buffer 
against acetonitrile (0-30%), flow rate: 5 mL/min. Kinetic analysis was performed on 300 x
3.9 mm [xBondapack Cis column (Waters Assoc., Milford MA). The compounds were eluted 
isocratically at a flow rate of 1 mL/min with a 10 mM ammonium phosphate buffer, pH 5.5,
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containing 0 .8 % (v/v) acetonitrile and detected by absorbance recordings at 260 nm.
7.2 Synthesis of 2-Fluoro Nicotinamide Adenine Dinucleotide (2-F-NAD+) 
7.2.1A-[9-(3,4-Dihydroxy-5-Hvdroxymethyl-Tetrahydrofuran-2-yl)-6-Pentafluorophe 
nyloxy-9H-Purin-2-yI]-2,2,2-Trifluoroacetamide (51)148
To a vigorously stirred suspension of guanosine (50, 320 mg, 1.5 
mmol) in dry pyridine (22 mL) was added TFAA (1.5 mL)
dropwise over 15 min at 0°C. A solution of pentafluorophenol (3.6
g, 19 mmol) in dry pyridine (75 mL) was then added under a
nitrogen atmosphere. The resulting yellow solution was kept at 
room temperature for another 24 h, concentrated to about 50 mL 
under reduced pressure and poured into water (200 mL). The 
mixture was partitioned using ethyl acetate (4x50 mL) and the combined organic layer was 
washed with water (3x20 mL). The solvent was evaporated and the resulting gum was 
dissolved in ethyl acetate (5 mL). The crude compound 51 was precipitated by dropwise
addition of its ethyl acetate solution into petroleum ether (250 mL). After filtration, the
analytical compound 51 was further purified on column chromatography eluting with 
DCM-methanol 10:1 to give compound 51 as a brown oil (647 mg, 79%). ]H NMR (DMSO, 
400 MHz) 8  12.2 (brs, 1H, NH), 8.34 (s, 1H H-8 ), 6.00 (d, J V# 5 A  Hz, 1H, H-l'), 5.55 (d, 
/ 2 -,o h  5.5 Hz, 1H, 2'-OH), 5.27 (d, / 3\o h  4.9 Hz, 1H, 3'-OH), 5.05 (m, 1H, 5'-OH), 4.65 (m, 
1H, H-2'), 4.21 (m, 1H, H-3'), 3.96 (m, 1H, H-4') and 3.63 (m, 2H, H-5'); m/z (FAB+) 546.0 
[(M+H)+, 95%].
7.2.2 2-Amino-Adenosine (52)
Compound 52 was synthesised according to literature protocol. 149 A 
suspension of compound 51 (100 mg, 0.18 mmol) in concentrated 
aqueous ammonia (10 mL) in a sealed pressure tube was heated to 55°C 
for 38 h. The resulting clear solution was concentrated under reduced 
pressure and was then purified by flash chromatography
(DCM-methanol, 5:1) to give the title compound 3 as brown oil (31 mg, 60%); ’H NMR
(D20 , 400 MHz) 8  7.93 (s, 1H, H-8 ), 5.86 (d ,7r ,2-6.2 Hz, 1H, H -l'), 4.71 (d d ,/2 ,r 6.2 Hz and
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F3COCHN N
7 2\3'5 .4  H z , 1H, H-2'), 4.37 (dd, 73-,2-5.4 Hz and 73-.4'3.0 Hz, 1H, H-3'), 4.22 (appq, 74<3< = 
^4-,5'a =Ja\5-b3 .0  Hz, 1H, H-4'), 3.87 (dd, 75'a,5-b 12.9 Hz and7 5a,4' 3 .0 Hz, 1H, H-5'a) and 3.77 
(dd, 7 5-b.5a 12.9 Hz and7 5’b,4' 3 .0  Hz, 1H, H-5'b); 13C NMR (D20 , 100.5 MHz) 5 159.3 (C-2),
155.7 (C-6 ), 150.6 (C-4), 138.3 (C-8 ), 113.5 (C-5), 88.1 (C-l'), 85.9 (C-4'), 73.5 (C-2'), 71.0 
(C-3') and 61.8 (C-5'); m/z(FAB+) 283.0 [(M+H)+, 80%].
7.2.3 2-Fluoro-Adenosine (53)150
2-NH2-Adenosine 52 (350 mg, 1.24 mmol) was dissolved in HF/Pyridine 
(1 mL, 70%) and dry pyridine (0.2 mL). The resulting dark yellow 
solution was then cooled to ca. -10°C using an ice-salt bath and an 
aqueous solution of K N 02 (0.1 mL, 1.67 g/mL) was added dropwise over 
1 h. The resulting light orange suspension was stirred at ca. - 6 ~-8 °C for 
an hour and at 3°C for another hour. The reaction mixture was then poured into ice-cold 
CaC 03 slurry (2 g in 4 mL H20). After stirred at 3°C for 2 h and room temperature for 14 h, 
the CaF/CaC03 was filtered and washed with H20  (3 mL) and H20/EtOH (4 mL, 1:1). TLC 
(n-BuOH: H20 : acetic acid) of the filtrate showed that all the starting 2-NH2-adenosine was 
reacted and a main new spot was produced at Rf 0 .6 8 , which was identical to that of the 
literature. 150 The crude product was purified by column chromatography, eluted with 
EtOAc-MeOH-H20  (10:2:1) to give the title compound 53 (190 mg, 54%); mp 199-202°C 
(lit.228 200°C); ]H NMR (DMSO, 400 MHz) 8  8.36 (s, 1H, H-8 ), 7.90 (brs, 2H, NH2), 5.78 (d, 
J v,t 5.9 H z , 1H, H -l'), 5.51 (d, 7t 0h 5.9 H z, 1H, 2'-OH), 5.25 (d, 73-,0h 5.1 H z, 1H, 3'-OH),
5.09 ( t , / 5-a,oH = / 5'b,OH5 .5  Hz, 1H, 5 -OH), 4.52 (dt, 72-, r = 72-,OH5.9 Hz and72,3-5.1 Hz, 1H, 
H-2'), 4.13 (m, 1H, H-3'), 3.92 (appq, 74«,s-a = •A-.s'b = 74-,3- 3.9 Hz, 1H, H-4') and 3.60 (m, 2H, 
H-5'); !H NMR (DMSO, D20  shake, 400 MHz) 8.35 (s, 1H, H-8 ), 5.80 (d, 7r , 2<= 5.9 Hz, 1H, 
H -l'), 4.53 (dd, / 2',1-5 .9  Hz and72',3'5.1 Hz, 1H, H-2'), 4.15 (dd, 73-,2-5.1 Hz and73-,4-3.5 Hz, 
1H, H-3'), ), 3.95 (appq, 74-,5-a = 74<,5t,= 74-i3-3.9 Hz, 1H, H-4'), 3.57 (dd, J5-a,5-b 12.1 Hz and 
75^ 4-3 .9  Hz, 1H, H-5'a) and 3.67 (dd, 7 5a,5-b 12.1 Hz and 75'M'3.9 Hz, 1H, H-S'b); 13C NMR 
(DMSO, 100.5 MHz) 5 158.9 (d, 7CF 203.7 Hz, C-2), 157.8 (d, 7CF22.0 Hz, C-6 ), 150.9 (d, 
7c f 20.6 Hz, C-4), 140.5 (C-8 ), 117.8 (C-5), 87.9 (C -l'), 86.0 (C-4'), 73.9 (C-2'), 70.7 (C-3') 






7.2.4 2-Fluoro-Adenosine 5 '-M onophosphate (54 ,2-F-AMP)
2-F-Adenosine (53, 250 mg, 0.87 mmol) was dissolved in TEP (2.5
H 2O (0.01 mL) was added followed by POCI3 (0.45 mL, 4.80 mmol) 
and the reaction mixture was stirred at 0°C for further 4 h after which
consumed. Excess POCI3 was then removed under vacuum and HoO (10 mL) was added at 
0°C and the mixture was stirred for 1 h. TEP was removed by partition between water and 
ice-cold ethyl acetate ( 3 x 1 0  mL). The aqueous layer was concentrated under vacuum and 
the resulting white residue was re-dissolved in 0.1% aq LiOH (15 mL). Crude 2-F-AMP 
lithium salt was precipitated in acetone (200 mL), and then purified by reverse phase 
chromatography eluted with a gradient of MeCN in 0.05 M TEAB buffer. The appropriate 
fractions were collected and evaporated under reduced pressure. The residue obtained was 
dissolved in H2O (10 mL) and treated with charcoal (2 spoons) for 1 h to remove any 
residual inorganic phosphate. Elution with EtOH: FLO: NH3 (400 mL, 25:24:1) provided the 
2-F AMP ammonium salt which was further treated with DOWEX-H+ to give the desired 
2-F AMP as its free acid (160 mg, 47%). F1PLC at 254 nm: 7.80 min (single peak); !H NMR 
(D20 , 4 0 0 MHz) 6  8.85 (s, 1H, H-8 ), 6.00 (d,7j-,2 -5.4Hz, 1H, H - l ') ,4.61 (m, 1H, H-2'), 4.33 
(m, 1H, H-3'), 4.13 (m, 1H, H-4') and 4.01 (m, 2H, H-5'); 13C NMR (D20 ,  100.5 MHz) 5
159.6 (d, 7cf212.6 Hz, C-2), 155.5 (d, 7Cf20.5 Hz, C-6 ), 149.4 (d, Jcf 21.0 Hz, C-4), 138.8 
(C-8 ), 112.9 (C-5), 89.4 (C-l'), 83.7 (d ,7Cp 8.3 Hz, C-4'), 74.6 (C-2'), 69.5 (C-3') and 64.3 (d, 
/ Cp5.4 Hz, C-5'); 31PNM R (D20 , *H decoupled, 161.8MHz) 60.68 (s, 5'-P); 19F NMR (D20 ,
376.3 MHz) 5 -52.70 (s, 2-F); m/z (FAB') 364.0 [(M-H)\ 100%]; HRMS Calcd. for 
C 10H 12N 5FO7F  (M-H)' 364.0464 found 364.0464.
7.2.5 2-Fluoro-Adenosine 5 '-M onophosphate M orpholidate (55)
2-Fluoro-AMP free acid (54, 160 mg, 0.44 mmol) was dissolved 
in DMSO (0.9 mL) and co-evaporated with DMF ( 3 x 2  mL). 
The resulting yellow residue was dissolved in DMSO (1 mL) 
and dipyridyl disulfide (300 mg, 1.36 mmol), morpholine (0.3 
mL, 3.44 mmol) and triphenylphosphine (300 mg, 1.15 mmol)
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were added in sequence. The reaction mixture was stirred at room temperature for 3 h after 
which 31P NMR showed completion of the reaction (disappearance of mono-phosphate peak 
at 0.6 ppm and formation of a new peak at ca 5.7 ppm, characteristic of the morpholidate). 
Precipitation of the product occurred by dropwise addition of a solution of Nal in acetone 
(0.1M, 20 mL) and the resulting precipitate was filtered and washed with acetone to yield the 
desired mopholidate as a yellow solid (159 mg, 87%). HPLC at 254 nm: 3.67 min (single 
peak); ]H NMR (D20 , 270 MHz) 6  8.31 (s, 1H, H-8 ), 5.93 (d, Jv,2<5A Hz, 1H, H -l'), 4.73 (t, 
J v x = J t? 5 A  H z , 1H, H-2'), 4.47 (dd, Jya>5A Hz and 7 3\4' 3 .5  Hz, 1H, H-3'), 4.30 (m, 1H, 
H-4'), 3.98 (m, 2H, H-5'), 3.54 (m, 4H, 2 x CH20 )  and 2.90 (m, 4H, 2 x CH2N); 13C NMR
(D20 , 67.5 MHz) 5 159.0 (d, 7 C f 2 1 0 . 6  H z, C-2), 157.2 (d, Jcf=  22.0 Hz, C-6 ), 150.2 (d, Jcf
22.0 Hz, C-4), 139.8 (C-8 ), 117.1 (C-5), 87.5 (C-l'), 83.7 (d, 7Cp8.2 Hz, C-4'), 74.1 (C-2'), 
70.3 (C-3'), 67.0, 66.9 (both CH20 ), 63.9 (d, JCp5.4 Hz, C-5') and 44.7 (2 x CH2N),; 31P
NMR (D20 , 'H decoupled, 109 MHz) 5 8.16 (s, 5'-P); 19FNM R (D20 , 376.3 MHz) 6  -52.81
(2-F); m/z (FAB') 433.0 [(M-H)\ 100%]; HRMS Calcd for C 14Hi9FN60 7P' (M-H)‘ 433.1042 
found 433.1021.
7.2.6 2-Fluoro Nicotinamide Adenine Dinucleotide (56 ,2-F-NAD+)
To a solution of 2-fluoro-AMP morpholidate (55,25 
mg, 0.068 mmol) in MnCl2 in formamide (0.56 mL, 
0.2M) was added (3-NMN+ (25 mg, 0.074 mmol) and 
M gS04 (17 mg, 0.14 mmol). The resulting 
suspension was stirred at room temperature for 48 h, 
after which HPLC analysis showed completion of 
the reaction with formation of a new peak at 3.70 
min. Precipitation of the product occurred by addition of MeCN (3 mL). It was filtered, 
dissolved in MilliQ water (2 mL) and treated with Chelex resin (sodium form) to remove any 
residual manganese and then purified on a reverse phase system eluted with 0-30% 
acetronitrile against 0.05 M TEAB buffer. The appropriate fractions were combined and 
evaporated under reduced pressure. Excess TEAB buffer was destroyed by co-evaporation 
with methanol (3 x) to give 2-F NAD+ 56 (26 mg, 55%) as its triethylaminium salt. HPLC at 
254 nm: 3.70 min (single peak); UV (H20)/nm  261.6 (£/dm3 m o f1 cm ' 1 16308); ]H
NMR (D20 , 270 MHz) 8  9.34 (s, 1H, HN-2), 9.17 (d, 76.5 6.2 Hz, 1H, HN-6 ), 8 .8 6  (d, 7 4,5 8.1 
Hz, 1H, Hn-4), 8.33 (s, 1H, H-8 ), 8.22 (dd, J5A 8.1 Hz, J5,6 6.2 Hz, 1H, HN-5), 6.08 (d, J r ,r
5.7 Hz, 1H, H-l"), 5.89 (d, 7r ,2'5.9 Hz, 1H, H -l '), 4.78 (m, 1H, H-2') and 4.52-4.20 (m, 9H,
ribose-H); 13C NMR (D20 , 100.5 MHz) 8  165.1 (CO), 158.7 (d, JCf21 1.6 Hz, C-2), 156.7 (d,
128.6 (Cn5), 118.2 (C-5), 99.9 (C-l"), 87.00 (C-l'), 86.7 (C-4'), 83.7 (C-4"), 77.5 (C-2"),
73.9 (C-2'), 70.6 (C-3"), 70.2 (C-3'), 65.3 (C-5") and 64.9 (C-5'); 31P NMR (D20 , 109 MHz) 
8  -10.77 (m, 5'-P-P); 19F NMR (D20 , 376.3 MHz) 8  -52.73 (s, 2-F); m/z (FAB ) 681.0 [(M )\ 
100%]; HRMS Calcd for [M]-C2iH26FN7Oi4P2‘ (FAB ) 681.0997 found 681.0975.
7.2.7 2-Fluoro-Adenosine-5'-Diphosphate Ribose (5 9 ,2-F-ADPR)
2-Fluoro-NAD+ (56, 61 jimol) was incubated with
the conductivity was reduced to less than 200 pS/cm and product was purified by on a 
Q-sepharose column, eluted with 0-50% gradient of 1M TEAB against MilliQ water. The 
appropriate fractions were collected and concentrated under reduced pressure. Excess 
TEAB was removed by co-evaporating with methanol to give the hydrolysed product 2-F 
ADP ribose 59 (42 pmol, 70%) as a glassy solid in the triethylammonium form. HPLC at 
254 nm: 10.51 min (single peak); UV (H20)/nm  A-max 261.6 (£/dm3 m of1 cm ' 1 13759); *H 
NMR (D20 , 400 MHz) 8  8.28 (s, 1H, H-8 ), 5.85 (d ,Jv,2<5.9 Hz, 1H, H -l'), 5.18 (d, / r ,2»4.4 
Hz, 1/3H, H-1"P), 5.06 (d, / r ,r 2.4 Hz, 2/3H, H-l "a), 4.59 (dd, / 2-,i-5.9 Hz a n d /2-,3-5.4 Hz, 
1H, H-2'), 4.38 (m, 1H, H-3'), 4.24 (m, 1H, H-4') and 4.15-3.86 (m, 7H, ribose-H); 31PNM R 
(D20 , 109 MHz) 8  -10.82 (d, JPP18.2 Hz) and -10.39 (d, 7PP18.2 Hz); 19F NMR (D20 , 376.3 
MHz) 8  -53.94 and -53.98 (a, (3 mixture); m/z (FAB') 575.9 [(M-H)\ 60%]; HRMS Calcd. 
for Ci5H21FN50 i4P2~ (M-H)‘ 576.0550 found 576.0556.
Jcf 22.0 Hz, C-6 ), 150.3 (C-4), 145.8 (CN4), 142.4 (CN6 ), 139.8 (C-8 , CN2), 134.6 (CN3),
O OH
Aplysia califomica ADP ribosyl cyclase (300 pmol) 
in a 25 mM Hepes buffer (pH 7.4, 110 mL) at room 
temperature. After 48 h, HPLC analysis indicated that 
all starting 2-F-NAD+ was consumed. The crude 
reaction solution was diluted with MilliQ water until
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7.3 Synthesis of 2-Amino-Nicotinamide Adenosine Dinucleotide
(2-NH2-NAD+)
7.3.1 2-Am ino-Adenosine-5'-M onophosphate M orpholidate (62)
NH2 A solution of 2 -NH2-AMP free acid (150 mg, 0.41 mmol) in
N i r \  ^M SO 0*5 mL) was coevaporated with DMF ( 3 x 2  mL). To
H2N N y the resulting yellow solution (ca 1.5 mL), triphenylphosphine
,P^q/^  \  I (300 mg, 1.15 mmol), morpholine (0.15 mL, 1.72 mmol) and 
O -
HO" "OH dipyridyl disulfide (200 mg, 0.91 mmol) were added in sequence. 
This green solution was stirred at rt. for 4h and then quenched by a solution of sodium iodide 
in acetone (0.2 M, 12 mL). The white precipitate was collected by filtration and washed with 
acetone. It was purified on a Q-sepharose column, eluted with a gradient of 0-50% 1M 
TEAB against MilliQ water. 2 -NH2-AMP morpholidate 62 was eluted from the column with 
8%-10% of 1M TEAB. The fractions were collected and the solvent was removed in vacuo. 
The resulting white residue was co-evaporated with MeOH (3 x) to afford the title 
compound 62 as a glassy solid in its triethylammonium form (110 mg, 46%); HPLC: single 
peak at 3.19 min at 254 nm. 'H NMR (D20 , 270 MHz) 6 8.06 (s, 1H, H-8), 5.88 (d, 7r ,2'5.2 
Hz, 1H, H -l'), 4.75 (m, 1H, H-2') (part of this peak is overlap with D2O signal), 4.49 (m, 1H, 
H-3'), 4.27 (m, 1H, H-4'), 3.98 (m, 2H, H-5'), 3.53 (m, 4H, 2 x CH20 ) and 2.89 (m, 4H, 2 x 
CH2N); 31P NMR (D20 , 109 MHz) 5 8.19 (s). m/z (FAB ) 430.2 [(M-H)\ 100%]; HRMS 
calcd. for [M -H ]'C i4H2iN7 0 7P‘ (FAB-) 430.1246 required 430.1246.
7.3.2 2-Amino-Nicotinamide Adenine Dinucleotide (63, 2-NH2-NAD+)
To a mixture of dry 2 -NH2-AMP morpholidate 62
Nh2 /NH2 (20 mg, 34 pmol), p-NMN+ (20 mg, 58 pmol) and 
- N==\
V ^ \  H // N\ M gS04 (12 mg, 100 jimol) was added a solution of
I P  2
N MnCL in formamide (0.2 M, 0.4 ml). The resulting
9  ■ 'OH mixture was stirred at rt. for 60 h after which MeCN
p -r iO ^ O
O OH
O _ q H (2 mL) was added. The white precipitate obtained
was filtered, washed with acetone, redissolved in 
small amount of MilliQ water and treated with Chelex resin (sodium form) for 1 h to remove
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any remaining Mn2+. The aqueous solution was further purified by ion-exchange column 
twice and the appropriate fractions were collected and the solvent was evaporated in vacuo. 
Excess TEAB was evaporated with MeOH (3 x) and the title compound was given as glassy 
solid in its triethyl ammonium form (10 mg, 35%). HPLC: single peak at 3.66 min at 254 nm; 
'H NMR (D20 , 270 MHz) 5 9.31 (s, 1H, HN-2), 9.11 (d, J6,5 5.2 Hz, 1H, HN-6), 8.82 (d, / 4)5
7.9 Hz, 1H, Hn-4), 8.16 (dd, J 5.4 7.9 Hz and J5,6 5.2 Hz, 1H, HN-5), 8.07 (s, 1H, H-8) 6.05 (d, 
J v ,r  3.2 Hz, 1H, H-l"), 5.80 (d, J v?  5.0 Hz, 1H, H -l') and 4.52-4.18 (m, 10H, ribose-H); 
13C NMR (D20 , 100.5 MHz) 8 166.6 (CONH2), 158.6 (C-6), 154.9 (C-2), 145.8 (CN-4, C-8),
142.4 (Cn-6), 140.0 (CN-2), 133.7 (CN-3), 128.7 (CN-5), 100.1 (C-l"), 87.2 (d, Jcp 12.2 Hz, 
C-4"), 86.6 (C-n, 83.8 (d, Jc? 12.3, C-4'), 77.7 (C-2"), 73.7 (C-2'), 70.8 (C-3"), 70.5 (C-3'),
65.6 (C-5") and 65.1 (C-5'), C-4 and C-5 not visible; 31P NMR (D20 , 109 MHz) 8 -10.60 
(brs).
7.3.3 2-Amino-Adenosine 5 '-Diphosphate Ribose (64)
A solution of 2-amino-NAD+ 63 (22 mg, 26 pmol) 
and Aplysia cyclase (100 pL) in HEPES buffer (25 
mM, pH 7.4, 70 mL) was incubated at rt. for 48 h. 
HPLC analysis indicated that all starting material had 
reacted and a new peak was given at 7.27 min for the 
hydrolysed compound. The reaction solution was 
diluted with MilliQ water and product was purified on a Q-Sepharose column eluted with a 
gradient of 0-50% 1M TEAB against MilliQ water. The appropriate fractions were collected, 
evaporated and the excess TEAB was removed by co-evaporated with MeOH (3 x) to afford 
the title molecule 64 as its triethylammonium salt (16 mg, 84%). HPLC: single peak at 7.27 
min at 254 nm; UV (H20 )  ^  256.9 nm (sh), 280.6 nm; ]H NMR (D20 , 270 MHz) 8 8.15 (s, 
1H, H-8), 5.90 (d, J v.2'5.1 H z , 1H, H -l'), 5.31 (d, J r ,r  3.5 Hz, 0.35H, H -l"p), 5.18 (brs, 
0.65H, H -l "a), 4.48 (m, 1H, H-2'), 4.32 (m, 1H, H-3'), 4.29 (m, 1H, H-4') and 4.18 (m, 7H, 
ribose-H); m/z (ES‘) 573.38 [(M-H)\ 50%]; HRMS Calcd. for (M -H y C isH ^ N e O ^ ' (ES') 
573.0753 found 573.0754.
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7.4 Synthesis of 6-A-Methyl-Nicotinamide Adenine 5 '-Dinucleotide 
(6-A-Methyl-NAD+)
7.4.1 6-Chloro-Adenosine 2', 3 ', 5 '-Triacetate (71)
Compound 71 was synthesised according to a modified Vorbriiggen 
condensation. 160 To a vigorously stirred solution of 6 -chloro-purine 
(500 mg, 3.23 mmol), p-D-ribofuranose 1,2,3,5-tetraacetate (926 mg, 
2.91 mmol) and DBU (1.3 mL, 8 mmol) in dry MeCN (22 mL) was 
AcO' OAc added TMSOTf (2.12 mL) at 0 °C under an argon atmosphere. The 
reaction mixture was heated at 60°C for 1 h and carefully quenched by addition of a 
saturated solution of NaHC0 3  (100 mL). The crude compound was extracted with DCM (3 x 
100 mL) and the organic layers were combined, dried over MgSC>4 and evaporated under 
reduced pressure. The yellow residue obtained was further purified by flash column 
chromatography, eluting with DCM-MeOH 20:1 to give the desired compound as a yellow 
oil (960 mg, 72%). *H NMR (CDC13, 270 MHz) 8  8.76 (s, 1H, H-8 ), 8.28 (s, 1H, H-2), 6.21 
(d, J y y  5.2 Hz, 1H, H -l'), 5.92 (dd, JT,v 5.2 Hz, J2>,3-5 .4  Hz, 1H, H-2'), 5.62 (dd, Jy,2- 5.4 Hz, 
JyA' 4.9 Hz, 1H, H-3'), 4.37 (m, 3H, H-4' and H-5'), 2.14,2.10 and 2.07 (3 x CH3); 13C NMR 
(CDCI3, 100.5 MHz) 8 170.4,169.7,169.5 (3 x C=0), 152.4 (C-2), 151.6 (C-6 ), 151.3 (C-4),
143.7 (C-8 ), 132.4 (C-5), 86.9 (C -l'), 80.6 (C-4'), 73.18 (C-2'), 70.5 (C-3'), 63.0 (C-5'), 20.9, 




7.4.2 6-N-Methyl-Adenosine 5 '-Acetate (72)
Compound 72 was synthesised according to a literature protocol. 167 To a
HN^
I suspension of 6 -chloro-adenosine triacetate (800 mg, 1.94 mmol) and
N iT  \sL JJ /  methylamine hydrochloride (573 mg, 8.42 mmol) in a mixture of DCM
N N
O I  (20 mL) and ethanol (4.2 mL) was added triehtylamine (3.8 mL). The
AcO^^X^ 7
>— ' resulting mixture was stirred at 60°C for overnight. TLC analysis
HO° OH
indicated that the starting material was completely consumed and three 
more polar spots were given. The reaction mixture was transferred into a pressure tube with 
triethylamine (4 mL), methylamine hydrochloride (500 mg, 7.35 mmol) and ethanol (4 mL). 
The mixture was heated at 60°C for 6  h and left at rt. for 2 days. TLC of the mixture
158
indicated only one major spot at Rf 0.25 (DCM-MeOH 10:1). The solvent was removed and 
the crude compound was purified by flash column chromatography, eluting with 
DCM-MeOH 30:1 to give a mixture of the desired compound and the methylamine 
hydrochloride. Pure title compound was obtained as a white solid by washing the resulting 
mixture with MilliQ water (420 mg, 67%). ]H NMR (DMSO. 270 MHz) 8  8.35 (s, 1H, H-8 ), 
8.24 (brs, 1H, H-2), 7.81 (brs, 1H, NH), 5.91 (d ,7 r,2-5.0 Hz, 1H, H -l'), 5.61 (m, 1H, 2'-OH), 
5.42 (m, 1H, 3 -OH), 4.67 (m, 1H, H-2'), 4.31-4.18 (m, 4H, H-3', H-4', H-5'a and H-S'b), 
2.95 (brs, 3H, CH3N), 1.95 (s, 3H, CH3 of acetate); 13C NMR (DMSO, 100.5 MHz) 8 170.8 
(CO), 155.7 (C-6 ), 153.3 (C-2), 148.8 (C-4), 140.0 (C-8 ), 120.1 (C-5), 88.3 (C-l'), 82.1 
(C-4'), 73.4 (C-3'), 70.9 (C-2'), 64.5 (C-5'), 27.6 (CH3) and 21.2 (CH3 of acetate); mJz (ES+) 
324.39 [(M+H)+, 100%]; HRMS Calcd for [M+H]+Ci3H 18N50 5+ 324.1308 found 324.1302.
7.4.3 6-N-MethyI-Adenosine (68)
A suspension of 6-A^-methyl-adenosine-5'-acetate 72 (400 mg, 1.23 mmol) 
in a saturated methanolic ammonia (50 mL) was stirred at rt. for 3 h and
l  JL N> after which the solvent was removed in vacuo. The residue obtained was
purified by flash column chromatography, eluting with DCM-methanol
HO
HO' o h  to produce the title compound 6 8  as a white solid (300 mg, 8 6 %); mp: 
178-180°C; *H NMR (DMSO, 270 MHz, D20  shake) 8  8.31 (s, 1H, H-8 ), 
8.20 (brs, 1H, H -2),5.85 (d, J Vt2> 6.4 Hz, 1H, H -l ') ,4.57 (dd, lH ,J 2-,r  6.4 Hz and 72-j3 5.2 H z ,  
H-2'), 4.12 (dd, Jy,x 5.2 Hz and JyA< 3.0 Hz, 1H, H-3'), 3.97 (app.q, / 4\s'a = = J*\y 3.0 Hz,
1H, H-4'), 3.64 (dd, J5%5>h 12.9 Hz and / 5'a,4'3.0 Hz, 1H, H-5'a), 3.55 (dd, Jsvs'a 12.9 Hz and 
y5-b,4' 3.0 Hz, 1H, U S 'b )  and 2.94 (brs, 3H, CH3N); 13C NMR (D20 , 100.5 MHz) 8  155.5 
(C-6 ), 153.0 (C-2), 148.3 (C-4), 140.3 (C-8 ), 120.2 (C-5), 88.5 (C-l'), 86.4 (C-4'), 73.9 
(C-2'), 71.0 (C-3'), 62.1 (C-5'), 27.5 (CH3); LCMS (ES+) m/z 282.43 [(M+H)+ 100%]; 
HRMS Calcd for [M+H]+ C 11H 15N5O /  (ES+) 282.1202 found 282.1201.
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7.4.4 6-A-Methyl-Adenosine 5 '-M onophosphate (73a, 6-A-MethyI-AMP)
A suspension of 6-A-methyl-adenosine 68 (110 mg, 0.39 mmol,
dried in vacuo at 100°C for 2 h) in triethylphosphate (1.4 mL) was
heated strongly with a heating gun for 5 min. To the resulting clear
solution was added POCl3 (0.3 mL, 3.20 mmol) and H2O (1 pJL) at
0°C and it was stirred for 1 h. The reaction mixture was quenched by
addition of ice (15 mL). The resulting solution was extracted with 
R = PO3 H; 73b ' 5
cold ethyl acetate (5 x 20 mL) and the aqueous layer was neutralised 
with NaOH (5 M) and loaded onto a reverse phase system, eluted with a gradient of 0-30% 
MeCN against 0.05 M TEAB. The fractions containing desired compound were pooled, 
evaporated and the excess TEAB was co-evaporated with MeOH (3 x) to give a mixture of 
title compound 73a (150 mg, 0.20 mmol, 51%) and the bis-phosphate 73b; 'H NMR (D2O, 
270 MHz) 8 8.17 (s, 1H, H-8), 7.71 (s, 1H, H-2), 5.83 (d, J v?  5.7 Hz, 1H, H-L), 4.57 (m, 1H, 
H-2'), 4.37 (m, 1H, H-3'), 4.25 (m, 1H, H-4'), 4.03 (m, 2H, H-5') and 2.78 (m, 3H, CH3N); 
31P NMR (D20 , 109 MHz) 5 1.12 (s). Impurity 73b *H NMR (D20 , 270 MHz) 8 8.13 (s, 1H, 
H-8), 7.81 (s, 1H, H-2), 6.06 (d, J V,T 4.5 Hz, 1H, H -l'), 5.25 (m, 1H, H-2'), 5.05 (m, 1H, 






R = H; 73a
7.4.5 6-A-Methyl-Adenosine 5 '-M onophosphate M orpholidate (74)
HN^ A suspension of 6-A-methyl-AMP 73a/73b (73a, 0.20 mmol,
calculated by *HNMR integration) in dry DMSO (0.9 mL) was 
N evaporated with dry DMF ( 3 x 2  mL). To the residue was added
/ *n sequence triphenylphosphine (280 mg, 1.07 mmol),
HO ) — (
HO' "OH morpholine (0.15 mL, 1.72 mmol) and dipyridyl disulfide (235 
mg, 1.07 mmol). The resulting yellow solution was stirred at rt. for 4 h, after which a 
solution of sodium iodide in acetone (0.2 M, 15 mL) was added and the precipitate was 
filtered and washed with acetone. The crude product was further purifed by ion-exchange 
chromatography, eluting with a gradient of 0-50% 1M TEAB against MilliQ water. The 
solvent was evaporated in vacuo and excess TEAB was co-evaporated with MeOH (3 x) to
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give the title compound 74 as its triethylammonium salt (93 mg, 78%). HPLC: single peak at 
2.78 min at 254 nm; UV (H20 ) tanax 266.4 nm; *H NMR (D20 , 270 MHz) 5 8.23 (s, 1H, 
H-8), 7.98 (s, 1H, H-2), 5.93 (d, J V,T 4.9 Hz, 1H, H -l'), 4.68 (m, 1H, H-2'), 4.42 (m, 1H, 
H-3'), 4.26 (m, 1H, H-4'), 3.94 (m, 2H, H-5'), 3.44 (m, 4H, 2 x CH20 ), 2.91 (m, 3H, CH3N) 
and 2.80 (m, 4H, 2 x CH2N); 13C NMR (D20 , 100.5 MHz) 6 154.5 (C-6, C-4), 152.4 (C-2),
138.9 (C-8), 118.7 (C-5), 87.3 (C -l'), 83.7 (d, Jcp 8.7 Hz, C-4'), 74.2 (C-2'), 70.3 (C-3'), 66.9 
(2 x CH20 ), 63.9 (d, Jc? 6.1 Hz, C-5'), 44.7 (2 x CH2N) and 27.4 (CH3); 31P NMR (D20 , 109 
MHz) 6 8.10 (s); m/z (ES’) 429.16 [(M-H)\ 100%]; HRMS Calcd for [M+H]+ C is H ^ O tP *  
431.1439 found 431.1441.
7.4.6 6-iV-Methyl-Nicotinamide Adenine Dinucleotide (75, 6-V-MethyI-NAD+)
To a mixture of 6-V-methyl-AMP morpholidate 74 
(56 mg, 95 jimol), (3-NMN (55 mg, 165 jimol) and 
M gS04(38 mg, 317 pmol) was added a solution of 
MnCl2 in formamide (0.2 M, 1.18 mL). The 
resulting suspension was stirred at rt. for 48 h under 
a nitrogen atmosphere and the reaction mixture was 
quenched by dropwise addition of MeCN (2 mL). 
The yellow precipitate was filtered, washed with acetone and dissolved in small amount of 
MilliQ water. The aqueous solution was treated with Chelex (sodium form) to remove any 
residual manganese and purified by reverse-phase chromatography. The title compound 75 
was isolated as a glassy solid in the triethylammonium form (51 mg, 64%). HPLC: single 
peak at 3.43 min at 254 nm; UV (H20 )  A,max 262.5 nm; ‘H NMR (D20 , 400 MHz) 6 9.25 (s, 
1H, Hn-2), 9.07 (d, 76 5 5.9 Hz, 1H, HN-6), 8.71 (d, 74,5 8.2 Hz, 1H, HN-4), 8.26 (s, 1H, H-8),
8.09 (dd ,75,4 8.2 H z a n d /5,65.9 Hz, 1H, HN-5), 7.97 (s, 1H, H-2), 5.99 (d ,J r ,2"5.5 Hz, 1H, 
H -l"), 5.91 (d, (2-5.9 Hz, 1H, H-l'), 4.70 (dd,72,r5 .9  H z ,/2vr5.5 Hz, 1H, H-2'), 4.48 (m, 
1H, H-4"), 4.44 (m, 2H, H-3" and H-3'), 4.37 (m, 1H, H-2"), 4.32-4.16 (m, 5H, H-4', H-5'a, 
H-S'b, H-5 "a and H-5"b) and 2.93 (CH3N); 13C NMR (D20 , 100.5 MHz) 6 164.9 (CO),
154.4 (C-6), 152.4 (C-2), 147.3 (C-4), 145.4 (CN-4), 142.1 (CN-6), 139.8(CN-2), 138.8 (C-8),
133.4 (C n-3 ) , 128.5 (CN-5), 118.3 (C-5), 99.9 (C -l"), 86.9 (d, Jcp 8.4 Hz, C-4"), 86.4 (C-l'),
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(C-5') and 27.1 (CH3N); 31P NMR (D20 , 109 MHz) 5-10.73 (brs); m/z (ES*) 676.36 [(M-H)', 
100%]; HRMS Calcd for [M-H]' C22H28N7O 14F  (ES*) found 676.1175 found 676.1158.
7.4.7 6-A-Methyl-Adenosine 5 '-Diphosphate Ribose (76, 6-A-Methyl-ADPR)
To a solution of 6-./V-methyl-NAD+ 75 (20 mg, 24 
pmol) in HEPES buffer (25 mM, pH 7.4, 60 mL) 
was added Aplysia ADP ribosyl cyclase (80 pL). 
The resulting solution was stirred at rt. until
OH
RP-HPLC indicated all the staring material had 
reacted. The solution was diluted and then product 
purified by ion-exchange chromatography, eluting with a gradient of 0-50 1M TEAB buffer 
against MilliQ water. The appropriate fractions were collected, evaporated and excess 
TEAB was removed by co-evaporating with MeOH (3 x) to give compound 76 as a glassy 
solid in its triethylammonium form (10 mg, 59%). HPLC: single peak at 12.62 min at 254 
nm; UV(H20 )  A™* 265.1 nm (fi'dm3 m ol'1 cm'1 13780); ]H NMR (D20 ,  200 MHz) 5 8.37 (s,
1H, H-8), 8.10 (s, 1H, H-2), 6.02 (d, Jv,t 5.9 Hz, 1H, H -lf), 5.24 (d, J V',2" 4.0 Hz, 0.3H,
H-1"P), 5.14 (m, 0.7H, H -l''a ) , 4.70-3.94 (m, 10H, H-ribose) and 2.87 (m, 3H, CH3N); 31P 
NMR (D20 , 109 MHz) 5 -10.65 (brs); m/z (ES') 572.37 [(M-H)', 45%]; HRMS Calcd. for 
[M -H]'Ci6H24 0 14N5P2' (ES') 572.0801 found 572.0792.
7.5 Attempt to Synthesise Nicotinamide 6-A-Methyl-8-Bromo-Adenine 
Dinucleotide (6-A-Me-8-Br-NAD+).
7.5.1 8-Br-6-A-Me-Adenosine 2 ',3 ',5 '-Triacetate (77)
To a solution of 6-A-Me-adenosine (68, 200 mg, 0.71 mmol) in dry 
pyridine (0.8 mL) was added acetic anhydride (0.6 mL). The resulting 
solution was stirred at rt. until TLC analysis indicated that all starting 
material was consumed. The reaction was quenched by addition of 
methanol and the solvent was removed in vacuo. The residue was 
dissolved in DCM (20 mL), washed with a saturated solution of
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NaHCC>3 (20 mL) and water (20 mL). The organic layer was dried, evaporated and the 
resulting residue was purified by flash column chromatography, eluting with a gradient of 
0-5% M eOH against DCM to give the 6-/V-methyl-adenosine-2',3',5' triacetate in 
quantitative yield; ]H NM R (CDCI3, 270 MHz) 5 8.31 (s, 1H, H-2), 7.86 (s, 1H, H-8), 6.53 
(brs, 1H, NH), 6.11 (d, h  -2- 5.2 Hz, 1H, H -l'), 5.84 (m, 1H, H-2'), 5.61 (m, 1H, H-3'), 4.34 (m, 
3H, H-4' and H-5'), 3.10 (brs, 3H, CH3N), 2.06 (s, 3H, CH3), 2.05 (s, 3H, CH3) and 2.01 (s, 
3H, CH3).
To a solution of Na2HP0 4  in MilliQ water (10% w/v, 12.5 mL) was added Br2 (0.2 mL) and 
the reaction mixture was stirred vigorously at rt. for 15 min until most o f the Br2 dissolved. 
To the bromine solution was added 6 -N-Me-adenosine 2 ',3 ',5'-triacetate (180 mg, 0.50 
mmol) and dioxane (7.5 mL). The resulting dark red solution was stirred a trt. for 2 days after 
which a solution of Na2HPC>4 (10% w/v, 3.5 mL) was added, and the reaction was allowed to 
stir at rt. for further 3 days. It was quenched by dropwise addition of a solution of NaHSC>3 in 
MilliQ water until the solution became colourless. It was then washed with DCM (20 mL x  3) 
and the organic layers were combined, dried over MgSC>4 and was evaporated under reduced 
pressure. The crude product obtained was purified by flash column chromatography, eluting 
with a gradient of 0-5% M eOH against DCM to give the title compound 77 as a white solid 
(196 mg, 81%); mp: 210-212 °C; ]H NMR (CDC13, 270 M Hz) 6  8.31 (s, 1H, H-2), 6.30 (dd, 
J2\3-6 .2  Hz and J2r  4.5 Hz, 1H, H-2'), 6.05 (d, -,2-4 .5  Hz, 1H, H -l'), 5.93 (appt, JyA>=Jy,2>
6.2 Hz, 1H, H-3'), 4.47-4.30 (m, 3H, H-4' and H-5'), 3.13 (s, 3H, CH3N), 2.12 (s, 3H, CH3), 
2.08 (s, 3H, CH3) and 2.01 (s, 3H, CH3); 13C NMR (CDC13, 67.5 MHz) 5 170.7,169.6,169.6 
(all C =0), 154.3 (C-6  and C-4), 153.4 (C-2), 126.0 (C-8 ), 120.5 (C-5), 88.7 (C-l'), 80.2 
(C-4'), 72.3 (C-2'), 70.5 (C-3'), 63.0 (C-5'), 27.1,20.79,20.64 and 20.58 (all CH3); m/z (ES+) 
487.58 [(M)+, 100%, 81Br]; HRMS calcd. for [M+H]+C n H 2i0 7N579Br+ (ES+) 486.0619 
found 486.0617.
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7.5.2 Nicotinamide 6 -/V-MethyI-8 -Br-Adenosine Dinucleotide (6-7V-Me-8-Br-NAD+).
A mixture of 6 -A-methyl-8 -bromo-AMP 
morpholidate (7 mg, 13.7 (xmol), (3-NMN4- (9.6 mg,
\ + W  N H 2 H N ^
^  27.9 pmol) and M gS04 (5.7 mg, 47.5 pmol) in a
H0V W \ (x
O m--^ C ^  solution of MnCl2 in acetone (0.2 M, 0.2 mL) was
✓ W  ' N Br
/  stirred under argon atmosphere at rt for 3 days. ToHO
q ' P - q  resul0ng clear solution, MeCN (2 mL) was
o  XOH ^  added and the yellow precipitate was collected, 
washed with MeCN and redissolved in MilliQ water (5 mL). The solution was then treated 
with Clelax resin (Na+ form) to remove any residual Mn2+ and was purified on a reverse 
phase media eluting with a gradient of 0-30% MeCN against 0.05 M TEAB. The appropriate 
fractions were collected and the solvent was evaporated. The resulting white solid was 
co-evaporated with MeOH (3 x) to give the title compound (10 mg, 10.9 pmole, 79%) as a 
triethylammonium salt; *H NMR (D20 , 270 MHz) 6  9.23 (s, 1H, HN-2), 9.03 (d, J6,5 6.2 Hz, 
1H, Hn-6 ), 8.71 (d, 74.5 7.9 Hz, HN-4), 8.10 (m, 2H, HN-5, H-2), 5.89 (m, 2H, H-L, H - l"),
5.07 (m, 1H, H-2'), 4.56-4.06 (m, 9H, ribose-H); 31P NMR (D20 , 109 MHz) 5 -10.99 (brs).
7.6 Synthesis of Cyclic Guanosine Diphosphate Ribose (cGDPR)
7.6.1 Guanosine 5 '-Monophosphate M orpholidate (83, 5'-GM P morpholidate)
O A solution of GMP free acid (82, 90 mg, 0.25 mmol) in
anhydrous DMSO (1.5 mL) was coevaporated with anhydrous 
H2N N ^ DMF ( 3 x 3  mL). The resulting yellowish residue was again
W dissolved in anhydrous DMSO (1.5 mL) and finely powdered
O -  w  \ — {
HC> OH triphenylphosphine (220 g, 0.84 mmol), morpholine (0.15 mL,
1.73 mmol) and dipyridyl disulfide (200 mg, 0.90 mmol) were added in sequence. The
reaction mixture was stirred at rt. for 2.5 h after a solution of sodium iodide in acetone (0.1
M, 15 mL) was added dropwise. The precipitate was filtered, washed with acetone and dried
in vacuo and was used in next step without further purification (91 mg, 84%); HPLC: single
peak at 4.04 min at 254 nm; ‘H NMR (D20 , 400 MHz) 8  7.88 (s, 1H, H-8 ), 5.74 (d, J Vr  5.1
Hz, H-l'), 4.62 (m, 1H, H-2'), 4.35 (m, 1H, H-3'), 4.13 (brs, 1H, H-4'), 3.85 (m, 2H, H-5'),
3.40 (m, 4H, 2 x CH.O) and 2.76 (m, 4H, 2 x CH2N); 31P NMR (D20 , 109 MHz) 8.45 (s);
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m/z (FAB ) 431.2 [(M-H)', 100%]; HMRS Calcd. for (M-H)' Ci4H2oN60 8F  (FAB') 
431.1086 found 431.1096.
7.6.2 Nicotinamide Guanine Dinucleotide (85, NGD+)
To a mixture of GMP morpholidate (83, 61 mg, 0.14 
mmol), p-NMlSC (52 mg, 0.15 mmol) and M gS04 
(32 mg, 0.27 mmol) was added a solution of MnCl2 
in formamide (0.2 M, 1.05 mL) under a nitrogen
, ,OH atmosphere and the reaction mixture was stirred at rt
for 62h. Precipitation of the product occurred by 
dropwise addition of MeCN (2 mL). It was filtered, 
washed with acetone, dissolved in MilliQ water (3 mL) and treated with Chelex to remove 
any Mn2+ residues. The crude product was purified by ion exchange AG-MP1 column, 
eluting with a gradient of 0-30% 150 nm TFA against MilliQ water. The appropriate
fractions (8-10% TFA) were combined and the solvent was evaporated in vacuo. The
resulting yellow oil was applied to another ion exchange Q-sepharose column, eluting with a 
0-50% gradient of 1M TEAB against MQ. The fractions containing the title compound were 
collected, lyophilised and the excess TEAB was evaporated with MeOH (3 x) to give the 
title compound as a glassy solid in its triethylammonium form (46 mg, 48%). HPLC: single 
peak at 6.53 min at 254 nm; *H NMR (D20 , 270 MHz) 5 9.32 (s, 1H, HN-2), 9.16 (d, 76.5 5.5 
Hz, 1H, Hn-6 ), 8.24 (d, J4,5 5.4 Hz, 1H, HN-4), 8.20 (m, 1H, HN-5), 7.97 (s, 1H, H-8 ), 6.07 (d, 
7i»,2"5.1 Hz, 1H, H-l"), 5.77 (d ,J r ,2-5.9Hz, 1H, H-L) and 4.73-4.13 (m, 10H, ribose-H); 31P 
NMR (D20 , 109 MHz) 5 -11.43 (m); m/z (FAB+) 680.0 [(M+H)+, 32%].
7.6.3 Cyclic Guanosine 5 '-Diphosphate Ribose (79, cGDPR )143
NGD+ 85 (26 mg, 40 (imol) was incubated with ADP 
ribosyl cyclase (150 pL) in HEPES buffer (25 mM, pH
7.4, 90 mL) at rt. for overnight after which HPLC 
showed that a new peak at 11.29 min for the cyclic 
product. The crude product was purified by Q-sepharose 
ion-exchange chromatography, eluting with a 0-50%
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gradient of 1M TEAB against MQ. The appropriate fractions (29-31% TEAB) were 
collected, evaporated and excess TEAB was removed by co-evaporating with MeOH. The 
title compound cGDPR 79 was given as a glassy solid in the triethylammonium salt (15 mg, 
70%). HPLC: single peak at 11.29 min at 254 nm; *H NMR (D20 , 270 MHz) 8  9.02 (s, 1H, 
H-8 ), 6.31 (brs, 1H, H -l"), 6.07 (d, J V2>2.8 Hz, 1H, H -l') and4.63-4.12 (m, 10H, ribose-H); 
m/z (FAB+) 558.0 [(M+H)+, 8 8 %]; HRMS Calcd. for C i s H ^ N s O ^  [M+H]+ 558.0633 
found 558.0632.
7.7 Synthesis of Nicotinamide Xanthine Dinucleotide (NXD+)
7.7.1 Xanthosine-5'-M onophosphate M orpholidate (87)
O To a solution of XMP triethylammonium salt (8 6 , 100 mg, 0.19
H N '^ j j ' ' 1^  m m ol) in dry DMSO (0.6 mL) was added in sequence dipyridyl
N J1 disulfide (160 mg, 0.73 mmol), morpholine (130 pL, 1.49 mmol)
and triphenylphosphine (190 mg, 0.73 mmol) at which point the 
HO' "OH solution turned green-yellow. It was stirred at rt. for 3 h after 
which HPLC analysis indicated that a new peak was formed at ca 9.7 min precipitation of the 
product occurred by dropwise addition of a solution of sodium iodide in acetone (0.2 M, 20 
mL); the resulting precipitate was filtered, washed with acetone and dried in vacuo to give 
the title compound as a yellow solid (0.17 mmol, 89%), which was used in the next step 
without further purification. HPLC: single peak at 9.70 min at 254 nm; UV (H20 ) 249.8,
277.0 (sh); ]H NMR (D20 , 300 MHz) 6  7.90 (s, 1H, H-8 ), 5.81 (d, 7r,2-5.3 Hz, 1H, H-l'), 
4.59 (m, 1H, H-2', overlap with HOD peak), 4.39 (m, 1H, H-3'), 4.21 (m, 1H, H-4'), 3.93 (m, 
2H, H-5'), 3.49 (m, 4H, 2 x CH20 )  and 2.87 (m, 4H, 2 x CH2N); 31P NMR (D20 , 109 Hz) 
8  8.10 (s); m/z (ES ) 432.12 [(M-H)\ 78%]; HRMS Calcd for (M+H)+ C ^ H ^ N ^  (ES+) 
434.1071 found 434.1074.
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To a mixture of XMP morpholidate (87, 30 mg, 51 
pmol), p-NMN+ (29 mg, 87 |Limol) and MgSC>4 (20 
mg, 167 prnol) was added a solution of MnCl2 in 
formamide (0.2 M, 0.63 mL). The resulting mixture 
was stirred under a nitrogen atmosphere for 3 days 
and the progress was monitored by HPLC. The 
reaction was quenched by dropwise addition of
MeCN and the yellow precipitate was filtered, washed with MeCN and dissolved in small 
amount of MilliQ water. Residual manganese ions were removed by the treatment of Chelex 
resin (sodium form) and the crude solution was purified by reverse-phase chromatography, 
eluting with a gradient of 0-30% MeCN against 0.05 M TEAB. The appropriate fractions 
were collected and the solvent was co-evaporated in vacuo. Excess TEAB was evaporated 
with MeOH (3 x) to afford the title compound as a glassy solid in its triethylammonium form 
(27 mg, 63%). HPLC: single peak at 12.41 min at 254 nm; UV A™* (H20 )  249.8,277.0 (sh); 
'H NMR (D20 , 400 MHz) 5 9.32 (s, 1H, HN-2), 9.16 (d, J6.5 6.3 Hz, 1H, HN-6 ), 8.84 (d, 7 4,5
8.2 Hz, 1H, Hn-4), 8.18 (dd, 75,4 8 .2  Hz, 75,6 6.3 Hz, 1H, HN-5), 7.98 (brs, 1H, H-8 ), 6.09 (d, 
7i»,2»5.1 Hz, 1H, H -l"), 5.73 ( d , / r ,2-6.3 Hz, 1H, H-l'), 4.49 (dd,72-,r 6.3 Hz, / 2-,v5.5 Hz, 1H, 
H-2'), 4.48 (m, 2H, H-2" and H-4") and 4.39-4.17 (m, 7H, ribose-H); 3,P NMR (D20 , 109 
MHz) 5 -11.54 (brs); m/z (ES') 679.0 [(M-H)', 18%]; HRMS Calcd. For (M-H)' 
C2]H25Oi6N6P2" (FAB ) 679.0808 found 679.0810.
7.8 Synthesis of 8-Bromo-Nicotinamide Guanine Dinucleotide 
(8-Br-NGD+)
7.8.1 8 -Bromo-Guanosine 5 '-M onophosphate M orpholidate (92).
O To a solution of 8 -bromo-GMP di-sodium salt (91,50 mg) in 
MilliQ water (20 mL) was added Dowex resin (hydrogen 
form) (3 g). The mixture was stirred at rt. for 2 h, filtered and
I washed with MilliQ water (500 mL). Removal of the MilliQ
HO' "OH water gave 8 -Br-GMP free acid (50 mg, 0.11 mmol), which
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was again dissolved in DMSO (0.6 mL). To the resulting suspension, triphenylphosphine 
(lOOmg, 0.38mmol), dipyridyl disulfide (100 mg, 0.46 mmol) and morpholine (0.13 mL,
1.48 mmol) were added in sequence and the reaction mixture was stirred at the temperature
converted. The reaction was quenched with a solution of sodium iodide in acetone (0.2 M,
10 ml), the precipitate filtered and washed with acetone, and dried over P2O5 in vacuo for 2 
days. The crude product was again dissolved in DMSO (0.6 mL) and co-evaporated with 
DMF (3 x 1 mL). To the resulting yellow solution were added in sequence of 
triphenylphosphine (200 mg, 0.76 mmol), morphorline (0.2 ml, 2.29 mmol) and dipyridyl 
disulfide (200 mg, 0.91 mmol). After 4h at r.t, the reaction was again quenched with 
Nal/acetone (10 mL) and washed with acetone. HPLC analysis showed that 70% of the 
starting material was consumed. The crude product was purified on an ion-exchange column, 
and product eluted with a 0-50% gradient of 1M TEAB against MilliQ water. The 
appropriate fractions were collected and solvent was evaporated under reduced pressure. 
The resulting white solid was coevaporated with methanol (3 x) to yield the title compound 
92 as a glassy solid (23 mg, 32%). HPLC: single peak at 5.90 min at 254 nm; ‘H NMR (D2O, 
270 MHz) 6  5.87 (d, 1H, H -l '), 5.26 (m, 1H, H-2'), 4.68 (m, 1H, H-3'), 4.15 (m, 1H, H-4'),
3.99 (m, 2H, H-5'), 3.44 (m, 4H, 2 x CH20 )  and 2.82 (m, 4H, 2 x CH2N);13C NMR (D20 ,
100.5 MHz) 5 158.1 (C=0) 154.8 (C-2), 152.7 (C-4), 124.8 (C-8 ), 116.0 (C-5), 90.4 (C -l'),
84.5 (C-4'), 71.2 (C-2'), 69.8 (C-3'), 66.9,6 6 .8  (2 x  CH20), 64.1 (C-5') and 46.8 (2 x CH2N); 
31P (D20 , 109 MHz) 6  8.37 (s); m/z (FAB+) 511.2 [(M+H)+, 10%]. m/z (ES‘) 509.30,511.30 
[(M-H)’, 100%); HRMS Calcd for [M-H]' Ci4H i9N60 8 79BrP' (ES') 509.0185 found 
509.0182.
7.8.2 8 -Bromo-Nicotinamide Guanine Dinucleotide (89, 8 -Br-NGD+)
for further 4h. HPLC analysis indicated that only small amount of the starting material was
O To a mixture of 8 -Bromo-GMP morpholidate 92
O OH
(23 mg, 34 (Ltmol), (LNMN+ (19 mg, 57 jLtmol) and 
— Mg S 0 4 (12 mg, 100 ^immol), was added a solution 
N Br of MnCl2 in formamide (0.2 M, 0.4 mL). The 
V .iq h  reaction mixture was stirred at rt. for 60 h after
which HPLC analysis indicated the formation of a
168
new peak at 7.68 min. MeCN (2ml) was then added to the solution and the white precipitate 
was filtered, washed with acetone and redissolved in small amount of MilliQ water. It was 
treated with chelex (sodium form) for an hour at rt to remove any remaining Mn2+, and 
purified by ion-exchange chromatography (Q-sepharose column), eluting with a 0-50% 
gradient of 1M TEAB against MilliQ water. The appropriate fractions were collected and 
lyophilised. Excess TEAB was removed by co-evaperating with methanol to gave the 
desired dinucleotide 89 as a white solid in its triethylammonium form (22 mg, 24 pmol, 
71%). HPLC: single peak at 7.68 min at 254 nm; *H NMR (D20 , 400 MHz) 6 9.35 (s, 1H, 
Hn-2), 9.07 (d, 76,5 5.1 Hz, 1H, HN-6), 8.85 (d, A 5 7.8 Hz, 1H, HN-4), 8.22 (dd, J5A 7.8 Hz 
and J5,6 5.1 Hz, 1H, HN-5), 5.96 (d, J V\ r  3.2 Hz, 1H, H-l"), 5.75 (d, J v#  5.4 Hz, 1H, H -l'),
5.19 (m, 1H, H-2') and 4.77-4.22 (m, 9H, H-2", H-3', H-3", H-4', H-4", H-5' and H-5"); 13C 
NMR (D20 , 100.5 MHz) 6 162.8 (CO), 157.5 (C-6), 153.3 (C-2), 152.6 (C-4), 145.9 (CN-4),
142.3 (Cn-6), 139.7 (CN-2), 133.8 (CN-3), 128.9 (CN-5), 123.8 (C-8), 116.5 (C-5), 100.1 
(C -l '), 89.7 (C-l"), 87.0 (d, 7Cp 8.4 Hz, C-4"), 83.5 (d, 7Cp 6.9 Hz, C-4'), 77.6 (C-2"), 70.7 
(C-2'), 70.5 (C-3"), 69.9 (C-3'), 65.7 (C-5") and 64.8 (C-5'); 31P NMR (D20 ,  109 MHz) 6 
-11.16 (brs) and -10.68 (brs); HRMS Calcd. for [M ]'C2iH2679BrN7Oi5P2'(FA B ) 757.0146 
found 757.0169; Calcd. for C2iH2681BrN7O i5P2' 759.0125 found 759.0145.
7.9 Synthesis of Cyclic 8-Bromo-Adenosine Diphosphate Ribose 
(8-Br-cADPR)
7.9.1 8-Bromo-Adenosine-5 '-M onophosphate (102)174
To a solution of AMP free acid (200 mg, 0.55 mmol) in NaOAC
buffer (8 mL, 0.9 M, pH 4.05) was added dropwise a saturated
Br
solution of bromine in MilliQ water (12 mL). The resulting 
dark-red solution was stirred at rt. for 1.5 h and was quenched by 
HO' OH addition of a saturated solution of NaHSO^. The solution was 
adjusted to ca. pH 7 and was purified by reverse-phase chromatography, eluting with a 
gradient of 0-30% MeCN against 0.05 M TEAB. The appropriate fractions were collected, 
evaporated in vacuo and the excess TEAB was removed by coevaporation with MeOH (3 x)




270 MHz) 5 8.16 (s, 1H, H-2), 6.11 (d, J v?  5.9 Hz, 1H, H -l '), 5.30 (appt, h .v  = Ji\y 5.9 Hz, 
1H, H-2'), 4.63 (m, 1H, H-3'), 4.30 (m, 1H, H-4') and 4.15 (m, 2H, H-5'); 
8-Bromo-Adenosine (104) was synthesised in the same manner. Purification using flash 
chromatography gave 104 in more than 80% yield. *H NMR (DMSO, 270 MHz) 8 8.11 (s, 
1H, H-2), 7.57 (brs, 2H, NH2), 5.81 (d, J,-.2- 7.3 Hz, 1H, H - l '), 5.50 (m, 2H, 2 x OH), 5.27 
(m, 1H, H-2'), 5.07 (m, 1H, OH), 4.19 (m, 1H, H-3'), 3.95 (m, 1H, H-4') and 3.59 (m, 2H, 
H-5').
7.9.2 8 -Bromo-Adenosine 5 '-M onophosphate M orpholidate (127)
To a solution of 8-bromo-AMP 102 (110 mg, 220 pmol) in 
DMSO (0.6 mL) was added triphenylphosphine (200 mg, 
763 pmol), morpholine (130 pL, 1.49 mmol) and dipyridyl 
disulfide (168 mg, 763 pmol). The resulting yellow solution 
was stirred at rt. for 3 h and was quenched with a solution of 
sodium iodide in acetone (0.2 M, 20 mL). The resulting precipitate was filtered, washed with 
acetone and dried under reduced pressure to afford the desired morpholidate 127 as a yellow 
solid (187 pmol, 85%). ]H NMR (D20 , 270 MHz) 5 8.08 (s, 1H, H-2), 6.00 (d, Jr>2' 4.7 Hz, 
1H, H -l'), 5.29 (m, 1H, H-2'), 4.70 (m, 1H, H-3'), 4.16 (m, 1H, H-4'), 3.95 (m, 2H, H-5'), 
3.39 (m, 4H, 2 x CH20 ) and 2.75 (m, 4H, 2 x CH2N); 13C NMR (D20 ,  100.5 MHz) 5 154.2 
(C-6), 152.9 (C-2), 150.0 (C-4), 128.6 (C-8), 119.2 (C-5), 90.2 (C-l'), 82.9 (C-4'), 71.3 
(C-2'), 69.1 (C-3'), 66.3 (2 x CH20 ), 64.0 (C-5') and 45.2 (2 x CH2N); 31P NMR (D20 , 109 
MHz) 5 8.26 (s); m/z (ES') 493.37 [(M-H)', 100%], 495.25 [(M-H)', 100%] HRMS Calcd for 
[M-H]' Ci4Hi90 7N679BrP" (ES') 493.0236 found 493.0240.
HO
7.9.3 8 -Bromo-Nicotinamide Adenine Dinucleotide (137, 8 -Br-NAD+)
O To a mixture of 8-bromo-AMP morpholidate (36 mg,
NH2 NH2 73 pmol), p-NMN4 (31 mg, 92 pmol) and MgSCL
-N hJk \ —n (1 ^ mg, 150 pmol) was added a solution of MnCl2 in
q  v    / /  yy
y ^ ~ /  N N '^ B r  formamide (0.2 M, 0.56 mL) under a nitrogen
"OH atmosphere. The reaction mixture was then stirred at
O - P - n
^  ^  rt. for 2 days and was quenched by dropwise
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addition of MeCN (2 mL). The resulting yellow precipitate was filtered, washed with MeCN 
and treated with Chelex to remove any residual manganese. The crude product was purified 
on reverse phase column, eluted with a gradient of 0-30% MeCN against 0.05 M TEAB 
buffer. The appropriate fractions were pooled, evaporated in vacuo and co-evaporated with 
MeOH (3 x) to give the title compound 137 as a triethylammonium salt (46 pmol, 63%). 
HPLC: 3.31 min at 254 nm; ]H NMR (D20 , 270 MHz) 8 9.27 (s, 1H, HN-2), 9.09 (d, 76,5 5.4 
Hz, 1H, Hn-6), 8.79 (d,74-,5'8.1 Hz, 1H, HN-4), 8.28 (m, 1H, HN-5), 8.07 (s, 1H, H-2),5.96 (d, 
A ",2''3.4 Hz, 1H, H - l"), 5.93 (d ,7r ,2'5.5 Hz, 1H, H-l'), 5.17 (m, 1H, H-2') and 4.57-4.24 (m, 
9H, H-ribose); 13C NMR (D20 , 100.5) 8 154.0 (C-6), 152.9 (C-2), 150.1 (C-4), 145.9 (CN-4),
142.6 (Cn-6), 139.8 (CN-2), 128.9 (CN-5), 128.0 (C-8), 119.0 (C-5), 100.1 (C-l"), 89.6 
(C-l'), 87.1 (C-4"), 83.2 (C-4'), 77.7 (C-2"), 71.0(C-2'), 70.7 (C-3"), 69.5 (C-3'), 65.7 (C-5") 
and 65.0 (C-5'), C = 0  and CN-3 not visible; 3lP NMR -10.46 (brs); m/z (ES’) 739.57 [(M-H)’, 
100%, 79Br], 741.45 (81Br).
7.9.4 Cyclic 8 -Bromo-Adenosine 5 '-Diphosphate Ribose (17, 8 -Br-cADPR)183
8-Bromo-NAD+ (8 mg, 10.8 pmol) in HEPES buffer (25 mM, 
pH7.4, 21 mL) was incubated with Aplysia ADP ribosyl 
cyclase (30 pL) at rt. for 1 h according to previously described 
conditions. The title compound 17 was formed as a
"OH
triethylammonium salt (8.4 pmol, 78%). HPLC: single peak
OH
at 8.40 min at 254 min; UV (H20 )  ^3x265.2 nm; ]H NMR 
(D20 , 400MHz) 8 8.89 (s, 1H, H-2), 6.02 (d, J r ,r5.3 Hz, 1H, H -l'), 5.99 ( d , / r ,r 4.0Hz, 1H, 
H-l"), 5.35 (dd, Jr  i'5.3 Hz, J2\y 5.0 Hz, 1H, H-2'), 4.62 (m, 3H, H-2", H-3' and H-4"), 4.25 
(m, 4H, H-3", H-5'a, H-5"a and H-4'), 4.00 (m, 1H, H-5"b) and 3.86 (m, 1H, H-5'b); 13C 
NMR (D20 , 100 MHz) 8 148.6 (C-6), 148.3 (C-2), 142.2 (C-4), 132.0 (C-8), 119.7 (C-5),
95.7 (C -l"), 91.1 (C -l '), 88.4 (d, Jcp 10.6 Hz, C-4"), 84.8 (d, 7Cp 10.7 Hz, C-4'), 76.6 (C-2"),
72.13 (C-2'), 71.8 (C-3"), 70.1 (C-3'), 64.5 (C-5", C-5'); 3,P NMR (D20 , 109 
MHz) 8-9 .81  (brs), -10.75 (brs); HRMS Calcd. for [M-H]’ C15Hi9 0 i3N5Br79P2' (ES’) 
617.9643 found 617.9641.
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7.10 Synthesis of Cyclic 8-Bromo-2'-Deoxy-Adenosine 5 '-Diphosphate
Ribose (8-Br-2'-Deoxy-cADPR)
7.10.1 8-Bromo-2'-Deoxy-Adenosine (105)
Compound 105 was synthesised according to literature protocol.174 A 
suspension of 2'-deoxy-adenosine (300 mg, 1.20 mmol) in 
NaOAc/AcOH buffer (0.9 M, pH 4.05, 15 mL) was heated strongly 
with a heat-gun until the formation of a colourless clear solution. The 
resulting solution was cooled down to room temperature to which was 
added dropwise in the dark a solution of bromine in MilliQ water (15 mL, 1.3% v/v) over 20 
min. The reaction solution was stirred at room temperature for further 4 h. Excess bromine 
was destroyed by addition of solid NaHSO .3 and the pH of the solution was adjusted to ca 7 
with 5N NaOH. The resulting precipitate was then kept at 4°C overnight and was filtered, 
washed with water and dried in vacuo to afford the title compound 105 as a yellowish solid 
(1.0 mmol, 84%). *H NMR (DMSO, 270 MHz) 8 8.11 (s, 1H, H-2), 7.52 (brs, 2H, NH2),
6.29 (t,7r,2'a=7i',2'b7.3 Hz, 1H, H-l'), 5.24 (m, 2H, 5'-OH, 3'-OH), 4.47 (m, 1H, H-3'), 3.89 
(m, 1H, H-4'), 3.49 (m, 2H, H-5'), 3,23 (m, 1H, H-2'a) and 2.17 (m, 1H, H-2'b); 13C NMR 
(DMSO, 100.5 MHz) 8 155.1 (C-6), 152.4 (C-2), 149.9 (C-4), 126.7 (C-8), 119.7 (C-5), 88.3 
(C-l'), 86.4 (C-4'), 71.2 (C-3'), 62.1 (C-5') and 38.9 (C-2'); m/z: (FAB+) 330.0 [(M+H)+, 
100%], 332.0 [(M+H)+, 95%].
7.10.2 8-Bromo-2'-Deoxy-Adenosine 5 '-M onophosphate (103).
Compound 103 was synthesised according to literature.174 A 
suspension of 2'-deoxy-AMP di-sodium salt (100 mg, 0.27 
mmol) in NaOAc/AcOH buffer (4 mL, 0.9 M, pH 4.05) was 
heated strongly with a heat-gun for 2 min. The resulting solution 
was cooled to rt. and was added dropwise a solution of bromine 
in MilliQ water over 20 min. The reaction mixture was then stirred at rt in the dark for 2 h 
after which another portion of a bromine water solution (1 mL) was added. The reaction 
mixture was stirred for a further hour, after which HPLC analysis indicated that more than
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90% of the starting material was consumed. The reaction was quenched by dropwise 
addition of a saturated solution of NaHSCb until the colour of the solution became just 
yellowish and the pH was adjusted to 7 with NaOH (5 N). The crude product was purified by 
reverse-phase system, eluted with a linear gradient of 0 to 30% acetonitrile against 0.05M 
TEAB buffer. The appropriate fractions were collected and the solvent was removed in 
vacuo. Excess TEAB was co-evaporated with MeOH (3 x) generating the title compound 
103 as a yellow solid in the triethylammonium form (0.15 mmol, 55%). HPLC: single peak 
at 7.87 min at 254 nm; UV (H20 ) K&* 265.2; ]H NMR (D20 , 270 MHz) 8 8.06 (s, 1H, H-2), 
6.43 (t, J Vt2'a = */r,2'b7.2 Hz, 1H, H -l'), 4.73 (m, 1H, H-3'), 4.12 (m, 1H, H-4'), 4.06 (m, 2H, 
H-5'), 3.26 (m, 1H, H-2'a) and 2.43 (m, 1H, H-2T3); 13C NMR (D20 , 67.5 MHz) 6 153.9 
(C-6), 152.5 (C-2), 149.9 (C-4), 128.0 (C-8), 119.0 (C-5), 85.5 (d, 7Cp8.8 Hz, C-4',), 85.2 
(C -l'), 71.0 (C-3'), 64.6 (C-5') and 36.2 (C-2'); 31P NMR (D20 , 109 MHz) 8 1.50 (s); m/z 
(FAB') 407.8 [(M-H)\ 95%], 409.8 [(M -Hf, 95%].
7.10.3 8-Bromo-2'-Deoxy-Adenosine 5 '-M onophosphate M orpholidate (126)
To a solution of 8-bromo-2'-deoxy AMP triethylammonium salt (39 mg, 69 pmol) in dry
DMSO (0.6 mL) was added in sequence the dipyridyl 
disulfide (180 mg, 0.82 mmol), morpholine (0.1 mL, 1.15 
mmol) and triphenylphosphine (214 mg, 0.82 mmol). The 
resulting yellow solution was stirred at rt. for 3.5 h and was 
quenched by dropwise addition of a solution of sodium 
iodide (0.2 M, 20 mL). The resulting sodium salt precipitate was filtered, washed with 
acetone and dried in vacuo to give the title compound as a sticky solid (24 mg, 50 pmol, 
72%). 1H N M R (D 20 , 270 M H z ) 8 8 .02 ( s , 1H, H -2 ),6 .50 (dd ,/n2<a7 .4 H z ,/r ,2-b 7.2Hz, 1H, 
H -l'), 4.15 (m, 1H, H-3'), 4.00 (m, 3H, H-4' and H-5'), 3.38 (m, 5H, 2 x CH20  and H-2'a),
2.72 (m, 4H, 2 x CH2N) and 2.48 (m, 1H. H ^ 'b ); 3IP NMR (D20 , 109 MHz) 8 8.20 (s);
HRMS Calcd for [M-H]’ C ]4Hi9Br79N60 6p- (FAB") 477.0287 found 477.0279; Calcd for 
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7.10.4 8-Bromo-2'-Deoxy-Nicotinamide Adenine Dinucleotide (122, 
8-Br-2'-Deoxy-NAD+)
To a suspension of (3-NMN* (50 mg, 149 pmol) in
dry DMF (0.4 mL) was added freshly distilled
triethylamine (22 pL) and carbonyldiimidazole (CDI, 
100  mg, 0.61 mmol) under a nitrogen atmosphere. 
The reaction mixture was stirred at rt. for 3 h. 31P 
NMR spectrum indicated that all starting p-NMhT 
was consumed and a new peak at -9 ppm was formed 
for the newly formed imidazolium intermediate. The reaction was stopped by addition of dry 
methanol (few drops) and the solution was stirred at rt. for 10  min to completely destroy the 
remaining CDI. The reaction solution was then concentrated to dryness in vacuo and was 
coevaporated with dry DMF 3 times to remove any residual methanol. To the resulting
yellow residue was added 8-bromo-2'-deoxy-AMP triethylammonium salt (40 mg, 71 pmol,
dried over P2O5 in vacuo for 2 days) and DMF (0.4 mL). The clear yellow solution was 
stirred at rt. for 3 days (HPLC analysis indicated that over 80% of the starting material was 
reacted). DMF was removed under vacuum and the residue was purified by reverse phase 
chromatography. The appropriate fractions were pooled, evaporated and excess TEAB was 
removed by co-evaporating with MeOH to afford the title compound 122 as a glassy solid in 
the triethylammonium form (19 mg, 22 pmol, 31%). HPLC: single peak at 3.69 min at 254 
nm; UV (H20 )  Kax 265.2; *H NMR (D20 , 400 MHz) 8  9.29 (s, 1H, HN-2), 9.09 (d, y6-,5-6 .2  
Hz, 1H, Hn-6 ), 8.82 (d,74-,5-8.2 Hz, 1H, HN-4), 8.18 (dd, JyA>8.2 Hz, JV,6-6.2 Hz, 1H, HN-5),
8.10 (s, 1H, H-2), 6.38 (dd, / r , 2<a7.4 Hz, / r ,2-b7.2 Hz, 1H, H - l '), 5.98 (d, J r ,r  4.7 Hz, 1H, 
H -l"), 4.42-4.15 (m, 9H, H-ribose), 3.33 (m, 1H, H-2'a) and 2.40 (m, 1H, H-2'b); 13C NMR 
(D20 , 100.5 MHz) 8  165.0 (CO), 153.8 (C-6 ), 152.5 (C-2), 149.7 (C-4), 145.7 (CN-4), 142.3 
(Cn-6 ), 139.7 (Cn-2), 133.6 (CN-3), 128.7 (CN-5), 127.7 (C-8 ), 118.8 (C-5), 99.9 (C-l"),
87.0 (d, Jq?9.2 Hz, C-4"), 85.1 (d, Jcp 8.4 Hz, C-4'), 84.9 (C -l'), 77.5 (C-2"), 70.5 (C-3"),
70.5 (C-3'), 65.6 (d,7Cp4.6 Hz, C-5"), 64.7 (d,7Cp5.4 Hz, C-5'), 36.0 (C-2'); 31PNM R (D20 ,
109 MHz) 8  -11.17 (d, JpP 18.7 Hz), -10.52 (d, 7PP18.7 Hz); m/z (FAJET) 725.0,727.0 [(M-H)', 
60%] ; HRMS Calcd for [M+H]+ C 21H2779BrN7Oi3P2+ (FAB+) 726.0325 found 726.0325;
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Calcd for [M+H]+ C2iH2681BrN7Oi3P2+(FAB+) 728.0305 found 728.0348.
7.10.5 Cyclic 8-Bromo-2'-Deoxy-Adenosine 5 '-Diphosphate Ribose (98,
8-Br-2 '-Deoxy-c ADPR)
< 200 pS/cm) and purified by Q-sepharose ion-exchange chromatography, and product 
eluted with a gradient of 1M TEAB buffer against MilliQ water. The fractions containing the 
title compound were collected and evaporated in vacuo. The resulting white residue was 
co-evaporated with MeOH (3 x) to give the title compound 98 in its triethylammonium form 
(14.7 mg, 19 pmol, 86%). HPLC: single peak at 7.78 min at 254 nm; UV (H2O, pH 5.2) A™*
265.2 nm (fi'dm3 m o f1 cm '111300) ]H NMR (D20 , 400 MHz) 5 8.96 (s, 1H, H-2), 6.55 (dd, 
7i-.2-a6.7 Hzand7i-.2-b6.2Hz, 1H, H-l'), 6.11 ( d , / r ,2»4.0 Hz, 1H, H-l"), 4.99 (m, lH ,H -3'), 
4.67 (m, 1H, H-2"), 4.61 (m, 1H, H-4"), 4.35 (m, 1H, H-3"), 4.25 (m, 2H, H-5"a and H-5'a),
4.11 (m, 1H, H-4'), 3.88 (m, 1H, H-5"b), 3.79 (m, 1H, H-5T>), 3.20 (m, 1H, H-2'a) and 2.54 
(m, 1H, H-2T5); 13C NMR (D20 , 100.5 MHz) 5 148.72 (C-6), 148.1 (C-2), 141.9 (C-4),
131.5 (C-8), 119.8 (C-5), 95.8 (C-l"), 88.4 (d, JP? 11.0 Hz, C-4"), 87.6 (C-l'), 86.4 (d, 7Cp
8.0 Hz, C-4"), 76.5 (C-2"), 71.9 (C-3"), 70.8 (C-3') and 64.4 (C-5"), 64.4 (C-5") and 36.6 
(C-2'); 31P NMR (D20 , 109 MHz) 5 -10.10 (d, 7PP 14.0 Hz), -10.58 (d, 7PP 14.0 Hz); m/z 
(FAB+) 604.0 (M+H)+, 80%], 606.0 [(M+H)+, 80%]; HRMS Calcd for [M+H]+ 
C 15H2i79BrN5 0 12P2+ (FAB+) 603.9845 found 603.9838; Calcd for [M+H]+ 
Ci5H2i81BrN5Oi2P2+ (FAB+) 605.9825 found 605.9840.
O H A solution of 8-bromo-2'-deoxy NAD+ 122 (19 mg, 22 pmol) 
in HEPES buffer (25 mM, pH 7.4, 76 mL) was incubated with 
Aplysia cyclase (115 pL) at rt. for 40 min, after which HPLC 
analysis of the solution indicated the completion of the 
reaction (a new peak was produced at ca. 7.78 min). The 
reaction solution was diluted with MilliQ water, (conductivity
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7.11 Synthesis of Cyclic 8-Amino-Adenosine 5 '-Diphosphate Ribose
(8-NH2-cADPR)
7.11.1 8 -Azido-Adenosine (106)
Compound 106 was synthesised according to a modified literature
178protocol. To a solution of 8-bromo-adenosine (104, 600 mg, 1.73 
mmol) in DMF (25 mL) was added sodium azide (343 mg, 5.28 
mmol). The reaction solution was heated at 80°C in the dark 
overnight. DMF was removed in vacuo and the yellow residue was 
purified by flash column chromatography, eluted with DCM-methanol 4:1 to afford the 
desired compound 106 as a yellow solid (474 mg, 1.54 mmol, 89%); mp: 198-200°C (lit.184 
196°C), IR: 2156, 1661, 1606, 1547; ]H NMR (DMSO, 400 MHz) 6 8.10 (s, 1H, H-2), 7.36 
(br s, 2H, NH2), 5.65 (d, J v, t  6.6 Hz, 1H, H -l '), 5.44 (m, 2H, 3'-OH and 5'OH), 5.21 (d, 7 2 ,o h
4.7 Hz, 1H, 2'-OH), 4.92 (dt, J 2\ r  = J x s  6.6 Hz and 7 2 -.o h  4.7 Hz, 1H, H-2'), 4.17 (m, 1H, 
H-3'), 3.94 (m, 1H, H-4'), 3.68 (m, 1H, H-5'a) and 3.52 (m, 1H, H-ST)); 13C NMR (DMSO,
100.5 MHz) 8 154.9 (C-6), 152.0 (C-2), 149.8 (C-4), 144.9 (C-8), 117.5 (C-5), 88.1 (C -l'),
86.8 (C-4'), 71.7 (C-2'), 71.3 (C-3') and 62.6 (C-5').
7.11.2 8 -Amino-Adenosine (109)
Compound 109 was synthesised using a literature protocol.184 To a 
solution of 8-azido-adenosine 106 (400 mg, 1.29 mmol) in TEAB 
buffer (140 mL, pH 7.5-8.0) was added dithiothreitol (293 mg, 1.90 
mmol) in the dark. The resulting solution was stirred at rt overnight 
and was evaporated in vacuo. The residue was evaporated with 
MeOH (3 x) and was purified by flash column chromatography, and product eluted with a 
gradient of 20-50% MeOH against DCM to give the title compound 109 as a yellow solid 
(330 mg, 83%); mp: 146-148°C. *H NMR (DMSO, 270 MHz) 8 7.88 (s, 1H, H-2), 6.62 (brs, 
2H, NH2), 6.53 (brs, 2H, NH2), 5.84 (m, 2H, H - l ' and 5'-OH), 5.27-5.18 (m, 2H, 2'-OH and 
3'-OH), 4.70 (m, 1H, H-2'), 4.12 (m, 1H, H-3'), 3.96 (m, 1H, H-4') and 3.67 (m, 2H, H-5'); 
’H NMR (DMSO, D20  shake, 270MHz) 8 7.89 (s, 1H, H-2), 5.85 (d , / r . 2 - 7 . 4  Hz, 1H, H -l'),
HO' 'OH
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4.61 (appt, J2\\' — Ji\y  7.4 Hz, H-2'), 4.13 (m, 1H, H-3'), 4.00 (m, 1H, H-4') and 3.62 (m, 2 H, 
H-5').
7.11.3 8 -Amino-Adenosine 5 '-M onophosphate (108, 8 -NH2-AMP)
Compound 108 was synthesised by adapting a literature 
protocol. 184 To a clear solution of 8 -azido-adenosine 106 (139 
mg, 0.41 mmol) in TEP (5 mL) was added MilliQ water (12 pL) 
and POCI3 (0.41 mL, 2.05 mmol) at 0°C. The resulting clear 
solution was stirred at this temperature for 2  h and the reaction 
was quenched by addition of ice (20 mL). The solution was extracted with cold ethyl acetate 
(5 x 20 mL) and the aqueous phase was collected and then neutralised by addition of NaOH 
(5 N). The aqueous solution was then purified by reverse phase chromatography, eluted with 
a gradient of 0-30% MeCN against 0.05 M TEAB. The appropriate fractions were collected, 
evaporated and excess TEAB was removed by coevaporation with MeOH (3 x) to afford 
8 -azido-AMP (107, 150 mg, 0.27 mmol) in its triethylammonium salt (HPLC 6.81 min). It 
was re-dissolved in TEAB buffer (50 mL, 0.05 M, pH 7.5-8.0) and dithiothreitol (85 mg, 
0.55 mmol) was added. The resulting solution was stirred in the dark at rt overnight. It was 
evaporated and the residue was purified by reverse phase chromatography, eluted with a 
gradient of 0-30% MeCN against 0.05 M TEAB, yielding the title compound 108 after 
coevaporating with MeOH (3 x) in its triethylammonium salt (0.23 mmol, 56% over 2 steps). 
HPLC: single peak at 7.99 min at 254 nm; UV (H2O) A™* 274.7 nm (a shift of UVmax from 
281 nm to 274 nm was observed in the experiment); ]H NMR (D2 0 , 270 MHz) 6  7.83 (s, 1H, 
H-2), 5.90 (d, / r ,2’7.6 Hz, 1H, H -l'), 4.66 (appt, Jr,v= J2\y 7.4 Hz, 1H, H-2'), 4.38 (m, 1H, 
H-3'), 4.26 (m, 1H, H-4') and 4.08 (m, 2H, H-5'); 13C NMR (D20 , 67.5 MHz) S 152.2 (C-6 ),
150.5 (C-4), 148.7 (C-8 ), 148.3 (C-2), 115.3 (C-5), 8 6 .6  (C-l'), 84.3 (d, Jcp 8.4 Hz, C-4'),
70.9 (C-2'), 70.3 (C-3') and 62.2 (C-5'); 31PN M R (D20 , 109 MHz) 6  1.48 (s).
7.11.4 8 -Amino-Adenosine 5 '-M onophosphate M orpholidate (128)
To a solution of 8 -amino AMP triethylammonium salt 108 
(110 mg, 0.21 mmol) in dry DMSO (0.6 mL) was added a 
sequence of triphenylphosphine (200 mg, 0.76 mmol),
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morpholine (0.13 mL, 1.49 mmol) and dipyridyl disulfide (168 mg, 0.76 mmol). The 
resulting solution was stirred at rt. for 3.5 h and was quenched with a solution of sodium 
iodide in acetone (0.2 M, 20 mL). The resulting precipitate was filtered, washed with 
acetone and dried in vacuo giving the desired morpholidate 128 as a yellow solid (82 mg, 
67%), which was used in the next step without further purification. HPLC: single peak at 
2.70 min at 254 nm; NMR (D20 , 270 MHz) 8  7.89 (s, 1H, H-2), 5.92 (d, 7r ,2'7.2 Hz, 1H, 
H - l ') ,4.73 (m, 1H, H -2'),4.42 (m, 1H, H-3'),4 .26 (m, 1H, H -4 '),4.03 (m, 2H ,H -5 '),3.58 (m, 
4H, 2 x CH20 )  and 2.96 (m, 1H, 2 x CH2N); 13C NMR 8  152.3 (C-6 ), 151.7 (C-4), 149.4 
(C-2), 149.1 (C-8 ), 116.3 (C-5), 86.7 (C-l'), 83.8 (C-4'), 71.0 (C-2'), 69.9 (C-3'), 67.0 (2 x 
CH20 ), 64.1 (C-5') and 44.6 (2 x CH2N); 31P NMR (D20 , 109 MHZ) 8  7.90 (s); m/z (ES’)
430.48 [(M-H)', 100%]; HRMS Calcd for [M-H]' C ,4H2i0 7 N7P' (ES') 430.1246 found 
430.1249.
7.11.5 8 -Amino-Nicotinamide Adenine Dinucleotide (132, 8 -NH2-NAD+)
O To a mixture of 8 -amino-AMP morpholidate (60
NH2 NH2 139 pmol), p-NMN* (58 mg, 174 pmol) and
N Na5(
HCL j; / \  N M gS04 (38 mg, 317 pmol) was added a solution of
T o  ^  J L




""O "OH resulting suspension was stirred at rt. for 2 days
and was stopped by dropwise addition of MeCN (2
- °  o  OH OH
mL). The yellow precipitate was filtered, washed 
with acetone and redissolved in small amount of MilliQ water. The aqueous solution was 
treated with Chelex (sodium form) to remove any residual manganese and product was 
purified by reverse phase chromatography. The appropriate fractions were collected and the 
solvent was evaporated in vacuo to give a white residue, which was evaporated with 
methanol (3 x) to form the title compound as a triethylammonium salt (59 mg, 71 pmol, 
51%). HPLC: single peak at 3.25 min at 254 nm; UV (H20 )  ^0x269.9 nm; *H NMR (D20 , 
400 MHz) 8  9.29 (s, 1H, HN-2), 9.16 (d, 76,5 6.3 Hz, 1H, HN-6 ), 8.76 (d, 74t5 8.2 Hz, 1H, HN-4),
8.16 (dd, 75,4 8.2 Hz and 75,6 6.3 Hz, 1H, HN-5), 7.96 (s, 1H, H-2), 6.08 (d, 7 r ,r 5.1 Hz, 1H, 
H -l"), 5.84 (d ,7 r ,2-7.1 Hz, 1H, H - l ') ,4.66 (m, 1H ,H -2 '),4.43 (m, 1H, H-4") and4.42-4.23 
(m, 8 H, ribose-H); 13C NMR (D20 , 100.5 MHz) 8  160.4 (CO), 152.1 (C-6 ), 151.1 (C-4),
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148.9 (C-8 , C-2), 145.7 (CN-4), 142.5 (CN-6 ), 140.2 (CN-2), 133.5 (CN-3), 128.8 (CN-5),
117.8 (C-5), 100.3 (C-l"), 85.6 (C-l', C-4"), 83.8 (C-4'), 77.6 (C-2"), 70.5 (C-2'), 70.2 
(C-3"), 69.7 (C-3'), 65.5 (C-5") and 64.9 (C-5'); 31P NMR (D20 , 109 MHz) 5 -10.42 (d, J PP
17.1 Hz) and -11.24 (d, J PP 17.1 Hz); HRMS Calcd for [M-H]’ C2]H27N8Oi4P2' 677.1127 
(ES') found 677.1122.
7.11.6 Cyclic 8 -Amino-Adenosine 5 '-Diphosphate Ribose (16, 8 -NH2-cADPR)183
A solution of 8 -amino-NAD+ 132 (39 mg, 47 pmol) and 
Aplysia cyclase (170 pL) in HEPES buffer (25 mM, pH 7.4, 
110 mL) was incubated at rt. for 40 min. HPLC analysis 
indicated that all starting material was consumed and a new 
peak was formed for the cyclic product at ca. 4.0 min. The 
reaction solution was diluted (conductivity < 200 pS/cm) 
and was purified by ion-exchange chromatography. The fractions containing desired 
compound were pooled and evaporated in vacuo. Excess TEAB was removed by 
coevaporation of the white residue with MeOH (3 x) to afford the title compound 16 as a 
glassy solid in the triethylammonium form (25 mg, 35 pmol, 74%). HPLC: single peak at
4.41 min at 254 nm; UV (H20 )  ^ 2 7 5 . 8  nm; ]H NMR (D20 , 400 MHz) 5 8.72 (s, 1H, H-2),
6.01 (d, J\",2»4 .0 Hz, 1H, H -l") ,5 .8 0 (d ,7 r .2-5.6Hz, 1H, H -l'),5 .3 6 (d d ,7 2-,r 5 .6H zand7r 
3-4 .8  Hz, 1H, H-2'), 4.65 (m, 3H, H-3', H-4" and H-2"), 4.38 (m, 1H, H-3"), 4.29 (m, 2H, 
H-5'a and H-5"b), 4.22 (m, 1H, H-4'), 4.04 (m, 1H, H-5"b) and 3.94 (m, 1H, H-5b); 13C 
NMR (D20 , 100.5 MHz) 6  155.6 (C-8 ), 147.7 (C-4), 145.8 (C-6 ), 139.1 (C-2), 117.6 (C-5),
95.5 (C-l"), 88.3 (d, JCP 10.7 Hz, C-4"), 88.1 (C-l'), 84.3 (C-4'), 76.8 (C-2"), 71.9 (C-2', 
C-3"), 70.2 (C-3') and 64.6 (C-5" and C-5'); 31P NMR (D20 ,  109 MHz) 6  -9.87 (d, JPP11.6  
Hz) and -10.21 (d, 7PP 11.6 Hz); HRMS Cald for [M-H]' C i5H2]N6O u?2' (FAB ) 555.0647 
found 555.0645.
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7.12 Synthesis of Cyclic 8-Amino-2 '-Deoxy 5 '-Diphosphate Ribose
(8-NH2-2 -Deoxy-c ADPR)
7.12.1 8-Azido-2'-Deoxy-Adenosine (110)178
To a solution of 8-bromo-2-deoxy-adenosine (200 mg, 0.61 mmol) in 
dry DMF (20 mL) was added sodium azide (160 mg, 2.46 mmol) 
under a nitrogen atmosphere. The reaction mixture was heated to 
90°C for 1.5 h. DMF was removed in vacuo and the yellow residue 
was purified by flash column chromatography, and product eluted 
with a gradient of 0-10% MeOH/DCM to generate the desired compound 110 as a yellow 
solid (164 mg, 91 %). HPLC: single peak at 1.89 min at 254 nm; IR: 2154,1648; UV (MeOH) 
^naX 281.8 nm; ]H NMR (270 MHz, DM S06) 5 8.07 (s, 1H, H-2), 7.28 (brs, 2H, NH2), 6.10 
( d d , 7 r , 2 a ' 7 . 6  Hz andyr.2-b 6.7 Hz, 1H, H -l'), 5.29 (m, 1H, 3'-OH), 5.24 (m, 1H, 5'-OH), 4.43 
(m, 1H, H-3'), 3.83 (m, 1H, H-4'), 3.63-3.49 (m, 2H, H-5'), 3.04 (m, 1H, H-2'a) and 2.12 (m, 
1H, H-2'b); I3C NMR (D20 , 67.5 MHz) 5 154.9 (C-6 ), 152.0 (C-2), 149.8 (C-4), 144.5 (C-8 ),
117.5 (C-5), 8 8 .6  (C-l'), 83.9 (C-4'), 71.6 (C-3'), 62.6 (C-5') and 37.6 (C-2'); m/z (FAB+)
293.0 [(M+H)+, 100%].
7.12.2 8-Amino-2'-Deoxy-Adenosine (111)
Compound was synthesised according to a literature protocol. 184 To 
a suspension of 8-azido-2'-deoxy-adenosine 110 (147 mg, 0.50 
mmol) in TEAB buffer (pH 7.5-8.0, 0.05 M, 65 mL) was added 
dithiothreiol (108 mg, 0.70 mmol). The resulting clear solution was 
stirred at rt overnight. TLC analysis indicated that starting azido 
compound (Rf 0.45) was completely consumed and a more polar spot was given at R f 0.14 
(DCM-MeOH 5:1). The crude product was purified by flash column chromatography, eluted 
with DCM-MeOH 5:1 to form the desired compound 111 as a yellow oil (0.43 mmol, 85%). 
]H NMR: (CD3OD, 270Mz) 8  7.97 (s, 1H, H-2), 6.75 (brs, 2H, NH2), 6.35 (brs, 2H, NH2),
6.30 (dd, 7r.2'a5.7 Hz and Jr,21,3 .5 Hz, 1H, H - l '), 4.59 (m, 1H, H-3'), 4.02 (m, 1H, H-4'), 3.81 
(m, 2H, H-5'), 2.81 (m, 1H, H-2'a) and 2.19 (m, 1H, H-2'b); 13C NMR (CD3OD, 67.5 MHz)
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5 152.3 (C-6), 152.0 (C-2), 148.8 (C-4), 148.5 (C-8), 116.6 (C-5), 87.9 (C -l'), 84.5 (C-4'),
72.0 (C-3'), 61.9 (C-5') and 38.1 (C-2'); m/z (FAB+) 267.1 [(M+H)+, 100%].
7.12.3 8 -Azido-2'-Adenosine 5 '-M onophosphate (115, 8 -N3-2 '-Deoxy-AMP)
Method 1. To a solution of sodium azide (34 mg, 0.52 mmol) in 
dry DMF (5 mL) was added 8-Br-2'-deoxy-AMP (60 mg, 147 
pmol) under a nitrogen atmosphere. This clear solution was 
heated at 80°C in the dark overnight. HPLC analysis of the 
resulting yellow precipitate indicated that no new compound 
was produced in this reaction (both HPLC retention time and UV were identical to the 
starting material).
Method 2. To the solution of sodium azide (34 mg, 0.52 mmol) in DMF (5 mL) was added 
8-Br-2'-deoxy-AMP (60 mg, 147 pmol) and H2O (1 mL). Heated at 80°C in the dark 
overnight, the resulting yellow solution was evaporated in vacuo and purified by reverse 
phase column chromatography. The appropriate fractions were collected, concentrated and 
the excess TEAB was removed by co-evaporating with MeOH (3 x) to give the title 
compound 115 (30 mg, 87 pmol, 59%). HPLC: single peak at 8.32 min at 254 nm; UV (H2O) 
Xmax 281.8; *H NMR (D20 , 270 MHz) 5 7.97 (s, 1H, H-2), 6.23 (dd, 6.8 Hz and J va*
6.7 Hz, 1H, H-l'), 4.66 (m, 1H, H-3'), 4.06-3.98 (m, 3H, H-4' and H-5'), 3.00 (m, 1H, H-2'a) 
and 2.31 (m, 1H, H ^'b); 13C NMR (D20 , 67.5 MHz) 5 153.1 (C-6), 151.4 (C-2), 149.1 (C-4),
146.3 (C-8), 117.3 (C-5), 85.2 (C-l'), 82.8 (C-4'), 71.1 (C-3'), 64.5 (C-5') and 36.3 (C-2'); 
31PN M R (D20 , 109 MHz) 6 1.29 (s); m/z (FAB+) 373.0 [(M+H)+, 65%]; HRMS: Calcd. for 
CioHi5N80 6P+ [M+H]+ 374.0784 found 374.0790.
7.12.4 8 -Amino-2'-Deoxy-Adenosine 5 '-M onophosphate (112, 8-NH2-2 '-Deoxy-AMP)
To a solution of 8-azido-2'-deoxy-AMP 115 (28 mg, 53 pmol) 
NH2  &
N TEAB buffer (pH 8.0, 7.5 mL) was added 1,
• | /  * 4-dithiol-(DL)-threitol (20 mg, 129.9 pmol) and the reactionN
HCX. P  solution was stirred at rt in the dark overnight. HPLC analysis
> 0  _
.• indicated that a new peak was formed at 8.7 min with a UV
HO'
peak at 274 nm. The crude product was purified by
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reverse-phase system and excess TEAB was removed by coevaporating with MEOH. Title 
compound 112 was obtained as a glassy solid (42 pmol, 79%). HPLC: single peak at 8.41 
min at 254 nm; UV (H20 )  A a^x 274.7 nm; *H NMR (D20 , 270 MHz) 5 7.94 (s, 1H, H-2), 
6.33 (dd, 7r,2'a8.1 Hz and J v2<b5.4 Hz, 1H, H -l'), 4.66 (m, 1H, H-3'), 4.19 (m, 1H, H-4'),
4.12 (m, 2H, H-5'), 2.69 (m, 1H, H-2'a) and 2.25 (m, 1H, H-2T3); 13C NMR (D20 , 67.5 
MHz) 5 152.6 (C-6), 151.0 (C-2), 148.8 (C-4), 148.3 (C-8), 115.7 (C-5), 85.7 (C-l'), 83.5 
(C-4'), 71.2 (C-3'), 64.4 (C-5') and 37.2 (C-2'); 31P NMR (D20 , 109 MHz) 5 1.55 (s); m/z 







7.12.5 8-Amino-2'-Deoxy Nicotinamide Adenine Dinucleotide (123,
8-NH2-2 '-Deoxy-N AD+)
O To a suspension of p-NMbT (60 mg, 180 pmol) in
DMF (400 pL) was added TEA (30 pL) and CDI
(100 mg). This reaction mixture was stirred under
argon atmosphere at rt for 3 h after which 31P NMR 
spectrum of the reaction mixture indicated that all 
starting P-NMhT was consumed and a new singlet 
was assigned for the imidazolium intermediate (ca. 
-9.0 ppm). A few drops of methanol were added and the reaction mixture was stirred at rt. for 
a further 10 min and was evaporated in vacuo. The resulting yellow residue was 
coevaporated with DMF ( 3 x 2  mL) to remove any remaining methanol. The residue was 
dissolved in dry DMF (0.4 mL) to which was added 8-amino-2'-deoxy AMP (40 mg, 80 
pmol) and the mixture was stirred at rt for 2 days. DMF was removed in vacuo and the
residue was purified on a Q-sepharose ion-exchange column, eluted with a gradient of 1M
TEAB against MilliQ water. The title compound was produced as its triethylammonium 
form (25 mg, 31 pmol, 39%). HPLC: single peak at 2.95 min at 254 nm; UV (H20 ) Amax
269.9 nm; ]H NMR (D20 , 270 MHz) 8 9.29 (s, 1H, HN-2), 9.17 (d, 5.9 Hz, 1H, HN-6),
8.77 (d, 74.5 7.9 Hz, 1H, HN-4), 8.20 (dd, J5A1.9 Hz and / 5,6 5.9 Hz, 1H, HN-5), 7.94 (s, 1H, 
H-2), 6.23 (dd, 7 r .2-a 8.1 Hz and 7 ivn> 7 .1  Hz, 1H, H-l'), 6.08 (d, 7 ,» r 4.5 Hz, 1H, H-l"), 
4.73-4.15 (m, 9H, H-ribose), 2.72 (m, 1H, H-2'a) and 2.23 (m, 1H, H-2'b); 13C NMR (D20 ,
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100 MHz) 8 165.4 (CO), 152.4 (C-6), 151.7 (C-2), 149.2 (C-4), 148.4 (C-8), 145.8 (CN-4),
142.4 (Cn-6), 140.0 (CN-2), 133.6 (CN-3), 128.8 (CN-5), 115.8 (C-5), 100.4 (C-l"), 87.1
(C-4"), 84.8 ( C-4'), 83.1 (C-l'), 77.7 (C-2"), 70.6 (C-3"), 70.3 (C-3'), 65.6 (C-5"), 64.9
(C-5') and 37.0 (C-2'); 31P NMR (D20 , 109 MHz) 5 -10.68 (m); m/z (FAB+) 663.1 [(M+H)+, 
65%]; HRMS Calcd. for [M+H]+C2iH29N8Oi3P2+ (FAB+) 663.1324 found 663.1321.
7.12.6 Cyclic 8-Amino-2'-Deoxy 5 '-Diphosphate Ribose (99, 8-NH2-2'-Deoxy-cADPR)
A solution of 8-amino-2'-deoxy-NAD+ (4 mg, 4.8 pmol) 
and Aplysia cyclase (20 pL) in HEPES buffer (25 mM, pH
7.4, 12 mL) was stirred at rt. for 1 h after which HPLC 
analysis suggested the formation of a cyclic compound (Rt 
= 3.6 min). The reaction mixture was purified by 
Q-sepharose ion-exchange chromatography, and product 
eluted with 0-50 % 1M TEAB against MilliQ water to give the title compound 99 as a glassy 
solid in the triethylammonium form (3.7 pmol, 77%). HPLC: single peak at 3.97 min at 254 
nm; UV (H20 , pH 5.0) A™* 277.0 nm (fi'dm3 m o f1 cm '1 13400). *H NMR (400 MHz, D20 )  
8 8.60 (s, 1H, H-2), 6.06 (d d ,/i Ta6.9 Hz and7 1 ^ 6 .6  Hz, 1H, H -l'), 5.89 (d ,J r ,2" = 4.1 Hz, 
1H, H-l"), 4.69 (m, 1H, H-3'), 4.55 (m, 2H, H-2" and H-4"), 4.25 (m, 1H, H-5"a), 4.18 (m, 
2H, H-3"and H-5'a),4.02 (m, 1H, H-4'), 3.92(m, 1H, H-5"b),3.81 (m, 1H, H-5T>), 3.19 (m, 
1H, H-2'a) and 2.35 (m, 1H, H-2'b); 13C NMR (D20 , 100.5 MHz) 8 153.0 (C-6), 145.5 (C-4),
143.5 (C-2), 136.6 (C-8), 115.3 (C-5), 93.3(C-1"), 86.1 (C-4"), 83.9 (C-4'), 82.4(C-1'), 74.5 
(C-2"), 69.7 (C-3"), 68.9 (C-3'), 63.6 (C-5"), 62.2 (C-5') and 34.2 (C-2'); 13P NMR (D20 , 
109 MHz) 8 -10.09 (m) and -10.56 (m); HRMS Calcd for [M-H]' C^HzoNeOnPf 538.0620 
(FAB') found 538.0618.
7.13 Synthesis of Cyclic 8-Phenyl-Adenosine 5 '-Diphosphate Ribose 
(8-Ph-cADPR)
7.13.1 8-Phenyl-Adenosine 5 '-M onophosphate (116, 8-Ph-AMP)
To a stirred solution of 8-bromo-AMP triethylammonium 
salt (102, 140 mg, 0.24 mmol), phenylboronic acid (40 mg,
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HO' 'OH
34 |Limol) and sodium carbonate (76 mg, 0.92 mmol) in MilliQ-MeCN 2:1 (4.1 mL, degassed) 
was added Pd(PPh3)4 (40 mg, 34 pmol) under argon atmosphere. The resulting yellow 
suspension was vigorously stirred at 80°C for 3 h. The reaction mixture was filtered and the 
filtrate was purified using reverse phase chromatography, and product eluted with a gradient 
of 0-30% MeCN against 0.05 M TEAB buffer. The appropriate fractions were collected and 
evaporated and, the resulting residue was co-evaporated with MeOH (3 x) to give the title 
compound 116 in triethylammonium salt (77 mg, 55%). HPLC: single peak at 12.10 min; 
UV (H20 )  A^x 275.8 nm; ]H NMR (D20 , 270 MHz) 5 8.21 (s, 1H, H-2), 7.66 (m, 2H, ArH),
7.56 (m, 3H, ArH), 5.85 (d, J v, t 6 2  H z , 1H, H - l '), 5.16 (appt, J2,v = J2,y 6.2 Hz, 1H, H-2'), 
4.35 (m, 1H, H-3') and 4.21 (m, 3H, H-4' and H-5'); 13C NMR (D20 , 67.5 MHz) 6 155.2 
(C-8), 153.4 (C-6), 152.5 (C-2), 150.2 (C-4), 131.3, 129.7, 129.2, 128.0 (ArC and ArCH),
118.8 (C-5), 88.9 (C -l'), 83.4 (C-4'), 70.4 (C-2'), 69.7 (C-3') and 64.6 (C-5f); 31P NMR (D20 ) 
5 1.59 (s); HRMS: Calcd for [M+H]+Ci6H i9N50 7 P+ (ES+) 424.1017 found 424.1019.
7.13.2 8-Phenyl-Adenosine 5 '-M onophosphate M orpholidate (129)
To a solution of 8-phenyl-AMP triethylammonium salt 
(116, 40 mg, 95 pmol) in dry DMSO (0.4 mL) was 
added triphenylphosphine (113 mg, 431 pmol), 
morpholine (100 |iL, 1.14 mmol) and dipyridyl 
disulfide (95 mg, 431 pmol). The resulting yellow 
solution was stirred at rt for 2 h and HPLC analysis indicated that all starting 8-phenyl-AMP 
was consumed. The reaction was quenched by dropwise addition of a solution of sodium 
iodide in acetone (0.2 M, 15 mL) and the resulting yellow precipitate was filtered, washed 
with acetone and dried in vacuo. The title compound 129 was obtained as a yellow solid (70 
pmol, 74%). HPLC: single peak at 4.53 min; UV (H20 )  A™* 273.5 nm; 'H NMR (D20 , 270 
MHz) 5 8.17 (s, 1H, H-2), 7.53 (m, 5H, ArH), 5.79 (d, 1H, 7r,2-4.9 Hz, H -l'), 5.21 (m, 1H, 
H-2'), 4.52 (m, 1H, H-3'), 4.06 (m, 3H, H-4' and H-5'), 3.42 (m, 4H, 2 x CH20 )  and 2.83 (m, 
4H, 2 x CH2N); I3C NMR (D20 , 67.5 MHz) 5 155.0 (C-8), 153.0 (C-6), 152.5 (C-2), 150.0 
(C-4), 131.1 (ArCH), 129.1 (2ArCH), 128.8 (2 x ArCH), 127.7 (ArC), 118.5 (C-5), 89.4 
(C-l'), 82.9 (d, JCp 12 Hz, C-4'), 70.8 (C-3'), 69.7 (C-2'), 66.9, 66.8 (2 x CTLO), 64.2 (C-5') 
and 44.5 (2 x CH2N); 31P NMR (D20 , 109 MHz) 5 8.29 (s); HRMS Calcd. for
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[M+H]+C2oH26N60 6 P+ (ES+) 493.1595 found 493.1596.
7.13.3 8-Phenyl-Nicotinamide Adenine Dinucleotide (133, 8-Ph-NAD+)
A suspension of 8 -phenyl-AMP morpholidate
NH2
N J  (28 mg, 57 nmol), (3-NMN (23 mg, 6 8  pmol)
and M gS04 (13 mg, 108 pmol) in a solution of 
MnCl2 in formamide (0.2 M, 0.42 mL) was 
1 stirred at rt for 48 h. Precipitation of the product 
occurred by dropwise addition of MeCN (2 mL); 
it was filtered and treated with Chelex resin to remove any residual manganese. The crude 
compound was purified on a reverse phase column, eluted with a 0-30% gradient of 
MeCN/0.05 M TEAB. The fractions containing the product was pooled and evaporated in 
vacuo and excess TEAB was coevaporated with MeOH (5 x) to afford the desired 
dinucleotide as a glassy solid in its triethylammonium form (38 pmol, 6 6 %); HPLC: single 
peak at 4.53 min at 254 nm; UV (H20 )  ?w 273.5  nm; ]H NMR (D20 , 400 MHz) 8  9.21 (s, 
1H, Hn-2), 9.05 (d, 76,5 6.4 Hz, 1H, HN-6 ), 8.67 (d, 74,5 8.1 Hz, 1H, HN-4), 8.15 (dd, 75.4 8.1 
Hz and 75f66.4 Hz, 1H, HN-5), 8.13 (s, 1H, H-2), 7.62-7.46 (m,5H, phenyl), 5.91 ( d , / r ,r 5.0 
Hz, 1H, H-l"), 5.78 (d, 7r .2-5.9 Hz, 1H, H -l'), 5.13 (m, 1H, H-2'), 4.40 (m, 1H, H-3'), 4.34 
(m, 1H, H-2") and 4.38-4.13 (m, 7H, H-ribose); 13C NMR (D20 , 67.5 MHz) 8  164.1 (CO),
154.0 (C-8 ), 151.8 (C-6 ), 151.6 (C-4), 149.1 (CN-4), 144.8 (CN-6 ), 141.5 (C-2), 138.9 (CN-2),
132.7 (Cn-3), 130.3, 128.6, 128.4, 128.2 (ArC and ArCH), 127.9 (CN-5), 117.3 (C-5), 99.2 
(C-l"), 88.1 (C-l'), 86.1 (d, 7CP9.2 Hz, C-4",), 82.0 (d, 7CP8.4 Hz, C-4'), 76.7 (C-2"), 69.6 
(C-2'), 69.5 (C-3"), 68.5 (C-3'), 64.8 (C-5") and 63.9 (C-5'); 31P NMR (D20 , 109 MHz) 
8  -11 .50 (m); m/z (FAB') 738.1 [(M -H)\ 100%]; HRMS: Calcd. for [M-H]' CT7H30N7O 14P2’ 
(FAB') 738.1331; found 738.1329.
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7.13.4 Cyclic 8-Phenyl-Adenosine 5 '-Diphosphate Ribose (97, 8-Ph-cADPR)
HQ NH2 T o a solution of 8-phenyl-NAD+ (133, 5 mg, 5.5 pmol)
T "  /  ',iN<V N4 / = \  in HEPES buffer (25 mM, pH 7.4, 13 mL) was added
O N f  Aplysia cyclase (19.5 pL). The resulting clear solution
'P_  0 —(
'<oh  was st r^re<^  at rt for 1 h and product was purified on
0  <“>H oh  Q-sepharose ion-exchange chromatography. The desired
compound 97 was obtained as a glassy solid in its triethylammonium form (3.8 pmol, 69%). 
HPLC: single peak at 11.46 min at 254 nm; UV (H2O) 275.8 nm (£/dm3 m of1 cm'1
20264); *H NMR (D20 , 400 MHz) 5 9.07 (s, 1H, H-2), 7.77-7.62 (m, 5H, Ar-H), 6.20 (d, 
J r ,r  4.2 Hz, 1H, H-l "), 6.07 (d, J r ,2- 6.0 Hz, 1H, H -l'), 5.56 (dd, Jr , 1- 6.0 Hz and J ry  5.3 Hz, 
1H, H-2'), 4.77 (m, 3H, H-4", H-2" and H-3'), 4.48 (m, 3H, H-3”, H-5"a and H-5'a), 4.29 (m, 
1H, H-4') and 4.13 (m, 2H, H-5”b and HS'b)-, 13C NMR (D20 , 100.5 MHz) 6 156.2 (C-8),
149.2 (C-6), 148.6 (C-4), 141.8 (C-2), 131.6, 129.7, 129.7, 126.8 (all Ar-C), 118.9 (C-5),
95.7 (C-l"), 89.9 (C-l'), 88.5 (d, Jcp 10.7 Hz C-4"), 84.8 (d, 7Cp 9.9 Hz, C-4'), 76.9 (C-2"),
72.3 (C-2'), 71.9 (C-3"), 70.3 (C-3') and 64.7 (C-5' and C-5"); 3,P NMR 8 -10.09 (brs) and 
-10.84 (brs); mJz (FAB ) 616 [(M-H)\ 100%]; HRMS Calcd for [M-H]‘ C2iH24N5Oi3P2' 
(FAB ) 616.0851 found 616.0856.
7.14 Synthesis of 8-Phenyl-2'-Deoxy-Adenosine 5'-Diphosphate Ribose 
(8-Ph-2 '-Deoxy-cADPR)
7.14.1 8-Phenyl-2'-Deoxy-Adenosine 5 '-M onophosphate (117, 8-Ph-2'-Deoxy-AMP)
To a stirred solution of 8-Br-adenosine 5 '-monophosphate 
(190 mg, 0.34 mmol), phenylboronic acid (80 mg, 0.65 
mmol) and Na2CC>3 (220 mg, 2.07 mmol) in aqueous 
MeCN (33%, 5 mL, degassed) was added Pd(PPh3)4 (70 mg, 
60 pmol) under argon atmosphere. The resulting yellow 
suspension was vigorously stirred at 80°C for 3 h after which further portions of 
phenylboronic acid (80 mg, 0.65 mmol) and Pd(PPh3)4 (70 mg, 60 pmol) were added. The 
resulting suspension was stirred at 80°C for further 2 h. HPLC analysis indicated that all 
starting 8-bromo AMP had been consumed and a single new peak was formed at 13.71 min.
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The resulting green-brown suspension was filtered and then purified on a reverse-phase 
column, and product eluted with a gradient of 0-30% MeCN against 0.05 M TEAB. The 
appropriate fractions were collected, concentrated and co-evaporated with MeOH, giving 
the title compound 117 as a glassy solid in its triethylammonium form (175 mg, 92%). 
HPLC: 13.71 min at 254 nm; UV (H20 ) 275.8 nm; ‘H NMR (CD3OD, 270 MHz) 8  8.22
(s, 1H, H-2), 7.77 (m, 2H, ArH), 7.53 (m, 3H, ArH), 6.25 (appt, J v2'a = /p,20, 6 .8  Hz, 1H, 
H -l '), 4.79 (m, 1H, H-3'), 4.11 (m, 3H, H-4' and H-5'), 3.62 (m, 1H, H-2'a) and 2.20 (m, 1H, 
H ^ 'b ); m/z (ES') 406.18 [(M-H)\ 100%]; HRMS Calcd for [M+H]+ Ci6Hi9N50 6P+ (ES+) 
408.1068 found 408.1071.
7.14.2 8-Phenyl-2'-Deoxy-Adenosine 5 '-M onophosphate M orpholidate (130)
To a solution of 8-phenyl-2'-deoxy AMP (130 mg, 230 
pmol) in dry DMSO (0.6 mL) was added dipyridyl 
disulfide (190 mg, 8 6 6  pmol), morpholine (0.25 mL, 
2.86 mmol) and triphenylphosphine (220 mg, 839 
pmol). The resulting green solution was stirred at rt for 
3 h and was quenched with a solution of Nal in acetone (0.2 M, 20 mL). The resulting 
precipitate was filtered, washed with acetone and dried in vacuo to afford the desired 
morpholidate as a yellow solid (189 pmol, 82%), which was used in the next step without 
further purification; *H NMR (D20 , 270 MHz) 8  8.21 (s, 1H, H-2), 7.68 (m, 5H, ArH), 6.26 
(appt, J 1 ',2*a= J rj*b 7.4 Hz, 1H, H -l'), 4.73 (m, 1H, H-3', overlap with HOD peak), 3.98 (m, 
3H, H-4' and H-5'), 3.35 (m, 5H, 2 x CH20 , H-2'a), 2.76 (m, 4H, 2 x CH2N) and 2.27 (m, 1H, 
H-2'b); 13C NMR (D20 , 67.5 MHz) 8  155.2 (C-8 ), 153.0 (C-6 ), 152.2 (C-2), 149.7 (C-4),
131.3 (ArCH), 129.5 (2ArCH), 129.0 (2ArCH), 128.0 (ArC), 118.4 (C-5), 85.3 ( d , /Cp 11 Hz, 
C-4'), 84.8 (C -l'), 71.0 (C-3'), 6 6 .8 , 66.7 (2 x CH20 ), 64.6 (d, / Cp4.3 Hz, C-5'), 44.6 (2 x 
CH2N) and 36.2 (C-2'); 31P NMR (D20 , 109 MHz) 8  8.10 (s); m/z (ES-) 475.18 [(M -H)\ 
100%]; HRMS Cald for [M-H]- C2oH24N60 6F  (ES-) 475.1500 found 475.1493.
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7.14.3 8-Phenyl-2'-Deoxy Nicotinamide Adenine Dinucleotide (134, 
8-Ph-2 '-Deoxy-N AD+)
(2 mL) and the yellow precipitate was filtered, washed with MeCN and treated with Chelex 
resin (sodium form) to remove any residual manganese. The crude product was further 
purified on a reverse-phase column, giving the title compound 134 as a glassy solid in its 
triethylammonium form (38 mmol, 60%). HPLC: single peak at 4.62 min; UV (H2O) A™*
275.8 nm; 'H NMR (D20 , 400 MHz) 6 9.11 (s, 1H, HN-2), 8.94 (d, 76,5 6.1 Hz, 1H, HN-6),
8.57 (d, 74.5 8.4 Hz, 1H, HN-4), 8.05 (dd, 1H, J5A 8.4 Hz and y5.66.1 Hz, HN-5), 8.03 (s, 1H, 
H-2), 7.42 (m, 5H, ArH), 6.09 (dd, /p,21,7.5 Hz and J v&6.& Hz, 1H, H - l '), 5.80 (d, / r ,2"4.7 
Hz, 1H, H -l"), 4.56 (m, 1H, H-3'), 4.24 (m, 1H, H-2"), 4.24-3.96 (m, 7H, H-ribose), 2.89 
(m, 1H, H-2'a,) and 2.02 (m, 1H, H-2T3); 13C NMR (D20 , 100.5 MHz) 6 164.9 (CO), 154.6 
(C-8), 152.4 (C-6), 152.0 (C-2), 149.7 (C-4), 145.6 (CN-4), 142.2 (CN-6), 139.7 (CN-2),
133.4 (Cn-3), 130.9 (ArC), 129.2 (2ArCH), 128.9 (2ArCH), 128.7 (ArCH), 127.7 (CN-5),
118.2 (C-5), 99.9 (C-l"), 86.9 (d, / Cp9.1 Hz, C-4"), 84.8 (C-4'), 84.4 (C -l'), 77.5 (C-2"),
70.6 (C-3"), 70.4 (C-3'), 65.8 (C-5"), 64.6 (C-5') and 35.8 (C-2'); 31P NMR (D20 , 109 MHz) 
5 -11.43 (brs) and -11.76 (brs); m/z (ES') 599.94 [(M-nicotinamide)+, 100%], 721.94 
[(M-H)', 20%]; HMRS Calcd. for [M-H]' C^HsqNtOuPz' (ES') 722.1382 found 722.1382.
HO
HO
O To a mixture of 8-Ph-2'-deoxy-AMP 
morpholidate (30 mg, 63 mmol), p-NMN* (25 
mg, 75 mmol), and M gS04 (14 mg, 117 mmol) 
was added a solution of MnCl2 in formamide 
(0.2 M, 460 mL). The resulting suspension was 
stirred at rt and monitored by HPLC. After 48 h, 
the reaction was quenched by addition of MeCN
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7.14.4 8-Phenyl-2'-Deoxy-Adenosine 5 '-Diphosphate Ribose (101, 
8-Ph-2 '-Deoxy-c ADPR)
To a solution of 8-phenyl-2'-deoxy-NAD+ (24 mg, 27 
pmol) in HEPES buffer (40 mL, pH 7.4, 25mM) was 
added Aplysia ADP ribosyl cyclase (56 pL). The 
resulting clear solution was stirred at rt for 1 h and was 
purified on Q-sepharose ion-exchange chromatography 
to give the desired compound 101 in its 
triethylammonium form (27 pmol, 100%). HPLC: 12.57 min at 254 nm; UV (H2O) X^ ax 277 
nm (£/dm3 m o l1 cm '1 21349); *H NMR (D20 , 400 MHz) 8 9.02 (s, 1H, H-2), 7.67 (m, 5H, 
ArH), 6.41 ( a p p t , 7 . 0Hz, 1H, H -l'), 6 .15( d , / r -,r3 .9H z, 1H, H -l"), 4.94 (m, 1H, H-3'),
4.77 (m, 2H, H-2” and H-4"), 4.49 (m, 2H, H-3" and H-5'a), 4.39, (m, 1H, H-5"a), 4.19 (m, 
1H, H-4'), 4.14 (m, 1H, H-5"b), 4.06 (m, 1H, H-5b), 3.46 (m, 1H, H-2'a) and 2.46 (m, 1H, 
H-2h); I3C NMR (D20 , 100.5 MHz) 5 155.7 (C-8), 149.1 (C-6), 148.4 (C-2), 141.4 (C-4),
131.4 (ArC), 129.5 (2ArCH), 129.1 (2ArCH), 127.1 (ArCH), 118.8 (C-5), 95.8 (C-l"), 88.4 
(C-4"), 86.4 (C -l' and C-4'), 76.8 (C-2"), 71.9 (C-3"), 71.0 (C-3'), 64.6 (C-5' and C-5") and
37.0 (C-2'); 31P NMR (D20 , 109 MHz) 8 -9.95 (d, JPP 16.4 Hz) and -10.85 (d, JPP 16.4 Hz); 
m/z (ES‘) 600.06 [(M-H)", 100%]; HRMS Calcd [M-H]" C2,H 24N5Oi2P2" (ES") 600.0902 
found 600.0902.
7.15 Synthesis of 8-Methoxy-2'-Deoxy 5 '-Diphosphate Ribose
(8-OMe-2 '-Deoxy-cADPR)
7.15.1 8-Methoxy-2'-Deoxy-Adenosine (118)178
To a solution of 8-bromo-2'-deoxy adenosine (267 mg, 0.81 mmol) in 
dry methanol (11 mL) was added sodium methoxide (114 mg, 2.11 
mmol) under an argon atmosphere. The resulting yellow suspension 
was heated to reflux for 24 h. The reaction solution was evaporated in 
vacuo and the resulting yellow residue was purified by flash column 
chromatography, eluted with DCM-methanol (8:1). The title compound 118 was produced 
as a yellow solid (216 mg, 95%). ‘H NMR (DMSO, 270 MHz) 8 8.00 (s, 1H, H-2), 6.92 (brs,
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4.38 (m, 1H, H-3'), 4.08 (s, 3H, CH30), 3.50 (m, 2H, H-5'), 2.97 (m, 1H, H-2'a) and 2.08 (m, 
1H, H-2T3); 13C NMR (DMSO, 100.5 MHz) 5 154.5 (C-8), 154.5 (C-6), 151.0 (C-2), 149.2 
(C-4), 115.3 (C-5), 88.4 (C-l'), 83.0 (C-4'), 71.7 (C-3'), 62.7 (C-5'), 57.7 (OMe) and 37.3 
(C-2'); m/z (FAB+) 282.1 [(M+H)+, 98%]; HRMS Calcd. for [M+H]+ CnH i6N50 4 (ES+) 
282.1197 found 282.1199.
7.15.2 8-Methoxy-2'-Deoxy-Adenosine 5 '-M onophosphate (119)
NH A suspension of 8-methoxy-2'-deoxy-adenosine (165 mg, 0.59
further 2 h, quenched by addition of ice (10 mL) and neutralised immediately with NaOH (5 
N). It was extracted with cold ethyl acetate (5 x 20 mL) and the aqueous layers were pooled, 
dried and purified on reverse phase column, eluted with a gradient of 0-30% MeCN against 
0.05 M TEAB. The fractions containing the desired compound were pooled, evaporated and
was further purified on Q-sepharose ion exchange chromatography giving the pure title 
compound in its triethylammonium salt (60 mg, 20%). HPLC: single peak at 6.21 min; UV
H-5'), 3.07 (m, 1H, H-2'a) and 2.38 (m, 1H, H-2'b); 13C NMR (D20 , 67.5 MHz) 8 155.5 
(C-8), 152.6 (C-6), 150.4 (C-2), 148.4 (C-4), 114.3 (C-5), 85.2 (C-l'), 82.3 (C-4'), 71.2 
(C-3'), 64.6 (C-5'), 57.8 (CH30 )  and 35.95 (C-2'); m/z (FAB ) 359.1 [(M-H)’, 70%]; HRMS 
Calcd for [M -H]'ChHisNsOtF (FAB') 360.0715 found 360.0652.
mmol, dried in vacuo at 110°C) in trimethylphosphate (2.0 mL) 
was heated strongly with a heat-gun. The resulting clear solution 
was cooled to -20°C, to which was added POCl3 (0.16 mL) 
under an argon atmosphere. The reaction mixture was stirred for
co-evaporated with MeOH to afford the crude 8-methoxy 2'-deoxy AMP as a glassy solid. It
(H20 ) 259.3 nm; lU NMR (270 MHz, D20 )  6 8.03 (s, 1H, H-2), 6.34 (appt, b





7.15.3 8-Methoxy-2'-Deoxy-Nicotinamide Adenine Dinucleotide (124, 
8-OMe-2 '-Deoxy-N AD+)
To a suspension of P-NMN+ (60 mg, 180 pmol) in 
DMF (400 pL) was added TEA (30 pL) and CDI 
(100 mg). This reaction mixture was stirred under 
argon atmosphere at rt for 3 h after which 31P NMR 
spectrum indicated that all starting P-NMM+ was 
consumed and a new singlet was assigned for the 
imidazolium intermediate (ca. -9.0 ppm). A few 
drops of methanol were added and the reaction mixture was stirred at rt for further 10 min 
and was evaporated under reduced vacuum. The resulting yellow residue was coevaporated 
with DMF ( 3 x 2  mL) to remove any remaining methanol. The residue was dissolved in dry
DMF (0.4 mL) to which was added 8-methoxy-2'-deoxy AMP (40 mg, 77 pmol) and the
mixture was stirred at rt for 2 days. DMF was removed in vacuo and the residue was purified 
on Q-sepharose ion-exchange column, and product eluted with a gradient of 1M TEAB 
against MilliQ water. The appropriate fractions were pooled, evaporated in vacuo and 
co-evaporated with MeOH (3 x) to generate the desired dinucleotide in its 
triethylammonium form (26 mg, 31 pmol, 39%); HPLC a single peak at 2.97 min; UV 
(H20 ) ^  259.3 nm; NMR (400 MHz, D20 )  6 9.15 (s, 1H, HN-2), 8.96 (d, J6y56.3 Hz, 
1H, Hn-6), 8.62 (d, 74(5 8.0 Hz, 1H, HN-4), 8.02 (dd, 74,58.0 Hz and J 5,6 6.3 Hz, 1H, HN-5), 
7 .84(s, 1H, H-2), 6.09 (d d ,/r ,2.a7 .2 H zan d /i- ,^  6.9 Hz, 1H, H - l ') ,5.88 ( d , / ^  5.0 Hz, 1H, 
H-l"), 4.50 (m, 1H, H-3'), 4.37 (m, 1H, H-4"), 4.28 (m, 2H, H-2" and H-3"), 4.18-3.94 (m, 
5H, H-ribose), 4.02 (s, 3H, CH30), 2.88 (m, 1H, H-2'a) and 2.22 (m, 1H, H-2'b); 13C NMR 
(D20 , 100.5 MHz) 8 164.9 (CO), 155.2 (C-8), 152.6 (C-6), 150.7 (C-2), 148.2 (C-4), 145.5 
(Cn-4), 142.1 (Cn-6), 139.6 (CN-2), 133.5 (CN-3), 128.6 (CN-5), 113.8 (C-5), 99.9 (C -l"),
86.9 (d, Jcp 9.2 Hz, C-4"), 84.9 (d, 7Cp9.2 Hz, H-4'), 81.7 (C-l'), 77.5 (C-2"), 70.6 (C-3"),
70.4 (C-3'), 65.8 (C-5"), 64.7 (d, 7Cp 5.3 Hz, C-5'), 57.6 (CH30 ) and 35.75 (C-2'); 31P NMR 
(D20 , 109 MHz) 8 -10.53 (d, J pp 17.1 Hz) and -11.03 (d, 7PP 17.1 Hz); m/z (FAB') 675.9 
[(M-H)', 40%]. HRMS: Calcd. for [M +H f C22H30N 7Oi4P2' (ES+) 678.1321 found 678.1321.
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7.15.4 8-Methoxy-2'-Deoxy 5 '-Diphosphate Ribose (100, 8-OMe-2'-Deoxy-cADPR)
8-Methoxy-2'-deoxy-NAD+ 124 (5 mg, 5.9 pmol) and 
Aplysia cyclase (22 pL) were incubated in HEPES buffer (15 
mL, pH 7.4, 25 mM) for 25 min after which HPLC analysis 
indicated that the starting dinucleotide was completely 
consumed. The reaction mixture was diluted with MilliQ and
OH
loaded onto Q-sepharose ion exchange column, and product 
eluted with a gradient of 1M TEAB against MilliQ water. The appropriate fractions were 
pooled, concentrated under reduced pressure and coevaporated with MeOH to give the title 
compound as a glassy solid (5.6 pmol, 95%). HPLC: single peak at 3.90 min at 254 nm; UV 
(H20 )  ^  259.3 nm; *H NMR (400 MHz, D20 ) 5 8.79 (s, 1H, H-2), 6.28 (dd, J y ^  6 .8  Hz 
a n d /r ,2-a6 .4 Hz, 1H, H -l'), 5.99 (d,7i»3 -4 .2H z, 1H, H -l"), 4.83 (m, 1H, H-3'), 4.69 (m, 1H, 
H-2", overlap with HOD signal), 4.62 (m, 1H, H-4"), 4.35 (m, 1H, H-3"), 4.26 (m, 2H, H-5'a 
and H-5 "a), 4.09 (m and s, 4H, H-4' and OCH3), 4.01 (m, lH,H-5"b), 3.86 (m, 1H, H-5T)),
3.19 (m, 1H, H-2'a) and 2.38 (m, 1H, H-2'b); 13C NMR (D20 , 100.5 Hz) 5 157.3 (C-8 ),
147.2 (C-6 ), 147.1 (C-4), 140.5 (C-2), 115.6 (C-5), 95.8 (C-l"), 88.5 (d, Ja? 6 .6  Hz, C-4'),
86.0 (d, Jcp 9.7 Hz, C-4"), 83.9 (C-l/), 76.7 (C-2"), 72.1 (C-3"), 70.9 (C-3'), 64.7 (C-5"),
64.6 (C-5'), 58.1 (CH3O) and 36.3 (C-2'); 31P NMR (D20 , 109 MHz) 6  -10.82 (m), -11.46 




7.16 Synthesis of 2'-Deoxy- Nicotinamide Adenine Dinucleotide 
(2'-Deoxy-NAD+)
7.16.1 2'-Deoxy- Nicotinamide Adenine Dinucleotide (125)
O
%
+ / n h 2 n h 2
N
To a suspension of (3-NMN^ (30 mg, 90 pmol) in dry 
DMF (0.26 mL) was added TEA (16 pL) and
y
W  ^  /) n carbonyldiimidazole (50 mg, 0.30 mmol). The resulting
J - V  N
HO - /  mixture was stirred at rt under a nitrogen atmosphere for
3 h after which 31P NMR spectrum indicated the 
.0  g  no h  o h  formation of the imidazolium intermediate (-9 ppm). The
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O
O - ^ O
reaction was quenched by stirring with MeOH (few drop) for 10 min. The solvent was 
evaporated and to the resulting red residue was added 2'-deoxy AMP (20 mg, 60 |nmol) and 
dry DMF (0.2 mL). After stirring for 2 days at rt, DMF was removed and the crude product 
was purified by Q-sepharose ion-exchange chromatography. The title compound was 
obtained as a white solid in its triethylammonium salt (20 mg, 42%); HPLC: single peak at
3.00 min at 254 nm; *H NMR (D20 , 400 MHz) 5 9.29 (s, 1H, HN-2), 9.09 (d, J6<5 6.2 Hz, 1H, 
Hn-6), 8.77 (d, 74.5 8.4 Hz, 1H, HN-4), 8.33 (s, 1H, H-2), 8.14 (dd, J5A8.4 Hz and J5t66.2 Hz, 
1H, Hn-5), 6.34 (appt, 7r,2V= J y ^ 6.7 Hz, H -l'), 6.04 (d, J r ,2- 5.2 Hz, 1H, H - l"),4.69-4.13 
(m, 9H, ribose-H), 2.77 (m, 1H, H-2'a) and 2.55 (m, 1H, H-2'b); 13C NMR (D20 , 100.5 MHz) 
6 164.5 (CO), 155.3 (C-6), 152.6 (C-2), 148.6 (C-4), 145.8 (CN-4), 145.7 (CN-6), 140.0 
(Cn-2), 139.8 (C-8), 133.7 (CN-3), 128.6 (CN-5), 118.3 (C-5), 100.1 (C-l"), 87.21 (C-4"),
85.9 (C-4'), 83.5 (C-l'), 77.7 (C-2"), 71.3 (C-3"), 70.8 (C-3'), 66.1 (C-5"), 65.0 (C-5') and
38.9 (C-2'); 31P NMR (D20 , 109 MHz) 8 -10.60 (d, Jpp 18.5 Hz) and -10.98 (d, 7PP 18.5 Hz).
7.17 Attempt to Synthesise 2', 3'-Dideoxy-Cyclic Adenosine
5 '-Diphosphate Ribose (2', 3'-Dideoxy-cADPR)
7.17.1 5'-0-te7t-Butyldimethylsilyl-2'-Deoxy-Adenosine (137)
Compound 137 was synthesised according to a literature protocol.194
N
y  To a stirred suspension of 2'-deoxy-adenosine (136, 500 mg, 1.99 
N
mmol) and imidazole (330 mg, 4.79 mmol) in dry DMF was added 
terr-butyldimethylsilyl chloride (361 mg, 2.39 mmol) under an 
argon atmosphere. The reaction mixture was stirred at rt for 24 h 
after which tic analysis indicated that all starting material has reacted and a new spot was 
given (Rf 0.51, DCM-MeOH 5:1). DMF was removed and the residue was purified by flash 
column chromatography, and product eluted with DCM-MeOH 9:1 to form the title 
compound 137 as a white solid (691 mg, 1.89 mmol, 94%); mp: 160-161 °C; ‘H NMR 
(DMSO, 270 MHz) 8 8.27 (s, 1H, H-8), 8.13 (s, 1H, H-2), 7.30 (s, 2H, NH2), 6.34 (appt, J vpj
6.7 Hz, 1H, H -l'), 5.36 (m, 1H, 3'-OH), 4.39 (m, 1H, H-3'), 3.81 (m, 3H, H-4' and 5'), 2.73 
(m, 1H, H-2'), 2.33 (m, 1H, H-2'), 0.84 (s, 9H, 3 x CH3) and 0.02 (s, 6H, 2 x CH3); I3C NMR 
(DMSO, 67.5 MHz) 8 156.6 (C-6), 153.1 (C-2), 149.6 (C-4), 139.6 (C-8), 119.5 (C-5), 87.6
TBDMSO'
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(C -l'), 83.8 (C-4'), 70.9 (C-3'), 63.79 (C-5'), C-2' overlap with DMSO peak, 26.4 (3 x CH3),
18.6 (C) and -4.9 (2 x CH3).
7.17.2 5 '-O-terr-Butyldimethylsilyl-2 '-Deoxy-3 '-0 -( 1 -imidazolylthiocarbonvl)
Adenosine (138).
A solution of 5'-0-rerr-butyldimethylsilyl-2'-deoxy adenosine (500 
mg, 1.17 mmol) and l,l'-thiocarbonyldiimidazole (380 mg, 1.87 
mmol) in dry DMF was stirred under argon atmosphere for 
overnight. TLC analysis indicated that small amount of starting 
material remained. The reaction solution was stirred for another 24 h 
and then evaporated in vacuo. The resulting residue was purified by 
flash column chromatography, eluted with a gradient of 0-5% 
MeOH against DCM to give the title compound 138 as a yellow oil (1.06 mmol, 91%); ]H 
NMR (DMSO, 270 MHz) 5 8.63 (s, 1H, CH), 8.33 (s, 1H, H-8 ), 8.16 (s, 1H, H-2), 7.94 (d, 
^ c h ,c h  0.7 Hz, 1H, CH), 7.36 (s, br, 2H, NH2), 7.13 ( d ,  1H, 7 Ch . c h  0.7 Hz, CH), 6.55 (dd, 
7 i-.2'b 6.2 Hz and Jyo'a 5.9 Hz, 1H, H-l'), 6.05 (m, 1H, H-3'), 4.50 (m, 1H, H-4'), 3.92 (m, 2H, 
H-5'), 3.23 (m, 1H, H-2'a), 2.91 (m, 1H, H-2'b), 0.85 (s, 9H, rBu) and 0.05 (s, 6 H, 2CH3); 13C 
NMR (DM S06. 67.5 MHz) 6  184.1 (CS), 170.8 (CN), 156.7 (C-6 ), 153.2 (C-2), 149.8 (C-4),
139.7 (C-8 ), 131.4 (CH), 119.3 (C-5), 119.3 (CH), 85.0 (C-l'), 84.2 (C-3', 4'), 63.7 (C-5'),
39.1 (C-2'), 26.3 (rBu), 18.6 (C) and -4.9 (2 x CH3); m/z (ES+) 476.44 [(M+H)+, 100%].
7.17.3 5 '-O-terT-Butyldimethylsilyl-2',3 '-Dideoxy-Adenosine (139).
To a solution of compound 138 (600 mg, 1.35 mmol) in degassed 
toluene (31 mL) was added a solution of Bu3SnH (1.27 mL, 4.70 
mmol) and AIBN (1.76 mg, 1.07 mmol) in degassed toluene (23 mL) 
over 40 min. The resulting solution was heated to reflux for 2.5-3 h 
after which tic analysis indicated that all starting material has 
reacted. The solvent was removed in vacuo and the residue was purified by flash 
chromatography, eluted with a gradient of 0-5% MeOH against DCM to give the title 
compound as a white solid (325 mg, 69%). *H NMR: (CD3OD, 270 MHz) 5 8.54 (s, 1H, 




3.99 (dd, 7 5-a.5'b 12.9 Hz and 74-,5 -a 2.7 Hz, 1H, H-5 'a), 3.77 (dd, 7 5'a.5'b 12.9 Hz and J 4 '.5-b 2.7 Hz,
1H. H-5’b), 2.52-2.43 (m, 2H, H-3'or H-2'), 2.19-2.06 (m, 2H, H-2'or H-3'), 0.92 (s, 9H, rBu) 
and 0.07 (s, 6 H, 2 x CH3); 13C NMR (CD3OD, 67.5 MHz) 6  C-6 , C-4, C-5 not visible, 152.3 
(C-2), 139.4 (C-8 ), 85.5 (C-l'), 82.5 (C-4'), 63.8 (C-5'), 32.8 (C-2' or 3'), 25.1 (rBu), 24.4 
(C-2' or 3'), 18.6 (C) and -6 .6 6  (2 x CH3); m/z (ES+) 350.46 [(M+H)+, 100%]; HRMS Calcd 
for [M+H]+ C 16H28N5 0 2Si+ (ES+) 350.2007 found 350.2007.
7.17.4 2 ',3 '-Dideoxy-Adenosine (140).
To a solution of TBAF (1M in THF, 2.37 mmol) in THF (5 mL) was added 
compound 139 (300 mg, 0.79 mmol). The reaction solution was stirred at 
rt for 4 h and the solvent was removed by evaporation in vacuo. The 
residue was purified by column chromatography, eluted with a gradient of 
0-10% MeOH against DCM to give the title compound as a colourless oil (146 mg, 79%). 'H 
NMR (CD3OD, 270 MHz) 5 8.42 (s, 1H, H-8 ), 8.15 (s, 1H, H-2), 6.28 (dd, J vpj 5.7 Hz and 
7,-,3' 4.6 Hz, 1H, H-l'), 4.26 (m, 1H, H-4'), 3.86 (dd, 7 5'a,5-b 12.4 Hz and 7 5a'.4 ' 2.9 Hz, 1H, 
H-5'a), 3.66 (dd, /s-a.s-b 12.4 Hz and J51)A 3.9 Hz, 1H, U S'b), 2.47 (m, 2H, H-2' or H-3') and
2.16 (m, 2H, H-2' or H-3'); 13C NMR (CD3OD, 67.5 MHz) 6  156.0 (C-6 ), 152,2 (C-2), 148.4 
(C-4), 139.7 (C-8 ), 119.2 (C-5), 86.1 (C-l'), 82.3 (C-4'), 63.2 (C-5'), 32.4 (C-2' or C-3') and
25.13 (C-2' or C-3'); m/z (ES+) 236.27 [(M+H)+, 100%]; HRMS Calcd for [M+H]+ 
C,0Hi4N5O2+ (ES+) 236.1142 found 236.1143.
7.17.5 2 ',3 '-Dideoxy-Adenosine 5'-Dibenzylphosphate (141).
To a solution of imidazole (0.77 g, 11.3 mmol) in DCM (15 mL) at 
0°C was added triflic acid (1 mL, 11.3 mmol). The reaction solution 
was warm up to rt for 20 min. Ether (20 mL) was added and the 
resulting precipitate was filtered and washed with ether. 
Imidazolium thiflate was given as a white solid.
To a solution of 2',3'-dideoxy-adenosine (60 mg, 0.28 mmol) in dry DCM (11 mL) was 
added imidazolium triflate (204 mg, 0.94 mmol) and 
^/5,(benzyloxy)diisopropylaminophosphine (122 mg, 0.46 mmol). The resulting solution 
was stirred at rt for 1 h after which another portion of
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^/5,(benzyloxy)diisopropylaminophosphine (0.28 mmol) was added and the reaction mixture 
was left for further 1 h. Tic analysis indicate that all starting material disappeared and a less 
polar spot was given. The reaction mixture was then cooled to -78°C and mCPBA (128 mg, 
0.75 mmol) was added. After stirring 20 min, an aqueous solution of Na2SC>3 (10%, 26 mL) 
and ethyl acetate (35 mL) were added and the mixture was allowed to warm up to rt. It was 
washed with a saturated solution of NaHSCb (25 mL) and brine (25 mL), dried over M gS04, 
concentrated in vacuo and purified by flash column chromatography, eluted with a gradient 
of 0-5% MeOH against DCM to give the title compound 141 (52 mg, 37%, Rf 0.25). 'H 
NMR (CD3OD, 270 MHz) 8  8.21 (s, 1H, H-8 ), 8.15 (s, 1H, H-2), 7.26 (m, 10H, H-Bn), 6.23 
(t, -,2'5 .2 Hz, 1H, H - l ') ,4.90 (m,4H, 2 x C H 2),4.32 (m, 1H, H-4'), 4.13 (m, 1H, H-5'), 2.52 
(m, 2H, H-3' or H-2') and 2.07 (m, 2H, H-2' or H-3'); 13C NMR (CD3OD, 67.5 MHz) 8  155.9 
(C-6 ), 152.5 (C-2), 148.8 (C-4), 139.2 (C-8 ), 135.7, 135.6 (both ArC), 128.4, 128.3, 127.8 
(ArCH), 119.2 (C-5), 85.4 (C -l'), 79.7 (d, Jcp 12 Hz, C-4'), 69.6, 68.5 (2 x  CH2), 68.5 (C-5'),
31.4 (C-3' or C-2') and 25.3 (C-2' or C-3'); 31P NMR (CD3OD, 109 MHz) 8  -0.64 (s); m/z 
(ES‘) 494.31 [(M-H)', 100%]; HRMS Calcd for [M+H]+ C s^ N sO .sP *  (ES+) 496.1744 
found 496.1740.
7.17.6 Hydrogenolysis of 2 ',3 '-Dideoxy-Adenosine 5'-Dibenzylphosphate (142)
To a solution of 2',3'-dideoxy-adenosine 5'-dibenzylphosphate 141 (52 mg, 0.11 mmol) in 
methanol (1.5 mL) and H2O (80 jllL) was added cyclohexane (0.7 mL) and Pd(OH )2 (52 mg). 
The mixture was heated to 80°C for 2 h after which the Pd catalyst was filtered. ]HNMR 
spectrum of the crude compound however indicated that the molecule had degraded.
7.18 Synthesis of Cyclic 7-Deaza-8-Bromo-Adenosine 5 '-Diphosphate
Ribose (7-Deaza-8-Br-cADPR)
7.17.1 7-Deaza-8-Bromo-Adenosine (144)
To a stirred solution of dry 7-deaza-adenosine (143, 125 mg, 0.47 
mmol) and potassium acetate (100 mg, 1.02 mmol) in dry DMF (1.6 
mL) was added dropwise a solution of freshly recrystallised 
A-bromosuccinimide (180 mg, 1.02 mmol) in dry DMF (1.2 mL). The
HO' OH
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resulting dark red reaction mixture was stirred at rt for further 15 min after which DMF was 
removed by evaporation in vacuo. The residue was purified by column chromatography, 
eluted with a gradient of 0-10% methanol/DCM to afford the title compound 144 as a yellow 
oil (71 mg, 44%). 'H  NMR (CD3OD, 400 MHz) 5 8.03 (s, 1H, H-2), 6.74 (s, 1H, H-7), 6.08 
(d, J r,2' 7.4 Hz, 1H, H - l '), 5.12 (dd, JT,v 7.4 Hz a n d /2\3' 5.3 Hz, 1H, H-2'), 4.35 (dd, JV,2-5 .3  
Hz and 7 3',4-1.7 Hz, 1H, H-3'), 4.16 (m, 1H, H-4'), 3.87 (dd, 12.6 Hz and J 5-a,4-2 .4  Hz,
1H, H-5'a) and 3.73 (dd, Jg-b.s-a 12.6 Hz and 7vb,4-2 .4  H z , 1H, H-5'b); I3C NMR (D20 , 100.5 
MHz) 5 158.1 (C-6 ), 151.9 (C-2), 150.5 (C-4), 111.5 (C-8 ), 105.9 (C-5), 103.9 (C-7), 92.2 
(C-l'), 88.3 (C-4'), 73.7 (C-2'), 73.1 (C-3') and 64.3 (C-5'); m/z (ES+) 345.11 [(M+H)+ 
100%], 347.12 [(M+H)+, 100%]; HRMS Calcd for [M+H]+ CnH ,4N479Br0 4 + (ES+) 
345.0193 found 345.0190.
7.18.2 7-Deaza-8-Bromo-Adenosine 5 '-M onophosphate (145, 7-Deaza-8-Br-AMP)
A suspension of 7-deaza-8-bromo-adenosine 144 (50 mg, 145 
pmol) in triethyl phosphate (0.8 mL) was heated strongly with a 
heat gun for 10 min and the resulting clear solution was cooled to 
0°C in an ice bath. H20  (4 pL) was then added followed by 
dropwise addition of POCI3 (150 pL, 750 pmol). After stirring 
further 1 h at 0°C, the reaction was quenched with ice (10 mL) and the excess triethyl 
phosphate was removed by partitioning between aqueous solution and cold ethyl acetate (5 x 
20 mL). The aqueous layer was neutralised using 5 M NaOH and then loaded on top of the 
reverse phase column, eluted with a 0 -30%  gradient of MeCN against MilliQ water. The 
appropriate fractions were combined, evaporated under reduced vacuum and excess TEAB 
buffer was removed by co-evaporating with methanol (3 x). The resulting glassy residue was 
further purified on Q-sepharose ion exchange chromatography, eluted with 0 -  50% gradient 
of 1M TEAB/MilliQ. After combining and evaporating the appropriate fractions, the 
resulting white solid was co-evaporated with methanol (3 x) to produce the desired 
compound 145 as a glassy solid in its triethylammonium form (112 pmol, 77%). HPLC: 9.17 
min at 254 nm; !H NMR (D20 , 400 MHz) 5 7.92 (s, 1H, H-2), 6.42 (s, 1H, H-7), 6.04 (d, J VT
5.3 Hz, 1H, H-l'), 5.07 (dd, J2\y5.& Hz and Jr.1-5 .3  Hz, 1H, H-2'), 4.53 (dd, Jy;r 5.8 Hz and 
Jy.4-5 .7  Hz, 1H, H-3') and 4.15-4.08 (m, 3H, H-4' and H-5'); 13C NMR (D20 , 67.5 MHz)
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5 153.2 (C-6 ), 148.9 (C-4), 148.2 (C-2), 109.9 (C-8 ), 104.4 (C-7), 103.2 (C-5), 89.2 (C -l'),
82.8 (d, 7Cp7.4 Hz, C-4'), 71.4 (C-2'), 69.5 (C-3') and 64.4 (C-5'); 31P NMR (D20 , 161.7 
MHz) 5 2.35 (s); m/z (FAB+) 425.0, 427.0 (M+H)+; HRMS: Calcd. for [M+H]+ 
C nH 150 7 N4BrP+ (ES+) 424. 9862 found 424. 9860.
7.18.3 7-Deaza-8-Bromo-Adenosine 5 '-M onophosphate M orpholidate (146).
A solution of 7-deaza-8-bromo-AMP triethylammonium 
salt (145, 65 mg, 112 pmol) in dry DMSO (0.5 mL) was 
co-evaporated with dry DMF (3 x 1 mL). The resulting 
residue was dissolved in dry DMSO (0.5 mL), to which was 
added triphenylphosphine (100 mg, 381 pmol), morpholine 
(65 pL, 744 pmol) and dipyridyl disulfide (84 mg, 381 pmol). The reaction mixture was 
stirred at rt for 3 h and quenched by addition of a solution of Nal in acetone (0.2 M, 10 mL). 
The precipitated sodium salt obtained was filtered, washed with acetone and dried under 
reduced pressure. The crude 146 was purified on a Q-sepharose ion-exchange 
chromatography, eluted with a gradient of 1M TEAB buffer against MilliQ water. The 
appropriate fractions were collected, evaporated in vacuo and excess TEAB was removed by 
co-evaporating with methanol (3 x) to give the title compound 146 as a glassy solid in the 
triethylammomium form (97 pmol, 87%); HPLC: single peak at 3.21 min at 254 nm; ]H 
NMR (D20 , 270 MHz) 5 7.93 (s, 1H, H-2), 6.48 (s, 1H, H-7), 6.02 (d, J V,T 5.7 Hz, 1H, H - l '),
5.21 (dd, JXtj-5.7 Hz and J2\y 5.2 Hz, 1H, H-2'), 4.61 (m, 1H, H-3'), 4.00 (m, 3H, H-4' and 
H-5'), 3.26 (m, 4H, 2 x CH20 ) and 2.76 (m, 4H, 2 x CH2N); 13C NMR (D20 , 67.5 MHz) 6
155.4 (C-6 ), 150.9 (C-2), 149.9 (C-4), 109.6 (C-8 ), 104.2 (C-7), 103.9 (C-5), 89.5 (C -l'),
82.3 (d, JCp 12.8 Hz, C-4'), 71.3 (C-2'), 69.4 (C-3'), 6 6 .8 8 , 66.78 (2 x CH20), 64.1 (d, 7PP7.3 
Hz, C-5') and 44.7 (2 x CH2N); 31P NMR (D20 , 109 MHz) 6  8.33 (s); m/z (ES’) 492.05, 
494.19 [(M -Hf, 100%]; HRMS calcd for [M-H] C i5H2oN5Br790 7 F  (ES') 492.0284 found 
492.0282.
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7.18.4 7-Deaza-8-Bromo-Nicotinamide Adenine Dinucleotide (147, 
O 7-Deaza-8-Br-NAD+)
NH2 NH2 Method 1. To a solution of 7-deaza-8-bromo AMP
1 4 5  (55  m§’ 94  mmo1) and P-NMN+ (20 mg, 60 
N n ^ B r  mmol) in MilliQ water (1 mL) was added pyridine (4
\  olj mL) and an excess of DCC (0.5 g). The reaction\ I > ■1 ' ( j h
® A ° 'P T  ' - mixture was stirred at rt for 7 days, quenched by
- °  o '  OH OH
addition of MilliQ water (50 mL) and kept at 4°C for 
2 h. The resulting mixture was filtered and the filtrate was washed with CHCI3 (3 x 20 mL). 
The aqueous phase was purified on Q-sepharose ion exchange chromatography, eluted with 
a gradient of 1M TEAB against MilliQ water. The fractions containing the desired product 
were combined and the solvent was removed in vacuo. Coevaporation of the residue with 
methanol yielded the title compound 147 (26 mmol, 28%).
Method 2. A suspension of 7-deaza-8-Br AMP morpholidate (146, 52 mg, 80 pmol), 
p-NMN* (45 mg, 135 pmol) and M gS04 (30 mg, 250 pmol) in MnCL/formamide solution
(0.95 mL) was stirred at rt for 48 h. To the resulting clear yellow solution, MeCN (2 mL) was
added dropwise with constant stirring and the yellow precititate obtained was filtered, 
washed with acetone and treated with Chelex (sodium form). The crude product was purified 
on a reverse-phase system to give the desired dinucleotide 147 in its triethylammonium form 
(63 pmol, 79%) HPLC: single peak at 3.97 min at 254 nm; ]H NMR (D2 0 , 400 MHz) 8  9.16 
(s, 1H, Hn-2), 9.00 (d, 76,5 6.4 Hz, 1H, HN-6 ), 8.63 (d, 74,5 8.0 Hz, 1H, HN-4,), 8.05 (dd, J5A
8.0 Hz and 75,6 6.4 Hz, 1H, HN-5), 7.87 (s, 1H, H-2), 6.36 (s, 1H, H-7), 5.96 (d, 7 r ,2- 5.6 Hz, 
1H, H -l'), 5.91 (d,7j",2"4.3 Hz, 1H, H - l”), 5.06 (m, 1H, H-2'), 4.48 (m, 1H, H-3'), 4.42 (m, 
1H, H-4”) and 4.33-4.11 (m, 7H, ribose-H); 13C NMR (D20 , 100.5 MHz) 8  164.8 (CO),
155.2 (C-6 ), 151.0 (C-2), 149.6 (C-4), 145.2 (CN-4), 142.1 (CN-6 ), 139.5 (CN-2), 133.2 
(Cn-3), 128.5 (Cn-5), 108.8 (C-8 ), 103.8 (C-7), 103.1 (C-5), 100.0 (C -l”), 88.7 (C-l'), 86.7 
(d, 7CP 9.2 Hz, C-4”), 82.2 (d, 7CP8.4 Hz, C-4'), 77.5 (C-2”), 70.9 (C-2'), 70.3 (C-3”), 69.0 
(C-3'), 65.6 (d, 7CP 5.4 Hz, C-5”) and 64.7 (d, 7CP 5.4 Hz, C-5'); 3,P NMR (D20 ,  109 MHz) 8 
-10.57 (d, 7PP 30.9 Hz) and -11.02 (d, 7PP30.9 Hz); m/z (ES') 739.31,741.20 [(M-H)+, 100%]; 





7.18.5 Cyclic 7-Deaza-8-Bromo-Adenosine 5 '-Diphosphate Ribose (22, 
7-Deaza-8-Br-cADPR)
7-Deaza-8-bromo-NAD+ (147, 20 mg, 22 pmol) was 
incubated with Aplysia califomica ADP ribosyl cyclase (100 
pL) in HEPES buffer (25 mM, pH 7.4, 52 mL) at rt for 30 min 
(HPLC analysis indicated that all starting dinucleotide 147
"OH
was consumed). The clear reaction solution was diluted with
OH
MilliQ water (conductivity < 200 pS/cm) and purified on a 
Q-sepharose ion-exchange column, eluted with a gradient of 1M TEAB buffer against 
MilliQ water. The desired compound 22 was generated as a glassy solid in its 
triethylammonium form (16 pmol, 72%). HPLC: single peak at 5.31 min at 254 nm; UV 
(H20 )  ^  277 nm (s'dm3 mol' 1 cm ' 1 10850) ]H NMR (D20 , 400 MHz) 6  8.84 (s, 1H, H-2), 
6.97 (s, 1H, H-7), 6.12 (d, J v,i' 5-9 Hz, 1H, H-l'), 6.05 (d, J va» 4.1 Hz, 1H, H -l"), 5.52 (dd, 
J 2\v  5.9 Hz and JTy  5.7 Hz, 1H, H-2'), 4.66 (m, 2H, H-3' and H-4"), 4.65 (m, 1H, H-2"), 
4.42 (m, 2H, H-3" and H-5'a), 4.34 (m, 1H, H-5"a), 4.29 (m, 1H, H-4'), 4.12 (m, 1H, H-5"b) 
and 4.04 (m, 1H, H-S'b); 13C NMR (D20 , 100.5 MHz) 8  149.4 (C-6 ), 147.0 (C-4), 139.7 
(C-2), 114.2 (C-8 ), 104.6 (C-7), 104.0 (C-5), 95.0 (C-l"), 90.3 (C -l'), 88.1 (d, 7Cp 10.7 Hz, 
C-4"), 84.4 (d, Jcp 10.7 Hz, C-4'), 76.8 (C-2"), 72.1 (C-2'), 71.8 (C-3"), 70.2 (C-3'), 64.7 (d, 
7Cp4.8 Hz, C-5") and 64.0 (JCp 4.7 Hz, C-5'); 31P NMR (D20 , 109 MHz) 8  -10.00 (brs) and 
-10.71 (brs); m/z (ES+) 617.25, 619.20 (M+, 100%); HRMS Calcd for
[M-H] Ci6H2oN4Oi3Br79P2'(ES') 616.9691 found 616.9699.
7.19 Synthesis of Cyclic 7-Deaza-2'-Deoxy Adenosine 5 '-diphosphate
Ribose (7-Deaza-2'-Deoxy-cADPR)
7.19.1 Ethyl 2-Cyano-4, 4-Diethoxybutanoate (150)
OEt CN A mixture o f bromoacetic aldehyde diethylacetal (149, 13.2 g, 68.9
E tO ^ N^ v ]|^OEt mmol), ethyl cyanoacetate (148, 34 g, 273.2 mmol), K2C 0 3 (8  g, 60.1 
O
mmol) and KI (0.61 g, 3.71 mmol) was refluxed at rt. for 5-6 h. The 
dark yellow suspension obtained was diluted with water (150 mL) and then washed with 
ether (3 x 200 mL). The combined organic layer was dried over M gS04 and was evaporated
2 0 0
under vacuum. The dark brown residue was purified by column chromatography, eluting 
with DCM-methanol 95:5 to give the title compound as a slightly yellow oil (9.0 g, 54%). *H 
NMR (CDCI3, 270MHz) 5 4.57 (t, 7 Ch .c h 2 5.7 Hz, 1H, CH), 4.13 (q, 2H, 7 CH2,c h 3 7.2 Hz, 
OCH2), 3.57-3.41 ( m ,  5H, 2CH2 and CHCN), 2.11 (m, 2H ,C H 2), 1.20 (t, 3 H , / CH3.c h 2 7.2 Hz, 
CH3), 1.09 (m, 6 H, 2CH3); 13C NMR (CDC13, 67.5 MHz) 8  165.6 (CO), 115.7 (CN), 99.3
(CH), 62.1 (3CH2), 33.5 (CH2), 33.2 (CHCN), 29.9 (CH3), 14.7 (CH3), 13.6 (CH3).
7.19.2 6-Amino-5- (2,2-Diethoxyethyl)-2,3-Dihydro-2-Thioxopyrimidin-4 (lH )-One 
(151).
To a solution of ethyl 2-cyano-4, 4-diethoxybutanoate (150,4.88 g, 20 
mmol) and thiourea (1.68 g, 22 mmol) in dry ethanol (100 mL) was 
added sodium ethoxide (1.5 g, 22 mmol). The resulting reaction 
mixture was refluxed under a nitrogen atmosphere for 6  h. The dark
colored solution obtained was concentrated to dryness in vacuo and then re-dissolved in 
small amount of water (ca 10 mL). After adjusting pH to 4, yellow precipitate was formed 
and was left at 4°C overnight. Filtered and dried under vacuum, the desired compound was 
produced as a yellow solid (12 mmol, 60%). ’H NMR (DMSC>6, 270 MHz) 8 11.76 (s, 1H, 
NH), 11.45 (s, 1H, NH), 6.08 (s, 2H, NH2), 4.50 (t, 7 C h .c h 2  5.7 Hz, 1H, CH), 3.56-3.40 (m, 
4H, 2CH2), 2.43 (d, Jch 2 . c h  5.7 Hz, 2H, CH2), 1.05 (m, 6 H, 2CH3); 13C NMR (DMS06, 67.5 
MHz) 8  173.3 (CO), 161.9 (CS), 151.6 (CNH2), 101.9 (CH), 85.8 (C), 61.5 (2CH2), 27.9 
(CH2), 15.6 (2CH3).
7.19.3 2-Thioxo-l,2,3,7-Tetrahydro-Pyrrolo [2,3-</]Pyrimidin-4-One (152).
A solution of compound 151 (2.0 g, 8.26 mmol) in 0.2 N HC1 (40 mL) was 
stirred at rt. for overnight. The resulting yellow suspension was filtered and 
dried under reduced pressure. Yellow solid was given in more than 90% 
yield. *H NMR (D M S06, 270MHz) 8  11.88 (s, 1H, NH), 11.28 (s, 1H, NH), 6.71 (dd, 7 8 .n h
2.1 Hz, / 8,7 3.2 Hz, 1H, H-8 ), 6.33 (dd, 7 7 ,n h  2.5 Hz, J1S 3.2 Hz, 1H, H-7); m/z (El) 167.0 
(M+, 15%); HRMS Calcd for C6H5N5OS+ (M + H)+ 168.0226 found 168.0223.
2 01
7 .19 .4  4 -H y d r o x y -P y r r o lo - [2 ,3 -^ -P y r in iid in e  (153)
To a suspension of 152 (1.5 g, 8.93 mmol) in water (50 mL) containing 
concentrated aqueous ammonium (35%, 3 mL), was added Raney nickel (3.1 
g). This reaction mixture was refluxed for 6  h. After reaction came to 
completeness, the mixture was filtered and washed with hot water. Combined filtrates were 
collected and evaporated in vacuo. Title compound was produced as a pinkish solid (8 8 6  mg, 
73%). *H NMR (DM S06, 270MHz) 6  11.87 (s, 1H, NH), 7.83 (s, 1H, H-2), 7.03 (d, J 8,7 3.2 
Hz, 1H, H-8 ), 6.43 (d, 77.8 3.2 Hz, 1H, H-7); 13C NMR (DM S06, 67.5 MHz) 6  159.0 (CO),
148.6 (C-4), 143.8 (C-2), 120.9 (C-8 ), 108.2 (C-5), 102.5 (C-7); m/z (El) 135.0 (M+, 100%); 
HRMS Calcd for C6H5N30 + 136.0505 found 136.0506.
7.19.5 4-Chloropyrrolo[2,3-d]pyrimidine (154).
A suspension of 153 (1.0 g, 8.1 mmol) in phosphorus oxychloride (24.75 g, 15 
mL, 89.1 mmol) was heated at reflux under an argon atmosphere until a clear 
solution was given. Excess phosphorus oxychloride was removed by 
evaporation and the residue was quenched with ice (10 mL). The resulting suspension was
filtered and washed with ether (3 x 50 ml). Combined organic layer was dried over
anhydrous MgSC>4 and concentrated into dryness under reduced pressure. Title compound 
154 was given as a yellow solid (750 mg, 65%). *H NMR (DMSO, 270 MHz) 6  8.59 (s, 1H, 
H-2), 7.70 (d, J8j  3.2 Hz, 1H, H-8 ) and 6.61 (d, / 7,8 3.2 Hz, 1H, H-7); 13C NMR (DMSO,
67.5 Hz) 6  152.3 (C-6 ), 151.1 (C-4), 150.8 (C-2), 128.8 (C-8 ), 117.1 (C-5) and 99.3 (C-7); 
m/z (EC) 153.0 (M+, 100%), 155.0 (M+, 35%); HRMS Calcd for [M+H]+C6H5C1N3+(ES+) 
154.0167 found 154.0166.
7.19.6 l-Chloro-2-Deoxy-3,5-Di-0-p-Toluoyl-a-D-E/jf^ro-Pentofuranose (158).209
To a suspension of 2'-deoxy-D-ribose (155, 1.36 g, 10 mmol) in
iCI
dry methanol (25 mL) was added a solution of HC1 in dry
methanol (1% w/w, 3 mL). The resulting solution was stirred
under an argon atmosphere at rt for 15 min after which silver
carbonate (400 mg) was added to the reaction system to remove
excess HC1. The yellowish precipitate was filtered and the filtrate was concentrated to a
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syrup, which was then evaporated with dry pyridine three times to remove any residual 
methanol. The resulting yellow gum was dissolved in dry pyridine (8  mL) and was added 
p-toluoyl chloride (3.4 g, 22 mmol) under an argon atmosphere. The yellow solution 
obtained was heated at 50 °C for 1 h and was left at rt overnight. To the reaction solution, 
water (20 mL) was added and the resulted mixture was extracted with ether (3 x 100 mL). 
The combined organic layers were washed with water (50 mL), 1M H2SO4 (3 x 50 mL) and 
then saturated NaHC03 (100 mL) The ether solution was dried over anhydrous Na2S0 4 and 
evaporated under vacuum to a liquid residue. The residue was dissolved in AcOH (3 mL), 
and to this mixture was added a saturated solution of HC1 in acetic acid (8  mL). After stirring 
at rt for 1.5 h, a white precipitate was formed. The white solid was filtered and dried in vacuo 
to give the title compound in ca. 50% yield; mp: 106-108 °C (lit.204 109°C). ]H NMR (CDCI3, 
270MHz) 5 8.00-7.97 (d, 78.1 Hz, 2H, 2ArCH), 7.90-7.87 (d, 2H, 7 8.1 Hz, 2ArCH), 7.24 
(m, 4H, 4ArCH), 6.46 (m, 1H, H -l'), 5.55 (m, 1H, H-3'), 4.85 (m, 1H, H-4'), 4.59 (m, 2H, 
H-5'), 2.83-2.76 (m, 2H, H-2') and 2.40 (m, 6 H, 2 x CH3); 13C NMR (CDC13, 67.5 MHz) 5 
130.0-129.3 (ArCH and ArC), 95.5 (C -l'), 84.9 (C-4'), 73.5 (C-3'), 63.3 (C-5'), 44.6 (C-2'),
21.8 (2 x CH3) and CO (not visible).
7.19.74-Chloro-7-(2-Deoxy-3,5-Di-0-(jp-ToluoyI)-p-D-Erythro-Pentofuranosyl)-7//-Py
rrolo[2,3-7]Pyrimidine (159).210
To a fast stirred suspension of powdered potassium hydroxide (81 
mg, 1.44 mmol) in dry MeCN (4.9 mL) was added TDA-1 (8.1 pL) 
under an argon atmosphere. This mixture was stirred at rt for 5 min 
after which compound 154 (100 mg, 0.66 mmol) was added and 
the mixture was stirred for another 5 min. Compound 158 (259mg, 
0.67mmol) was then added and the reaction mixture was stirred for 
further 20 min until TLC (DCM-ethyl acetate 12: 1) showed that 
all the starting material had reacted and a less polar spot (Rf 0.46) 
was produced. The crude product was co-evaporated with silica gel, loaded on top of a silica 
column and eluted with DCM-ethyl acetate 20:1. The appropriate fractions were collected 
and concentrated under reduced pressure to produce the title compound 159 as a white foam
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(262 mg, 81%). NMR (CDCI3, 270MHz) 6  8.62 (s, 1H, H-2), 7.97 (d, J  8.2 Hz, 2H, 2 x 
ArCH), 7.91 (d, J 8.4 Hz, 2H, 2 x ArCH), 7.41 (d,78.7 3.7 Hz, 1H, H-8 ), 7.28 (d, J 8.2 Hz,2H, 
2 x ArCH), 7.25 (d, J  8.4 Hz, 2H, 2 x ArCH), 6.80 (dd, Hz and / r ji-a5.9 Hz, 1H,
H-l 0,6.59 (d, 77f8 3.7 Hz, 1H, H-7), 5.76 (m, 1H, H-3'), 4.64 (m, 3H, H-4' and H-5'), 2.82 (m, 
2H, H-2'), 2.43 (s, 3H, CH3) and 2.39 (s, 3H, CH3); 13C NMR (CDC13, 67.5 MHz) 6  166.2 (2 
x CO), 151.1 (C-6 ), 151.1 (C-2), 151.1 (C-4), 144.9 (ArC), 144.4 (ArC), 130.0,129.7,129.4 
(ArCH), 126.8, 126.5 (ArC), 126.1 (C-8 ), 118.4 (C-5), 101.0 (C-7), 84.7 (C-l'), 82.6 (C-4'),
75.2 (C-3'), 63.9 (C-5'), 38.1 (C-2') and 21.9 (2 x CH3); m/z (ES+) 506.45 [(M+H)+, 80%),
508.47 [(M+H)+, 35%]; HRMS Calcd for [M+H]+C27H250 5N3C r  (ES+) 506.1477 found 
506.1474.
7.19.8 7-Deaza-2'-Deoxy Adenosine (160)
Ammonia gas was bubbled into a suspension of compound 159 (250 mg, 
0.52 mmol) in methanol (20 mL) at 0°C for 40 min. The resulting clear 
saturated methanolic ammonia solution was warmed up to rt and then 
heated to 60°C in a pressure tube for 4 days. TLC of the reaction mixture 
HO' showed that the starting material was completely consumed and a more
polar product was formed (Rf 0.23 DCM-methanol 5: 1). After removal of the solvent, the 
residue was purified by flash column chromatography, eluted with DCM-methanol 6:1 to 
afford the desired compound 160 as a yellow oil (70 mg, 53%). ]H NMR (DMSO, 270 MHz) 
6  8.04 (s, 1H, H-2), 7.35 (d, J 8,7 3.7 Hz, 1H, H-8 ), 7.05 (s, 2H, NH2), 6.57 (d, / 7.8 3.7 Hz, 1H, 
H-7), 6.48 (dd,/,<,2<a6.2 Hz and J v2'b 5.9 Hz, 1H, H -l'), 5.24 (m, 2H, 3'-OH and 5'-OH), 4.34 
(m, 1H, H-3'), 3.81 (m, 1H, H-4'), 3.52 (m, 2H, H-5'), 2.49 (m, 1H, H-2'a) and 2.16 (m, 1H, 
H-2'b); ]H NMR (DMSO, D20  shake, 270MHz) 8  8.02 (s, 1H, H-2), 7.32 (d, / 8,7 3.7 Hz, 1H, 
H-8 ), 6.57 (d, 77,8 3.7 Hz, 1H, H-7), 6.42 (dd, yr,2-b6.2 Hz and J r ,2-a5.9 Hz, 1H, H -l'), 4.33 
(m, 1H, H-3'), 3.83 (m, 1H, H-4'), 3.53 (m, 2H, H-5'), 2.48 (m, 1H, H-2'a) and 2.18 (m, 1H, 
H-2'b); 13C NMR (DMSO, 67.5 MHz) 8  158.1 (C-6 ), 152.2 (C-2), 150.2 (C-4), 122.2 (C-8 ),
103.5 (C-5), 100.2 (C-7), 87.3 (C-l'), 83.7 (C-4'), 71.6 (C-3'), 62.6 (C-5') and C-2' overlap 
with DMSO peak.; m/z (ES+) 251.37 [(M+H)+,100%]; HRMS Calcd. for
[M+H]+C i,H ,5N40 3+(ES+) 251.1139 found 251.1144.
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7.19.9 7-Deaza-2f-Deoxy-Adenosine 5 '-Monophosphate (161a,
7-Deaza-2'-Deoxy-AMP)
A solution of 7-deaza-2'-deoxy adenosine (160, 60 mg, 240 pmol, 
dried in vacuo at 60°C overnight) in triethyl phosphate (0.7 mL) 
was heated 10 mins with a heat-gun and cooled to -15-20°C in a 
ice-salt bath. To the resulting clear solution was added POCI3 (70 
jllL, 350 pmol). The reaction mixture was stirred at the 
temperature for 2 h, quenched by addition of ice (10 mL) and 
neutralized to pH 7 immediately with a NaOH solution (5 M). The resulting solution was 
extracted with cold ethyl acetate (5 x 20 mL) and the aqueous layer was purified on a reverse 
phase column, and product eluted with 0-30% gradient MeCN against 0.05 M TEAB. The 
appropriate fractions were collected, evaporated in vacuo and excess TEAB was 
co-evaporated with MeOH (3 x) to generate a mixture of compound 161a (135 pmol, 56%) 
and 161b (57 pmol, 23.8%). The mixture was used in the next step without further 
purification; HPLC: single peak at 6.83 min at 254 nm; ]H NMR (D2O, 270MHz) 8 7.86 (s, 
1H, H-2), 7.32 (d, / 8,7 3.7 Hz, 1H, H-8 ), 6.43(d, 77,8 3.7 Hz, 1H, H-7), 6.39 (m, 1H, H -l'), 
4.53 (m, 1H, H-3'), 4.01 (m, 1H, H-4'), 3.74 (m, 2H, H-5'), 2.57 (m, 1H, H-2'a) and 2.31 (m, 
1H, H-2 T3); 31P NMR: 4.48 (s); 161b 'H NMR (D20 , 270MHz) 8  7.91 (s, 1H, H-2), 7.47 (d,
78.7 3.7 Hz, 1H, H-8 ), 6.44 (d, J7,8 3.7 Hz, 1H, H-7), 6.43 (m, 1H, H-l'), 4.69 (m, 1H, H-3'), 
4.22 (m, 1H, H-4'), 3.76 (m, 2H, H-5') and 2.58 (m, 2H, H-2'); 31P NMR (D20 , 109 MHz):
4.47 (s) and 3.95 (s).
7.19.10 7-Deaza-2'-Deoxy Adenosine 5 '-M onophosphate M orpholidate (162a).
A solution of 7-deaza-2'-deoxy AMP 161a/161b (70 mg, 161a, 
98 pmol) in dry DMSO (0.4 mL) was co-evaporated with dry 
DMF (3 x 1 mL). To the resulting solution (ca. 0.4 mL) was 
added dipyridyl disulfide (189 mg, 862 pmol), morpholine (150 
HO' pL, 1.72 mmol) and triphenylphosphine (190 mg, 724 pmol).
The reaction mixture was stirred at rt for 3 h after which HPLC analysis indicated that all 
starting material was consumed and two new peaks were produced (2.5 min for 5 '-AMP 





R = H, 161a
R = PO3H, 161b
quenched by dropwise addition of a solution of Nal in acetone (0.2 M, 10 mL) and the 
sodium salt precipitate obtained was filtered, washed with acetone and dried in vacuo. The 
residue was purified on a Q-sepharose ion-exchange chromatography to afford the title 
compound 162a as a glassy solid in its triethylammonium form (81 pmol, 83%). A small 
amount of 7-deaza-2'-deoxy adenosine 3', 5'- diphosphate morpholidate 162b (14 pmol, 
34%) was also isolated. HPLC: single peak at 2.56 min at 254 nm; UV (H2O) A^ax 272 nm; 
]H NMR (D20 , 270MHz) 5 7.96 (s, 1H, H-2), 7.31 (d, J8j  3.7 Hz, 1H, H-8), 6.47 (d, A 8 3.7 
Hz, 1H, H-7), 6.45 (m, 1H, overlap with H-7, H-L), 4.63 (m, 1H, H-3'), 4.09 (m, 1H, H-4'),
3.84 (m, 2H, H-5'), 3.43 (m, 4H, 2 x CH20 ), 2.83 (m, 4H, 2 x CH2N), 2.67 (m, 1H, H-2'a) 
and 2.45 (m, 1H, H-2b); 13C NMR 6 156.6 (C-6), 150.4 (C-2), 148.9 (C-4), 122.1 (C-8),
103.2 (C-5), 100.6 (C-7), 85.1 (d, J Cp9.3 Hz, C-4'), 82.9 (C-l'), 71.3 (C-3'), 67.0, 66.8 (2 x 
CH20 ), 64.5 (d, JcP5.6 Hz, C-5'), 44.6 (2 x CH2N) and 38.5 (C-2'); 31P NMR (D20 , 109 
MHz) 8-8.22 (s); m/z (ES') 398.42 [(M-H)', 100%]; HRMS Calcd for [M-H]' C i5H21N50 6P‘ 
(ES') 398.1235 found 398.1226.
7.19.11 7-Deaza-2'-Deoxy-Adenosine 3 ', 5 '- Bisphosphate M orpholidate (162b).
NH? HPLC: 7.26 min at 254 nm; UV (H2Q) A™* 271.1 nm; *H NMR
(D20 , 270MHz) 8 8.09 (s, 1H, H-2), 7.47 (d, J8j  3.7 Hz, 1H, 
j 1 H-8), 6.63 (d, J7,s 3.7 Hz, 1H, H-7), 6.59 (dd, 1H, overlap with
^ N ' * P - 0 H " 7 ’ J  n o t  S i v e n ’ H " r ) ’ 4 *8 5  1 H ’ 4 -2 8  <m ’ 1 H ’ H " 4 ' ) ’
O' 3.89 (m, 2H, H-5'), 3.66 (m, 4H, 5' morpholidate 2 x CH20),
\Q-  3.45 (m, 4H, 3' morpholidate 2 x CH20), 3.08 (m, 4H, 5'
morpholidate 2 x CH2N), 2.85 (m, 4H, 3' morpholidate 2 x 
CH2N), 2.71 (m, 1H, H-2'a) and 2.59 (m, 1H, H-2T3); 13C NMR 8 155.4 (C-6), 149.0 (C-4),
148.5 (C-2), 123.0 (C-8), 103.0 (C-5), 101.3 (C-7), 83.4 (dd, Jqp 11.5 Hz and / Cp5.6 Hz, 
C-4'), 83.4 (C-l'), 75.1 (d, JcP5.6 Hz, C-3'), 67.1-66.9 (4 x CH20), 64.7 (C-5'), 44.9-44.7 (4 
x CH2N) and 38.3 (C-2'); 31P NMR (D20 , 109 MHz) 8 8.05 (s), 7.77 (s); m/z (ES+) 547.44 
[M+, 40%]; HRMS Calcd. for (M+H)+C19H3,0 9N6P2+ (ES+) 549.1622 found 549.1630.
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7.19.12 7-Deaza-2'-Deoxy Nicotinamide Adenine Dinucleotide (163, 
7-Deaza-2'-Deoxy-NAD+)
A suspension of 7-deaza-2'-deoxy AMP morpholidate 
(162a, 54 mmol), |3-NMN+ (31 mg, 93 mmol), MgS0 4  
(20 mg, 167 mmol) in MnCl2/formamide (0.2 M, 0.68 
mL) was stirred at rt for 48 h in an argon atmosphere and 
was quenched by addition of MeCN (2 mL). The 
resulting yellow precipitate was filtered, washed with 
acetone and treated with Chelex resin (sodium form). 
The crude 7-deaza-2'-deoxy NAD+ sodium salt was purified on a reverse phase column, 
eluted with a gradient of 0-30% MeCN/0.05 M TEAB buffer. The fractions containing the 
desired compound were collected, concentrated under reduced pressure and co-evaporated 
with MeOH (3 x) to give the compound 163 in its triethylammonium form (32 mmol, 59%). 
Rt = 3.25 min at 254 nm; ]H NMR (D20 , 400 MHz) 5 9.25 (s, 1H, HN-2), 9.05 (brs, 1H, 
Hn-6), 8.67 (d, y4.57.4 Hz, 1H, HN-4), 8.00 (m, 1H, HN-5), 7.90 (s, 1H, H-2), 7.36 (brs, 1H, 
H-8), 6.43 (m, 2H, H -l' and H-7), 6.06 (d, J V T 4.1 Hz, 1H, H -l"), 4.64 (m, 1H, H-3'), 4.52 
(m, 1H, H-4"), 4.11 (m, 7H, ribose-H), 2.60 (m, 1H, H-2'a) and 2.38 (m, 1H, H-2B); 13C 
NMR (D20 , 100.5 MHz) 5 154.9 (C-6), 148.6 (C-2), 148.1 (C-4), 145.4 (CN-4), 142.2 
(Cn-6), 140.1 (Cn-2), 132.0 (CN-3), 128.5 (C-8), 122.8 (CN-5), 102.5 (C-5), 101.1 (C-l"),
100.1 (C-7), 87.0 (C-4"), 85.2 (C-4'), 83.0 (C-l'), 77.7 (C-2"), 71.6 (C-3"), 70.6 (C-3'), 66.1 
(C-5"), 65.0 (C-5') and 38.8 (C-2'); 31P NMR (D20 , 109 MHz) 8-11 .44  (brs); m/z (ES )
645.07 [(M-H)\ 100%] HMRS Calcd for [M-H]' C22H27N6Oi3P2‘ (ES') 645.1117 found 
645.1111.
7.19.13 Cyclic 7-Deaza-2'-Deoxy Adenosine 5 '-diphosphate Ribose (164)
OH 7-Deaza-2'-deoxy NAD+ (163, 5 mg, 6 mmol) was incubated with
H O ^^J li,H2 Aplysia ADP ribosyl cyclase (23 mL) in HEPES buffer (25 mM,
f  °  pH 7.4, 16 mL). The reaction mixture was stirred at rt and the
O J
O^P'-O P  \  progress was monitored by HPLC. After 1 h, reaction solution
_0
O oh was diluted with MilliQ water (conductivity < 200 mS/cm) and
OH
purified on a Q-sepharose ion exchange system. The final
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compound was obtained as a glassy solid in its triethylammonium form (4 mmol, 67%). 
HPLC: Rt = 4.28 min at 254 nm; UV (H20 ,  pH 4.9) 275.8 nm (fi'dm3 m ol'1 cm '110900);
*H NMR (D20 , 400 MHz) 6 8.69 (s, 1H, H-2), 7.22 (d, JSj  3.5 Hz, 1H, H-8), 6.63 (dd, Jn,8
3.5 Hz, 1H, H-7), 6.15 ( t , / r ,2-7.0Hz, 1H ,H -l'), 5.91 (d ,./r ,r 3 .9H z, 1H ,H -l"), 4.71 (m, 1H, 
H-3'), 4.56 (m, 1H, H-4"), 4.51 (m, 1H, H-2"), 4.40 (m, 1H, H-5'a), 4.30 (m, 1H, H-3"), 4.29 
(m, 1H, H-5 "a), 4.22 (m, 1H, H-4'), 4.12 (m, 1H, H-5"b), 4.00 (m, 1H, H-S'b), 3.23 (m, 1H, 
H-2'a) and 2.36 (m, 1H, H ^ 'b ); 13C NMR (D20 ,  100.5 M Hz) 6 150.5 (C-6), 146.0 (C-4),
139.2 (C-2), 129.8 (C-8), 104.3 (C-5), 100.7 (C-7), 94.8 (C -l"), 89.5 (C -l'), 87.8 (d,7Cpl0.1 
Hz, C-4"), 86.4 (d, J cp 10.8, C-4'), 76.8 (C-2"), 71.6 (C-3' and C-3"), 65.4 (C-5"), 64.6 (C-5') 
and 37.6 (C-2'); 31P NM R (D20 , 109 MHz) 8 -10.05 (brs) and-10.60 (brs); m/z (ES‘) 523.08 
[(M-H)', 100%]; HRMS Calcd for [M-H]+ C]6H2iN40 12P2' (ES') 523.0637 found 523.0632.
7.19.14 Hydrolysis o f 8-Bromo-cADPR (165).
A solution of 8-bromo-cADPR (0.5 pmol) in MilliQ water (1 mL) was heated at 70°C until 
HPLC analysis indicated all the starting cADPR was consumed and a single new peak was 
given at 7.68 min. After removal of the solvent, 8-bromo-ADP-ribose was given in 
quantitative yield and was used as HPLC standard without further purification. NMR of this 
compound was collected from larger scale reactions; HPLC: R t = 7.68 min at 254 nm; UV 
(H20 , pH 4.9) ^  264.6 nm (£/dm3 m ol'1 cm '1 16460); NM R (D20 , 400 MHz) 8 8.18 (s, 
1H, H-2), 6.09 (d, Jv,2> 5.9 Hz, 1H, H - l '), 5.29-5.26 (m, 1H, H - l" p and H -l"a), 4.60-3.95 (m, 
10 H, ribose-H); 31P NM R (D20 , 169 MHz) 8 -11.43 (brs). By this method, ADP-ribose was 
also synthesised as a HPLC and NMR standard; HPLC (system A) at 254 nm: 10.00 min 
(single peak); *H NM R (270 MHz; D20 )  8 8.57 (s, 1H, H-8 or H-2), 8.35 (s, 1H, H-2 or 
H-8), 6.10 (d, Jy,2-5.4 Hz, 1H, H -l'), 5.31 (d, / r ,r 4.1 Hz, 1/3 H, H -l"p), 5.17 (m, 2/3H, 
H -l"a), 4.72-3.97 (m, 10H, ribose-H); 31P NMR (109 MHz; D 20 ;  *H decoupled) 8 -10.52 
(brs).
7.20 Synthesis of Bromoacetylamides
General protocol. To a stirred solution of 2-bromo-acetylbromide (1 mL, 12 mmol) in ether
(10 mL) at -10°C was added drop wise a solution of amines (24 mmol) in ether (10 mL) over
30 min. The resulting clear solution was stirred at -15-20°C for 15-30 min and then
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quenched by addition of cold water (20 mL). The organic layer was separated and washed 
successively with hydrochloride solution (1 M, 20 mL), NaOH solution (1 M, 20 mL) and 
brine (20 mL). The solvent was removed and the residue was dried in vacuo and used in next 
step without further purification or purified by flash column chromatography as specified.
7.20.1 2-Bromo-A, A-Diethyl-Acetamide (168)
f  2-Bromo-acetylbromide and diethylamine were reacted under the general
protocol giving the desired compound 168 as a colourless oil (1.39 g, 60%).
O 1
]H NMR (CDC13, 270 MHz) 5 3.73 (s, 2H, CH2CO) 3.25(q, J  7.5 Hz, 4H, CH2 
CH3), 1.24(t, J  7.5 Hz, 3H, CH3) and 1.03 (t, J  7.5 Hz, 3H, CH3).
7.20.2 2-Bromo-A-Butyl-Acetamide (169)
|_|
^ 2-Bromo-acetylbromide and n-butylamine were reacted under the
O general protocal affording the desired product 169 as a low melting point
solid (1.77g, 76%). mp: ca 30°C; *H NMR (CDC13,270 MHz) 6 6.65 (brs, 1H, NH), 3.81 (s, 




2-Bromo-acetylamine and aniline were reacted under the general
Br Y
O protocol generating the title compound 170 as a yellow solid (1.82 g,
71%); mp: 128-131°C; IR (KBr) vmax 3296, 3203, 3146, 3099, 1657, 1618, 1555, 1486; ]H 
NMR (CDC13, 270 MHz) 58.13 (brs, 1H, NH) 7.52(d, J  2.7 Hz, 2H, ArH-2 and ArH-6), 7.34 
(m, 2H, ArH-3 and ArH-5), 7.17 (m, 1H, ArH-4) and 4.00(s, 2H, CH2CO); 13C NMR (CDC13,
100.5 MHz) 5 163.3, 137.1 (both C), 129.3, 125.4, 120.3 (all CH), 29.9 (CH2); m/z (FAB+)
213.9 [(M +l)+,100%]; HRMS calcd. for [M+H]+ C8H979BrNO+ (FAB+) 213.9868 found 
213.9858; Calcd for [M+H]+ C8H981BrNO+ 215.9847 found 215.9839.
7.20.4 2-Bromo-A^-CyclohexyI-Acetamide (171)
2-Bromo-acetylbromide and cyclohexylamine were reacted under the
Br ¥
O general protocol giving the title molecule 171 as a white fine powder
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(2.38 g, 90%); mp: 106-108°C; IR (KBr) vmax 3284, 3072,2937,2919,2853, 1645; ]H NMR 
(CDC13, 270 MHz) 8  6.33 (brs, 1H, NH), 3.84(s, 2H, CH2CO), 3.74 (m, 1H, CHN) and
1.10-1.92 (m, 10H, ring-H); 13C NMR (CDCI3, 100.5 MHz) 8  164.7 (C), 49.6 (CH), 33.4,
30.2, 26.1 and 25.3 (all CH2); m/z (FAB+) 220.0 [(M+l)+, 70%]; 222.0 [(M+H)+, 70%]; 
HRMS Calcd. for [M+H]+C8Hi579BrNO (FAB+) 220.0337 found 220.0333; Calcd [M+H]+ 
C8H ,581BrNO+ 222.1317 found 222.0317.
7.20.5 2-Bromo-A- (4-Ethyl-Phenyl)-Acetamide (172)
H 2-Bromo-acetylbromide and 4-ethyl-aniline were reacted under
general protocol forming the title compound 172 as a yellow solid 
(2.12 g, 73%); mp: 131-132°C; lH NMR (CDC13,270 MHz) 8  8.07 
(brs, 1H, NH), 7.40 (d, J  8.4 Hz, 2H, ArH), 7.15 (d, /  8.4 Hz, 2H, ArH), 4.00 (s, 2H, CH2CO), 
2.59 (q, J  7.7 Hz, 2H, CH2 CH3) and 1.18 (t, J  7.7 Hz, 3H, CH3); m/z (FAB+) 242.0 [(M +l)+, 
100%], 242.0 [(M+H)+, 93%]; HRMS calcd. for [M+H]+ C 10Hi379BrNO+ (FAB+) 242.0197 
found 242.0182; Calcd for [M+H]+ Ci0H L381BrNO+ 244.0160 found 244.0174.
7.20.6 2-Bromo-A- (2-Bromophenyl)-Acetamide (173)
2-Bromo-acetylbromide and 2-bromo-aniline were reacted under 
general protocol. The crude product was purified by flash column 
chromatography, eluted with DCM-Hexane 10: 1 to afford the title 
compound as a yellow solid (1.83 g, 52%); mp: 96-98°C; IR (KBr) vmax 3184, 3107, 1653, 
1609, 1591, 1542, 1472; *H NMR (CDC13, 270 MHz) 8  8.15 (brs, 1H, NH), 7.77 (m, 1H, 
ArH-3), 7.43 (d, J  7.8 Hz, 1H, ArH-6 ), 7.23 (m, 2H, ArH-4 and ArH-5) and 4.00 (s, 2H, 
CH2CO); 13C NMR (CDCI3, 100.5 MHz) 8  164.3, 138.1, 122.6 (all C), 130.3, 128.2, 123.0,
118.5 (all CH) and 29.3 (CH2); m/z (FAB) 293.9 [(M+H)+, 100%].
7.20.7 2-Bromo-A, A-Dibutylacetamide (174)
2-Bromo-acetylbromide and di-butylamine were reacted under the 
general protocol giving the desired compound 174 as a colourless oil
(2.30 g, 76%); IR (KBr) vmax 2959, 2932, 2872,1648; *H NMR (CDCI3,
210
270 MHz) 8 3.77 (s, 2H, CH2CO), 3.23 (m, 4H, 2 x  CH2N), 1.48 (m, 4H, 2 x CH2), 1.25 (m, 
4H, 2 x CH2) and 0.86 (m, 6H, 2 x CH3); 13C NMR (CDC13, 100.5 MHz) 8 166.3 (C), 49.0,
46.2, 31.6,29.7, 27.0, 20.5 (all CH2), 14.3 and 14.2 (both CH3); m/z (FAB+) 252.0 [(M+H)+, 
95%], 250.0 [(M+H)+, 100%], 170 [(M-Br)+, 12%]; HRMS calcd. for (M+H)+ 
C ]0H2179BrNO (FAB+) 250.0807 found 250.0798; Calcd for [M+H]+ C,0H2i81BrNO+ 
252.0786 found 252.0783.
7.20.8 2-Bromo-A, A-Dicyclohexylacetamide (175)
2-Bromo-acetylbromide and di-cyclohexylamine were reacted under 
general protocol. The crude product was purified by flash 
chromatography, eluted with DCM-hexane 12:1 to give title compound 
175 as a white solid (1.45 g, 40%). Analytical data was given by
“ T O
crystallisation from DCM; mp: 122-124°C; IR (KBr) vmax 3466, 2933,2869, 2857,1637; ]H 
NMR (CDC13, 270 MHz) 8 3.80 (s, 2H, CH2CO), 2.41 (m, 2H, 2CH) and 1.17-1.86 (m, 18H, 
cyclohexyl-H); 13C NMR (CDC13, 100.5 MHz) 8 165.2 (C), 56.3 (CH), 31.0, 29.4, 29.1, 26.5,
25.8, 25.2 and 25.2 (all CH2); m/z (FAB+) 302.0 [M+, 100%], 304.0 [M+, 96%]; HRMS 
Calcd. for [M+H]+C14H2579BrNO+ (FAB+) 302.1120 found 302.1126; Calcd. for [M+H]+ 
C 14H2581BrNO+304.1099 found 304.1118.
7.20.9 2-Bromo-A-Decylacetamide (176)
2-Bromo-acetylbromide and n-decylamine were reacted under 
general protocol. The crude product was purified by flash 
column chromatography, eluted with DCM-hexane 10: 1 to give 
the title compound 176 as a colourless oil (2.72 g, 81%); IR (KBr) vmax 3282, 2920, 2852, 
1640; ’H NMR (CDC13,270 MHz) 8 6.49 (s, brs, 1H, NH), 3.86 (s, 2H, CH2CO), 3.25 (m, 
2H, CH2), 1.52 (m, 2H, CH2), 1.24 (m, 14H, 7CH2) and 0.86 (m, 3H, CH3); 13C NMR 
(CDC13, 67.5 MHz) 8 165.4 (C), 40.7, 32.3, 29.9, 29.8, 29.7, 29.67, 29.65, 27.2, 23.1 (all 
CH2) 14.6 (CH3); m/z (FAB+) 278.1[(M+H)+, 98%], 279.1 [(M+H)+, 91%]; HRMS Calcd. 
for [M+H]+ Ci2H2579BrNO (FAB+) 278.1120 found 278.1120; Calcd. for [M+H]+ 
Ci2H2581BrNO 280.1099 found 280. 1103.
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7.20.10 2-Bromo-A-methyl-jV-Phenylacetamide (177)
J, 2 -Bromo-acetylbromide and (V-methyl-aniline were reacted under the
BO f  ft* )O general protocol giving the title compound as a yellow solid (2 .2 1  g,
80%); mp: 43-45°C; IR (KBr) vmax 1646, 1595, 1498; *H NMR (270 
MHz, CDCI3) 6  7.28 (m, 5H, Ar-H), 3.87 (s, 2H, CH2CO) and 3.29 (s, 3H, CH3); m/z (FAB+)
228.0 [(M+H)+, 100%], 230.0 [(M+H)+, 96%]; HRMS Calcd. for [M+H]+ C9Hn79BrNO 
(FAB+) 228.0024 found 228.0015; Calcd. for [M+H]+ C9H n 81BrNO 230.0004 found 
299.9998.
7.20.11 2-Bromo-A/-(3-Methoxybenzyl)Acetamide (178).
I_l 2-Bromo-acetylbromide and 3-methoxy-benzylamine were
R r |] | reacted under general protocol. The crude product was purified by
O 1
flash chromatography, eluted with DCM-hexane 10:1 to give the 
title compound 178 as a yellow solid (2.25 g, 72%); mp: 79-80°C; IR (KBr) vmax 3289, 3048, 
1641, 1543, 1489; *H NMR (CDC13, 270 MHz) 6  7.24-6.83 (m, 4H, ArH), 4.40 (s, 2H, 
CH2NH), 3.86 (s, 2H, CH2CO) and 3.77 (s, 3H, CH3). 13C NMR (CDC13, 100.5 MHz) 6
165.8, 160.0, 139.1 (all C), 130.0, 120.0, 113.5, 113.2 (all CH), 55.6, 29.4 (both CH2) and
44.4 (CH3); m/z (FAB+) 257.9 [(M+H)+, 100%], 259.9 [(M+H)+, 95%], 178.0 [(M-Br)+, 
71%]; HRMS Calcd. for [M+H]+ C ,0H,379BrNO+ (FAB+) 258.0130 found 258.0136; Calcd. 
for [M+H]+ C,0H 1381BrNO+ 260.0109 found 260.0119.
7.20.12 2-Bromo-A-Dipropylacetamide (179)
2-Bromo-acetylbromide and di-propylamine were reacted under the
1 general protocol affording title compound 179 as a yellow oil (1.72 g,
O
65%); IR (KBr) vr a  3451, 2966, 2876, 1645, 1456; *H NMR (CDC13, 
270 MHz) 6 3.81 (s, 2H, CH2CO), 3.24 (m, 4H, 2CH2), 1.55 (m, 4H, 2CH2) and 0.86 (m, 6 H, 
2CH3); 13C NMR (CDCI3, 100.5 MHz) 6  166.5 (C), 50.4,47.7,26.2,22.2,20.4 (all CH2) and
11.2 (CH3). m/z (FAB+) 222.0 [(M+H)+, 100%], 224.0 [(M+H)+, 90%].
2 1 2
7.20.13 2-Brom(WV-Dioctylacetamide (180)
2-Bromo-acetylbromide and di-octylamine were reacted 
under general protocol. The crude product was purified by
flash chromatography (DCM: hexane 9:1) affording
compound 180 as a yellow oil (3.52 g, 81%); IR (KBr) vmax 2925, 2855, 1649, 1460; ’H
NMR (CDCI3, 270 MHz) 6  3.80 (s, 2H, CH2CO), 3.26 (m, 4H, 2CH2), 1.54 (m, 4H, 2CH2),
1.25 (m, 20H, 10CH2) and 0.84 (m, 6H, 2CH3); 13C NMR (CDCI3, 100.5 MHz) 5 166.3 (C),
49.1, 46.5, 27.6, 32.2-23.0 (all CH2) and 14.6 (CH3); m/z (FAB+) 362.0 [(M+H)+, 100%],
364.0 [(M+H)+, 95%]; HRMS Calcd. for [M+H]+ C 18H3679BrNO (FAB+) 362.2059 found 
362.2059; Calcd for (M+H)+ Ci8H3681BrNO 364.20381 found 364.2044.
7.20.14 2-Bromo-N-Octylacetamide (181)
H 2-Bromo-acetylbromide and octylamine were reacted
q under general protocol. The crude product was purified by
column chromatography, eluted with DCM-hexane 10: 1 to 
give title compound 181 a yellow oil (71%); 'H NMR (CDCI3, 400 MHz) 6  6.52 (brs, 1H, 
NH), 3.92 (s, 2H, CH2CO), 3.30 (s, 2H, CH2N), 1.56 (m, 2H, CH2), 1.31 (m, 10H, 5CH2) and 
0.91 (t, J  6.5 Hz, 3H, CH3); 13C NMR (CDC13, 100.5 MHz) 6  165.2 (C), 40.3, 31.8, 29.5,
29.3, 29.2, 29.2, 26.8, 22.7 (all CH2) and 14.1 (CH3); HRMS Calcd. for [M+H]+ 
C 10H2179BrNO+ (FAB+) 250.0807; found: 250.0801; Calcd. for [M+H]+ Ci0H2181BrNO+ 
252.0786; found: 252.0787.
7.21 G eneral Procedure for Alkylation Reaction.
Nicotinic acid (1.62 mmol) and 2-bromoacetylamides (1.62 mmol) were dissolved in dry 
DMF (4 mL) and the reaction solution was heated at 60-70°C for overnight in the dark. DMF 
was evaporated in vacuo and the resulting residue was dissolved in small amount of MeOH. 
The desired compounds were precipitated by dropwise addition of ether.
7.21.1 3-Carboxy-l-D iethylcarbam oylm ethyI-Pyridinium  (182)
j? Nicotinic acid ( 1 .62 mmol) and 2-bromo-//, TV-dietylacetamide were reacted
(I + I under the general protocol to afford the desired compound as a yellow oil
n
(0.34 mmol, 21%); IR (KBr)vmax 3429, 3072, 2981, 2934, 1729, 1659 cm '1; !H NMR (D20 , 
270 MHz) 5 9.06 (s, 1H, HN-2), 8.87 (m, 1H, HN-6), 8.74 (m, 1H, HN-4), 8.03 (m, 1H, HN-5), 
5.68 (s, 2H, CH2CO), 3.33 (q, 4H, J  7.5 Hz, 2 x CH2), 1.19 (t, 3H, / 7.5Hz, CH3) and 1.00 (t, 
3H, J  7.5Hz, CH3); m/z (FAB+) 237.0 [(M)+, 100%]; HRMS Calcd. for [M]+Ci2H]7N20 3+ 
(FAB+) 237.1234 found 237.1238.
7.21.2 3-Carboxy-l-Butylcarbam oylm ethyl-Pyridinium  (183)
Nicotinic acid (1.62 mmol) and 2-bromo-N-butylacetamide (1.62 mmol) 
were reacted under the general protocol giving the desired compound 
as a white solid (447 mg, 87%); mp: 190-194°C; IR (KBr)vmaX: 3235, 
3078, 2958, 2931, 2873, 2750, 2494, 1727, 1672 cm '1; ]H NMR (270 
MHz, D20 )  5 9.25 (s, 1H, HN-2), 8.96 (d, J6,s 5.3 Hz, 1H, HN-6), 8.85 (d, 74,5 5.9 Hz, 1H, 
Hn-4), 8.13 (dd, J5A5.9 Hz and 75.65.3 Hz, 1H, HN-5), 5.43 (s, 2H, CH2CO), 3.16 (m, 2H, 
CH2N), 1.40 (m, 2H, CH2), 1.20 (m, 2H, CH2) and 0.77 (m, 3H, CH3); m/z (FAB+) 237.0 
[(M)+, 100%]; HRMS Calcd. for [M]+ C,2H17N20 3+ (FAB+) 237.1234 found 237.1240; 
Calcd. for Ci2Hi7N20 3+.Br' C: 45.4; H: 5.40; N: 8.83 found C: 44.8; H: 5.24; N: 8.62.
7.21.3 3-Carboxyl-l-Phenylcarbam oylm ethyl-Pyridinium  (184)
Nicotinic acid (1.62 mmol) and 2-bromo-N-phenylacetamide (1.62 mmol) 
were reacted under the general protocol affording the desire compound as 
a white solid (454mg, 83%); mp: 148-149°C; IR (KBr) vmax 3393, 3277, 
3080, 3019, 1699,1637,1599,1558, 1498 cm '1; ]H NMR (D20 , 270 MHz) 
5 9.18 (s, 1H, Hn-2), 8.90 (d, J6JS 6.6 Hz, 1H, HN-6), 8.83 (d, / 4.5 5.4 Hz,
1H, Hn-4), 8.07 (dd, J5,66.6 Hz and J5A 5.4 Hz, 1H, HN-5), 7.25 (m, 5H, ArH) and 5.59 (s, 2H, 
CH2CO); 13C NMR (D20 , 100.5 MHz) 5 163.8, 163.5, 146.2, 138.9 (all C), 148.2, 147.9,
129.6,127.9,124.6, 119.8 (all CH) and 62.9 (CH2); m/z (FAB+) 257.1 [(M]+, 100%]; HRMS 
Calcd. for [M]+ C,4H 13N20 3+ (FAB+) 257. 0921 found 257.0933.
7.21.4 3-Carboxy-l-Cyclohexylcarbam oylm ethyl-Pyridinium  (185).
Nicotinic acid (1.62 mmol) and 2-bromo-N-cyclohexylacetamide (1.62 
mmol) were reacted under general protocol giving the title compound 185
214
as a white solid (521 mg, 94%); mp: 188-192°C. IR (KBr)vmax; 3244,3073,2931,1709,1679, 
1530 cm '1, !H NMR (D20 , 270 MHz) 8 9.32 (s, 1H, HN-2), 9.00 (d, 1H, A  s 5.2 Hz, HN-6),
8.84 (d, 1H, A s 4.5 Hz, HN-4), 8.23(dd, A ,  5.2 Hz, A ,4 4.5 Hz, 1H, HN-5), 5.50 (s, 1H, 
CH2CO), 3.65 (m, 1H, NCH) and 1.87-1.25 (m, 11H, ring-H); 13C NMR (D20 , 100.5 MHz) 
8 163.6,163.5,131.0 (all C), 149.7,148.0,146.4,128.3, 39.7 (all CH), 62.5, 33.1,26.0,25.2 
(all CH2); m/z (FAB+) 263.3 [(M)+, 100%]; Calcd. for Ci4H ]9N20 3 +.Br' C: 48.99 H: 5.58 N: 
8.16. Found C: 48.9 H: 5.46 N: 8.04.
7.21.5 3-Carboxy-l-[(4-ethyl-phenylcarbam oyl)-M ethyl]-Pyridinium  (186)
Nicotinic acid (1.62 mmol) and 2-bromo-4-ethyl-phenylacetamide 
(1.62 mmol) were reacted under general protocol (461 mg, 78%); 
mp: 210-214°C. IR (KBr) vmax 3424, 3243, 3190, 3063, 2962, 2930, 
1717, 1697, 1608, 1543 cm'1; *H NMR (D20 , 270 MHz) 8 9.29 (s, 
3.52, HN-2), 8.98 (d, A  8.7 H z,lH , HN-6), 8.91 (d, A  6.5 Hz, 1H, 
Hn-4), 8.14 (dd, A 6 8.7 Hz and J5A6.5 Hz, 1H, HN-5), 7.28 (d, J  8.1 Hz, 2H, ArH-2 and 
ArH-6), 7.18 (d, J  8.1 Hz, 2H, ArH-3 and ArH-5), 5.60 (s, 1H, CH2CO), 2.49 (q, J  7.7 Hz, 
2H, CH2) and 1.06 ( t , /7 .7  Hz, 3H, CH3); 13C NMR (D20 , 100.5 MHz) 8 163.6,163.4,140.0,
136.5,131.1 (all C); 149.9, 148.3,146.7,128.8, 128.4, 119.9 (all CH); 63.1, 28.5 (both CH2) 
and 16.5 (CH3); m/z (FAB+) 285.1 [(M)+, 100%]; HRMS Calcd. for [M]+ Ci6Hi7N20 3+ 
(FAB+) 285.1234 found 285.1239.
7.21.6 3-Carboxy-l -[(2-Bromo-PhenyIcarbamoyI)-M ethyI]-Pyridinium (187)
Nicotinic acid (1.62 mmol) and 2-bromo-A-(2-bromo-phenyl)-acetamide 
(1.62 mmol) were reacted giving desired compound as a white solid (544 
mg, 81%); mp: 216-218°C; IR (KBr)vmax 3177, 3055, 2743, 1727, 1687, 
1608, 1588,1477; ]H NMR (D20 , 270 MHz) 8 9.36 (s, 1H, HN-2), 9.04 (d, 
A s  8.1 Hz, 1H, Hn-6), 8.99 (d, A s5 .6  Hz, 1H, HN-4), 8.23 (dd, Aa8.1 Hz 
and A 45.6 Hz, 1H, HN-5), 7.68 (s, 1H, ArH-3), 7.31 (m, 3H, ArH-4, ArH-5 and ArH-6) and
5.70 (s, 2H, CH2CO), 13C NMR (DM S06, 100.5 MHz) 8 164.2, 163.5, 139.9, 131.1, 121.6 
(all C), 149.9, 148.3, 146.1, 131.5, 127.8, 126.7, 121.1, 116.0 (all CH) and 62.5 (CH2); m/z 
(FAB+) 335.1 [(M+H)+, 100%].
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7.21.7 3-Carboxy-l-D ibutylcarbam oylm ethyl-Pyridinium  (188)
Nicotinic acid (1.62 mmol) and 2-bromo-./V, N-dibutylacetamide (1.62 
mmol) were reacted under general protocol. The crude product was 
purified by flash chromatography, eluted with a gradient of 0-5% 
methanol against DCM to afford the title compound 188 as a yellow oil 
(483 mg, 80%). IR(KBr)vmax 2924, 2854, 1720, 1657, 1459; *H NMR (D20 ,  270 MHz) 
5 9.26 (s, 1H, H n -2), 9.10 (m, 1H, HN-6 ), 8.90 (m, 1H, HN-4), 8.24 (m, 1H, HN-5), 5.82 (s, 
2H, COCH2), 3.44 (m, 4H, 2CH2), 1.72 (m, 2H, CH2), 1.54 (m, 2H, CH2), 1.40 (m, 2H, CH2),
1.30 (m, 2H, CH2) and 0.92 (m, 6 H, 2 x CH3); 13C NMR (D20 , 100.5 MHz) 5 164.3, 163.6,
131.0 (all C), 149.9, 148.20, 146.5, 128.3 (all CH), 62.0, 47.3, 46.6, 30.9, 30.1, 20.5, 20.4 
(all CH2), 14.7 and 14.6 (both CH3); m/z (FAB+) 293.0 [(M)+, 100%]; HRMS Calcd. for 
[M]+ C 16H25N20 3+ (FAB+) 293.1860 found 293.1876.
7.21.8 3-Carboxy-l-[(3-M ethoxy-Benzylcarbamoyl)-M ethyl]-Pyridinium (189)
Nicotinic acid (1.62 mmol) and
2-bromo-(3-methoxy-benzyl)-acetamide (1.62 mmol) were reacted 
under the general protocol, giving desired compound 189 as a white 
solid (568 mg, 92%); mp: 194-196°C; IR (KBr)vmax 3217, 1722, 1675, 
1588, 1556, 1397; ]H NMR (D20 , 270 MHz) 6  9.33 (s, 1H, HN-2), 9.07 (d, 76.5 7.8 Hz, 1H, 
H n -6 ), 8.96 (d, J ^ 6 2  Hz, 1H, HN-4), 8.24 (dd, J5,61.S Hz and J5.4 6.2 Hz, 1H, HN-5), 7.37 
(m, 1H, ArH-2), 6.98 (m, 3H, ArH-4, H-5 and H-6 ), 5.62 (s, 2H, CH2CO), 4.47 (s, 2H, CH2N) 
and 3.84 (s, 3H, CH3); 13C NMR (D20 , 100.5 MHz) 6  164.2, 163.1, 158.3,139.3, 130.4 (all 
C), 148.9, 147.4, 145.9, 129.4, 127.7, 119.6, 113.2, 112.3 (all CH), 61.6,42.6 (both CH2);
55.0 (CH3); m/z (FAB+) 301.0 [(M)+, 100%]; HRMS Calcd. for [M]+ C 16Hi7N20 4+ (FAB+) 
301.1183 found 301.1200.
7.21.9 3-Carboxy-l-D ipropylcarbam oylm ethyl-Pyridinium  (190)
Nicotinic acid (1.62 mmol) and 2-bromo-A,A-dipropylacetamide (1.62 
mmol) were reacted under general protocol giving the title compound 190 
as a yellow oil (252 mg, 45%); IR (KBr)vmax 3392, 2964, 2875, 1729,
1649; ]H NMR (D20 , 270 MHz) 8  9.23 (s, 1H, HN-2), 9.04 (d, J6,5 8 .1 Hz,
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1H, H n - 6 ) ,  8.87 (d, 74,5 5.1 Hz, 1H, HN-4), 8.20 (dd, J 5.6 8 .I Hz and 7 5.4 5.1 Hz, 1H, HN-5), 
5.80 (s, 2H, CH2CO), 3.34 (m, 4H, 2CH2), 1.71 (m, 2H, CH2), 1.54 (m, 2H, CH2), 0.92 (t, J  
1A  Hz, CH3) and 0.82 (t, J 1 A  Hz, CH3); 13C NMR (D20 , 100.5 MHz) 6  164.7,164.6, 132.1 
(all C), 148.6,147.4,146.8,128.1 (all CH), 62.1,49.4,48.9,21.41, 20.38 (all CH2), 10.9 and
10.8 (both CH3); m/z (FAB+) 266.3 [(M+H)+, 100%]; HRMS Calcd. for [M]+ C l4H2]N20 3+ 
(FAB+) 265.1547 found 265.1556.
7.21.10 3-Carboxy-l-Decylcarbamoylmethyl-Pyridinium  (191)
Nicotinic acid (1.62 mmol) and 2-bromo-A-decylacetamide (1.62 
mmol) were reacted under general protocol to give the desired 
compound as a white solid (625 mg, 96%); mp: 185-186°C; IR 
(KBr)vmax 3229, 3079, 2924, 1726, 1679; ]H NMR (DMSO, 270 
MHz) 8  9.53 (s, 1H, HN-2), 9.19 (d, J6,5 8.1 Hz, 1H, HN-6 ), 9.03 (d, 74,54.6 Hz, 1H, HN-4),
8.70 (brs, 1H, NH), 8.31 (m, 1H, HN-5), 5.57 (s, 2H, CH2CO), 3.13 (m, 2H, CH2N), 
1.24-1.61 (m, 16H, 8 CH2) and 0.83 (m, 3H, CH3); 13C NMR (DMSO, 100.5 MHz) 8  164.5,
163.6, 131.1 (all C), 149.7, 148.0, 146.4, 128.3 (all CH), 62.4, 32.2, 29.9, 29.7, 29.7, 29.6,
27.3, 23.0 (all CH2) and 14.9 (CH3); HRMS Calcd. for [M]+ Ci8H29N 20 3 (FAB+) 321.2173 
found 321.2166; Calcd. for C 18H29N20 3+.Br C: 53.87 H: 7.28 N: 6.98 found C: 54.00 H:
7.30 N: 6.99.
+<2N
7.21.11 l-[(2-Bromo-phenylcarbamoyl)-M ethyl]-3-M ethoxycarbonyl-Pyridinium (192)
O Nicotinic acid methyl ester (1.62 mmol) and
'O '' 2-bromo-AL(2-bromo-phenyl)-acetamide were reacted under the general 
H protocol giving the desired compound as a white solid (481 mg, 69%); mp:
Y j  171-172°C; IR (KBr)vmax 3225, 3173, 3057, 3015, 1743,1687, 1596, 1549; 
JH NMR (DMSO, 270 MHz) 8  10.97 (s, brs, 1H, NH), 9.68 (s, 1H, HN-2),
9.26 (d, / 6,5 6.2 Hz, 1H, HN-6 ), 9.11 (d, J4,s 8 .1 Hz, 1H, HN-4), 8.38 (dd, J5A 8 .1 Hz and J5.6
6.2 Hz, 1H, Hn-5), 7.92 (brs, 1H, ArH), 7.32-7.50 (m, 3H, ArH), 5.78 (s, 2H, CH2CO) and
3.99 (s, 3H, CH3); ,3C NMR (DMSO, 100.5 MHz) 8  164.1, 162.6, 140.3, 131.7, 129.8 (all 
C), 150.4, 148.1, 146.6, 128.5, 127.3, 122.3, 122.2, 118.7 (all CH), 63.2 (CH2) and 54.4 
(CH3); m/z (FAB+) 349.0, 351.0 [(M+H)+, 100%]; HRMS Calcd. for C i5H]479BrN20 3+
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(FAB+) 349.0188 found 349.0181.
7.21.12 3-Brom o-5-Carboxy-l-Decylcarbam oylm ethyl-Pyridinium  (193)
O 5-Bromo-nicotinic acid (1.62 mmol) and
BrY V ^ ° H 2-bromo-N-decylacetamide (1.62 mmol) were reacted under
H 
,N
N }_| the general protocol affording the desired compound 193 as a
white solid (631 mg, 81%); mp: 118-120°C. H NMR (DMSO, 
O
270 MHz) 6 9.58 (s, 1H, HN-2), 9.53 (s, 1H, HN-6), 9.19 (s, 
1H, H n - 4 ) ,  8.56 (brs, 1H, NH), 5.45 (s, 2H, CH2CO), 3.09 (m , 2H, CH2N), 1.42-1.23 (m , 
16H, 8CH2) and 0.83 (m, 3H, CH3); 13C NMR (DMSO, 100.5 MHz) 6 164.0, 162.7, 146.9,
131.8 (all C), 150.6,148.6,121.8 (all CH), 62.2,34.7,31.8, 31.2,29.5,29.5,29.3,29.2,26.8,
22.6 (all CH2) and 14.5 (CH3); HRMS Calcd. for [M]+ C18H2879BrN20 3+ (FAB+) 399.1283 
found 399.1290; Calcd. for [M]+ Ci8H2881BrN20 3+ 401.1263 found 401.1274.
7.21.13 3-Carboxy-l-O ctylcarbam oylm ethyl-Pyridinium  (194)
Nicotinic acid (1.62 mmol) and 2-bromo-J/V-octylacetamide (1.62
OH
mmol) were reacted under the general protocol giving desired 
compound 194 as a white solid. Purification using flash column 
O chromatography, eluted with a gradient of 0-10% MeOH against
DCM gave the title compound as a white solid (507 mg, 84%). The title compound was 
further purified by crystallisation in MeOH/acetone giving BZ194 as a needle like 
crystalline; mp: 195-197°C; 'H  NMR (DMSO, 270 MHz) 8 9.45 (s, 1H, HN-2), 9.07 (s, Je<5
5.9 Hz, 1H, H n - 6 ) ,  8.94 (s,74.5 8.2 Hz, 1H, HN-4),8.51 (m, 1H, NH), 8.22 (dd, / 5.4 8.2 Hz and 
/ 5.65.9 Hz, 1H, H-5), 5.45 (s, 2H, CH2CO), 3.03 (m, 2H, CH2), 1.39-1.18 (m, 12H, 6CH2) 
and 0.78 (m, 3H, CH3); 13C NMR (DMSO, 100.5 MHz) 8 164.4, 163.5, 130.9 (all C), 149.7, 
147.9, 146.4,128.1 (all CH), 62.1,31.7,29.3,29.2,29.1, 26.8, 22.6 (all CH2) and 14.5 (CH3); 
HRMS (FAB+) Calcd. for [M]+ C ,6H25N20 3+ 293.1860 found 293.1870; Calcd. for 
C 16H25N20 3 C 51.48, H 6.75, N 7.50; found C 51.10, H 6.76, N 7.33.
N
7.21.14 3-Carboxy-l-H eptylcarbam oylm ethyl-Pyridinium  (195)
Nicotinic acid (1.62 mmol) and 2-bromo-jV-heptylacetamide
OH
(1.62 mmol) were reacted under the general protocol,
N H
producing desired compound 195 as a white solid. The compound was further purified by 
crystallisation in MeOH/acetone, give pure 195 as a colourless crystalline (366 mg, 63%); 
mp: 182-184°C; JH NMR (D20 , 270 MHz) 5 9.30 (s, 1H, HN-2), 9.04 (d, J6.5 8.1 Hz, 1H, 
H n-6 ) , 8.92 (d , J4,57.2 Hz, 1H, HN-4), 8.20 (dd, J5A1 2  Hz a n d 7 5.6 8.1 Hz, 1H, HN-5),5.49 (s, 
2H, CH2CO), 3.22 (m, 2H, CH2N), 1.49 (m, 2H, CH2), 1.23 (m, 8H, 4CH2), 0.79 (m, 3H, 
CH3); 13C NMR (D20 ,  67.5 MHz) 5 164.5, 163.6 132.0 (all C), 148.3, 147.2, 146.9, 128.2 
(all CH), 62.1, 40.1, 31.1, 28.2, 28.1, 26.0, 22.1 (all CH2) and 13.5 (CH3); Calcd for 
Ci5H23BrN20 3 C 50.15, H 6.45, N 7.80; found C 50.1, H 6.39, N 7.76.
7.21.15 3-Carboxy-l-H exylcarbam oylm ethyl-Pyridinium  (196)
Nicotinic acid (1.62 mmol) and 2-bromo-/V-hexylacetamide (1.62 
mmol) were reacted under the general protocol, giving crude 
product 196 as a white solid. 196 was further purified by 
crystallisation in MeOH/acetone, producing pure 196 as a 
colourless crystalline (319 mg, 57%); mp: 177-179°C; NMR 
(D20 , 270 M H z )  6  9.30 ( s , 1H, H n -2 ), 9.04 (d,76,5 8.1 Hz, 1H, HN-6), 8.92(d,74.5 6.2Hz, 1H, 
H n -4 ) , 8.20 (d d , J5A 6.2 Hz and / 5.6 8.1 Hz, 1H, HN-5), 5.49 (s, 2H, CH2CO), 3.22 (m, 2H, 
CH2N), 1.49 (m, 2H, CH2), 1.24 (m, 6H, 3CH2), 0.80 (CH3); 13C NMR (D20 , 67.5 MHz) 6
164.5, 163.6, 132.8 (all C), 148.2,147.1, 146.8, 128.2 (all CH), 62.1, 40.1, 30.7, 28.2, 25.8,
22.0 (all CH2) and 13.4 (CH3); Calcd for C ,4H21BrN20 3 C 48.71, H 6.13, N 8.11; found C 
48.6, H 6.12, N 8.07.
7.22 3-C arbam oyl-l- (2,4-Dinitro-Phenyl)-Pyridinium  (Zincke Salt, 197).
A mixture of nicotinamide (0.5 g, 4.0 mmol) and 2,4-dinitrochlorobenzene 
(2.5 g, 12.0 mmol) was heated at 90°C for 2 h, after which the resulting 
orange gum was cooled down to rt and was dissolved in methanol (2 mL). 
Ether (40 mL) was added and the precipitate obtained was filtered and 
N02 redissolved in methanol (2 mL). The procedure was repeated four times and
the final precipitate was collected and dried to produce the Zincke salt as an orange foam 
(879 mg, 71%). IR (KBr) 1690, 1616, 1543 cm’1; ]H NMR (D20 , 270 MHz) 6 9.62 (s, 
1H, H n-2 ) , 9.35 (d, J3,5 2.7 Hz, 1H, ArH3), 9.29 (d , J 6.5 6.5 Hz, 1H, HN-6), 9.22 (d, J4,5 8.4 Hz,
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1H, H n - 4 ) ,  8 .8 8  (dd, 75,6 8.5 Hz and 75,3 2.7 Hz, 1H, ArH5), 8.43 (dd, 75,4 8.4 Hz and75.6 6.5 
Hz, 1H, H n - 5 ) ,  8.30 (d,76„5 8.5 Hz, 1H, ArH6 ); 13CNM R (D20 , 100.4 MHz) 5 165.0, 150.0,
147.7, 147.5, 145.8,142.9,138.5,134.2, 131.4,131.0,128.9,122.9; m/z (FAB+) 289.0 [(M)+, 
1 0 0 %], 273.0 [(M-NH2)+, 15%].
7.23 G eneral Procedure for the Zincke Reaction
To a solution of Zincke salt (270 mg, 0.83 mmol) in dry methanol (20 mL) was added the 
amines (0.80 mmol) under a nitrogen atmosphere. The resulting dark red solution was stirred 
at rt. for 5 h, after which the solvent was removed and the red residue was purified by flash 
column chromatography or by crystallisation (methanol/ether) as specified.
7.23.1 l-Butyl-3-Carbam oyl-Pyridinium  (198)
The Zincke salt (0.83 mmol) and n-butylamine (0.80 mmol) were reacted 
NH2 under the general protocol. Crystallisation from methanol/ether gave the 
title compound as a yellow solid (150 mg, 80%); mp: 205-207°C; IR (KBr) 
Vmax 1669, 1648; ]H NMR (D20 , 270 MHz) 8  9.30 (s, 1H, HN-2), 9.00 (d, 
/ 6,5 8.1 Hz, 1H, Hn-6 ), 8.87 (d, J4 5 8.2 Hz, 1H, HN-4), 8.17 (dd, J5A 8.2 Hz 
and 75,6 8.1 Hz, 1H, HN-5), 4.66 (m, 2H, CH2), 2.01 (m, 2H, CH2), 1.38 (m, 2H, CH2) and 
0.93 (m, 3H, CH3); m/z (FAB+) 179.0 [(M)+, 100%]; HRMS Calcd. for [M]+Ci0H i5N2O+ 
(FAB+) 179.1179 found 179.1179.
7.23.2 3-Carbam oyI-l-Cyclohexyl-Pyridinium  (199)
The Zincke salt (0.83 mmol) and cyclohexylamine (0.80 mmol) were 
reacted under the general protocol. Crystallisation from methanol and ether 
gave the title compound as a yellow solid (120 mg, 63%); mp: 275-276°C; 
IR ( K B r ) v max 3278, 3137, 2857, 1695; lH NMR (D20 , 270 MHz) 8  9.12 (s, 
1H, Hn-2), 8.95 (d, y6,5 8.1 Hz, 1H, HN-6 ), 8.77 (d, 74.5 8.2 Hz, 1H, HN-4),
8.01 (dd, 75,4 8.2 Hz and 75.6 8.1 Hz, 1H, HN-5) and 1.13-2.05 (m, 11H, ring-H); 13C NMR 
(D20 , 100.5 MHz) 8  163.3,134.5 (both C), 145.6, 144.6, 143.9, 128.7, 72.03 (all CH), 33.1,
25.8 and 24.9 (CH2); m/z (FAB+) 205.0 [(M)+, 100%]; HRMS Calcd. for [M]+C i2H i7N20  
(FAB+) 205.1335 found 205.1339.
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7.23.3 3-Carboxy-l-Phenyl-Pyridinium  (200)
O The Zincke salt (0.83 mmol) and aniline (0.80 mmol) were reacted under the 
NH2 general protocol. Purification on flash chromatography (DCM-methanol 5:2)
N gave the title compound as a yellow solid (132 mg, 71%). Analytical data
was obtained by crystallisation from methanol and ether; mp: 235-237°C; 
IR (KBr) vmax 3370, 3140, 1687 cm '1; *H NMR (D20 , 270 MHz) 6 9.55 (s, 
1H, H n -2), 9.27 (d ,J 6,55.5 Hz, 1H, HN-6), 9.06 ( d , /4,58.1 Hz, 1H, HN-4), 8.34 (dd,75,4 8.1 
Hz and J5,65.5 Hz, 1H, HN-5) and 7.75 (s, 5H, ArH); 13C NMR (D20 , 100.5 MHz) 5 165.7,
142.5, 134.0 (all C), 146.7,144.9, 144.5, 132.0,130.7,128.5 and 124.2 (all CH); m/z (FAB+)
199.1 [(M)+, 100%]; HRMS Calcd. for [M]+ Ci2HnN20 + (FAB+) 199.0866 found 199.0871.
7.23.4 3-Carbam oyl-l-D ecyl-Pyridinium  (201)
0  The Zincke salt (1.23 mmol) and n-decylamine (1.48 mmol) were reacted
under the general protocol. The crude product was purified by column 
chromatography (DCM: methanol 5:1) to yield the desired product as a 
yellow oil (200 mg, 53%); IR (KBr)vmax 3257, 3075, 2920, 2852, 1703 
cm '1; *H NMR (D20 , 270 MHz) 6 9.29 (s, 1H, HN-2), 9.00 (d, J6.5 6.0 Hz, 
1H, H n-6), 8.88 (d, 74.5 8.3 Hz, 1H, H-4), 8.17 (dd, 75,4 8.3 Hz and 7 5.6 6.0 Hz, 1H, HN-5), 
4.78 (m, 2H, CH2N), 2.05 (m, 2H, CH2), 1.23 (m, 14H, 7 x CH2) and 0.83 (m, 3H, CH3); 13C 
NMR (D20 , 100.5 MHz) 6 165.3, 134.0 (both C), 146.6, 144.3, 144.0, 128.7 (all CH), 62.8,
31.8, 31.2, 29.3, 29.2, 29.2, 28.9, 25.8, 22.6 (all CH2), 14.0 (CH3); m/z (FAB+) 263.0 [(M)+, 
100%]; HRMS calcd. for [M]+ C i6H27N20 + (FAB+) 263.2118 found 263.2126.
7.23.53-Carbam oyl-l-(2-Hydroxy-l-Hydroxym ethyl-2-Phenyl-Ethyl)Pyridinium (202)
O The Zincke salt (1.23 mmol) and 2-amino-1-phenyl-propane 1,3-diol 
NH2 (1.48 mmol) were reacted under the general protocol. The crude product 
was purified by flash column chromatography, eluted with 
DCM-methanol 5:1 to give the title compound as a yellow oil (385 mg, 
100%); IR (KBr) vmax 3350, 3158, 1702, 1646, 1448, 1401 cm '1; ]H 
NMR (D20 , 270 MHz) 6 9.27 (s, 1H, HN-2), 9.04 (d, J 6,5 6.2 Hz, 1H, 
H n -6), 8.94 (d, J4<5 8.4 Hz, 1H, HN-4), 8.18 (dd, J5A 8.4 Hz and J5,66.2 Hz, 1H, HN-5), 7.35
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(m, 5H, ArH), 5.45 (m, 1H, CHN) and 5.12 (m, 1H, CHOH), 4.14 (m, 2H, CH2OH); 13C 
NMR (D20 , 100.5 MHz) 5 165.7, 138.3, 133.7 (all C), 146.4, 144.9, 144.1, 129.2, 128.2,
126.1, 79.5, 71.7 (all CH) and 60.3 (CH2) m/z (FAB+) 273.1 [(M)+, 98%]; HRMS calcd. for 
[M]+ C 15H]7N20 3 + (FAB+) 273.1234 found 273.1238.
7.23.6 3-Carboxy-l- (2-Hydroxy-l-Hydroxym ethyl-2-Phenyl-ethyI)-Pyridinium  (203) 
Compound 202 (200 mg, 0.65 mmol) was dissolved in concentrated 
HC1 (3 mL) and was heated to reflux for 2 h and then kept at rt overnight. 
The solvent was evaporated in vacuo and the resulting residue was 
crystallised from acetone to give the title compound as a yellow solid 
(160 mg, 80%); HPLC: single peak at 7.45min; IR (KBr)vmax 1731, 
1636, 1402, 1298, 1173 cm '1; *H NMR (D20 , 270 MHz) 6 9.27 (s, 1H, HN-2), 9.02 (m, 2H, 
H n-6 and HN-4), 8.16 (m, 1H, HN-5), 7.38 (m, 5H, ArH), 5.48 (m, 1H, CHN), 5.12 (m, 1H, 
CHOH) and 4.12 (m, 2H, CH2OH); 13C NMR (D20 , 100.5 MHz) 8 CO not visible, 146.6,
146.5,145.3,138.3,129.2 (2ArCH), 128.1,126.1 (2ArCH), 79.2,71.6 and 60.3; m/z (FAB+)
274.3 [(M)+, 98%]. HRMS calcd. for C ,5H 16N 0 4+ (FAB+) 274.1074 found 274.1077.
7.24 Synthesis of CMA008 Analogues by Zincke route
7.24.1 Zincke Salt (Acid Form ) (204)
A solution of Zincke salt (200 mg, 0.62 mmol) in concentrated HC1 (3 mL, 
37%) was heated at reflux for 2 h and kept at rt overnight. The solvent was 
evaporated in vacuo and the residue was precipitated in acetone to give the 
desired compound 204 as a yellow solid (159 mg, 79%); !H NMR (D20 , 270 
MHz) 8 9.60 (s, 1H, HN-2), 9.24 (d, Jx5 1.6 Hz, 1H, ArH-3), 9.22 (m, 2H, 
H n-6 and HN-4), 8.81 (dd, / 5,6 5.9 Hz and J5,3 1.6 H z ,, 1H, ArH-5), 8.34 (m, 1H, HN-5) and
8.14 (d, 76,s5.9 Hz, 1H, ArH-6); 13C NMR (D20 , 67.5 MHz) 8 164.4, 149.7, 149.0, 147.7,
146.8, 142.8, 138.3, 133.1, 131.2, 130.7, 128.6 and 122.7; m/z 290.1 [(M)+, 100%]; HRMS 
Calcd. for [M]+ Ci2H8N30 6+ (FAB+) 290.0408 found 290.0404.
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7.24.2 2-(l,3-Dioxoisoindolin-2-yl)-/V-Phenylacetamide (205)
To a suspension of potassium phthalimide (200 mg, 1.03 mmol) in 
DMF (2 mL) was added 2-bromo-iV-phenylamide (160 mg, 0.72 
mmol). The mixture was heat at 80°C until TLC suggested that the 
starting material was consumed and a new spot was given (Rf 0.71, 
EtOAc-MeOH-H20  10: 2: 1). DMF was removed in vacuum and the crude product was 
re-dissolved in water (5 mL), extracted with DCM (20 mL) and then concentrated to dryness. 
Crystallisation in ethyl acetate-hexane 1:1 gave the analytical sample (237 mg, 82%). ’H 
NMR (CD3CN, 400 MHz) 8 10.36 (s, 1H, NH), 7.90 (m, 4H, ArH), 7.57 (m, 2H, ArH-2 and 
ArH-6), 7.33 (m, 2H, ArH-3 and ArH-5), 7.08 (m, 1H, ArH-4) and 4.45 (s, 2H, CH2N); 13C 
NMR (CD3CN, 100.5 MHz) 8 168.1 (2 x CO), 165.3, 139.0, 135.2 (2 x CH), 134.8, 132.1,
129.3 (2 x CH), 124.1, 123.8 (2 x CH), 119.7 (2 x C) and 41.2; m/z (FAB+) 281.2 [(M +H )\ 
100%].
7.24.3 2-(l,3-E)ioxoisoindolin)-A,A-Dipropylacetamide (206)
To a suspension of potassium phthalimide (200 mg, 1.03 mmol) in 
DMF (2 mL) was added 2-bromo-A^, iV-dipropylacetamide (163 
mg, 0.74 mmol). The resulting mixture was heated at 80 °C for 
2.5h. TLC showed that all starting material was consumed and a 
more polar product was given (Rf 0.15 DCM- Hexane 10:1). After 
removal of DMF, the crude product was dissolved in water (5 mL) and extracted by DCM 
(20 mL). DCM was removed under reduced pressure and the residue was used in next step 
without further purification. Analytical sample was given by crystallisation in ethyl 
acetate-hexane 1:1 and the title compound was produced as a white solid (171 mg, 80%); *H 
NMR (CD3CN, 400 MHz) 8 7.79 (m, 4H, ArH), 4.43 (s, 2H, CH2N), 3.24 (m, 4H, 2 x CH2), 
1.67 (m, 2H, CH2), 1.49 (m, 2H, CH2), 0.95 (m, 3H, CH3) and 0.82 (m, 3H, CH3); 13C NMR 
(CD3CN, 100.5 MHz) 8 168.9 (2 x CO), 166.2, 135.3 (2 x CH), 124.0 (2 x CH), 118.3 (2 x 
C), 49.2,48.3, 40.1, 22.7, 21.5,11.5 and 11.3; m/z (FAB+) 289.2 [(M+H)+, 100%].
7.24.4 2-Amino-A-Phenylacetamide (207)
^ N/ ~sY N'T / ^ ]  3 S0*Ut'° n 2-(L3-dioxoisoindolin-2-yl)-iV-phenylacetamide (100
o  Kjp  223
mg, 0.36 mmol) in ethanol (10 mL) was added a solution of hydrazine in ethanol (1M, 0.8 
mL, 0.8 mmol). The reaction solution was heated at reflux for 3 h. After cooling down, 
ethanol was removed in vacuum and aqueous HC1 solution (4 mL, 10% v/v) was added to the 
residue (part of the residue dissolved). The suspension was heated at40°C for 5 min and the 
resulting solution was cooled to rt The aqueous solution was extracted with ethyl acetate (3 x 
10 mL) and the pH of the solution was adjusted to 12-14 by addition of a solution of NaOH 
(saturate). The aqueous phase was again extracted by ethyl acetate ( 3 x 1 0  mL) and the 
organic layers were combined and evaporated in vacuo. Title compound was given as a 
white solid (35 mg, 65%). NMR (CD6CO, 270 MHz) 6 9.70 (s, br, NH), 7.70 (m, 2H, 
ArH-2, 6), 7.31 (m, 2H, ArH-3, 5), 7.06 (m, 1H, ArH-4), 3.81 (s, 2H, CH2N) and 2.87 (brs, 
2H, NH2).
7.24.5 P reparation  of Compound 184 by Zincke Reaction
To a solution of 2-amino-Ar-phenylacetamide 205 (84 mg, 0.56 mmol) in dry methanol (10 
mL) was added Zincke salt (acid form) (132 mg, 0.46 mmol). The reaction mixture was 
stirred at rt. for 5 h and the solvent was removed in vacuo. The crude product was purified by 
flash column chromatography, eluted with DCM-methanol 5:1 then with 100% methanol. 
After removal of the solvent, title compound was given as an orange colored solid (yield not 
given, containing silica gel). Proton NMR and IR confirmed that the product was identical to 
compound 184; IR (KBr) vmax 1691, 1641, 1610, 1557, 1497 cm'1; JH NMR (CDC13, 270 
MHz) 6 9.09 (s, 1H, HN-2), 8.84 (m, 2H, HN-6 and HN-4), 8.09 (m, 1H, HN-5), 7.38 (m, 4H, 
ArH-2, ArH-3, ArH-5 and ArH-6), 7.19 (m, 1H, ArH-4) and 5.62 (s, 2H, CH2CO); m/z 
(FAB+) 257.2 [(M+H)+, 98%].
7.25 Synthesis of 5-Modifed Pyridinium salt.
7.25.1 5-Bromo-Nicotinic Acid Methyl E ster (209)
To a suspension of 5-bromo-nicotinic acid (300 mg, 1.5 mmol) in
methanol (6 mL) was added concentrated H2SC>4 (1.1 mL). The reaction
mixture was heated at reflux for overnight, after which the solution was
cooled to rt. and an aqueous solution of N aH C 03 (saturated, 5 mL) was added to adjust the
pH to 7-8. The aqueous solution was extracted with DCM (20 mL) and the solvent was
224
removed to give the title compound 209 as white solid (262 mg, 81%). IR (KBr) vmax 3450, 
3047, 1722, 1577; *H NMR (CDCI3, 270 MHz) 5 9.12 (s, 1H, HN-2), 8.85 (m, 1H, HN-6 ), 
8.44 (m, 1H, Hn-4) and 3.99 (s, 3H, CH3); 13C NMR (CDCI3, 100.4 MHz) 5 164.4, 127.4,
120.7 (all C), 154.4, 148.8, 139.6 (all CH), and 53.0 (CH3); m/z (FAB+) 216.2 [(M+H)+, 
100%).
7.25.2 5-(4-Methoxy-Phenyl)-Nicotinic Acid Methyl E ster (210)
To a solution of 5-bromo-nicotinic acid methyl ester 207 (153 
mg, 0.70 mmol) in toluene (1.4 mL) and aqueous Na2C0 3 (2 M,
0.70 mL) was added Pd(PPh3)4 (24 mg) under a nitrogen 
atmosphere. A solution of p-methoxyphenylboronic acid (127.6 mg, 1.05 mmol) in 
methanol (0.35 mL) was then added. The reaction mixture was vigorously stirred and heated 
at 80°C for 6  h. After cooling to rt, the crude product was partitioned between DCM (7 mL) 
and aqueous Na2C0 3 (2 M, 3.5 mL + 0.35 mL NH3). The organic layer was collected, 
evaporated in vacuo and the resulting light yellow crude product was purified by flash 
column chromatography, eluted with DCM to afford the title compound 210 as a white solid 
(70 mg, 41%). IR (KBr) vmax 3036, 2956, 2844, 1716, 1609, 1518, 1443; lH NMR (CDC13, 
270 MHz) 5 9.13 (d, J2,6 1.9 Hz, 1H, HN-2), 8.95 (brs, 1H, HN-6 ), 8.43 (brs, 1H, HN-4), 7.55 
(d, J  5.4 Hz, 2H, ArH-2 and ArH-6 ), 7.03 (d, J  5.4 Hz, 2H, ArH-3 and ArH-5), 3.97 (s, 3H, 
CH3) and 3.86 (s, 3H, CH3); m/z (FAB+) 244.3 [(M+H)+. 100%].
7.25.3 3-Carboxy-l-Cyclohexylcarbam oylm ethyl-5-(4-M ethoxy-Phenyl)-Pyridinium
To a mixture of compound 210 (50 mg, 0.20 mmol) and 
2-Bromo-A-cyclohexyl-acetamide (115 mg, 0.52 mmol) was 
added DMF (1 mL) under a nitrogen atmosphere. The 
resulting solution was heated at 60°C overnight. After 
removal of the solvent, the residual was dissolved in 
methanol (0.5 mL) and ether (20 mL) was added. The resulting precipitate was filtered and 
dried in vacuo to give the title compound 211 as a yellow oil (40 mg, 52%); IR (KBr) vmax 
3436, 2929,1738, 1652,1557, 1450; *H NMR (CDCI3, 270 MHz) 5 9.66 (s, 1H, HN-2), 9.46
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(m , 1H, H n-6 ) , 9.15 (m , 1H, H N-4 ), 8.62 (m , 1H, NH), 7.93 (m , 2H, ArH-2 and ArH-6 ), 7.16 
(m, 2H, ArH-3 and ArH-5), 5.58 (s, 2H, CH2CO), 4.01 (s, 3H, CH3), 3.85 (s, 3H, CH3CO) 
and 1.79-1.22 (m, 11H, ring-H).
7.26 Modeling Study of 2-F-NAD+
The compounds minimised using DFT (Density Functional Theory) method using the 
6-31G** basis set as implemented in the CAChe software package from Fujitsu (CAChe 
Version 4.4 2000 Fujitsu Limited). As a part of the calculation the electron density surface 
was calculated this was then displayed on the final minimised geometry of the molecule. 
This work was carried out by Dr Andrew Smith in the Department of Pharmacy and 
Pharmacology, University of Bath.
7.27 Enzymology of 2-F-NAD+
The Enzymology studies of 2-F NAD+ were carried out by Professor Francis Schuber and Dr 
Helene Muller-Steffner (Universite Louis Pasteur (Strasbourg I), Departement de Chimie 
Bioorganique, Faculte de Pharmacie, France).
7.27.1 Enzyme Kinetics
The ADP-ribosyl cyclase-catalysed transformation of 2-fluoro-NAD+ was measured by 
incubation at 37°C in a 10 mM  potassium phosphate buffer, pH 7.4 (200 pL final volume) in 
the presence of the substrate (5 to 500 pM) and purified enzyme (15 mU). At selected times, 
aliquots (50 pL) were removed and the reaction was stopped by addition of ice-cold 
perchloric acid (2% final concentration). After neutralisation with 3.5 M K2CO3, the 
precipitated proteins were removed by centrifugation. Product formation was analyzed by 
HPLC. Kinetic parameters were determined from the plot o f the initial rates as a function of 
substrate concentrations (8  data points) using a non-linear regression program (GraphPad 
Prism).
7.27.2 Reaction Product of Treatment with Nucleotide Pyrophosphatase
The product obtained by ADP-ribosyl cyclase-catalysed transformation of 2-fluoro-NAD+
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was further incubated at 37°C for 10 min in the presence of nucleotide pyrophosphatase (= 
50 mU) and analysed by HPLC.
7.27.3 M ethanolysis of 2-F-NAD+
2-F-NAD+ (200 and 300 fiM) was incubated at 37°C in a 10 mM potassium phosphate buffer, 
pH 7.4 (200 pL final volume) in the presence of methanol (2M and 3M) and 15 mU of highly 
purified Aplysia  cyclase. At different time points, aliquots were analysed by HPLC.
7.28 Test of cADPR Analogues in Permeabilised T-Cells.
The in vitro studies o f cADPR analogues were carried out by Professor Andreas Guse et al in 
in the University Medical Centre Hamburg-Eppendorf, Germany.
7.28.1 Cell Culture.
229Jurkat T-lymphocytes (clone JMP) were cultured as described earlier. In brief, cells were 
cultured in RPM I 1640 supplemented with Glutamax I, 25 mM HEPES, 100 units/ml 
penicillin, 50 |ig/m l streptomycin, and 7.5% (v/v) newborn calf serum.
7.28.2 Determination of [Ca2+]i in Permeabilised Cells.
Jurkat T cells were permeabilised by saponin and experiments were done as described in an 
earlier report.230 Briefly, cells were incubated with saponin in an intracellular buffer (20 mM  
HEPES, 110 mM KC1, 2 mM MgCL, 5 mM KH2PO4, 10 mM NaCl, pH 7.2) in the absence 
of extracellular Ca2+. Then, saponin was removed by repeated wash procedures, and the cells 
were finally resuspended in intracellular buffer. Then, the cells were kept on ice for 2 h to 
allow for re-sealing o f intracellular stores. At the start of each individual experiment the 
stores of permeabilised cells were re-loaded with Ca2+ upon addition of ATP and an 
ATP-regenerating system consisting of creatine phosphate and creatine kinase229 [Ca2+] was 
determined fluorimetrically by fura2/free acid added to the suspension. Changes in fura2 
fluorescence were measured using a Hitachi F-2000 spectrofluorometer (alternating 
excitation at 340 and 380, emission 495 nm). W hen the Ca2+ stores were re-filled, test 
compounds were added. Usually, the quality of the permeabilised cell preparation was
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controlled by its responsiveness to InsP .3 and cADPR on each day. Each experiment was 
calibrated using excess CaCh and EGTA/Tris to obtain the maximal and minimal fura2 
ratios.
7.29 Test of cADPR Analogues in Sea Urchin Eggs.
This work was carried out by Professor Antony Galione, Dr Clive Gamham and D r Antony 
Morgan in the University Department of Pharmacology, Oxford.
7.29.1 Test o f cADPR Analogues in Sea Urchin Egg Homogenates.
Sea urchin eggs from Lytechinus pictus (Marinus, Long Beach, CA) were obtained by 
intracoelomic injection of 0.5 M KC1, shed into artificial seawater (in mM, NaCl 435, 
MgC12 40, M gS04 15, CaC12 11, KC110, N aH C03 2.5, EDTA 1, and [pH 8 ]), dejellied by
passing through 90 im nylon mesh, and then washed twice by centrifugation. Homogenates
21of sea urchin eggs were prepared as described. Briefly, eggs were disrupted in an 
intracellular-like medium consisting of 250 mM potassium gluconate, 250 mM 
A-methylglucamine, 20 mM HEPES, and 1 mM MgCU, [pH 7.2] supplemented with 1 mM 
ATP, 10 U/m L creatine kinase, and 10 mM phosphocreatine and protease inhibitors. Ca2+ 
concentrations were measured with fluo-3 (3 zM) at 17°C, using 500 zL of continuously 
stirred homogenate in a fluorimeter (Perkin-Elmer LS-50B) at 506 nm excitation and 526 
nm emission.
7.29.2 Test o f cADPR analogues in intact sea urchin eggs.
To the intact sea urchin eggs microinjected with Ca2+ dye rhod dextran (-10  pM  final) was 
added 2'-deoxy-8-bromo-cADPR 100 pM  and 400 pM. The Ca2+ response was monitored at 
excitation (543 nm), emission (>560nm) on a Zeiss LSM510 confocal.
7.30 In vitro and in vivo test of BZ compounds.
The in vitro  and in vivo studies of BZ compounds were carried out by Professor Adreas Guse, 
Professor Alexander Fliigel, Chiara Cordiglieri and W emer Dammermann.
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7.30.1 Calcium Imaging and Microinjection in vitro.
[C a2+]i in was determined in individual Jurkat T cells as described 223. In co-injection 
experiments BZ52 dissolved in DM SO was mixed with NAADP stock solution. Control 
injections were carried out using the appropriate vehicle concentration.
Calcium imaging using Fura2-loaded cells and an Improvision system (Tubingen, Germany) 
was carried out exactly as described 223.
7.30.2 Calcium Determination in T Cell Suspensions
r \ .
[Ca ]j was determined in Fura2-loaded rat T m b p  cells in a Hitachi F-2000 fluorometer. Rat 
T m b p  cells were incubated overnight with BZ194 or vehicle (DMSO).
7.30.3 Animals and Antigens.
Lewis rats were obtained from the animal breeding facilities of the Max Planck Institute for 
Neurobiology (Martinsried, Germany) and were kept under standardised conditions. 
Antigen specific T  cell clones used in the study were specific for guinea pig myelin basic 
protein (MBP), ovalbumin (OVA), SI 00(3, and myelin oligodendrocyte glycoprotein 
(MOG). MBP was purified from guinea pig brains.227 Hen egg ovalbumin and S 100(3 were 
obtained from Sigma (Munich, Germany), recombinant MOG (amino acids 1-120) was 
produced as described .224 A peptide comprising human myelin basic protein amino acids 
139 to 153 (hM BPl 39-153) (KGFKGVDAQGTLSKI) was synthesised by FMOC 
chemistry and purified by preparative C 8 reversed phase HPLC. Tetanus toxoid containing 
no preservatives was obtained from Behringwerke, Marburg, Germany.
All animal experiments were performed with the license of the Regierung von Oberbayem 
(No: 209.1/211-2531-56/99).
7.30.4 Generation of T Cells, EAE Induction, and BZ194 Application.
Rat MBP-, OVA-, S100J3-, and MOG-specific CD4+ T cells retrovirally engineered to
225express the marker gene EGFP have been generated as described. For EAE induction
5 x l0 6 cells were intravenously injected into healthy recipient rats. Animals were monitored
twice daily by measuring weight and examining disease scores as follows: 0  = no disease; 1
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= flaccid tail; 2 = gait disturbance; 3 = complete hind limb paralysis; 4 = tetraparesis; and 5 = 
death). The observation time was extended to more than 30 d during aEAE and 21 d during 
tEAE.
For treatment, daily intraperitoneal injections of BZ194 (500pM , 180mg/kg, solubilised in 
DMSO/1% Lewis rat serum), DMSO (0.8 ml/kg), or Niacin (500jlM, 61.5 mg/kg, 
solubilised in DMSO/1% Lewis rat serum) were performed. BZ194 was well tolerated. In 
particular, the treatment (tested up to lm M ) did not demonstrably influence the immune cell 
composition and immune competence of the animals (data not shown).
Human M BP139-153-specific T cell lines were established by the standard split-well 
method which allows generation of CD4+ T cell lines. Briefly, PBMC were seeded in 200 pi 
RPMI medium (Invitrogen/Gibco, Karlsruhe, Germany) containing 7.5 % pooled human AB 
serum (Sigma, Deisenhofen, Germany), 100 U/ml Pen/Strep and 2mM Glutamine in 
round-bottomed wells in the presence of 28 pM hMBP139-153. Every 3 to 4 days lOOpl of 
medium was substituted by fresh medium containing 5 U recombinant human DL-2 (Roche, 
Mannheim, Germany). After about 2 weeks the cells of each well were split into two wells. 
105 irradiated autologous PBM C were added to both wells, but hMBP139-153 was added to 
one of the wells only. The cultures were judged microscopically for antigen-specific 
proliferation and hMBP139-153 specific clones were expanded. After four rounds of 
restimulation of individual lines, nine lines were pooled for further experiments. Molecular 
HLA typing of the healthy donor revealed HLA-DR1, -DR7, -DQ3 and -DQ5.
7.30.5 T Cell Activation Assay
Rat T m b p -g fp  cells were co-cultured for 48 h in 96well plates (in DMEM 1 % rat serum) with 
professional thymic APCs in presence of specific antigen (10p.g/ml MBP) or without.
23 1Amplification of T m b p - g f p  cells was measured by cytofluorometry. Their numbers were 
determined in relation to a known absolute number of added phycoerythrin-labeled plastic 
beads (Becton-Dickinson). The amplification rate was calculated in relation to the GFP+ T 
cell numbers at day 0. Alternatively, [3H]dT (2 Ci/mmol; Amersham-Buchler) incorporation
was used to evaluate proliferation. The radioactive label present in the different cultures was
22 2determined as described.
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7.30.6 Proliferation Assays.
Rat effector T  cells: T m b p -g fp  cells isolated from spleens and LNs 72h p.t. were cultured 
together with irradiated (1000 rad) LN cells from BZ194-treated or DMSO/Niacin-treated 
control animals (in DMEM 1% rat serum) in the presence of specific or control antigen (10 
pg/ml MBP or OVA, respectively). Amplification of ex vivo-isolated T m b p -g fp  cells was 
measured by cytofluorometry in the presence o f BZ194 in DMSO at final concentrations o f
1.0 and 0.5 pM  or with DMSO alone. Their numbers were evaluated in relation to a known 
absolute number of added phycoerythrin-labeled plastic beads (Becton-Dickinson) .231 T g f p  
cell amplification rate was calculated in relation to the cell numbers at day 0 .
Human T cell lines: Pooled human MBP139-153-specific T  cell lines (1.0 x 105 cells/well) 
were preincubated for 45 min at with BZ194 in DMSO at final concentrations of 1.0 and 0.5 
pM, or with DM SO alone. 105 irradiated autologous PBMC/well were preincubated for 3 h 
with 28 pM hM BP peptide (aal39-153), 5 pg/ml tetanus toxoid, or without antigen. Then T 
cells and PBMC were merged and after 24 hours, 0.22 pCi [3H]-thymidine (2 Ci/mmol, 
Amersham, Braunschweig, Germany) was added. Proliferation was evaluated 16 h later 
measuring [3H] dT incorporation.
231
REFERENCE
1. Lennartz, M. R., The International Journal o f  Biochemistry and Cell Biology 1999, 
31,415-430.
2. Schindler, C.; Darnell, J. E., Annu. Rev. Biochem. 1995, 64, 621-651.
3. Ziemiecki, A.; Harpur, A. G.; WilKs, A. F., Trends Cell Biol. 1994,4,207-212.
4. Stahl, N.; Farruggella, T. J.; Boulton, T. G., Science 1995, 1349-1353.
5. Ringer, S., J. Physiol. 1883,4,29-42.
6 . McCormack, J. G.; Halestrap, A. P.; Denton, R. M., Physiol. Rev. 1990, 70, 391- 
425.
7. Means, A. R.; VanBerkum, M. F.; Bagchi, I.; Lu, K. P.; Rassmussen, C. D., 
Pharmacol. Ther. 1991, 50, 255-270.
8 . Liu, J.; Albers, M. W.; Wandless, T. J.; Luan, S.; Alberg, D. G.; Belshaw, P. J., 
Biochemistry 1992, 31,3896-3901.
9. Saimi, Y.; Kung, C., calmodulin as an ion channel subunit. Annu. Rev. Physiol. 
2002,64,289-311.
10. McCleskey, E. W., Curr. Opinion Neurobiol. 1994,17, 304-312.
11. Clapham, D. E , . Cell 1995, 80, 259-268.
12. Penner, R.; Fasolato, C.; Hoth, M., Curr. Opinion Neurobiol. 1993,3, 368-374.
13. Randriamampita, C.; Tsien, R. Y., Nature 1993, 364, 809-814.
14. Endo, M.; Tanaka, M.; Ogawa, Y., Nature 1970,228, 34-36.
15. Gilkey, J. C.; Jaffe, L. F.; Ridgway, E. B.; Reynolds, G. T., J. Cell. Biol. 1978, 76,
448-446.
16. Shmigol, A.; Kostyuk, P.; Verkhratsky, A., Neuroscience 1995, 6 5 ,1109-1118.
17. Fabiata, A.; Fabiato, F., Nature 1979, 281, 146-148.
18. Holz, G. G.; Leech, C. A.; Heller, R. S . , . J. Biol. Chem. 1999,2 74 ,14147-14156.
19. Bezprozvanny, I.; Watras, J.; Ehrlich, B. E., Nature 1991,351, 751-754.
20. Streb, H.; Irvine, R. F.; Berridge, M. J.; Schulz, I., Nature 1983,306, 67-69.
232
21. Clapper, D. L.; Walseth, T. F.; Dargie, P. J.; Lee, H. C., J. Biol. Chem. 1987, 262, 
9561-9568.
22. Lee, H. C.; Aarhus, R., J. B io l Chem. 1995,270, 2152-2157.
23. Missiaen, L.; Parys, J. B.; De Smedt, H.; Sienaert, I.; Sipma, H.; Vanlingen, S.; 
Maes, K.; Casteels, R., Biochem. J. 1997,325, 661-66.
24. Joseph, S. K.; Rice, H. L.; Williamson, J. R., Biochem. J. 1989,258, 261-265.
25. Joseph, S. K., Cell. Signal 1996, 8 , 1-7.
26. Sugawara, H.; Kurosaki, M.; Takata, M.; Kurosaki, T., EMBO J  1997, 16, 3078- 
3088.
27. Tu, H.; Wang, Z.; Miyakawa, I., Biophys. J. 2005, 88,1056-1069.
28. Miyakawa, T.; Maeda, A.; Yamazawa, T.; Hirose, K.; Kurosaki, T.; lino, M., 
EM BO J1999, 18,1303-1308.
29. Tu, H.; Wang, Z.; Nosyreva, E.; De Smedt, H.; Bezprozvanny, I., Biophys. J. 2005, 
8 8 , 1046-1055.
30. Sudhof, T. C.; Newton, C. L.; Archer, B. T.; Ushkaryov, Y. A.; Mignery, G. A., 
EMBO J 1991, 10, 3199-3206.
31. Maes, K.; Missiaen, L.; Parys, J. B.; De Smet, P.; Sienaert, I.; Waelkens, E., J. Biol. 
Chem. 2001,276, 3492-3497.
32. Mignery, G. A.; Sudhof, T. C., EMBO J 1990, 9, 3893-3898.
33. Marshall, I. C. B.; Taylor, C. W., J. Biol. Chem. 1993,268, 13214-13220.
34. Hajnoczky, G.; Thomas, A. P., Nature 1994, 370,474-477.
35. Veijans, B.; De Smedt, F.; Leococq, R.; Vanweyenberg, V.; Moreau, C.; Emeux, 
C., Biochem. J. 1994, 300, 85-90.
36. Millard, T. H.; Cullen, P. J.; Banting, G., Biochem. J. 2000, 352, 709-715.
37. Lee, H. C.; Walseth, T. F.; Bratt, G. T.; Hayes, R. N.; Clapper, D. L., J. Biol. Chem. 
1989,264, 1608-1615.
38. Lee, H. C.; Aarhus, R.; Levitt, D., Nature Struct. Biol. 1994, 1, 143-144.
233
39. Guse, A. H., Curr. Mol. M ed 2004,4, 239-248.
40. Guse, A. H.; da Silva, C. P.; Berg, I.; Skapenko, A. L.; Weber, K., Heyer, P.;
Hohenegger, M.; Ashamu, G. A.; Schulze-Koops, H.; Potter, B. V. L.; Mayr, G. W., 
Nature 1999, 398, 70-73.
41. Higashiaa, H., FEB SLett 1997,418,355-356.
42. Galione, A.; Lee, H. C.; Busa, W. B., Science 1991,253, 1143-1146.
43. Schwarzmann, N.; Kunerth, S.; Weber, K.; Mayr, G. W.; Guse, A. H., J. Biol.
Chem. 2002, 277, 50636-50642.
44. Ogawa, Y., Crit. Rev. Biochem. Mol. Biol. 1994, 29, 229-272.
45. Takeshima, H., Nature 1989,339,439-445.
46. O’Brien, J.; Valdivia, H. H., Biophys. J. 1995, 68, 471-482.
47. Walseth, T. F.; Aarhus, R.; Kerr, J. A.; Lee, H. C., J. Biol. Chem. 1993, 268, 
26686-26691.
48. Noguchi, N.; Takasawa, S.; Nata, K.; Tohgo, A.; Kato, I.; Ikehata, F., J. Biol. Chem. 
1997,272,3133-3136.
49. Hellmich, M. R.; Strumwasser, F., Cell Regul. 1991,2, 193-202.
50. Glick, D. L.; Hellmich, M. R.; Beushausen, S.; Tempst, P.; Bayley, H.; 
Strumwasser, F., Cell Regul 1991,2,211-218.
51. Love, L. L.; Szebenyi, D. M. E.; Kriksunov, I. A.; Thiel, D. J.; Munshi, C.; Graeff, 
R.; Lee, H. C.; Hao, Q., Structure 2004, 12, 477-486.
52. Summerhill, R. J.; Jackson, D. G.; Galione, A., FEBS Lett. 1993,335, 231-233.
53. Itoh, M.; Ishihara, K.; Tomizawa, H.; Tanaka, H.; Kobune, Y.; Ishikawa, J.; Kaisho, 
T.; Hirano, T., Biochem. Biophys. Res. Commun. 1994, 203, 1309-1317.
54. Reinherz, E. L.; Kung, P. C.; Goldstein, G.; Levey, R. H.; Schlossman, S. F., Proc. 
Natl. Acad. Sci. USA 1980, 77,1588-1592.
55. States, D. J.; Walseth, T. F.; Lee, H. C., Trends Biochem. Sci. 1992, 17,495-495.
234
56. Liu, Q.; Kriksunov, A.; Graeff, R.; Munshi, C.; Lee, H. C.; Hao, Q., Structure 2005, 
13, 1331-1339.
57. Munshi, C.; Aarhus, R.; Graeff, R.; Walseth, T. F.; Levitt, D.; Lee, H. C., J. Biol. 
Chem. 2 0 0 0 ,  275, 21566-21571.
58. Matsumura, N.; Tanuma, S.-I., Biochem. Biophys. Res. Commun. 1 9 9 8 , 253, 246- 
252.
59. Schuber, F.; Frances, E. L., Curr. Mol. Med. 2 0 0 4 ,4, 249-261.
60. Munshi, C.; Thiel, D. J.; Mathews, I. J.; Aarhus, R.; Walseth, T. F.; Lee, H. C., J. 
B iol Chem. 1 9 9 9 ,274, 30770-30777.
61. Sauve, A. A.; Deng, H. T.; Angeletti, R. H.; Schramm, V. L., J. Am. Chem. Soc. 
2 0 0 0 , 122, 7855-7859.
62. Liu, Q.; Kriksunov, I. A.; Graeff, R.; Munshi, C.; Lee, H. C.; Hao, Q., J. Biol. 
Chem. 2 0 0 6 ,  in press.
63. Sano, Y.; Inamura, K.; Miyake, A.; Mochizuki, S.; Yokoi, H.; Matsushime, H.; 
Furuichi, K., Science 2001,293, 1327-1330.
64. De Flora, A.; Franco, L.; Guida, L.; Bruzzone, S.; Usai, C.; Zocchi, E., Chem. 
Immunol. 2 0 0 0 ,  7 5 , 7 9 -9 8 .
65. Bruzzone, S.; Guida, L.; Zocchi, E.; Franco, L.; De Flora, A., FASEB J. 2 0 0 1 ,  15, 
10- 12.
66. Franco, L.; Guida, L.; Bruzzone, S.; Zocchi, E.; Usai, C.; De Flora, A., FASEB J. 
1 9 9 8 , 12,1507-1520.
67. Guida, L.; Bruzzone, S.; Sturla, L.; Franco, L.; Zocchi, E.; De Flora, A., J. Biol. 
Chem. 2 0 0 2 ,  277, 47097-47105.
68. Franco, L.; Zocchi, E.; Usai, C.; Guida, L.; Bruzzone, S.; Costa, A.; De Flora, A., J. 
Biol. Chem. 2 0 0 1 , 276,21642-21648.
69. Stemfeld, L.; Krause, E.; Guse, A. H.; Schulz, I., J. Biol. Chem. 2 0 0 3 , 278, 33629- 
33636.
70. Churchill, G. C.; O'Neill, J. S.; Masgrau, R.; Patel, S.; Thomas, J. M.; Genazzani, A. 
A.; Galione, A., Curr. Biol. 2003, 13, 125-128.
71. Masgrau, R.; Churchill, G. C.; Morgan, A. J.; Ashcrost, S. J.; Galione, A., Curr.
B io l 2003, 13,247-251.
72. Kinnear, N. P.; Boittin, F. X.; Thomas, J. M.; Galione, A.; Evans, A. M., J. Biol. 
Chem. 2004,279, 54319-54326.
73. Yamasaki, M.; Thomas, J. M.; Churchill, G. C.; Gamham, C.; M. Lewis, A. M.; M. 
Cancela, J. M.; Patel, S.; Galione, A., Curr. Biol. 2005, 15, 874-878.
74. Aarhus, R.; Dickey, D. M.; Graeff, R. M.; Gee, K. R.; Walseth, T. F.; Lee, H. C., J. 
Biol. Chem. 1996,271, 8513-8516.
75. Berg, I.; Potter, B. V. L.; Mayr, G. W.; Guse, A. H., J. Cell. Biol. 2000, 150, 581- 
588.
76. Cancela, J. M.; Churchill, G. C.; Galione, A., Nature 1999,398, 74-76.
77. Dammermann, W.; Guse, A. H., J. Biol. Chem. 2005,280, 21394-21399.
78. Bak, J.; White, P.; Timar, G.; Missiaen, L.; Genazzani, A. A.; Galione, A., Curr. 
Biol 1999,9, 751-754.
79. Brailoiu, E.; Hoard, J. L.; Filipeanu, C. M.; Brailoiu, G. C.; Dun, S. L.; Patel, S.;
Dun, N. J., J. Biol. Chem. 2005,280, 5646-5650.
80. Billington, R. A.; Genazzani, A. A., Biochem. Biophys. Res. Commun. 2000, 276, 
112-116.
81. Walseth, T. F.; Lee, H. C., Biochem. Biophys. Res. Commun. 1993,1178, 235-242.
82. Wang, L.; Aarhus, R.; Lee, H. C.; Walseth, T. F., Biochem. Biophys. Res. Commun. 
1999, 1472, 555-564.
83. Walseth, T. F.; Aarhus, R.; Gumack, M. E.; Wong, L.; Breitinger, H. G.; Gee, K. 
R.; Lee, H. C., Meth. Enzymol. 1997, 280, 294-305.




















Bailey, V. C.; Fortt, S. M.; Summerhill, R. J.; Galione, A.; Potter, B. V. L., FEBS 
Lett. 1996, 379,227-230.
Moffatt, J. G.; Khorana, H. G., J. Am. Chem. Soc. 1959, 81, 1265-1265.
Simon, E. S.; Grabowski, S.; Whitesides, G. M., J. Org. Chem. 1990, 55, 1834- 
1841.
Walt, D. R.; Rios-Mercadillo, V. M.; Auge, J.; Whitesides, G. M., J. Am. Chem. 
Soc. 1980, 102, 7805-7806.
Jeck, R.; Heik, P.; Oeneckhus, C., FEBS Lett. 1974,42, 161-164.
Walt, D. R.; Findeis, M. A.; Rios-Mercadillo, V. M.; Auge, J.; Whitesides, G. M., J. 
Am. Chem. Soc. 1984, 106, 234-239.
Lee, J.; Churchil, H.; Choi, W. B.; Lynch, J. E.; Roberts, F. E.; Volante, R. P.; 
Reider, P. J., Chem. Commun. 1999, 729-730.
Tanimori, S.; Ohta, T.; Kirihata, M., Bioorg, M ed Chem. Lett. 2002, 12, 1135-1137. 
Kuemmerle, J. F.; Makhlouf, G. M., J. Biol. Chem. 1995,270, 25488-25494.
Guse, A. H.; Berg, I.; Dasilva, C. P.; Potter, B. V. L.; Mayer, G. W., J. Biol. Chem. 
1997,272, 8546-8550.
Lee, H. C.; Aarhus, R.; Walseth, T. F., Science 1993,261, 352-355.
Verderio, C.; Bruzzone, S.; Zocchi, E.; Fedele, E.; Schenk, U.; De Flora, A.; 
Matteoli, M., J. Neurochem. 2001, 78, 646-657.
Rakovic, S.; Galione, A.; Ashamu, G. A.; Potter, B. V. L.; Terrar, D. A., Curr. Biol. 
1996,6, 989-996.
Linden, D. J.; Dawson, T. M.; Dawson, V. L., J. neurosci. 1995, 15, 5098-5105. 
Burdakov, D.; Cancela, J. M.; Petersen, O. H., Cell. Calcium. 2001,29, 211-216. 
Leckie, C. P.; McAinsh, M. R.; Allen, G. J.; Sanders, D.; Hetherington, A. M., 
Proc. Natl. Acad. Sci. USA 1998, 95, 15837-15842.
Sethi, J. K.; Empson, R. M.; Bailey, V. C.; Potter, B. V. L.; Galione, A., J. Biol. 
Chem. 1997, 272, 16358-16363.
237
102. Guse, A. H.; Dasilva, C. P.; Weber, K.; Armah, C. N.; Ashamu, G. A.; Schulze, C.; 
Potter, B. V. L.; Mayr, G. W.; Hilz, H., Eur. J. Biochem. 1 9 9 7 ,245,411-417.
103. Bailey, V. C.; Sethi, J. K.; Fortt, S. M.; Galione, B. V. L.; Potter, B. V. L., Chem. 
Bio. 1997,4,51-61.
104. Wagner, G.; Black, S. J.; Guse, A.; Potter, B. V. L., Chem. Commun. 2 0 0 3 , 1944- 
1945.
105. Zhang, F. J.; Gu, Q. M.; Jing, P.; Sih, C. J., Bioorg, Med. Chem. Lett. 1 9 9 5 , 5, 
2267-2272.
106. Aarhus, R.; Gee, K.; Lee, H. C., J. Biol. Chem. 1 9 9 5 , 270, 7745-7749.
107. Zhang, F. J.; Yamada, S.; Gu, Q. M.; Sih, C. J., Bioorg, Med. Chem. Lett. 1 9 9 6 , 6, 
1203-1208.
108. Xu, L.; Walseth, T. F.; Slama, J. T., J. Med. Chem. 2 0 0 5 ,48,4177-4181.
109. Wall, K. A.; Klis, N.; Komet, J.; Coyle, D.; Ame, J. C.; Jacobson, M. K.; Slama, J.
T., Biochem. J. 1998, 335, 631-636.
110. Shuto, S.; Matsuda, A., Curr. Med. Chem. 2 0 0 4 , 11, 827-845.
111. De Capua, A.; De Napoli, L.; Di Fabio, G.; Messere, A.; Montesarchio, D.;
Piccialli, G., Nucleoside Nucleotide Nucleic Acids 2000, 19, 1289-1299.
112. Shuto, S.; Shirato, M.; Sumita, Y.; Ueno, Y.; Matsuda, A., Tetrohedron Lett. 1 9 9 8 , 
39, 7341-7344.
113. Ikehara, M.; Uesugi, S.; Yoshida, K., Biochem. 1 9 7 2 , 11, 830-836.
114. Shuto, S.; Fukuoka, M.; Manikowsky, M.; Ueon, T.; Nakano, T.; Kuroda, R.;
Kuroda, H.; Matsuda, A., J. Am. Chem. Soc. 2 0 0 1 , 123, 8750-8759.
115. Dowden, J.; Moreau, C.; Brown, R. S.; Berridge, G.; Galione, A.; Potter, B. V. L., 
Angew. Chem. Int. E d  2 0 0 4 ,43,4637-4640.
116. Lee, H. C.; Aarhus, R ,  J. Biol. Chem. 1 9 9 7 ,272, 20378-20383.
117. Sleath, P. R.; Handlon, A. L.; Oppenheimer, N. J., J. Org. Chem. 1 9 9 1 , 56, 3608-
3613.
238
118. Muller-steffher, H. M.; Malver, O.; Hosie, L.; Oppenheimer, N. J.; Schuber, F., J. 
Biol. Chem. 1 9 9 2 ,267, 9606-9611.
119. Migaud, M. E.; Pederick, R. L.; Baily, V. C.; Potter, B. V. L., Biochemistry 1 9 9 9 ,  
38,9105-9114.
120. Slama, J. T.; Simmons, A. M., Biochemistry 1 9 8 9 ,28, 7688-7694.
121. Baddiley, J.; Todd, A., J. Chem. Soc. 1 9 4 7 , 647-651.
122. Falck, J. R.; Reddy, K. K.; Saady, J. Y. M.; Mioskowski, C.; Shears, S. B.; Tan, Z.; 
Safrany, S., J. Am. Chem. Soc. 1995, 117, 12172-12175.
123. Michelson, A. M., Biochim. Biophys. Acta. 1 9 6 4 , 91, 1-13.
124. Kim, H.; Haley, B. E., J. Biol. Chem. 1 9 9 0 ,265,3636-3641.
125. Slama, J. T.; Simmons, A. M., Biochemistry 1 9 9 1 , 30, 2527-2534.
126. Hughes, N. H.; Kenner, G. W.; Todd, A., J. Chem. Soc. 1 9 5 7 , 3733-3738.
127. Haynes, L. J.; Hughes, N. H.; Kenner, G. W.; Todd, A., J. Chem. Soc. 1 9 5 7 , 3727- 
3732.
128. Khorana, H. G., J. Am. Chem. Soc. 1 9 5 4 , 76, 3517-3522.
129. Moffatt, J. G.; Khorana, H. G., J. Am. Chem. Soc. 1 9 5 8 , 80, 3756-3761.
130. Chambers, R. W.; Khorana, H. G., J. Am. Chem. Soc. 1 9 5 8 , 80, 3749-3752.
131. Moffatt, J. G.; Khorana, H. G., J. Am. Chem. Soc. 1 9 6 1 , 83, 649-658.
132. Khorana, H. G., Chem. Revs. 1 9 5 3 ,53, 145-166.
133. Smith, M.; Moffat, J. G.; Khorana, H. G., J. Am. Chem. Soc. 1 9 5 8 , 80, 6204-6212.
134. Prabahar, K. J.; Cole, T. D.; Ferris, J. P., J. Am. Chem. Soc. 1 9 9 4 , 116, 10914-
10920.
135. Ivanovskaya, M. G.; Gottikh, M. B.; Sabarova, Z. A., nucleosides nucleotides 1 9 8 7 ,  
6, 913-934.
136. Ichikawa, Y.; Sim, M. M.; Wong, C. H., J. Org. Chem. 1 9 9 2 ,57,2943-2946.
137. Sim, M. M.; Kondo, H.; Wong, C. H., J. Am. Chem. Soc. 1 9 9 3 , 115,2260-2267.
138. Seth, A. K.; Jay, E., Nucleic Acid Res 1 9 8 0 , 8, 5445-5459.
139. Wittmann, V.; Wong, C. H., J. Org. Chem. 1997, 62, 2144-2147.
140. Guengerich, F. P.; Raney, V. M., J. Am. Chem. Soc. 1992, 114,1074-1080.
141. Zhang, F. J.; Sih, C. J., Bioorg, Med. Chem. Lett. 1995, 5, 1701-1706.
142. Yamamoto-Katayama, S.; Ariyoshi, M.; Ishihara, K.; Hirano, T.; Jingami, H.; 
Morikawa, K., J. Mol. Biol. 2002, 316, 711 -723.
143. Zhang, F. J.; Sih, C. J., Tetrahedron Lett. 1995,36, 9289-9292.
144. Potter, B. V. L.; Walseth, T. F., Curr. Mol. Med. 2004,4, 303-311.
145. Major, D. T.; Laxer, A.; Fischer, B., J. Org. Chem. 2002, 67, 790-802.
146. Laxer, A.; Major, D. T.; Gottlieb, H. E.; Fischer, B., J. Org. Chem. 2001, 66, 5463- 
5481.
147. Buchner, P.; Maurer, W.; Ruteijans, H., J. Magn. Reson. 1978, 29,45-63.
148. Fathi, R.; Goswami, B.; Kung, P. P.; Gaffney, B. L.; Jones, R. A., Tetrahedron Lett.
1990,31,319-322.
149. Gao, H.; Fathi, R.; Gaffney, B. L.; Goswami, B.; Kung, P. P.; Rhee, Y.; Jin, R.;
Jone, R. A .,J. Org. Chem. 1992, 57, 6954-6959.
150. Krolikiewicz, K.; Vorbrueggen, H., nucleosides nucleotides 1994, 13, 673-678.
151. Kemp, W., NMR in chemistry: a multinuclear introduction, Macmillan education 
Ltd, London, 1st edn. 1986, 102-107.
152. Ikemoto, T.; Haze, H.; Hatano, H.; Kitamoto, Y.; Ishida, M.; Nara, K., Chem 
Pharm Bull 1995,43, 210-215.
153. Yu, K. L.; Fraser-Reid, B., Tetrahedron Lett. 1988, 29, 979-982.
154. Yoshikawa, M.; Kato, T.; Takenishi, T., Bull. Chem. Soc. Jpn 1969,42, 3505-3508.
155. Mukaiyama, T.; Matsueda, R.; Suzuki, M., Tetrahedron Lett 1970,22, 1901-1904.
156. Lee, H. C., Chem. Immunol. 2000, 75, 39-59.
157. Tohgo, A.; Munakata, H.; Takasawa, S.; Nata, K ; Akiyama, T.; Hayashi, N.; 



















Berthelier, V.; Tixier, J. M.; Muller-Steffher, H.; Schuber, F.; Deterre, P., Biochem. 
J. 1 9 9 8 , 330,1383-1390.
Augustin, A. A.; Muller-Steffher, H.; Schuber, F., Biochem. J. 2 0 0 0 ,  345, 43-52. 
Muller-steffher, H. M.; Augustin, A. A.; Schuber, F., J. Biol. Chem. 19 9 6 , 271, 
23967-23972.
Jacobson, M. K.; Cervantes-Laurean, D.; Strohm, M. S.; Coyle, D. L.; Bummer, P. 
M.; Jacobson, E. L., Biochimie 1 9 9 5 , 77, 341-344.
Zhang, F. J.; Gu, Q. M.; Sih, C. J., Bioorg. M ed Chem. 1 9 9 9 , 7, 653-664. 
Cakir-Kiefer, C.; Muller-Steffher, H.; Schuber, F., Biochem. J. 2 0 0 0 ,349, 203-210. 
Tamus, C.; Muller, H. M.; Schuber, F., Bioorg. Chem. 1 9 8 8 , 16, 38-51.
Wilson, M. H.; McCloskey, J. A., J. Org. Chem 1 9 7 3 ,38,2247-2249.
Kristinsson, H.; Nebel, K.; O'Sullivan, A. C.; Struber, F.; Winkler, T.; Yamaguchi, 
Y., Tetrahedron 1 9 9 4 , 50, 6825-6838.
Rosenberg, H. J.; Riley, A. M.; Laude, A. J.; Tayor, C. W.; Potter, B. V. L., J. Med. 
Chem. 2 0 0 3 ,46,4860-4874.
Graeff, R. M.; Walseth, T. F.; Hill, H. K.; Lee, H. C., Biochemistry 1 9 9 6 , 35, 379- 
386.
Graeff, R. M.; Walseth, T. F.; Fryxell, K.; Branton, W. D.; Lee, H. C., J. Biol. 
Chem. 1 9 9 4 ,269, 30260-30267.
Jordan, F.; Niv, H., Nucleic Acid Res 1 9 7 7 ,4, 697-709.
Shuto, S.; Fukuoka, M.; Kudoh, T.; Gamham, G.; Guse, A.; Potter, B. V. L.; 
Matsuda, A., J. Med. Chem. 2 0 0 3 ,46,4741-4749.
Wagner, G. K.; Guse, A. H.; Potter, B. V. L., J. Org. Chem. 2 0 0 5 ,  70,4810-4819. 
Ikehara, M.; Kaneko, M., Tetrahedron 1 9 7 0 , 26, 4251-42;59.
Wlassoff, W. A.; Dobrikov, M. I.; Safronov, I. V.; Dudko, R. Y.; Bogachev, V. S.; 
Kandaurova, V. V.; Shishkin, G. V.; Dymshits, G. M.; Lavrik, O. I., Bioconjugate 
chem 1 9 9 5 , 6, 352-360.
241
175. Sumita, Y.; Shirato, M.; Ueno, Y.; Matsuda, A.; Shuto, S., Nucleosides Nucleotides 
Nucleic Acids 2000, 19, 175-188.
176. Jansons, J.; Maurinsh, Y.; Lidaks, M., nucleosides nucleotides 1 9 9 5 , 14, 1709-1724.
177. Repkova, M. N.; Ivanova, T. M.; Komarova, N. I.; Meshchaninova, M. I.; 
Kuznetsova, M. A.; Venyaminova, A. G., Russ. J. Bioorg. Chem. (Engl. Transl) 
1 9 9 9 ,25(9), 612-622.
178. Buenger, G. S.; Nair, V., Synthesis 1 9 9 0 , 962-966.
179. Laayoun, A.; Decont, J.-L.; Lhomme, J. L., Tetrahedron Lett. 1 9 9 4 ,35,4989-4990.
180. Kawai, K.; Saito, I.; Sugixama, H., Tetrahedron Lett. 1 9 9 8 , 39, 5221-5224.
181. Staros, J. V.; Bayley, H.; Standring, D. N.; Knowles, J. R., Biochem. Biophys. Res. 
Commun. 1 9 7 8 , 80, 568-572.
182. Handlon, A. L.; Oppenheimer, N. J., Pharm. Res. 1 9 8 8 ,5, 297-299.
183. Ashamu, G. A., PHD Thesis 1998.
184. Cartwright, I. L,; Hutchinson, D. W.; Armstrong, V. W., Nucleic Acid Res 1976, 3, 
2331-2339.
185. Garrett, E. R.; Mehta, P. J., J. Am. Chem. Soc. 1 9 7 2 , 94, 8532-8542.
186. De Clercq, E.; Desgranger, C.; Herdewijn, P.; Sim, I. S.; Jones, A. S.; McLean, M. 
J.; Walker, R. T., J. Med. Chem. 1 9 8 6 , 29, 213-217.
187. De Winter, H.; Herdewijn, P ,  J. Med. Chem. 1 9 9 6 , 39,4727-4737.
188. Minakawa, N.; Kojima, N.; Sasaki, T.; Matsuda, A., nucleosides nucleotides 1996, 
15,251-263.
189. Verlinde, C. L. M. J.; Callens, M.; Calenbergh, S. V.; Aerschot, A. V.; Herdewijn, 
P.; Hannaert, V.; Michels, P. A. M.; Opperdoes, F. R.; Hoi, W. G. J., J. Med. Chem. 
1 9 9 4 ,37, 3605-3613.
190. Western, E. C.; Shaughnessy, K. H., J. Org. Chem. 2 0 0 5 , 70, 6378-6388.
191. Amann, N.; Wagenknecht, H. A., Synlett 2002,5, 687-691.
242
192. Western, E. C.; Daft, J. R.; Johnson, E. M.; Gannett, P. M.; Shaughnessy, K. H., J. 
Org. Chem. 2003, 68, 6161-611A.
193. Armstrong, J. I.; Verdugo, D. E.; Bertozzi, C. R., J. Org. Chem 2003,68, 170-173.
194. Altona, C.; Sundaralingam, M., J. Am. Chem. Soc. 1973, 95, 2333-2344.
195. Bookser, B. C.; Matelich, M. C.; Ollis, K.; Ugarkar, B. G., J. Med. Chem. 2005,48, 
3389-3399.
196. Graham, S. M.; Macaya, D. J.; Sengupta, R. N.; Turner, K. B., 2004,6,233-236.
197. Sarnia, R. H.; Lee, H. C.; Evans, F. E.; Yathindra, N.; Sundaralingam, M., J. Am. 
Chem. Soc. 1974, 96, 7337-7348.
198. Takeshi, W.; Inageda, K.; Aritomo, K.; Tokita, K.-I.; Nishina, H.; Takahashi, K.; 
Katada, T.; Sekine, M., nucleosides nucleotides 1995, 14, 1301-1314.
199. Xu, J.; Yang, Z.; Dammermann, W.; Zhang, L.; Guse, A.; Zhang, L.-H., J. Med. 
Chem. 2006,49, 5501-5512.
200. Chu, C. K.; Bhadti, V. S.; Doboszewski, B.; Gu, Z. P.; Kosugi, Y.; Pullaiah, K. C.; 
Van Roey, P., J. Org. Chem. 1989, 54, 2217-2225.
201. Barton, D. H. R.; Subramanian, R., J. Chem. Soc. Perkin Trans 1 1977, 1718-1723.
202. Bailey, V. C.; Sethi, J. K.; Galione, A.; Potter, B. V. L., Chem Commun 1997, 695- 
696.
203. Bergstrom, D. E.; Brattesani, A. J., Nucleic Acid Res 1980, 8, 6213-6219.
204. Mitchell, R. H.; Lai, Y. H.; Williams, R. V., J. Org. Chem. 1979,44,4733-4735.
205. Lee, H. C.; Aarhus, R.; Levitt, D., Nat. Struct. Biol. 1994, 1, 143-144.
206. Kudoh, T.; Fukuoka, M.; Ichikawa, S.; Murayama, T.; Ogawa, Y.; Hashii, M.; 
Higashida, H.; Kunerth, S.; Weber, K.; Guse, A. H., J. Am. Chem. Soc. 2005, 127, 
8846-8855.
207. Hotoda, H.; Murayama, K.; Miyamoto, S.; Iwata, Y.; Takahashi, M.; Kawase, Y.; 
Tanzawa, K.; Kaneko, M., Biochemistry 1999, 38, 9234-9241.
243
208. Tsytovich, A. V.; Shamshin, D. V.; Burkovskii, V. B.; Shvets, V. I., Russ. J. Bioorg. 
Chem. (Engl. Transl) 1 9 9 5 , 21, 756-761.
209. Hoffer, M., Chem. Ber. 1960, 93, 2777-2780.
210. Seela, F.; Muth, H. P.; U., B., Synthesis 1 9 8 8 , 670-674.
211. Beigelman, L.; Haeberli, P.; Sweedler, D.; Karpeisky, A., Tetrahedron 2 0 0 0 , 56, 
1047-1056.
212. Moreau, C.; Woodman, T. J.; Potter, B. V. L., Chem. Commun 2 0 0 6 , 1127-1129.
213. Bak, J.; Billington, R. A.; Timar, G.; Dutton, A. C.; Genazzani, A. A., Curr. Biol. 
2 0 0 1 , 11,987-990.
214. Billington, R. A.; Tron, G. C.; Reichencach, S.; Sorba, G.; Genazzani, A. A., Cell 
Calcium 2 0 0 5 , 37, 81-86.
215. Dowden, J.; Berridge, G.; Moreau, C.; Yamasaki, M.; Churchill, G. C.; Potter, B. V. 
L.; Galione, A., Chem. Biol. 2 0 0 6 , 13, 659-665.
216. Eda, M.; Kurth, M. J., Tetrahedron Lett. 2 0 0 1 ,42, 2063-2068.
217. Hockova, D.; Votavova, H.; Holy, A., Tetrahedron Asymmetry 1 9 9 5 , 6, 2375-2384.
218. Ferandez, J.-C.; Sole-Feu, L.; Femandez-Fomer, D.; de la Figuera, N.; Foms, P.; 
Alberico, F., Tetrahedron Lett. 2005,46, 581-585.
219. Kennedy, J. S.; Raab, M.; Rudd, C. E., Cell. Calcium. 1 9 9 9 ,26, 227-235.
220. Guse, A. H., Crit. Rev. Immunol 1 9 9 8 , 18,419-448.
221. Wekerle, H., Curr. Opin. Neurobiol. 1 9 9 3 , 3, 779-787.
222. Hemmer, B.; Archelos, J. J.; Hartung, H. P., Nat. Rev. Neurosci. 2 0 0 2 ,3, 291-301.
223. Flugel, A.; Berkowicz, T.; Ritter, T.; Labeur, M.; Jenne, D. E.; Li, Z.; Ellwart, J. 
W.; Willem, M.; Lassmann, H.; Wekerle, H., Immunity 2001,14, 547-560.
224. Ademann, M., J. Neuroimmunol 1 9 9 5 , 63, 17-27.
225. Flugel, A.; Willem, M.; Berkowicz, T.; Wekerle, H., Nature Med 1 9 9 9 , 5, 843-847.
226. KoJima, K , J. Exp. Med. 1 9 9 4 , 180, 817-829.
227. Kawakami, N., J. Exp. Med. 2 0 0 4 , 199,185-197.
228. Montgomery, J. A.; Hewson, K. J., Am. Chem. Soc. 1957, 79 (16), 4559-4559.
229. Guse, A. H.; Roth, E.; Emmrich, F., Biochem. J. 1993, 291 (Part 2), 447-451.
230. Guse, A. H.; Cakir-Kiefer, C.; Fukuoka, M.; Shuto, S.; Weber, K.; Bailey, A. C.;
Matsuda, A.; Mayr, G. W.; Oppenheimer, N.; Schuber, F.; Potter, B. V. L.,
Biochemistry 2002, 41, 6744-6751.
231. Kawakami, N., J. Immunol. 2005. 175, 69-81.
245
APPENDIX: CRYSTALLOGRAPHIC STUDY OF BZ194
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Table 1. Crystal data and structure refinement for BZ194.
Identification cod e h06farm4
Empirical formula C16 H24.50 Br0.50 N2 0 3
Formula weight 332 .83
Temperature 150(2) K
Wavelength 0 .7 1 0 7 3  A
Crystal sys tem Triclinic
Space group P-1
Unit cell d imensions a = 8.7780(1 )A a  = 91.924(1)°
b = 9.2460(1 )A P = 99.210(1)°
c = 2 1 ,3480(4)A y = 102.398(1)°
Volume 1666.26(4) A3
Z 4
Density (calculated) 1.327 Mg/m3
Absorption coefficient 1.281 mm'1
F(000) 704
Crystal s iz e 0 .30 x 0 .30 x 0.07 mm
Theta range for data collection 3.81 to 27.48°
Index ranges _11 <=h<=11; -11 <=k<=11; -27<=l<=27
Reflections collected 255 3 2
Independent reflections 7561 [R(int) = 0.0406]
Reflections observed  (>2o) 6368
Data C om p le ten ess 0.990
Absorption correction Semi-empirical from equivalents
Max. and min. transmission 1.00 and 0.89
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 7561 / 2 / 4 0 3
Goodness-of-fit on F2 1.033
Final R indices [l>2a(l)] R l =  0 .0319  wR2 = 0 .0774
R indices (all data) Rl = 0 .0 4 4 2  wR2 = 0 .0827
Largest diff. peak and hole 0 .360  and -0.633 eA'3
Notes: A sy m m e tr ic  unit c o n s is ts  of 2 hy d ro g en  b o n d e d  m olecu les  and  one b ro m id e  
c o u n te r  ion. Nitrogen bound  h y d ro g e n s  w e re  located  and  refine at 0.89 A 
from  th e  p a ren t  a tom s. The hydro g en  a to m  a t ta c h e d  to  0 2  w a s  located  a n d  
refined  w ithou t  constra in ts .
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T able  2. Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (A2 x 103) for BZ194. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor.
Atom X y z U(eq)
Br(1) 11101(1) -5421(1) 3352(1) 28(1)
0 (1) 14849(2) -4994(1) 2612(1) 32(1)
0 (2) 14312(1) -2638(1) 4868(1) 24(1)
0 ( 3 ) 16803(1) -1737(1) 5363(1) 29(1)
0 (1  A) 7676(2) -67(1) 7122(1) 32(1)
0 (2 A ) 11127(1) -1705(1) 5148(1) 25(1)
0 (3 A ) 13640(1) -975(1) 5651(1) 25(1)
N (1) 15731(2) -5767(1) 3819(1) 19(1)
N(2) 13338(2) -7290(2) 2279(1) 25(1 )
N(1 A) 9761(2) 1282(1) 6296(1) 18(1)
N(2A) 6925(2) 2127(2) 7124(1) 23(1)
0 (1) 17275(2) -5817(2) 3894(1) 2 2 ( 1 )
0 (2) 18375(2) -4881(2) 4340(1) 2 3 ( 1 )
0 (3 ) 17894(2) -3865(2) 4707(1) 2 1 ( 1 )
0 (4 ) 16317(2) -3765(2) 4600(1) J 9 ( 1 )
0 (5 ) 15239(2) -4743(2) 4154(1) 19(1)
0 (6) 15805(2) -2599(2) 4979(1) 19(1)
0 (7 ) 14553(2) -6865(2) 3370(1) 22(1)
0 (8) 14265(2) -6277(2) 2713(1) 22(1)
0 (9 ) 12813(2) -6980(2) 1628(1) 27(1)
0 (10) 12806(2) -8272(2) 1169(1) 29(1)
0 (11) 12337(2) -7971(2) 475(1) 30(1)
0 (12) 12386(2) -9242(2) 13(1) 34(1)
0 (1 3 ) 11988(2) -8946(2) -685(1) 34(1)
0 (1 4 ) 12064(3) -10216(2) -1139(1) 39(1)
0 (1 5 ) 11692(3) -9931(2) -1840(1) 47(1 )
0 (1 6 ) 11802(4) -11213(3) -2284(1) 73 ( 1 )
0 (1 8 ) 8087(2) 1401(2) 6244(1) 21(1)
0(1  A) 10862(2) 2297(2) 6697(1) 21(1)
C(2A) 12433(2) 2262(2) 6758(1) 21(1)
C(3A) 12882(2) 1197(2) 6399(1) 2 1 ( 1 )
C(4A) 11738(2) 181(2) 5984(1) 19(1)
C(5A) 10161(2) 235(2) 5949(1) 19(1)
C(6A) 12160(2) -942(2) 5552(1) 20(1)
C(7A) 7559(2) 1098(2) 6880(1) 20(1)
C(8A) 6283(2) 1955(2) 7715(1) 26(1)
C(9A) 7455(2) 2679(2) 8299(1) 27(1)
C(10A) 6645(2) 2671(2) 8881(1) 30 ( 1 )
C(11A) 7723(2) 3467(2) 9477(1) 30 ( 1 )
C(12A) 6865(2) 3540(2) 10039(1) 31(1)
C(13A) 7917(2) 4376(2) 10636(1) 30(1)
C(14A) 7037(2) 4481(2) 11187(1) 35(1)
C(15A) 8082(3) 5332(2) 11781(1) 42(1)
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Table 3. Bond lengths [A] and angles [°] for BZ194.
0(1  )-C(8) 1.228(2) 0(2)-C (6) 1 .2861(18)
0(3)-C(6) 1 .2256(19) 0(1A)-C(7A) 1.228(2)
0(2A)-C(6A) 1.2245(19) 0(3A)-C(6A) 1.2896(19)
N(1)-C(1) 1.349(2) N(1)-C(5) 1 .350(2)
N(1 )-C(7) 1 .4780(19) N(2)-C(8) 1 .330(2)
N(2)-C(9) 1.451(2) N(1A)-C(5A) 1.339(2)
N(1A)-C(1 A) 1 .356(2) N(1A)-C(18) 1 .4833(19)
N(2A)-C(7A) 1.331(2) N(2A)-C(8A) 1.462(2)
C(1)-C(2) 1.371(2) C(2)-C(3) 1 .379(2)
C(3)-C(4) 1.390(2) C(4)-C(5) 1 .381(2)
C(4)-C(6) 1.512(2) C(7)-C(8) 1 .525(2)
C(9)-C(10) 1.519(2) C(10)-C(11) 1.525(2)
C(11)-C(12) 1.520(2) C(12)-C(13) 1.523(2)
C(13)-C(14) 1.517(3) C(14)-C(15) 1 .524(3)
C(15)-C(16) 1 .521(3) C(18)-C(7A) 1.519(2)
C(1A)-C(2A) 1.372(2) C(2A)-C(3A) 1.389(2)
C(3A)-C(4A) 1.389(2) C(4A)-C(5A) 1.386(2)
C(4A)-C(6A) 1.508(2) C(8A)-C(9A) 1.516(2)
C(9A)-C(10A) 1.527(2) C(10A)-C(11A) 1.520(2)
C(11A)-C(12A) 1.522(2) C(12A)-C(13A) 1.525(2)
C(13A)-C(14A) 1.518(3) C(14A)-C(15A) 1.523(3)
C(1 )-N(1 )-C(5) 121 .13(13) C(1)-N(1)-C(7) 119.61(13)
C(5)-N(1)-C(7) 119 .26(13) C(8)-N(2)-C(9) 123.55(15)
C(5A)-N(1 A)-C(1A) 121.80(13) C(5A)-N(1A)-C(18) 120.95(12)
C(1A)-N(1A)-C(18) 117 .24(12) C(7A)-N(2A)-C(8A) 122.19(14)
N(1)-C(1)-C(2) 120 .74(14) C(1)-C(2)-C(3) 119.26(15)
C(2)-C(3)-C(4) 119 .48(14) C(5)-C(4)-C(3) 119.44(14)
C(5)-C(4)-C(6) 121 .03(14) C(3)-C(4)-C(6) 119.53(14)
N(1)-C(5)-C(4) 119 .78(14) 0 (3 )-C (6)-0(2) 126.05(14)
0(3)-C(6)-C(4) 118 .94(14) 0(2)-C(6)-C(4) 114.99(13)
N(1)-C(7)-C(8) 111 .33(13) 0(1)-C(8)-N(2) 125.13(15)
0(1)-C(8)-C(7) 121 .86(14) N(2)-C(8)-C(7) 113.01(14)
N(2)-C(9)-C(10) 110 .86(14) C(9)-C(10)-C(11) 112.91(15)
C(12)-C(11 )-C(10) 112 .96(15) C(11 )-C(12)-C(13) 114.09(15)
C(14)-C(13)-C(12) 113 .44(16) C(13)-C(14)-C(15) 114.19(17)
C(16)-C(15)-C(14) 112 .99(19) N (1 A)-C (18 )-C(7 A) 108.81(12)
N( 1 A)-C(1 A)-C(2A) 120.05(14) C( 1 A)-C(2A)-C(3A) 119.37(14)
C(2A)-C(3A)-C(4A) 119.67(14) C(5A)-C(4A)-C(3A) 118.98(14)
C(5A)-C(4A)-C(6A) 118.81(13) C(3A)-C(4A)-C(6A) 122.17(14)
N(1A)-C(5A)-C(4A) 120.10(14) 0(2A)-C(6A)-0(3A) 126.20(14)
0(2A)-C(6A)-C(4A) 119.66(13) 0(3A)-C(6A)-C(4A) 114.14(13)
0 (  1 A)-C(7A)-N(2A) 124.36(15) 0(1A)-C(7A)-C(18) 119.78(14)
N(2A)-C(7A)-C(18) 115 .81(14) N(2A)-C(8A)-C(9A) 113.55(14)













Symmetry transformations u sed  to generate equivalent atoms:
249
Table 4. Anisotropic displacement parameters (A2 x 103) for BZ194. The 
anisotropic displacement factor exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 
2 h k a* b* U]
Atom U11 U22 U33 U23 U13 U12
Br(1) 22(1) 27(1) 36(1) -3(1) 6(1) 6(1)
0(1) 35(1) 25(1) 27(1) 2(1) -1(1) -7(1)
0(2) 17(1) 28(1) 27(1) -7(1) 1(1) 7(1)
0(3) 21(1) 30(1) 31(1) -12(1) 0(1) 4(1)
0(1 A) 40(1) 23 ( 1 ) 37(1) 7(1) 14(1) 9(1)
0(2A) 20(1) 26(1) 26(1) -7(1) 2(1) 4(1)
0(3A) 18(1) 30(1) 28(1) -7(1) 1(1) 9(1)
NO) 20(1) 19(1) 17( 1) -1(1) 2(1) 4(1)
N(2) 32(1) 20(1) 20(1) 0(1) 1(1) -1(1)
N(1A) 16(1) 20(1) 19(1) -1(1) 2(1) 4(1)
N(2A) 27(1) 22(1) 23(1) 2(1) 8(1) 8(1)
C(1) 22(1) 23(1) 22(1) 1(1) 7(1) 8(1)
0(2) 17(1) 28(1) 24(1) 3(1) 3(1) 8(1)
C(3) 19(1) 23(1) 21(1) 0(1) 2(1) 2(1)
0(4) 18(1) 20(1) 18(1) 2(1) 4(1) 3(1)
0(5) 17(1) 20(1) 19(1) 1(1) 3(1) 4(1)
0(6) 19(1) 20(1) 18(1) 1(1) 3(1) 3(1)
0(7) 23(1) 19(1) 21(1) -3(1) 2(1) 2(1)
0(8) 20(1) 22(1) 24(1) -2(1) 4(1) 4(1)
0(9) 31(1) 26(1) 22(1) 0(1) -1(1) 2(1)
0(10) 35(1) 27(1) 21(1) -1(1) 1(1) 1(1)
C(11) 36(1) 29(1) 23(1) 0(1) 2(1) 3(1)
C(12) 43(1) 32(1) 22(1) -1(1) 1(1) 4(1)
C(13) 42(1) 35(1) 23(1) 0(1) 3(1) 4(1)
C(14) 54(1) 33(1) 23(1) - 1( 1 ) 4(1) 2(1)
C(15) 75(2) 39(1) 22(1) -1(1) 5(1) 3(1)
C( 16) 142(3) 41(1) 24(1) -4(1) 14(1) -4(2)
C( 18) 16(1) 24(1) 22(1) -3(1) 2(1) 6(1)
C(1A) 23(1) 19(1) 19(1) - 4 ( 1 ) 2(1) 3(1)
C(2A) 20(1) 20(1) 21(1) -2(1) -1(1) 2(1)
C(3A) 16(1) 23(1) 23(1) 1(1) 1(1) 4(1)
C(4A) 19 ( 1 ) 1 9 ( 1 ) 18(1) 2(1) 3(1) 4(1)
C(5A) 19(1) 19(1) 17(1) -2(1) 1(1) 3(1)
C(6A) 19(1) 19(1) 20(1) 1(1) 4(1) 4(1)
C(7A) 14(1) 21(1) 24(1) -2(1) 0(1) 1(1)
C(8A) 25(1) 33 ( 1 ) 24 ( 1) 0(1) 9(1) 8(1)
C(9A) 26(1) 31(1) 27 ( 1 ) 0(1) 8(1) 8(1)
C(10A) 30(1) 34(1) 25(1) -1(1) 8(1) 7(1)
C(11A) 31(1) 34(1) 26(1) -1(1) 7(1) 8(1)
C(12A) 30(1) 36(1) 27(1) -2(1) 7(1) 6(1)
C(13A) 31(1) 33(1) 26(1) -1(1) 6(1) 6(1)
C(14A) 33(1) 41(1) 29(1) -5(1) 7(1) 5(1)
C(15 A) 44(1) 48(1) 29(1) -7(1) 8(1) 3(1)
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Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters 
(A2 x 103) for BZ194.
Atom X y 2 U(eq)
H(1) 17602 -6507 3635 26
H(2B) 19458 -4932 4395 27
H(3) 18635 -3238 5030 26
H(5) 14156 -4694 4082 23
H(7A) 13543 -7100 3536 26
H(7B) 14934 -7792 3336 26
H(9A) 13526 -6074 1521 33
H(9B) 11732 -6794 1586 33
H(10A) 12057 -9164 1268 35
H(10B) 13875 -8488 1231 35
H(11 A) 11252 -7792 409 36
H(11B) 13061 -7059 379 36
H(12A) 11630 -10143 99 40
H(12B) 13459 -9449 94 40
H(13A) 10909 -8755 -768 41
H(13B) 12735 -8039 -771 41
H(14A) 11306 -11119 -1056 46
H(14B) 13139 -10416 -1050 46
H(15A) 10610 -9749 -1934 57
H(15B) 12440 -9023 -1925 57
H(16A) 11067 -12118 -2201 109
H(16B) 12885 -11366 -2209 109
H(16C) 11523 -10982 -2726 109
H(18A) 7411 672 5908 25
H(18B) 7986 2408 6128 25
H(1A) 10545 3032 6936 25
H(2A) 13206 2961 7044 25
H(3A) 13967 1162 6437 25
H(5A) 9362 -474 5678 23
H(8A1) 5934 883 7771 32
H(8A2) 5340 2392 7678 32
H(9A1) 7929 3715 8221 33
H(9A2) 8318 2138 8380 33
H(10C) 5733 3145 8782 35
H(10D) 6226 1628 8968 35
H(11C) 8202 4489 9383 36
H(11D) 8592 2948 9596 36
H(12C) 6414 2516 10140 37
H(12D) 5974 4029 9915 37
H(13C) 8789 3870 10770 36
H(13D) 8394 5392 10533 36
H(14C) 6571 3466 11294 42
H(14D) 6156 4976 11052 42
H(15C) 8953 4845 11921 62
H(15D) 7452 5346 12120 62
H(15E) 8514 6352 11685 62
H(21A) 7090(20) 3004(18) 6990(9) 32(5)
H(2) 13970(30) -1830(30) 5235(13) 80(9)
H(21) 12930(20) -8124(18) 2409(9) 28(5)
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